{
  "drug_0": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/573501?name=100924&mode=orpha&region=",
    "regulatory_id": "573501",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 02/03/2020)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 02/03/2020)",
      "(Tradename                        - 02/03/2020)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=100924&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/573501?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "480914": {
    "name": "Givosiran",
    "substance_url": "/en/drug/substance/480914?name=100924&mode=orpha&region=&status=all",
    "substance_id": "480914",
    "regulatory_url": "/en/drug/regulatory/480915?name=100924&mode=orpha&region=",
    "regulatory_id": "480915",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "Givosiran(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "Givosiran(Medicinal product                        - 29/08/2016)",
      "(Medicinal product                        - 29/08/2016)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480914?name=100924&mode=orpha&region=&status=all",
        "text": "Givosiran",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480915?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_2": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/574106?name=100924&mode=orpha&region=",
    "regulatory_id": "574106",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 20/11/2019)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 20/11/2019)",
      "(Tradename                        - 20/11/2019)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=100924&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/574106?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_3": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=100924&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=100924&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689505": {
    "name": "Burixafor",
    "substance_url": "/en/drug/substance/689505?name=100924&mode=orpha&region=&status=all",
    "substance_id": "689505",
    "regulatory_url": "/en/drug/regulatory/689915?name=100924&mode=orpha&region=",
    "regulatory_id": "689915",
    "orpha_substance_code": "ORPHA:565779",
    "details": [
      "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "Burixafor(Medicinal product                        - 22/10/2024)",
      "(Medicinal product                        - 22/10/2024)",
      "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689505?name=100924&mode=orpha&region=&status=all",
        "text": "Burixafor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565779",
        "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689915?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "90799": {
    "name": "Treosulfan",
    "substance_url": "/en/drug/substance/90799?name=100924&mode=orpha&region=&status=all",
    "substance_id": "90799",
    "regulatory_url": "/en/drug/regulatory/136690?name=100924&mode=orpha&region=",
    "regulatory_id": "136690",
    "orpha_substance_code": "ORPHA:565779",
    "details": [
      "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "Treosulfan(Medicinal product                        - 08/04/2015)",
      "(Medicinal product                        - 08/04/2015)",
      "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/90799?name=100924&mode=orpha&region=&status=all",
        "text": "Treosulfan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213500",
        "text": "ORPHA:213500 Rare ovarian cancer",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565779",
        "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/136690?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "46335": {
    "name": "busulfan",
    "substance_url": "/en/drug/substance/46335?name=100924&mode=orpha&region=&status=all",
    "substance_id": "46335",
    "regulatory_url": "/en/drug/regulatory/131973?name=100924&mode=orpha&region=",
    "regulatory_id": "131973",
    "orpha_substance_code": "ORPHA:565779",
    "details": [
      "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "busulfan(Medicinal product                        - 21/04/1994)",
      "(Medicinal product                        - 21/04/1994)",
      "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/46335?name=100924&mode=orpha&region=&status=all",
        "text": "busulfan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565779",
        "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131973?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "24990": {
    "name": "Hemin",
    "substance_url": "/en/drug/substance/24990?name=100924&mode=orpha&region=&status=all",
    "substance_id": "24990",
    "regulatory_url": "/en/drug/regulatory/131924?name=100924&mode=orpha&region=",
    "regulatory_id": "131924",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "Hemin(Medicinal product                        - 16/03/1984)Disease(s) concernedORPHA:738 Porphyria",
      "Hemin(Medicinal product                        - 16/03/1984)",
      "(Medicinal product                        - 16/03/1984)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24990?name=100924&mode=orpha&region=&status=all",
        "text": "Hemin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131924?name=100924&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "686840": {
    "name": "Befiradol fumarate",
    "substance_url": "/en/drug/substance/686840?name=101109&mode=orpha&region=&status=all",
    "substance_id": "686840",
    "regulatory_url": "/en/drug/regulatory/686930?name=101109&mode=orpha&region=",
    "regulatory_id": "686930",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Befiradol fumarate(Medicinal product                        - 25/07/2024)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Befiradol fumarate(Medicinal product                        - 25/07/2024)",
      "(Medicinal product                        - 25/07/2024)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/686840?name=101109&mode=orpha&region=&status=all",
        "text": "Befiradol fumarate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686930?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "635854": {
    "name": "Rovatirelin",
    "substance_url": "/en/drug/substance/635854?name=101109&mode=orpha&region=&status=all",
    "substance_id": "635854",
    "regulatory_url": "/en/drug/regulatory/635855?name=101109&mode=orpha&region=",
    "regulatory_id": "635855",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Rovatirelin(Medicinal product                        - 10/11/2022)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Rovatirelin(Medicinal product                        - 10/11/2022)",
      "(Medicinal product                        - 10/11/2022)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/635854?name=101109&mode=orpha&region=&status=all",
        "text": "Rovatirelin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635855?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628292": {
    "name": "Troriluzole hydrochloride",
    "substance_url": "/en/drug/substance/628292?name=101109&mode=orpha&region=&status=all",
    "substance_id": "628292",
    "regulatory_url": "/en/drug/regulatory/628294?name=101109&mode=orpha&region=",
    "regulatory_id": "628294",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Troriluzole hydrochloride(Medicinal product                        - 10/12/2021)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Troriluzole hydrochloride(Medicinal product                        - 10/12/2021)",
      "(Medicinal product                        - 10/12/2021)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628292?name=101109&mode=orpha&region=&status=all",
        "text": "Troriluzole hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628294?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "479413": {
    "name": "Acetylleucine",
    "substance_url": "/en/drug/substance/479413?name=101109&mode=orpha&region=&status=all",
    "substance_id": "479413",
    "regulatory_url": "/en/drug/regulatory/529063?name=101109&mode=orpha&region=",
    "regulatory_id": "529063",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Acetylleucine(Medicinal product                        - 24/08/2018)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Acetylleucine(Medicinal product                        - 24/08/2018)",
      "(Medicinal product                        - 24/08/2018)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/479413?name=101109&mode=orpha&region=&status=all",
        "text": "Acetylleucine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529063?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "531922": {
    "name": "Trans-resveratrol",
    "substance_url": "/en/drug/substance/531922?name=101109&mode=orpha&region=&status=all",
    "substance_id": "531922",
    "regulatory_url": "/en/drug/regulatory/531923?name=101109&mode=orpha&region=",
    "regulatory_id": "531923",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Trans-resveratrol(Medicinal product                        - 12/01/2017)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Trans-resveratrol(Medicinal product                        - 12/01/2017)",
      "(Medicinal product                        - 12/01/2017)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/531922?name=101109&mode=orpha&region=&status=all",
        "text": "Trans-resveratrol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/531923?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "418160": {
    "name": "Ceftriaxone",
    "substance_url": "/en/drug/substance/418160?name=101109&mode=orpha&region=&status=all",
    "substance_id": "418160",
    "regulatory_url": "/en/drug/regulatory/437311?name=101109&mode=orpha&region=",
    "regulatory_id": "437311",
    "orpha_substance_code": "ORPHA:247765",
    "details": [
      "Ceftriaxone(Medicinal product                        - 15/01/2015)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxiaORPHA:1172 Autosomal recessive cerebellar ataxiaORPHA:247765 X-linked cerebellar ataxia",
      "Ceftriaxone(Medicinal product                        - 15/01/2015)",
      "(Medicinal product                        - 15/01/2015)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxiaORPHA:1172 Autosomal recessive cerebellar ataxiaORPHA:247765 X-linked cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/418160?name=101109&mode=orpha&region=&status=all",
        "text": "Ceftriaxone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1172",
        "text": "ORPHA:1172 Autosomal recessive cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247765",
        "text": "ORPHA:247765 X-linked cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/437311?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "704629": {
    "name": "Single stranded 2-methoxyethyl RNA nucleotide with a full-length phosphorothioate backbone",
    "substance_url": "/en/drug/substance/704629?name=101109&mode=orpha&region=&status=all",
    "substance_id": "704629",
    "regulatory_url": "/en/drug/regulatory/704757?name=101109&mode=orpha&region=",
    "regulatory_id": "704757",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "Single stranded 2-methoxyethyl RNA nucleotide with a full-length phosphorothioate backbone(Medicinal product                        - 09/05/2025)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "Single stranded 2-methoxyethyl RNA nucleotide with a full-length phosphorothioate backbone(Medicinal product                        - 09/05/2025)",
      "(Medicinal product                        - 09/05/2025)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/704629?name=101109&mode=orpha&region=&status=all",
        "text": "Single stranded 2-methoxyethyl RNA nucleotide with a full-length phosphorothioate backbone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704757?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "88874": {
    "name": "4-aminopyridine",
    "substance_url": "/en/drug/substance/88874?name=101109&mode=orpha&region=&status=all",
    "substance_id": "88874",
    "regulatory_url": "/en/drug/regulatory/687322?name=101109&mode=orpha&region=",
    "regulatory_id": "687322",
    "orpha_substance_code": "ORPHA:99",
    "details": [
      "4-aminopyridine(Medicinal product                        - 26/07/2024)Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "4-aminopyridine(Medicinal product                        - 26/07/2024)",
      "(Medicinal product                        - 26/07/2024)",
      "Disease(s) concernedORPHA:99 Autosomal dominant cerebellar ataxia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/88874?name=101109&mode=orpha&region=&status=all",
        "text": "4-aminopyridine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99",
        "text": "ORPHA:99 Autosomal dominant cerebellar ataxia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687322?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "646586": {
    "name": "Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate",
    "substance_url": "/en/drug/substance/646586?name=101109&mode=orpha&region=&status=all",
    "substance_id": "646586",
    "regulatory_url": "/en/drug/regulatory/646683?name=101109&mode=orpha&region=",
    "regulatory_id": "646683",
    "orpha_substance_code": "ORPHA:68380",
    "details": [
      "Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate(Medicinal product                        - 14/04/2023)Disease(s) concernedORPHA:68380 Mitochondrial disease",
      "Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate(Medicinal product                        - 14/04/2023)",
      "(Medicinal product                        - 14/04/2023)",
      "Disease(s) concernedORPHA:68380 Mitochondrial disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/646586?name=101109&mode=orpha&region=&status=all",
        "text": "Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/68380",
        "text": "ORPHA:68380 Mitochondrial disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/646683?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "644348": {
    "name": "Zagociguat",
    "substance_url": "/en/drug/substance/644348?name=101109&mode=orpha&region=&status=all",
    "substance_id": "644348",
    "regulatory_url": "/en/drug/regulatory/644353?name=101109&mode=orpha&region=",
    "regulatory_id": "644353",
    "orpha_substance_code": "ORPHA:68380",
    "details": [
      "Zagociguat(Medicinal product                        - 23/03/2023)Disease(s) concernedORPHA:68380 Mitochondrial disease",
      "Zagociguat(Medicinal product                        - 23/03/2023)",
      "(Medicinal product                        - 23/03/2023)",
      "Disease(s) concernedORPHA:68380 Mitochondrial disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/644348?name=101109&mode=orpha&region=&status=all",
        "text": "Zagociguat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/68380",
        "text": "ORPHA:68380 Mitochondrial disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644353?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "285822": {
    "name": "Vatiquinone",
    "substance_url": "/en/drug/substance/285822?name=101109&mode=orpha&region=&status=all",
    "substance_id": "285822",
    "regulatory_url": "/en/drug/regulatory/299940?name=101109&mode=orpha&region=",
    "regulatory_id": "299940",
    "orpha_substance_code": "ORPHA:254827",
    "details": [
      "Vatiquinone(Medicinal product                        - 21/12/2010)Disease(s) concernedORPHA:223713 Mitochondrial oxidative phosphorylation disorderORPHA:254827 Mitochondrial membrane transport disorder",
      "Vatiquinone(Medicinal product                        - 21/12/2010)",
      "(Medicinal product                        - 21/12/2010)",
      "Disease(s) concernedORPHA:223713 Mitochondrial oxidative phosphorylation disorderORPHA:254827 Mitochondrial membrane transport disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/285822?name=101109&mode=orpha&region=&status=all",
        "text": "Vatiquinone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223713",
        "text": "ORPHA:223713 Mitochondrial oxidative phosphorylation disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/254827",
        "text": "ORPHA:254827 Mitochondrial membrane transport disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/299940?name=101109&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:254827 Mitochondrial membrane transport disorder\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "66148": {
    "name": "Titanium dioxide and bisoctrizole",
    "substance_url": "/en/drug/substance/66148?name=101330&mode=orpha&region=&status=all",
    "substance_id": "66148",
    "regulatory_url": "/en/drug/regulatory/133941?name=101330&mode=orpha&region=",
    "regulatory_id": "133941",
    "orpha_substance_code": "ORPHA:659698",
    "details": [
      "Titanium dioxide and bisoctrizole(Medicinal product                        - 03/03/2005)Disease(s) concernedORPHA:97230 Solar urticariaORPHA:330061 Actinic prurigoORPHA:330064 Chronic actinic dermatitisORPHA:659698 Hepatic cutaneous porphyria",
      "Titanium dioxide and bisoctrizole(Medicinal product                        - 03/03/2005)",
      "(Medicinal product                        - 03/03/2005)",
      "Disease(s) concernedORPHA:97230 Solar urticariaORPHA:330061 Actinic prurigoORPHA:330064 Chronic actinic dermatitisORPHA:659698 Hepatic cutaneous porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/66148?name=101330&mode=orpha&region=&status=all",
        "text": "Titanium dioxide and bisoctrizole",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/97230",
        "text": "ORPHA:97230 Solar urticaria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/330061",
        "text": "ORPHA:330061 Actinic prurigo",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/330064",
        "text": "ORPHA:330064 Chronic actinic dermatitis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/659698",
        "text": "ORPHA:659698 Hepatic cutaneous porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133941?name=101330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_20": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=101330&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=101330&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=101330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_21": {
    "name": "RAXONE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/439188?name=104&mode=orpha&region=",
    "regulatory_id": "439188",
    "orpha_substance_code": "ORPHA:104",
    "details": [
      "RAXONE(Tradename                        - 08/09/2015)Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "RAXONE(Tradename                        - 08/09/2015)",
      "(Tradename                        - 08/09/2015)",
      "Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/439186?name=104&mode=orpha&region=&status=all",
        "text": "RAXONE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/104",
        "text": "ORPHA:104 Leber hereditary optic neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/439188?name=104&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "628268": {
    "name": "Adeno-associated virus vector serotype 2 expressing the human MT-ND4 codon-optimised gene",
    "substance_url": "/en/drug/substance/628268?name=104&mode=orpha&region=&status=all",
    "substance_id": "628268",
    "regulatory_url": "/en/drug/regulatory/628269?name=104&mode=orpha&region=",
    "regulatory_id": "628269",
    "orpha_substance_code": "ORPHA:104",
    "details": [
      "Adeno-associated virus vector serotype 2 expressing the human MT-ND4 codon-optimised gene(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "Adeno-associated virus vector serotype 2 expressing the human MT-ND4 codon-optimised gene(Medicinal product                        - 14/01/2022)",
      "(Medicinal product                        - 14/01/2022)",
      "Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628268?name=104&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector serotype 2 expressing the human MT-ND4 codon-optimised gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/104",
        "text": "ORPHA:104 Leber hereditary optic neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628269?name=104&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "260395": {
    "name": "Adeno-associated viral vector containing the human NADH dehydrogenase 4 gene (rAAV2/2-ND4)",
    "substance_url": "/en/drug/substance/260395?name=104&mode=orpha&region=&status=all",
    "substance_id": "260395",
    "regulatory_url": "/en/drug/regulatory/275216?name=104&mode=orpha&region=",
    "regulatory_id": "275216",
    "orpha_substance_code": "ORPHA:104",
    "details": [
      "Adeno-associated viral vector containing the human NADH dehydrogenase 4 gene (rAAV2/2-ND4)(Medicinal product                        - 13/05/2011)Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "Adeno-associated viral vector containing the human NADH dehydrogenase 4 gene (rAAV2/2-ND4)(Medicinal product                        - 13/05/2011)",
      "(Medicinal product                        - 13/05/2011)",
      "Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/260395?name=104&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector containing the human NADH dehydrogenase 4 gene (rAAV2/2-ND4)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/104",
        "text": "ORPHA:104 Leber hereditary optic neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/275216?name=104&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "73656": {
    "name": "idebenone",
    "substance_url": "/en/drug/substance/73656?name=104&mode=orpha&region=&status=all",
    "substance_id": "73656",
    "regulatory_url": "/en/drug/regulatory/134111?name=104&mode=orpha&region=",
    "regulatory_id": "134111",
    "orpha_substance_code": "ORPHA:104",
    "details": [
      "idebenone(Medicinal product                        - 15/02/2007)Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "idebenone(Medicinal product                        - 15/02/2007)",
      "(Medicinal product                        - 15/02/2007)",
      "Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/73656?name=104&mode=orpha&region=&status=all",
        "text": "idebenone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/104",
        "text": "ORPHA:104 Leber hereditary optic neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134111?name=104&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "643869": {
    "name": "Recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1)",
    "substance_url": "/en/drug/substance/643869?name=104&mode=orpha&region=&status=all",
    "substance_id": "643869",
    "regulatory_url": "/en/drug/regulatory/643870?name=104&mode=orpha&region=",
    "regulatory_id": "643870",
    "orpha_substance_code": "ORPHA:104",
    "details": [
      "Recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1)(Medicinal product                        - 13/01/2022)Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "Recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1)(Medicinal product                        - 13/01/2022)",
      "(Medicinal product                        - 13/01/2022)",
      "Disease(s) concernedORPHA:104 Leber hereditary optic neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/643869?name=104&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/104",
        "text": "ORPHA:104 Leber hereditary optic neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/643870?name=104&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "556445": {
    "name": "Elamipretide",
    "substance_url": "/en/drug/substance/556445?name=111&mode=orpha&region=&status=all",
    "substance_id": "556445",
    "regulatory_url": "/en/drug/regulatory/627409?name=111&mode=orpha&region=",
    "regulatory_id": "627409",
    "orpha_substance_code": "ORPHA:111",
    "details": [
      "Elamipretide(Medicinal product                        - 20/05/2021)Disease(s) concernedORPHA:111 Barth syndrome",
      "Elamipretide(Medicinal product                        - 20/05/2021)",
      "(Medicinal product                        - 20/05/2021)",
      "Disease(s) concernedORPHA:111 Barth syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/556445?name=111&mode=orpha&region=&status=all",
        "text": "Elamipretide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/111",
        "text": "ORPHA:111 Barth syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627409?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_27": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=111&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=111&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_28": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=111&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=111&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_29": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=111&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=111&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "588874": {
    "name": "motixafortide",
    "substance_url": "/en/drug/substance/588874?name=111&mode=orpha&region=&status=all",
    "substance_id": "588874",
    "regulatory_url": "/en/drug/regulatory/661036?name=111&mode=orpha&region=",
    "regulatory_id": "661036",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "motixafortide(Medicinal product                        - 12/01/2024)",
      "(Medicinal product                        - 12/01/2024)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588874?name=111&mode=orpha&region=&status=all",
        "text": "motixafortide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661036?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "589233": {
    "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
    "substance_url": "/en/drug/substance/589233?name=111&mode=orpha&region=&status=all",
    "substance_id": "589233",
    "regulatory_url": "/en/drug/regulatory/589234?name=111&mode=orpha&region=",
    "regulatory_id": "589234",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
      "(Medicinal product                        - 20/04/2020)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/589233?name=111&mode=orpha&region=&status=all",
        "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589234?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "589056": {
    "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
    "substance_url": "/en/drug/substance/589056?name=111&mode=orpha&region=&status=all",
    "substance_id": "589056",
    "regulatory_url": "/en/drug/regulatory/589057?name=111&mode=orpha&region=",
    "regulatory_id": "589057",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
      "(Medicinal product                        - 24/03/2020)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/589056?name=111&mode=orpha&region=&status=all",
        "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589057?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687120": {
    "name": "2-(1H-imidazol-1-yl)-N-(2-(2-methoxyethoxy) pyrimidin-5-yl)-6-(trifluoromethyl) pyrimidine-4-carboxamide",
    "substance_url": "/en/drug/substance/687120?name=111&mode=orpha&region=&status=all",
    "substance_id": "687120",
    "regulatory_url": "/en/drug/regulatory/687279?name=111&mode=orpha&region=",
    "regulatory_id": "687279",
    "orpha_substance_code": "ORPHA:206966",
    "details": [
      "2-(1H-imidazol-1-yl)-N-(2-(2-methoxyethoxy) pyrimidin-5-yl)-6-(trifluoromethyl) pyrimidine-4-carboxamide(Medicinal product                        - 26/08/2024)Disease(s) concernedORPHA:206966 Mitochondrial myopathy",
      "2-(1H-imidazol-1-yl)-N-(2-(2-methoxyethoxy) pyrimidin-5-yl)-6-(trifluoromethyl) pyrimidine-4-carboxamide(Medicinal product                        - 26/08/2024)",
      "(Medicinal product                        - 26/08/2024)",
      "Disease(s) concernedORPHA:206966 Mitochondrial myopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687120?name=111&mode=orpha&region=&status=all",
        "text": "2-(1H-imidazol-1-yl)-N-(2-(2-methoxyethoxy) pyrimidin-5-yl)-6-(trifluoromethyl) pyrimidine-4-carboxamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/206966",
        "text": "ORPHA:206966 Mitochondrial myopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687279?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "571152": {
    "name": "Besilesomab",
    "substance_url": "/en/drug/substance/571152?name=111&mode=orpha&region=&status=all",
    "substance_id": "571152",
    "regulatory_url": "/en/drug/regulatory/641081?name=111&mode=orpha&region=",
    "regulatory_id": "641081",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Besilesomab(Medicinal product                        - 28/03/2022)",
      "(Medicinal product                        - 28/03/2022)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/571152?name=111&mode=orpha&region=&status=all",
        "text": "Besilesomab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/641081?name=111&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "300660": {
    "name": "Human apotransferrin",
    "substance_url": "/en/drug/substance/300660?name=1195&mode=orpha&region=&status=all",
    "substance_id": "300660",
    "regulatory_url": "/en/drug/regulatory/326996?name=1195&mode=orpha&region=",
    "regulatory_id": "326996",
    "orpha_substance_code": "ORPHA:1195",
    "details": [
      "Human apotransferrin(Medicinal product                        - 17/07/2012)Disease(s) concernedORPHA:1195 Congenital atransferrinemia",
      "Human apotransferrin(Medicinal product                        - 17/07/2012)",
      "(Medicinal product                        - 17/07/2012)",
      "Disease(s) concernedORPHA:1195 Congenital atransferrinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/300660?name=1195&mode=orpha&region=&status=all",
        "text": "Human apotransferrin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1195",
        "text": "ORPHA:1195 Congenital atransferrinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/326996?name=1195&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "676678": {
    "name": "Peptide-oligonucleotide conjugate that targets OPA1 mRNA",
    "substance_url": "/en/drug/substance/676678?name=1215&mode=orpha&region=&status=all",
    "substance_id": "676678",
    "regulatory_url": "/en/drug/regulatory/676730?name=1215&mode=orpha&region=",
    "regulatory_id": "676730",
    "orpha_substance_code": "ORPHA:98673",
    "details": [
      "Peptide-oligonucleotide conjugate that targets OPA1 mRNA(Medicinal product                        - 22/05/2024)Disease(s) concernedORPHA:1215 Autosomal dominant optic atrophy plus syndromeORPHA:98673 Autosomal dominant optic atrophy, classic form",
      "Peptide-oligonucleotide conjugate that targets OPA1 mRNA(Medicinal product                        - 22/05/2024)",
      "(Medicinal product                        - 22/05/2024)",
      "Disease(s) concernedORPHA:1215 Autosomal dominant optic atrophy plus syndromeORPHA:98673 Autosomal dominant optic atrophy, classic form",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/676678?name=1215&mode=orpha&region=&status=all",
        "text": "Peptide-oligonucleotide conjugate that targets OPA1 mRNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1215",
        "text": "ORPHA:1215 Autosomal dominant optic atrophy plus syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98673",
        "text": "ORPHA:98673 Autosomal dominant optic atrophy, classic form",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/676730?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:98673 Autosomal dominant optic atrophy, classic form\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "628466": {
    "name": "Govorestat",
    "substance_url": "/en/drug/substance/628466?name=1215&mode=orpha&region=&status=all",
    "substance_id": "628466",
    "regulatory_url": "/en/drug/regulatory/650310?name=1215&mode=orpha&region=",
    "regulatory_id": "650310",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Govorestat(Medicinal product                        - 22/05/2023)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Govorestat(Medicinal product                        - 22/05/2023)",
      "(Medicinal product                        - 22/05/2023)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628466?name=1215&mode=orpha&region=&status=all",
        "text": "Govorestat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650310?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "499387": {
    "name": "2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine",
    "substance_url": "/en/drug/substance/499387?name=1215&mode=orpha&region=&status=all",
    "substance_id": "499387",
    "regulatory_url": "/en/drug/regulatory/499392?name=1215&mode=orpha&region=",
    "regulatory_id": "499392",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine(Medicinal product                        - 16/10/2017)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine(Medicinal product                        - 16/10/2017)",
      "(Medicinal product                        - 16/10/2017)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/499387?name=1215&mode=orpha&region=&status=all",
        "text": "2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/499392?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "449585": {
    "name": "Icerguastat acetate",
    "substance_url": "/en/drug/substance/449585?name=1215&mode=orpha&region=&status=all",
    "substance_id": "449585",
    "regulatory_url": "/en/drug/regulatory/449589?name=1215&mode=orpha&region=",
    "regulatory_id": "449589",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Icerguastat acetate(Medicinal product                        - 14/12/2015)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Icerguastat acetate(Medicinal product                        - 14/12/2015)",
      "(Medicinal product                        - 14/12/2015)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/449585?name=1215&mode=orpha&region=&status=all",
        "text": "Icerguastat acetate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/449589?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "695327": {
    "name": "Human Wharton's jelly-derived mesenchymal stem cells",
    "substance_url": "/en/drug/substance/695327?name=1215&mode=orpha&region=&status=all",
    "substance_id": "695327",
    "regulatory_url": "/en/drug/regulatory/695543?name=1215&mode=orpha&region=",
    "regulatory_id": "695543",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Human Wharton's jelly-derived mesenchymal stem cells(Medicinal product                        - 27/02/2025)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Human Wharton's jelly-derived mesenchymal stem cells(Medicinal product                        - 27/02/2025)",
      "(Medicinal product                        - 27/02/2025)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695327?name=1215&mode=orpha&region=&status=all",
        "text": "Human Wharton's jelly-derived mesenchymal stem cells",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695543?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "631561": {
    "name": "Bromophenoxyazole propanoic acid",
    "substance_url": "/en/drug/substance/631561?name=1215&mode=orpha&region=&status=all",
    "substance_id": "631561",
    "regulatory_url": "/en/drug/regulatory/692595?name=1215&mode=orpha&region=",
    "regulatory_id": "692595",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Bromophenoxyazole propanoic acid(Medicinal product                        - 02/12/2024)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Bromophenoxyazole propanoic acid(Medicinal product                        - 02/12/2024)",
      "(Medicinal product                        - 02/12/2024)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/631561?name=1215&mode=orpha&region=&status=all",
        "text": "Bromophenoxyazole propanoic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692595?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "684495": {
    "name": "Small molecule allosteric mitofusin activator",
    "substance_url": "/en/drug/substance/684495?name=1215&mode=orpha&region=&status=all",
    "substance_id": "684495",
    "regulatory_url": "/en/drug/regulatory/684706?name=1215&mode=orpha&region=",
    "regulatory_id": "684706",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Small molecule allosteric mitofusin activator(Medicinal product                        - 12/06/2024)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Small molecule allosteric mitofusin activator(Medicinal product                        - 12/06/2024)",
      "(Medicinal product                        - 12/06/2024)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/684495?name=1215&mode=orpha&region=&status=all",
        "text": "Small molecule allosteric mitofusin activator",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684706?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "661978": {
    "name": "Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor",
    "substance_url": "/en/drug/substance/661978?name=1215&mode=orpha&region=&status=all",
    "substance_id": "661978",
    "regulatory_url": "/en/drug/regulatory/661983?name=1215&mode=orpha&region=",
    "regulatory_id": "661983",
    "orpha_substance_code": "ORPHA:166",
    "details": [
      "Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor(Medicinal product                        - 25/07/2023)Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor(Medicinal product                        - 25/07/2023)",
      "(Medicinal product                        - 25/07/2023)",
      "Disease(s) concernedORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661978?name=1215&mode=orpha&region=&status=all",
        "text": "Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166",
        "text": "ORPHA:166 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661983?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "637248": {
    "name": "18-mer antisense oligonucleotide complementary to OPA1 pre-mRNA",
    "substance_url": "/en/drug/substance/637248?name=1215&mode=orpha&region=&status=all",
    "substance_id": "637248",
    "regulatory_url": "/en/drug/regulatory/637253?name=1215&mode=orpha&region=",
    "regulatory_id": "637253",
    "orpha_substance_code": "ORPHA:98672",
    "details": [
      "18-mer antisense oligonucleotide complementary to OPA1 pre-mRNA(Medicinal product                        - 29/07/2022)Disease(s) concernedORPHA:98672 Autosomal dominant optic atrophy",
      "18-mer antisense oligonucleotide complementary to OPA1 pre-mRNA(Medicinal product                        - 29/07/2022)",
      "(Medicinal product                        - 29/07/2022)",
      "Disease(s) concernedORPHA:98672 Autosomal dominant optic atrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/637248?name=1215&mode=orpha&region=&status=all",
        "text": "18-mer antisense oligonucleotide complementary to OPA1 pre-mRNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98672",
        "text": "ORPHA:98672 Autosomal dominant optic atrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/637253?name=1215&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628140": {
    "name": "Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene",
    "substance_url": "/en/drug/substance/628140?name=124&mode=orpha&region=&status=all",
    "substance_id": "628140",
    "regulatory_url": "/en/drug/regulatory/628141?name=124&mode=orpha&region=",
    "regulatory_id": "628141",
    "orpha_substance_code": "ORPHA:124",
    "details": [
      "Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene(Medicinal product                        - 12/11/2021)Disease(s) concernedORPHA:124 Diamond-Blackfan anemia",
      "Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene(Medicinal product                        - 12/11/2021)",
      "(Medicinal product                        - 12/11/2021)",
      "Disease(s) concernedORPHA:124 Diamond-Blackfan anemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628140?name=124&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/124",
        "text": "ORPHA:124 Diamond-Blackfan anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628141?name=124&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627883": {
    "name": "Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene",
    "substance_url": "/en/drug/substance/627883?name=124&mode=orpha&region=&status=all",
    "substance_id": "627883",
    "regulatory_url": "/en/drug/regulatory/627895?name=124&mode=orpha&region=",
    "regulatory_id": "627895",
    "orpha_substance_code": "ORPHA:124",
    "details": [
      "Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:124 Diamond-Blackfan anemia",
      "Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene(Medicinal product                        - 20/08/2021)",
      "(Medicinal product                        - 20/08/2021)",
      "Disease(s) concernedORPHA:124 Diamond-Blackfan anemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627883?name=124&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/124",
        "text": "ORPHA:124 Diamond-Blackfan anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627895?name=124&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_47": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=124&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=124&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=124&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_48": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=124&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=124&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=124&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "699871": {
    "name": "Cord blood derived T regulatory cells",
    "substance_url": "/en/drug/substance/699871?name=124&mode=orpha&region=&status=all",
    "substance_id": "699871",
    "regulatory_url": "/en/drug/regulatory/700242?name=124&mode=orpha&region=",
    "regulatory_id": "700242",
    "orpha_substance_code": "ORPHA:182040",
    "details": [
      "Cord blood derived T regulatory cells(Medicinal product                        - 04/04/2025)Disease(s) concernedORPHA:182040 Rare aplastic anemia",
      "Cord blood derived T regulatory cells(Medicinal product                        - 04/04/2025)",
      "(Medicinal product                        - 04/04/2025)",
      "Disease(s) concernedORPHA:182040 Rare aplastic anemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/699871?name=124&mode=orpha&region=&status=all",
        "text": "Cord blood derived T regulatory cells",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182040",
        "text": "ORPHA:182040 Rare aplastic anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700242?name=124&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "86787": {
    "name": "Tazarotene",
    "substance_url": "/en/drug/substance/86787?name=139&mode=orpha&region=&status=all",
    "substance_id": "86787",
    "regulatory_url": "/en/drug/regulatory/134099?name=139&mode=orpha&region=",
    "regulatory_id": "134099",
    "orpha_substance_code": "ORPHA:183435",
    "details": [
      "Tazarotene(Medicinal product                        - 18/12/2006)Disease(s) concernedORPHA:183435 Inherited ichthyosis",
      "Tazarotene(Medicinal product                        - 18/12/2006)",
      "(Medicinal product                        - 18/12/2006)",
      "Disease(s) concernedORPHA:183435 Inherited ichthyosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/86787?name=139&mode=orpha&region=&status=all",
        "text": "Tazarotene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/183435",
        "text": "ORPHA:183435 Inherited ichthyosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134099?name=139&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "697604": {
    "name": "mRNA encoding Cas9-deaminase and single guide RNA against TGM1",
    "substance_url": "/en/drug/substance/697604?name=139&mode=orpha&region=&status=all",
    "substance_id": "697604",
    "regulatory_url": "/en/drug/regulatory/697877?name=139&mode=orpha&region=",
    "regulatory_id": "697877",
    "orpha_substance_code": "ORPHA:183435",
    "details": [
      "mRNA encoding Cas9-deaminase and single guide RNA against TGM1(Medicinal product                        - 06/03/2025)Disease(s) concernedORPHA:183435 Inherited ichthyosis",
      "mRNA encoding Cas9-deaminase and single guide RNA against TGM1(Medicinal product                        - 06/03/2025)",
      "(Medicinal product                        - 06/03/2025)",
      "Disease(s) concernedORPHA:183435 Inherited ichthyosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/697604?name=139&mode=orpha&region=&status=all",
        "text": "mRNA encoding Cas9-deaminase and single guide RNA against TGM1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/183435",
        "text": "ORPHA:183435 Inherited ichthyosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/697877?name=139&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_52": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=139406&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=139406&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=139406&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_53": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=139406&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=139406&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=139406&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "699446": {
    "name": "Parahydroxybenzoic acid",
    "substance_url": "/en/drug/substance/699446?name=139485&mode=orpha&region=&status=all",
    "substance_id": "699446",
    "regulatory_url": "/en/drug/regulatory/704500?name=139485&mode=orpha&region=",
    "regulatory_id": "704500",
    "orpha_substance_code": "ORPHA:35656",
    "details": [
      "Parahydroxybenzoic acid(Medicinal product                        - 14/05/2025)Disease(s) concernedORPHA:35656 Coenzyme Q10 deficiency",
      "Parahydroxybenzoic acid(Medicinal product                        - 14/05/2025)",
      "(Medicinal product                        - 14/05/2025)",
      "Disease(s) concernedORPHA:35656 Coenzyme Q10 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/699446?name=139485&mode=orpha&region=&status=all",
        "text": "Parahydroxybenzoic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35656",
        "text": "ORPHA:35656 Coenzyme Q10 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704500?name=139485&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "484688": {
    "name": "Ubiquinol",
    "substance_url": "/en/drug/substance/484688?name=139485&mode=orpha&region=&status=all",
    "substance_id": "484688",
    "regulatory_url": "/en/drug/regulatory/484696?name=139485&mode=orpha&region=",
    "regulatory_id": "484696",
    "orpha_substance_code": "ORPHA:35656",
    "details": [
      "Ubiquinol(Medicinal product                        - 20/09/2016)Disease(s) concernedORPHA:35656 Coenzyme Q10 deficiency",
      "Ubiquinol(Medicinal product                        - 20/09/2016)",
      "(Medicinal product                        - 20/09/2016)",
      "Disease(s) concernedORPHA:35656 Coenzyme Q10 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/484688?name=139485&mode=orpha&region=&status=all",
        "text": "Ubiquinol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35656",
        "text": "ORPHA:35656 Coenzyme Q10 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484696?name=139485&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "189142": {
    "name": "(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt",
    "substance_url": "/en/drug/substance/189142?name=139507&mode=orpha&region=&status=all",
    "substance_id": "189142",
    "regulatory_url": "/en/drug/regulatory/208572?name=139507&mode=orpha&region=",
    "regulatory_id": "208572",
    "orpha_substance_code": "ORPHA:220489",
    "details": [
      "(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt(Medicinal product                        - 24/07/2009)Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:85 Congenital dyserythropoietic anemiaORPHA:75563 X-linked sideroblastic anemiaORPHA:139507 Dietary iron overload diseaseORPHA:220489 Rare hereditary hemochromatosis",
      "(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt(Medicinal product                        - 24/07/2009)",
      "(Medicinal product                        - 24/07/2009)",
      "Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:85 Congenital dyserythropoietic anemiaORPHA:75563 X-linked sideroblastic anemiaORPHA:139507 Dietary iron overload diseaseORPHA:220489 Rare hereditary hemochromatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/189142?name=139507&mode=orpha&region=&status=all",
        "text": "(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/846",
        "text": "ORPHA:846 Alpha-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/848",
        "text": "ORPHA:848 Beta-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/232",
        "text": "ORPHA:232 Sickle cell anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/85",
        "text": "ORPHA:85 Congenital dyserythropoietic anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/75563",
        "text": "ORPHA:75563 X-linked sideroblastic anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/139507",
        "text": "ORPHA:139507 Dietary iron overload disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/220489",
        "text": "ORPHA:220489 Rare hereditary hemochromatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/208572?name=139507&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:220489 Rare hereditary hemochromatosis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "638733": {
    "name": "Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA",
    "substance_url": "/en/drug/substance/638733?name=141&mode=orpha&region=&status=all",
    "substance_id": "638733",
    "regulatory_url": "/en/drug/regulatory/638735?name=141&mode=orpha&region=",
    "regulatory_id": "638735",
    "orpha_substance_code": "ORPHA:141",
    "details": [
      "Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA(Medicinal product                        - 09/12/2022)Disease(s) concernedORPHA:141 Canavan disease",
      "Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA(Medicinal product                        - 09/12/2022)",
      "(Medicinal product                        - 09/12/2022)",
      "Disease(s) concernedORPHA:141 Canavan disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/638733?name=141&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/141",
        "text": "ORPHA:141 Canavan disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/638735?name=141&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "589288": {
    "name": "Adeno-associated virus serotype 9 containing the human ASPA gene",
    "substance_url": "/en/drug/substance/589288?name=141&mode=orpha&region=&status=all",
    "substance_id": "589288",
    "regulatory_url": "/en/drug/regulatory/589289?name=141&mode=orpha&region=",
    "regulatory_id": "589289",
    "orpha_substance_code": "ORPHA:141",
    "details": [
      "Adeno-associated virus serotype 9 containing the human ASPA gene(Medicinal product                        - 04/06/2020)Disease(s) concernedORPHA:141 Canavan disease",
      "Adeno-associated virus serotype 9 containing the human ASPA gene(Medicinal product                        - 04/06/2020)",
      "(Medicinal product                        - 04/06/2020)",
      "Disease(s) concernedORPHA:141 Canavan disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/589288?name=141&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 9 containing the human ASPA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/141",
        "text": "ORPHA:141 Canavan disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589289?name=141&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "641663": {
    "name": "Recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA)",
    "substance_url": "/en/drug/substance/641663?name=141&mode=orpha&region=&status=all",
    "substance_id": "641663",
    "regulatory_url": "/en/drug/regulatory/641664?name=141&mode=orpha&region=",
    "regulatory_id": "641664",
    "orpha_substance_code": "ORPHA:141",
    "details": [
      "Recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA)(Medicinal product                        - 17/02/2022)Disease(s) concernedORPHA:141 Canavan disease",
      "Recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA)(Medicinal product                        - 17/02/2022)",
      "(Medicinal product                        - 17/02/2022)",
      "Disease(s) concernedORPHA:141 Canavan disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/641663?name=141&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/141",
        "text": "ORPHA:141 Canavan disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/641664?name=141&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_60": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=147&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=147&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_61": {
    "name": "AMMONAPS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131255?name=147&mode=orpha&region=",
    "regulatory_id": "131255",
    "orpha_substance_code": "ORPHA:187",
    "details": [
      "AMMONAPS(Tradename                        - 08/12/1999)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "AMMONAPS(Tradename                        - 08/12/1999)",
      "(Tradename                        - 08/12/1999)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34205?name=147&mode=orpha&region=&status=all",
        "text": "AMMONAPS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/187",
        "text": "ORPHA:187 Citrullinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131255?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "87861": {
    "name": "sodium phenylacetate / sodium benzoate",
    "substance_url": "/en/drug/substance/87861?name=147&mode=orpha&region=&status=all",
    "substance_id": "87861",
    "regulatory_url": "/en/drug/regulatory/559566?name=147&mode=orpha&region=",
    "regulatory_id": "559566",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "sodium phenylacetate / sodium benzoate(Medicinal product                        - 29/05/2019)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "sodium phenylacetate / sodium benzoate(Medicinal product                        - 29/05/2019)",
      "(Medicinal product                        - 29/05/2019)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/87861?name=147&mode=orpha&region=&status=all",
        "text": "sodium phenylacetate / sodium benzoate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/559566?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "83694": {
    "name": "Sodium benzoate",
    "substance_url": "/en/drug/substance/83694?name=147&mode=orpha&region=&status=all",
    "substance_id": "83694",
    "regulatory_url": "/en/drug/regulatory/480443?name=147&mode=orpha&region=",
    "regulatory_id": "480443",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Sodium benzoate(Medicinal product                        - 14/07/2016)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Sodium benzoate(Medicinal product                        - 14/07/2016)",
      "(Medicinal product                        - 14/07/2016)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/83694?name=147&mode=orpha&region=&status=all",
        "text": "Sodium benzoate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480443?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "356372": {
    "name": "Heterologous human adult liver-derived progenitor cells",
    "substance_url": "/en/drug/substance/356372?name=147&mode=orpha&region=&status=all",
    "substance_id": "356372",
    "regulatory_url": "/en/drug/regulatory/364068?name=147&mode=orpha&region=",
    "regulatory_id": "364068",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Heterologous human adult liver-derived progenitor cells(Medicinal product                        - 17/07/2013)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Heterologous human adult liver-derived progenitor cells(Medicinal product                        - 17/07/2013)",
      "(Medicinal product                        - 17/07/2013)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/356372?name=147&mode=orpha&region=&status=all",
        "text": "Heterologous human adult liver-derived progenitor cells",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/364068?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "102674": {
    "name": "Heterologous human adult liver derived stem cells",
    "substance_url": "/en/drug/substance/102674?name=147&mode=orpha&region=&status=all",
    "substance_id": "102674",
    "regulatory_url": "/en/drug/regulatory/300894?name=147&mode=orpha&region=",
    "regulatory_id": "300894",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Heterologous human adult liver derived stem cells(Medicinal product                        - 05/03/2012)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Heterologous human adult liver derived stem cells(Medicinal product                        - 05/03/2012)",
      "(Medicinal product                        - 05/03/2012)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/102674?name=147&mode=orpha&region=&status=all",
        "text": "Heterologous human adult liver derived stem cells",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/300894?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "90800": {
    "name": "Human heterologous liver cells (for infusion)",
    "substance_url": "/en/drug/substance/90800?name=147&mode=orpha&region=&status=all",
    "substance_id": "90800",
    "regulatory_url": "/en/drug/regulatory/260281?name=147&mode=orpha&region=",
    "regulatory_id": "260281",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Human heterologous liver cells (for infusion)(Medicinal product                        - 17/12/2010)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Human heterologous liver cells (for infusion)(Medicinal product                        - 17/12/2010)",
      "(Medicinal product                        - 17/12/2010)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/90800?name=147&mode=orpha&region=&status=all",
        "text": "Human heterologous liver cells (for infusion)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/260281?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "222387": {
    "name": "Glycerol phenylbutyrate",
    "substance_url": "/en/drug/substance/222387?name=147&mode=orpha&region=&status=all",
    "substance_id": "222387",
    "regulatory_url": "/en/drug/regulatory/240239?name=147&mode=orpha&region=",
    "regulatory_id": "240239",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Glycerol phenylbutyrate(Medicinal product                        - 10/06/2010)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Glycerol phenylbutyrate(Medicinal product                        - 10/06/2010)",
      "(Medicinal product                        - 10/06/2010)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/222387?name=147&mode=orpha&region=&status=all",
        "text": "Glycerol phenylbutyrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/240239?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "25062": {
    "name": "Sodium phenylbutyrate",
    "substance_url": "/en/drug/substance/25062?name=147&mode=orpha&region=&status=all",
    "substance_id": "25062",
    "regulatory_url": "/en/drug/regulatory/301032?name=147&mode=orpha&region=",
    "regulatory_id": "301032",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "Sodium phenylbutyrate(Medicinal product                        - 09/02/2012)Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "Sodium phenylbutyrate(Medicinal product                        - 09/02/2012)",
      "(Medicinal product                        - 09/02/2012)",
      "Disease(s) concernedORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/25062?name=147&mode=orpha&region=&status=all",
        "text": "Sodium phenylbutyrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/301032?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_69": {
    "name": "PHEBURANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/628626?name=147&mode=orpha&region=",
    "regulatory_id": "628626",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "PHEBURANE(Tradename                        - 17/06/2022)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "PHEBURANE(Tradename                        - 17/06/2022)",
      "(Tradename                        - 17/06/2022)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/628534?name=147&mode=orpha&region=&status=all",
        "text": "PHEBURANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628626?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_70": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=147&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=147&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_71": {
    "name": "BUPHENYL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131075?name=147&mode=orpha&region=",
    "regulatory_id": "131075",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "BUPHENYL(Tradename                        - 30/04/1996)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "BUPHENYL(Tradename                        - 30/04/1996)",
      "(Tradename                        - 30/04/1996)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25061?name=147&mode=orpha&region=&status=all",
        "text": "BUPHENYL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131075?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "629851": {
    "name": "Allogeneic adult liver-derived stem cells",
    "substance_url": "/en/drug/substance/629851?name=147&mode=orpha&region=&status=all",
    "substance_id": "629851",
    "regulatory_url": "/en/drug/regulatory/629852?name=147&mode=orpha&region=",
    "regulatory_id": "629852",
    "orpha_substance_code": "ORPHA:79167",
    "details": [
      "Allogeneic adult liver-derived stem cells(Medicinal product                        - 10/08/2022)Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
      "Allogeneic adult liver-derived stem cells(Medicinal product                        - 10/08/2022)",
      "(Medicinal product                        - 10/08/2022)",
      "Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/629851?name=147&mode=orpha&region=&status=all",
        "text": "Allogeneic adult liver-derived stem cells",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79167",
        "text": "ORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629852?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "of urea cycle metabolism and ammonia detoxification\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "688360": {
    "name": "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end",
    "substance_url": "/en/drug/substance/688360?name=147&mode=orpha&region=&status=all",
    "substance_id": "688360",
    "regulatory_url": "/en/drug/regulatory/688517?name=147&mode=orpha&region=",
    "regulatory_id": "688517",
    "orpha_substance_code": "ORPHA:79167",
    "details": [
      "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end(Medicinal product                        - 11/09/2024)Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
      "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end(Medicinal product                        - 11/09/2024)",
      "(Medicinal product                        - 11/09/2024)",
      "Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688360?name=147&mode=orpha&region=&status=all",
        "text": "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79167",
        "text": "ORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688517?name=147&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "of urea cycle metabolism and ammonia detoxification\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "317333": {
    "name": "Triheptanoin",
    "substance_url": "/en/drug/substance/317333?name=156&mode=orpha&region=&status=all",
    "substance_id": "317333",
    "regulatory_url": "/en/drug/regulatory/604948?name=156&mode=orpha&region=",
    "regulatory_id": "604948",
    "orpha_substance_code": "ORPHA:156",
    "details": [
      "Triheptanoin(Medicinal product                        - 13/11/2020)Disease(s) concernedORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
      "Triheptanoin(Medicinal product                        - 13/11/2020)",
      "(Medicinal product                        - 13/11/2020)",
      "Disease(s) concernedORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/317333?name=156&mode=orpha&region=&status=all",
        "text": "Triheptanoin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604948?name=156&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_75": {
    "name": "DOJOLVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623538?name=156&mode=orpha&region=",
    "regulatory_id": "623538",
    "orpha_substance_code": "ORPHA:26793",
    "details": [
      "DOJOLVI(Tradename                        - 30/06/2020)Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "DOJOLVI(Tradename                        - 30/06/2020)",
      "(Tradename                        - 30/06/2020)",
      "Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/615857?name=156&mode=orpha&region=&status=all",
        "text": "DOJOLVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157",
        "text": "ORPHA:157 Carnitine palmitoyltransferase II deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/746",
        "text": "ORPHA:746 Mitochondrial trifunctional protein deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26793",
        "text": "ORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623538?name=156&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_76": {
    "name": "DOJOLVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623538?name=157&mode=orpha&region=",
    "regulatory_id": "623538",
    "orpha_substance_code": "ORPHA:26793",
    "details": [
      "DOJOLVI(Tradename                        - 30/06/2020)Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "DOJOLVI(Tradename                        - 30/06/2020)",
      "(Tradename                        - 30/06/2020)",
      "Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/615857?name=157&mode=orpha&region=&status=all",
        "text": "DOJOLVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157",
        "text": "ORPHA:157 Carnitine palmitoyltransferase II deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/746",
        "text": "ORPHA:746 Mitochondrial trifunctional protein deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26793",
        "text": "ORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623538?name=157&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "42568": {
    "name": "Deferiprone",
    "substance_url": "/en/drug/substance/42568?name=157846&mode=orpha&region=&status=all",
    "substance_id": "42568",
    "regulatory_url": "/en/drug/regulatory/520903?name=157846&mode=orpha&region=",
    "regulatory_id": "520903",
    "orpha_substance_code": "ORPHA:385",
    "details": [
      "Deferiprone(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:385 Neurodegeneration with brain iron accumulation",
      "Deferiprone(Medicinal product                        - 27/06/2018)",
      "(Medicinal product                        - 27/06/2018)",
      "Disease(s) concernedORPHA:385 Neurodegeneration with brain iron accumulation",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/42568?name=157846&mode=orpha&region=&status=all",
        "text": "Deferiprone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/385",
        "text": "ORPHA:385 Neurodegeneration with brain iron accumulation",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/520903?name=157846&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "459199": {
    "name": "S-acetyl-(S)-4'-phosphopantetheine, calcium salt",
    "substance_url": "/en/drug/substance/459199?name=157850&mode=orpha&region=&status=all",
    "substance_id": "459199",
    "regulatory_url": "/en/drug/regulatory/459203?name=157850&mode=orpha&region=",
    "regulatory_id": "459203",
    "orpha_substance_code": "ORPHA:157850",
    "details": [
      "S-acetyl-(S)-4'-phosphopantetheine, calcium salt(Medicinal product                        - 28/04/2016)Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "S-acetyl-(S)-4'-phosphopantetheine, calcium salt(Medicinal product                        - 28/04/2016)",
      "(Medicinal product                        - 28/04/2016)",
      "Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/459199?name=157850&mode=orpha&region=&status=all",
        "text": "S-acetyl-(S)-4'-phosphopantetheine, calcium salt",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157850",
        "text": "ORPHA:157850 Pantothenate kinase-associated neurodegeneration",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/459203?name=157850&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "627847": {
    "name": "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one",
    "substance_url": "/en/drug/substance/627847?name=157850&mode=orpha&region=&status=all",
    "substance_id": "627847",
    "regulatory_url": "/en/drug/regulatory/627850?name=157850&mode=orpha&region=",
    "regulatory_id": "627850",
    "orpha_substance_code": "ORPHA:157850",
    "details": [
      "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one(Medicinal product                        - 19/07/2021)Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one(Medicinal product                        - 19/07/2021)",
      "(Medicinal product                        - 19/07/2021)",
      "Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627847?name=157850&mode=orpha&region=&status=all",
        "text": "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157850",
        "text": "ORPHA:157850 Pantothenate kinase-associated neurodegeneration",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627850?name=157850&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "456120": {
    "name": "Fosmetpantotenate",
    "substance_url": "/en/drug/substance/456120?name=157850&mode=orpha&region=&status=all",
    "substance_id": "456120",
    "regulatory_url": "/en/drug/regulatory/456121?name=157850&mode=orpha&region=",
    "regulatory_id": "456121",
    "orpha_substance_code": "ORPHA:157850",
    "details": [
      "Fosmetpantotenate(Medicinal product                        - 17/02/2016)Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "Fosmetpantotenate(Medicinal product                        - 17/02/2016)",
      "(Medicinal product                        - 17/02/2016)",
      "Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/456120?name=157850&mode=orpha&region=&status=all",
        "text": "Fosmetpantotenate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157850",
        "text": "ORPHA:157850 Pantothenate kinase-associated neurodegeneration",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/456121?name=157850&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "651182": {
    "name": "Small molecule activator of pantothenate kinases",
    "substance_url": "/en/drug/substance/651182?name=157850&mode=orpha&region=&status=all",
    "substance_id": "651182",
    "regulatory_url": "/en/drug/regulatory/651184?name=157850&mode=orpha&region=",
    "regulatory_id": "651184",
    "orpha_substance_code": "ORPHA:157850",
    "details": [
      "Small molecule activator of pantothenate kinases(Medicinal product                        - 07/10/2020)Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "Small molecule activator of pantothenate kinases(Medicinal product                        - 07/10/2020)",
      "(Medicinal product                        - 07/10/2020)",
      "Disease(s) concernedORPHA:157850 Pantothenate kinase-associated neurodegeneration",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/651182?name=157850&mode=orpha&region=&status=all",
        "text": "Small molecule activator of pantothenate kinases",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157850",
        "text": "ORPHA:157850 Pantothenate kinase-associated neurodegeneration",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/651184?name=157850&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_82": {
    "name": "CARNITOR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131068?name=158&mode=orpha&region=",
    "regulatory_id": "131068",
    "orpha_substance_code": "ORPHA:158",
    "details": [
      "CARNITOR(Tradename                        - 16/12/1992)Disease(s) concernedORPHA:158 Systemic primary carnitine deficiency",
      "CARNITOR(Tradename                        - 16/12/1992)",
      "(Tradename                        - 16/12/1992)",
      "Disease(s) concernedORPHA:158 Systemic primary carnitine deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25012?name=158&mode=orpha&region=&status=all",
        "text": "CARNITOR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158",
        "text": "ORPHA:158 Systemic primary carnitine deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131068?name=158&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "25013": {
    "name": "L carnitine",
    "substance_url": "/en/drug/substance/25013?name=158&mode=orpha&region=&status=all",
    "substance_id": "25013",
    "regulatory_url": "/en/drug/regulatory/136888?name=158&mode=orpha&region=",
    "regulatory_id": "136888",
    "orpha_substance_code": "ORPHA:158",
    "details": [
      "L carnitine(Medicinal product                        - 28/02/1984)Disease(s) concernedORPHA:158 Systemic primary carnitine deficiency",
      "L carnitine(Medicinal product                        - 28/02/1984)",
      "(Medicinal product                        - 28/02/1984)",
      "Disease(s) concernedORPHA:158 Systemic primary carnitine deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/25013?name=158&mode=orpha&region=&status=all",
        "text": "L carnitine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158",
        "text": "ORPHA:158 Systemic primary carnitine deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/136888?name=158&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_84": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=163684&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=163684&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=163684&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_85": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=163684&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=163684&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=163684&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "444708": {
    "name": "3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid",
    "substance_url": "/en/drug/substance/444708?name=163690&mode=orpha&region=&status=all",
    "substance_id": "444708",
    "regulatory_url": "/en/drug/regulatory/444712?name=163690&mode=orpha&region=",
    "regulatory_id": "444712",
    "orpha_substance_code": "ORPHA:306648",
    "details": [
      "3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid(Medicinal product                        - 19/06/2015)Disease(s) concernedORPHA:892 Von Hippel-Lindau diseaseORPHA:730 Autosomal dominant polycystic kidney diseaseORPHA:34149 Autosomal dominant tubulointerstitial kidney diseaseORPHA:88924 Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosisORPHA:90061 Non-infectious posterior uveitisORPHA:93545 Renal or urinary tract malformationORPHA:93548 Glomerular diseaseORPHA:93587 Genetic cystic renal diseaseORPHA:93603 Rare renal tubular diseaseORPHA:306648 Non-infectious anterior uveitis",
      "3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid(Medicinal product                        - 19/06/2015)",
      "(Medicinal product                        - 19/06/2015)",
      "Disease(s) concernedORPHA:892 Von Hippel-Lindau diseaseORPHA:730 Autosomal dominant polycystic kidney diseaseORPHA:34149 Autosomal dominant tubulointerstitial kidney diseaseORPHA:88924 Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosisORPHA:90061 Non-infectious posterior uveitisORPHA:93545 Renal or urinary tract malformationORPHA:93548 Glomerular diseaseORPHA:93587 Genetic cystic renal diseaseORPHA:93603 Rare renal tubular diseaseORPHA:306648 Non-infectious anterior uveitis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/444708?name=163690&mode=orpha&region=&status=all",
        "text": "3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/892",
        "text": "ORPHA:892 Von Hippel-Lindau disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/730",
        "text": "ORPHA:730 Autosomal dominant polycystic kidney disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/34149",
        "text": "ORPHA:34149 Autosomal dominant tubulointerstitial kidney disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/88924",
        "text": "ORPHA:88924 Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90061",
        "text": "ORPHA:90061 Non-infectious posterior uveitis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93545",
        "text": "ORPHA:93545 Renal or urinary tract malformation",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93548",
        "text": "ORPHA:93548 Glomerular disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93587",
        "text": "ORPHA:93587 Genetic cystic renal disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93603",
        "text": "ORPHA:93603 Rare renal tubular disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/306648",
        "text": "ORPHA:306648 Non-infectious anterior uveitis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/444712?name=163690&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:730 Autosomal dominant polycystic kidney disease\n                                \n\n\n\n\n                                    ORPHA:34149 Autosomal dominant tubulointerstitial kidney disease\n                                \n\n\n\n\n                                    ORPHA:88924 Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis\n                                \n\n\n\n\n                                    ORPHA:90061 Non-infectious posterior uveitis\n                                \n\n\n\n\n                                    ORPHA:93545 Renal or urinary tract malformation\n                                \n\n\n\n\n                                    ORPHA:93548 Glomerular disease\n                                \n\n\n\n\n                                    ORPHA:93587 Genetic cystic renal disease\n                                \n\n\n\n\n                                    ORPHA:93603 Rare renal tubular disease\n                                \n\n\n\n\n                                    ORPHA:306648 Non-infectious anterior uveitis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "605146": {
    "name": "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",
    "substance_url": "/en/drug/substance/605146?name=165991&mode=orpha&region=&status=all",
    "substance_id": "605146",
    "regulatory_url": "/en/drug/regulatory/605147?name=165991&mode=orpha&region=",
    "regulatory_id": "605147",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide(Medicinal product                        - 09/12/2020)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide(Medicinal product                        - 09/12/2020)",
      "(Medicinal product                        - 09/12/2020)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/605146?name=165991&mode=orpha&region=&status=all",
        "text": "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/605147?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "371566": {
    "name": "Exendin-(9-39)",
    "substance_url": "/en/drug/substance/371566?name=165991&mode=orpha&region=&status=all",
    "substance_id": "371566",
    "regulatory_url": "/en/drug/regulatory/572565?name=165991&mode=orpha&region=",
    "regulatory_id": "572565",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Exendin-(9-39)(Medicinal product                        - 13/11/2019)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Exendin-(9-39)(Medicinal product                        - 13/11/2019)",
      "(Medicinal product                        - 13/11/2019)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/371566?name=165991&mode=orpha&region=&status=all",
        "text": "Exendin-(9-39)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/572565?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "527458": {
    "name": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
    "substance_url": "/en/drug/substance/527458?name=165991&mode=orpha&region=&status=all",
    "substance_id": "527458",
    "regulatory_url": "/en/drug/regulatory/527462?name=165991&mode=orpha&region=",
    "regulatory_id": "527462",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Glucagon analogue linked to a human immunoglobulin Fc fragment(Medicinal product                        - 25/05/2018)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Glucagon analogue linked to a human immunoglobulin Fc fragment(Medicinal product                        - 25/05/2018)",
      "(Medicinal product                        - 25/05/2018)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/527458?name=165991&mode=orpha&region=&status=all",
        "text": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527462?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "489767": {
    "name": "Dasiglucagon",
    "substance_url": "/en/drug/substance/489767?name=165991&mode=orpha&region=&status=all",
    "substance_id": "489767",
    "regulatory_url": "/en/drug/regulatory/489772?name=165991&mode=orpha&region=",
    "regulatory_id": "489772",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Dasiglucagon(Medicinal product                        - 20/06/2017)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Dasiglucagon(Medicinal product                        - 20/06/2017)",
      "(Medicinal product                        - 20/06/2017)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489767?name=165991&mode=orpha&region=&status=all",
        "text": "Dasiglucagon",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489772?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "480436": {
    "name": "Ersodetug",
    "substance_url": "/en/drug/substance/480436?name=165991&mode=orpha&region=&status=all",
    "substance_id": "480436",
    "regulatory_url": "/en/drug/regulatory/480438?name=165991&mode=orpha&region=",
    "regulatory_id": "480438",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Ersodetug(Medicinal product                        - 14/07/2016)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Ersodetug(Medicinal product                        - 14/07/2016)",
      "(Medicinal product                        - 14/07/2016)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480436?name=165991&mode=orpha&region=&status=all",
        "text": "Ersodetug",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480438?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "299535": {
    "name": "Glucagon",
    "substance_url": "/en/drug/substance/299535?name=165991&mode=orpha&region=&status=all",
    "substance_id": "299535",
    "regulatory_url": "/en/drug/regulatory/300868?name=165991&mode=orpha&region=",
    "regulatory_id": "300868",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Glucagon(Medicinal product                        - 05/03/2012)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Glucagon(Medicinal product                        - 05/03/2012)",
      "(Medicinal product                        - 05/03/2012)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/299535?name=165991&mode=orpha&region=&status=all",
        "text": "Glucagon",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/300868?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "684497": {
    "name": "Solution stable glucagon analog",
    "substance_url": "/en/drug/substance/684497?name=165991&mode=orpha&region=&status=all",
    "substance_id": "684497",
    "regulatory_url": "/en/drug/regulatory/684707?name=165991&mode=orpha&region=",
    "regulatory_id": "684707",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Solution stable glucagon analog(Medicinal product                        - 17/06/2024)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Solution stable glucagon analog(Medicinal product                        - 17/06/2024)",
      "(Medicinal product                        - 17/06/2024)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/684497?name=165991&mode=orpha&region=&status=all",
        "text": "Solution stable glucagon analog",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684707?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "413075": {
    "name": "Glucagon infusion",
    "substance_url": "/en/drug/substance/413075?name=165991&mode=orpha&region=&status=all",
    "substance_id": "413075",
    "regulatory_url": "/en/drug/regulatory/413076?name=165991&mode=orpha&region=",
    "regulatory_id": "413076",
    "orpha_substance_code": "ORPHA:657",
    "details": [
      "Glucagon infusion(Medicinal product                        - 25/09/2014)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "Glucagon infusion(Medicinal product                        - 25/09/2014)",
      "(Medicinal product                        - 25/09/2014)",
      "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/413075?name=165991&mode=orpha&region=&status=all",
        "text": "Glucagon infusion",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/657",
        "text": "ORPHA:657 Congenital isolated hyperinsulinism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/413076?name=165991&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "605032": {
    "name": "Adeno-associated virus serotype 5 containing the human RDH12 gene",
    "substance_url": "/en/drug/substance/605032?name=171848&mode=orpha&region=&status=all",
    "substance_id": "605032",
    "regulatory_url": "/en/drug/regulatory/605033?name=171848&mode=orpha&region=",
    "regulatory_id": "605033",
    "orpha_substance_code": "ORPHA:71862",
    "details": [
      "Adeno-associated virus serotype 5 containing the human RDH12 gene(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "Adeno-associated virus serotype 5 containing the human RDH12 gene(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/605032?name=171848&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 5 containing the human RDH12 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71862",
        "text": "ORPHA:71862 Inherited retinal disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/605033?name=171848&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "588772": {
    "name": "Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'- coding sequences of human CEP290 fused to inteins",
    "substance_url": "/en/drug/substance/588772?name=171848&mode=orpha&region=&status=all",
    "substance_id": "588772",
    "regulatory_url": "/en/drug/regulatory/588773?name=171848&mode=orpha&region=",
    "regulatory_id": "588773",
    "orpha_substance_code": "ORPHA:71862",
    "details": [
      "Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'- coding sequences of human CEP290 fused to inteins(Medicinal product                        - 28/02/2020)Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'- coding sequences of human CEP290 fused to inteins(Medicinal product                        - 28/02/2020)",
      "(Medicinal product                        - 28/02/2020)",
      "Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588772?name=171848&mode=orpha&region=&status=all",
        "text": "Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'- coding sequences of human CEP290 fused to inteins",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71862",
        "text": "ORPHA:71862 Inherited retinal disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588773?name=171848&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "588591": {
    "name": "Adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence",
    "substance_url": "/en/drug/substance/588591?name=171848&mode=orpha&region=&status=all",
    "substance_id": "588591",
    "regulatory_url": "/en/drug/regulatory/588593?name=171848&mode=orpha&region=",
    "regulatory_id": "588593",
    "orpha_substance_code": "ORPHA:71862",
    "details": [
      "Adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence(Medicinal product                        - 28/02/2020)Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "Adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence(Medicinal product                        - 28/02/2020)",
      "(Medicinal product                        - 28/02/2020)",
      "Disease(s) concernedORPHA:71862 Inherited retinal disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588591?name=171848&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71862",
        "text": "ORPHA:71862 Inherited retinal disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588593?name=171848&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_98": {
    "name": "Livmarli",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/684334?name=172&mode=orpha&region=",
    "regulatory_id": "684334",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Livmarli(Tradename                        - 28/06/2024)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Livmarli(Tradename                        - 28/06/2024)",
      "(Tradename                        - 28/06/2024)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616473?name=172&mode=orpha&region=&status=all",
        "text": "Livmarli",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684334?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_99": {
    "name": "Bylvay",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610543?name=172&mode=orpha&region=",
    "regulatory_id": "610543",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Bylvay(Tradename                        - 16/07/2021)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Bylvay(Tradename                        - 16/07/2021)",
      "(Tradename                        - 16/07/2021)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/605017?name=172&mode=orpha&region=&status=all",
        "text": "Bylvay",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610543?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "589045": {
    "name": "Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A",
    "substance_url": "/en/drug/substance/589045?name=172&mode=orpha&region=&status=all",
    "substance_id": "589045",
    "regulatory_url": "/en/drug/regulatory/589046?name=172&mode=orpha&region=",
    "regulatory_id": "589046",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A(Medicinal product                        - 22/04/2020)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A(Medicinal product                        - 22/04/2020)",
      "(Medicinal product                        - 22/04/2020)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/589045?name=172&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589046?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "367965": {
    "name": "Maralixibat chloride",
    "substance_url": "/en/drug/substance/367965?name=172&mode=orpha&region=&status=all",
    "substance_id": "367965",
    "regulatory_url": "/en/drug/regulatory/377092?name=172&mode=orpha&region=",
    "regulatory_id": "377092",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Maralixibat chloride(Medicinal product                        - 18/12/2013)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Maralixibat chloride(Medicinal product                        - 18/12/2013)",
      "(Medicinal product                        - 18/12/2013)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/367965?name=172&mode=orpha&region=&status=all",
        "text": "Maralixibat chloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/377092?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "300656": {
    "name": "(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",
    "substance_url": "/en/drug/substance/300656?name=172&mode=orpha&region=&status=all",
    "substance_id": "300656",
    "regulatory_url": "/en/drug/regulatory/326933?name=172&mode=orpha&region=",
    "regulatory_id": "326933",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid(Medicinal product                        - 17/07/2012)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid(Medicinal product                        - 17/07/2012)",
      "(Medicinal product                        - 17/07/2012)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/300656?name=172&mode=orpha&region=&status=all",
        "text": "(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/326933?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_103": {
    "name": "Livmarli",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/686779?name=172&mode=orpha&region=",
    "regulatory_id": "686779",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Livmarli(Tradename                        - 24/07/2024)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Livmarli(Tradename                        - 24/07/2024)",
      "(Tradename                        - 24/07/2024)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616473?name=172&mode=orpha&region=&status=all",
        "text": "Livmarli",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686779?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_104": {
    "name": "Livmarli",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/665132?name=172&mode=orpha&region=",
    "regulatory_id": "665132",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Livmarli(Tradename                        - 13/03/2024)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Livmarli(Tradename                        - 13/03/2024)",
      "(Tradename                        - 13/03/2024)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616473?name=172&mode=orpha&region=&status=all",
        "text": "Livmarli",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665132?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_105": {
    "name": "Bylvay",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622270?name=172&mode=orpha&region=",
    "regulatory_id": "622270",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Bylvay(Tradename                        - 20/07/2021)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Bylvay(Tradename                        - 20/07/2021)",
      "(Tradename                        - 20/07/2021)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/605017?name=172&mode=orpha&region=&status=all",
        "text": "Bylvay",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622270?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "691421": {
    "name": "Modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA encoding multidrug resistance protein 3 (MDR3)",
    "substance_url": "/en/drug/substance/691421?name=172&mode=orpha&region=&status=all",
    "substance_id": "691421",
    "regulatory_url": "/en/drug/regulatory/691575?name=172&mode=orpha&region=",
    "regulatory_id": "691575",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA encoding multidrug resistance protein 3 (MDR3)(Medicinal product                        - 18/11/2024)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA encoding multidrug resistance protein 3 (MDR3)(Medicinal product                        - 18/11/2024)",
      "(Medicinal product                        - 18/11/2024)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/691421?name=172&mode=orpha&region=&status=all",
        "text": "Modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA encoding multidrug resistance protein 3 (MDR3)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/691575?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "687204": {
    "name": "Modified human ATP binding cassette subfamily B member 11 (ABCB11) messenger RNA encoding bile salts export pump",
    "substance_url": "/en/drug/substance/687204?name=172&mode=orpha&region=&status=all",
    "substance_id": "687204",
    "regulatory_url": "/en/drug/regulatory/687534?name=172&mode=orpha&region=",
    "regulatory_id": "687534",
    "orpha_substance_code": "ORPHA:172",
    "details": [
      "Modified human ATP binding cassette subfamily B member 11 (ABCB11) messenger RNA encoding bile salts export pump(Medicinal product                        - 29/07/2024)Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "Modified human ATP binding cassette subfamily B member 11 (ABCB11) messenger RNA encoding bile salts export pump(Medicinal product                        - 29/07/2024)",
      "(Medicinal product                        - 29/07/2024)",
      "Disease(s) concernedORPHA:172 Progressive familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687204?name=172&mode=orpha&region=&status=all",
        "text": "Modified human ATP binding cassette subfamily B member 11 (ABCB11) messenger RNA encoding bile salts export pump",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/172",
        "text": "ORPHA:172 Progressive familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687534?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_108": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=172&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=172&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=172&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_109": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=1947&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=1947&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "633481": {
    "name": "Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene",
    "substance_url": "/en/drug/substance/633481?name=1947&mode=orpha&region=&status=all",
    "substance_id": "633481",
    "regulatory_url": "/en/drug/regulatory/633482?name=1947&mode=orpha&region=",
    "regulatory_id": "633482",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene(Medicinal product                        - 11/10/2022)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene(Medicinal product                        - 11/10/2022)",
      "(Medicinal product                        - 11/10/2022)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/633481?name=1947&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/633482?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "489719": {
    "name": "Tamoxifen citrate",
    "substance_url": "/en/drug/substance/489719?name=1947&mode=orpha&region=&status=all",
    "substance_id": "489719",
    "regulatory_url": "/en/drug/regulatory/628437?name=1947&mode=orpha&region=",
    "regulatory_id": "628437",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Tamoxifen citrate(Medicinal product                        - 21/06/2022)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Tamoxifen citrate(Medicinal product                        - 21/06/2022)",
      "(Medicinal product                        - 21/06/2022)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489719?name=1947&mode=orpha&region=&status=all",
        "text": "Tamoxifen citrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628437?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "627814": {
    "name": "Autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene",
    "substance_url": "/en/drug/substance/627814?name=1947&mode=orpha&region=&status=all",
    "substance_id": "627814",
    "regulatory_url": "/en/drug/regulatory/627817?name=1947&mode=orpha&region=",
    "regulatory_id": "627817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene(Medicinal product                        - 19/07/2021)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene(Medicinal product                        - 19/07/2021)",
      "(Medicinal product                        - 19/07/2021)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627814?name=1947&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627817?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "627530": {
    "name": "Adeno-associated virus serotype 9 expressing human CLN5",
    "substance_url": "/en/drug/substance/627530?name=1947&mode=orpha&region=&status=all",
    "substance_id": "627530",
    "regulatory_url": "/en/drug/regulatory/627533?name=1947&mode=orpha&region=",
    "regulatory_id": "627533",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Adeno-associated virus serotype 9 expressing human CLN5(Medicinal product                        - 21/06/2021)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Adeno-associated virus serotype 9 expressing human CLN5(Medicinal product                        - 21/06/2021)",
      "(Medicinal product                        - 21/06/2021)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627530?name=1947&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 9 expressing human CLN5",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627533?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "65934": {
    "name": "Miglustat",
    "substance_url": "/en/drug/substance/65934?name=1947&mode=orpha&region=&status=all",
    "substance_id": "65934",
    "regulatory_url": "/en/drug/regulatory/604904?name=1947&mode=orpha&region=",
    "regulatory_id": "604904",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Miglustat(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Miglustat(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/65934?name=1947&mode=orpha&region=&status=all",
        "text": "Miglustat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604904?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "570598": {
    "name": "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene",
    "substance_url": "/en/drug/substance/570598?name=1947&mode=orpha&region=&status=all",
    "substance_id": "570598",
    "regulatory_url": "/en/drug/regulatory/570600?name=1947&mode=orpha&region=",
    "regulatory_id": "570600",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene(Medicinal product                        - 21/08/2019)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene(Medicinal product                        - 21/08/2019)",
      "(Medicinal product                        - 21/08/2019)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/570598?name=1947&mode=orpha&region=&status=all",
        "text": "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/570600?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "570594": {
    "name": "recombinant self-complementary adeno-associated viral vector serotype 9 (AAV9) containing the human CLN3 gene",
    "substance_url": "/en/drug/substance/570594?name=1947&mode=orpha&region=&status=all",
    "substance_id": "570594",
    "regulatory_url": "/en/drug/regulatory/570596?name=1947&mode=orpha&region=",
    "regulatory_id": "570596",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "recombinant self-complementary adeno-associated viral vector serotype 9 (AAV9) containing the human CLN3 gene(Medicinal product                        - 21/08/2019)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "recombinant self-complementary adeno-associated viral vector serotype 9 (AAV9) containing the human CLN3 gene(Medicinal product                        - 21/08/2019)",
      "(Medicinal product                        - 21/08/2019)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/570594?name=1947&mode=orpha&region=&status=all",
        "text": "recombinant self-complementary adeno-associated viral vector serotype 9 (AAV9) containing the human CLN3 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/570596?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "527480": {
    "name": "Adeno-associated viral vector serotype 9 containing the human CLN1 gene",
    "substance_url": "/en/drug/substance/527480?name=1947&mode=orpha&region=&status=all",
    "substance_id": "527480",
    "regulatory_url": "/en/drug/regulatory/527484?name=1947&mode=orpha&region=",
    "regulatory_id": "527484",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human CLN1 gene(Medicinal product                        - 25/05/2018)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Adeno-associated viral vector serotype 9 containing the human CLN1 gene(Medicinal product                        - 25/05/2018)",
      "(Medicinal product                        - 25/05/2018)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/527480?name=1947&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human CLN1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527484?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "511210": {
    "name": "Gemfibrozil",
    "substance_url": "/en/drug/substance/511210?name=1947&mode=orpha&region=&status=all",
    "substance_id": "511210",
    "regulatory_url": "/en/drug/regulatory/511211?name=1947&mode=orpha&region=",
    "regulatory_id": "511211",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Gemfibrozil(Medicinal product                        - 21/03/2018)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Gemfibrozil(Medicinal product                        - 21/03/2018)",
      "(Medicinal product                        - 21/03/2018)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/511210?name=1947&mode=orpha&region=&status=all",
        "text": "Gemfibrozil",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/511211?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "323236": {
    "name": "Recombinant human tripeptidyl-peptidase 1",
    "substance_url": "/en/drug/substance/323236?name=1947&mode=orpha&region=&status=all",
    "substance_id": "323236",
    "regulatory_url": "/en/drug/regulatory/331030?name=1947&mode=orpha&region=",
    "regulatory_id": "331030",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Recombinant human tripeptidyl-peptidase 1(Medicinal product                        - 12/03/2013)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Recombinant human tripeptidyl-peptidase 1(Medicinal product                        - 12/03/2013)",
      "(Medicinal product                        - 12/03/2013)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/323236?name=1947&mode=orpha&region=&status=all",
        "text": "Recombinant human tripeptidyl-peptidase 1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/331030?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "418127": {
    "name": "Trehalose",
    "substance_url": "/en/drug/substance/418127?name=1947&mode=orpha&region=&status=all",
    "substance_id": "418127",
    "regulatory_url": "/en/drug/regulatory/604892?name=1947&mode=orpha&region=",
    "regulatory_id": "604892",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Trehalose(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Trehalose(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/418127?name=1947&mode=orpha&region=&status=all",
        "text": "Trehalose",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604892?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "485379": {
    "name": "Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene",
    "substance_url": "/en/drug/substance/485379?name=1947&mode=orpha&region=&status=all",
    "substance_id": "485379",
    "regulatory_url": "/en/drug/regulatory/485380?name=1947&mode=orpha&region=",
    "regulatory_id": "485380",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene(Medicinal product                        - 12/12/2016)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene(Medicinal product                        - 12/12/2016)",
      "(Medicinal product                        - 12/12/2016)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/485379?name=1947&mode=orpha&region=&status=all",
        "text": "Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485380?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "94738": {
    "name": "Brivaracetam",
    "substance_url": "/en/drug/substance/94738?name=1947&mode=orpha&region=&status=all",
    "substance_id": "94738",
    "regulatory_url": "/en/drug/regulatory/133994?name=1947&mode=orpha&region=",
    "regulatory_id": "133994",
    "orpha_substance_code": "ORPHA:98261",
    "details": [
      "Brivaracetam(Medicinal product                        - 26/08/2005)Disease(s) concernedORPHA:98261 Progressive myoclonic epilepsy",
      "Brivaracetam(Medicinal product                        - 26/08/2005)",
      "(Medicinal product                        - 26/08/2005)",
      "Disease(s) concernedORPHA:98261 Progressive myoclonic epilepsy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/94738?name=1947&mode=orpha&region=&status=all",
        "text": "Brivaracetam",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98261",
        "text": "ORPHA:98261 Progressive myoclonic epilepsy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133994?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_123": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=1947&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=1947&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_124": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=1947&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=1947&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=1947&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "661197": {
    "name": "Adeno-associated viral vector serotype 9 containing the human PLA2G6 gene",
    "substance_url": "/en/drug/substance/661197?name=199351&mode=orpha&region=&status=all",
    "substance_id": "661197",
    "regulatory_url": "/en/drug/regulatory/691490?name=199351&mode=orpha&region=",
    "regulatory_id": "691490",
    "orpha_substance_code": "ORPHA:329303",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human PLA2G6 gene(Medicinal product                        - 29/11/2024)Disease(s) concernedORPHA:329303 PLA2G6-associated neurodegeneration",
      "Adeno-associated viral vector serotype 9 containing the human PLA2G6 gene(Medicinal product                        - 29/11/2024)",
      "(Medicinal product                        - 29/11/2024)",
      "Disease(s) concernedORPHA:329303 PLA2G6-associated neurodegeneration",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661197?name=199351&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human PLA2G6 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/329303",
        "text": "ORPHA:329303 PLA2G6-associated neurodegeneration",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/691490?name=199351&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "480199": {
    "name": "Modified mRNA encoding the UGT1A1 protein",
    "substance_url": "/en/drug/substance/480199?name=205&mode=orpha&region=&status=all",
    "substance_id": "480199",
    "regulatory_url": "/en/drug/regulatory/480201?name=205&mode=orpha&region=",
    "regulatory_id": "480201",
    "orpha_substance_code": "ORPHA:205",
    "details": [
      "Modified mRNA encoding the UGT1A1 protein(Medicinal product                        - 27/06/2016)Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "Modified mRNA encoding the UGT1A1 protein(Medicinal product                        - 27/06/2016)",
      "(Medicinal product                        - 27/06/2016)",
      "Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480199?name=205&mode=orpha&region=&status=all",
        "text": "Modified mRNA encoding the UGT1A1 protein",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/205",
        "text": "ORPHA:205 Crigler-Najjar syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480201?name=205&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "406528": {
    "name": "Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene",
    "substance_url": "/en/drug/substance/406528?name=205&mode=orpha&region=&status=all",
    "substance_id": "406528",
    "regulatory_url": "/en/drug/regulatory/414159?name=205&mode=orpha&region=",
    "regulatory_id": "414159",
    "orpha_substance_code": "ORPHA:205",
    "details": [
      "Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene(Medicinal product                        - 15/10/2014)Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene(Medicinal product                        - 15/10/2014)",
      "(Medicinal product                        - 15/10/2014)",
      "Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406528?name=205&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/205",
        "text": "ORPHA:205 Crigler-Najjar syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/414159?name=205&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "516992": {
    "name": "Adeno -associated viral vector serotype 8  containing the human functional version of UGT1A1 gene",
    "substance_url": "/en/drug/substance/516992?name=205&mode=orpha&region=&status=all",
    "substance_id": "516992",
    "regulatory_url": "/en/drug/regulatory/485026?name=205&mode=orpha&region=",
    "regulatory_id": "485026",
    "orpha_substance_code": "ORPHA:205",
    "details": [
      "Adeno -associated viral vector serotype 8  containing the human functional version of UGT1A1 gene(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "Adeno -associated viral vector serotype 8  containing the human functional version of UGT1A1 gene(Medicinal product                        - 18/11/2016)",
      "(Medicinal product                        - 18/11/2016)",
      "Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/516992?name=205&mode=orpha&region=&status=all",
        "text": "Adeno -associated viral vector serotype 8  containing the human functional version of UGT1A1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/205",
        "text": "ORPHA:205 Crigler-Najjar syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485026?name=205&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689451": {
    "name": "rAAV8-hUGT1A1",
    "substance_url": "/en/drug/substance/689451?name=205&mode=orpha&region=&status=all",
    "substance_id": "689451",
    "regulatory_url": "/en/drug/regulatory/689621?name=205&mode=orpha&region=",
    "regulatory_id": "689621",
    "orpha_substance_code": "ORPHA:205",
    "details": [
      "rAAV8-hUGT1A1(Medicinal product                        - 29/10/2024)Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "rAAV8-hUGT1A1(Medicinal product                        - 29/10/2024)",
      "(Medicinal product                        - 29/10/2024)",
      "Disease(s) concernedORPHA:205 Crigler-Najjar syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689451?name=205&mode=orpha&region=&status=all",
        "text": "rAAV8-hUGT1A1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/205",
        "text": "ORPHA:205 Crigler-Najjar syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689621?name=205&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "661199": {
    "name": "Adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA",
    "substance_url": "/en/drug/substance/661199?name=206554&mode=orpha&region=&status=all",
    "substance_id": "661199",
    "regulatory_url": "/en/drug/regulatory/661293?name=206554&mode=orpha&region=",
    "regulatory_id": "661293",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA(Medicinal product                        - 13/10/2023)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA(Medicinal product                        - 13/10/2023)",
      "(Medicinal product                        - 13/10/2023)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661199?name=206554&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661293?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "642490": {
    "name": "Patidistrogene bexoparvovec",
    "substance_url": "/en/drug/substance/642490?name=206554&mode=orpha&region=&status=all",
    "substance_id": "642490",
    "regulatory_url": "/en/drug/regulatory/642492?name=206554&mode=orpha&region=",
    "regulatory_id": "642492",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Patidistrogene bexoparvovec(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Patidistrogene bexoparvovec(Medicinal product                        - 15/02/2023)",
      "(Medicinal product                        - 15/02/2023)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/642490?name=206554&mode=orpha&region=&status=all",
        "text": "Patidistrogene bexoparvovec",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642492?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "642474": {
    "name": "Adeno-associated viral vector serotype 9 expressing fukutin-related protein",
    "substance_url": "/en/drug/substance/642474?name=206554&mode=orpha&region=&status=all",
    "substance_id": "642474",
    "regulatory_url": "/en/drug/regulatory/642475?name=206554&mode=orpha&region=",
    "regulatory_id": "642475",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Adeno-associated viral vector serotype 9 expressing fukutin-related protein(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Adeno-associated viral vector serotype 9 expressing fukutin-related protein(Medicinal product                        - 15/02/2023)",
      "(Medicinal product                        - 15/02/2023)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/642474?name=206554&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 expressing fukutin-related protein",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642475?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "626934": {
    "name": "Adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene",
    "substance_url": "/en/drug/substance/626934?name=206554&mode=orpha&region=&status=all",
    "substance_id": "626934",
    "regulatory_url": "/en/drug/regulatory/626946?name=206554&mode=orpha&region=",
    "regulatory_id": "626946",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene(Medicinal product                        - 16/05/2022)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene(Medicinal product                        - 16/05/2022)",
      "(Medicinal product                        - 16/05/2022)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/626934?name=206554&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/626946?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628271": {
    "name": "Adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a",
    "substance_url": "/en/drug/substance/628271?name=206554&mode=orpha&region=&status=all",
    "substance_id": "628271",
    "regulatory_url": "/en/drug/regulatory/628272?name=206554&mode=orpha&region=",
    "regulatory_id": "628272",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a(Medicinal product                        - 14/01/2022)",
      "(Medicinal product                        - 14/01/2022)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628271?name=206554&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628272?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "605071": {
    "name": "Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene",
    "substance_url": "/en/drug/substance/605071?name=206554&mode=orpha&region=&status=all",
    "substance_id": "605071",
    "regulatory_url": "/en/drug/regulatory/605072?name=206554&mode=orpha&region=",
    "regulatory_id": "605072",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene(Medicinal product                        - 09/12/2020)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene(Medicinal product                        - 09/12/2020)",
      "(Medicinal product                        - 09/12/2020)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/605071?name=206554&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/605072?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604874": {
    "name": "ribitol",
    "substance_url": "/en/drug/substance/604874?name=206554&mode=orpha&region=&status=all",
    "substance_id": "604874",
    "regulatory_url": "/en/drug/regulatory/604875?name=206554&mode=orpha&region=",
    "regulatory_id": "604875",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "ribitol(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "ribitol(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604874?name=206554&mode=orpha&region=&status=all",
        "text": "ribitol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604875?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "442799": {
    "name": "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",
    "substance_url": "/en/drug/substance/442799?name=206554&mode=orpha&region=&status=all",
    "substance_id": "442799",
    "regulatory_url": "/en/drug/regulatory/486674?name=206554&mode=orpha&region=",
    "regulatory_id": "486674",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase(Medicinal product                        - 27/02/2017)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase(Medicinal product                        - 27/02/2017)",
      "(Medicinal product                        - 27/02/2017)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/442799?name=206554&mode=orpha&region=&status=all",
        "text": "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/486674?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "371723": {
    "name": "Prednisone",
    "substance_url": "/en/drug/substance/371723?name=206554&mode=orpha&region=&status=all",
    "substance_id": "371723",
    "regulatory_url": "/en/drug/regulatory/665278?name=206554&mode=orpha&region=",
    "regulatory_id": "665278",
    "orpha_substance_code": "ORPHA:263",
    "details": [
      "Prednisone(Medicinal product                        - 05/03/2024)Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "Prednisone(Medicinal product                        - 05/03/2024)",
      "(Medicinal product                        - 05/03/2024)",
      "Disease(s) concernedORPHA:263 Limb-girdle muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/371723?name=206554&mode=orpha&region=&status=all",
        "text": "Prednisone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/263",
        "text": "ORPHA:263 Limb-girdle muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665278?name=206554&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_139": {
    "name": "KOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/399979?name=209902&mode=orpha&region=",
    "regulatory_id": "399979",
    "orpha_substance_code": "ORPHA:209902",
    "details": [
      "KOLBAM(Tradename                        - 04/04/2014)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "KOLBAM(Tradename                        - 04/04/2014)",
      "(Tradename                        - 04/04/2014)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/399978?name=209902&mode=orpha&region=&status=all",
        "text": "KOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79095",
        "text": "ORPHA:79095 Congenital bile acid synthesis defect type 4",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/209902",
        "text": "ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/399979?name=209902&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "133573": {
    "name": "Cholic acid",
    "substance_url": "/en/drug/substance/133573?name=209902&mode=orpha&region=&status=all",
    "substance_id": "133573",
    "regulatory_url": "/en/drug/regulatory/133807?name=209902&mode=orpha&region=",
    "regulatory_id": "133807",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "Cholic acid(Medicinal product                        - 18/12/2002)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "Cholic acid(Medicinal product                        - 18/12/2002)",
      "(Medicinal product                        - 18/12/2002)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/133573?name=209902&mode=orpha&region=&status=all",
        "text": "Cholic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133807?name=209902&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_141": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=209902&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=209902&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=209902&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_142": {
    "name": "Cystadrops",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/482274?name=213&mode=orpha&region=",
    "regulatory_id": "482274",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "Cystadrops(Tradename                        - 19/01/2017)Disease(s) concernedORPHA:213 Cystinosis",
      "Cystadrops(Tradename                        - 19/01/2017)",
      "(Tradename                        - 19/01/2017)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/482273?name=213&mode=orpha&region=&status=all",
        "text": "Cystadrops",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/482274?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_143": {
    "name": "CYSTAGON",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131237?name=213&mode=orpha&region=",
    "regulatory_id": "131237",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "CYSTAGON(Tradename                        - 23/06/1997)Disease(s) concernedORPHA:213 Cystinosis",
      "CYSTAGON(Tradename                        - 23/06/1997)",
      "(Tradename                        - 23/06/1997)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24961?name=213&mode=orpha&region=&status=all",
        "text": "CYSTAGON",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131237?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627153": {
    "name": "Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin",
    "substance_url": "/en/drug/substance/627153?name=213&mode=orpha&region=&status=all",
    "substance_id": "627153",
    "regulatory_url": "/en/drug/regulatory/627154?name=213&mode=orpha&region=",
    "regulatory_id": "627154",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin(Medicinal product                        - 19/02/2021)Disease(s) concernedORPHA:213 Cystinosis",
      "Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin(Medicinal product                        - 19/02/2021)",
      "(Medicinal product                        - 19/02/2021)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627153?name=213&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627154?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "165069": {
    "name": "Cysteamine hydrochloride",
    "substance_url": "/en/drug/substance/165069?name=213&mode=orpha&region=&status=all",
    "substance_id": "165069",
    "regulatory_url": "/en/drug/regulatory/415013?name=213&mode=orpha&region=",
    "regulatory_id": "415013",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "Cysteamine hydrochloride(Medicinal product                        - 15/10/2014)Disease(s) concernedORPHA:213 Cystinosis",
      "Cysteamine hydrochloride(Medicinal product                        - 15/10/2014)",
      "(Medicinal product                        - 15/10/2014)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/165069?name=213&mode=orpha&region=&status=all",
        "text": "Cysteamine hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/415013?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "24962": {
    "name": "Mercaptamine bitartrate",
    "substance_url": "/en/drug/substance/24962?name=213&mode=orpha&region=&status=all",
    "substance_id": "24962",
    "regulatory_url": "/en/drug/regulatory/246957?name=213&mode=orpha&region=",
    "regulatory_id": "246957",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "Mercaptamine bitartrate(Medicinal product                        - 20/09/2010)Disease(s) concernedORPHA:213 Cystinosis",
      "Mercaptamine bitartrate(Medicinal product                        - 20/09/2010)",
      "(Medicinal product                        - 20/09/2010)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24962?name=213&mode=orpha&region=&status=all",
        "text": "Mercaptamine bitartrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/246957?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_147": {
    "name": "CYSTAGON",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131053?name=213&mode=orpha&region=",
    "regulatory_id": "131053",
    "orpha_substance_code": "ORPHA:213",
    "details": [
      "CYSTAGON(Tradename                        - 15/08/1994)Disease(s) concernedORPHA:213 Cystinosis",
      "CYSTAGON(Tradename                        - 15/08/1994)",
      "(Tradename                        - 15/08/1994)",
      "Disease(s) concernedORPHA:213 Cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24961?name=213&mode=orpha&region=&status=all",
        "text": "CYSTAGON",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/213",
        "text": "ORPHA:213 Cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131053?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_148": {
    "name": "PROCYSBI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/364385?name=213&mode=orpha&region=",
    "regulatory_id": "364385",
    "orpha_substance_code": "ORPHA:411634",
    "details": [
      "PROCYSBI(Tradename                        - 06/09/2013)Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "PROCYSBI(Tradename                        - 06/09/2013)",
      "(Tradename                        - 06/09/2013)",
      "Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/364384?name=213&mode=orpha&region=&status=all",
        "text": "PROCYSBI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411629",
        "text": "ORPHA:411629 Infantile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411634",
        "text": "ORPHA:411634 Juvenile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/364385?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_149": {
    "name": "PROCYSBI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622241?name=213&mode=orpha&region=",
    "regulatory_id": "622241",
    "orpha_substance_code": "ORPHA:411634",
    "details": [
      "PROCYSBI(Tradename                        - 14/02/2020)Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "PROCYSBI(Tradename                        - 14/02/2020)",
      "(Tradename                        - 14/02/2020)",
      "Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/364384?name=213&mode=orpha&region=&status=all",
        "text": "PROCYSBI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411629",
        "text": "ORPHA:411629 Infantile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411634",
        "text": "ORPHA:411634 Juvenile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622241?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_150": {
    "name": "PROCYSBI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/405669?name=213&mode=orpha&region=",
    "regulatory_id": "405669",
    "orpha_substance_code": "ORPHA:411634",
    "details": [
      "PROCYSBI(Tradename                        - 30/04/2013)Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "PROCYSBI(Tradename                        - 30/04/2013)",
      "(Tradename                        - 30/04/2013)",
      "Disease(s) concernedORPHA:411629 Infantile nephropathic cystinosisORPHA:411634 Juvenile nephropathic cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/364384?name=213&mode=orpha&region=&status=all",
        "text": "PROCYSBI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411629",
        "text": "ORPHA:411629 Infantile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411634",
        "text": "ORPHA:411634 Juvenile nephropathic cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/405669?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_151": {
    "name": "CYSTARAN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/394197?name=213&mode=orpha&region=",
    "regulatory_id": "394197",
    "orpha_substance_code": "ORPHA:411641",
    "details": [
      "CYSTARAN(Tradename                        - 02/10/2012)Disease(s) concernedORPHA:411641 Ocular cystinosis",
      "CYSTARAN(Tradename                        - 02/10/2012)",
      "(Tradename                        - 02/10/2012)",
      "Disease(s) concernedORPHA:411641 Ocular cystinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/394195?name=213&mode=orpha&region=&status=all",
        "text": "CYSTARAN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/411641",
        "text": "ORPHA:411641 Ocular cystinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/394197?name=213&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627494": {
    "name": "L-ergothioneine",
    "substance_url": "/en/drug/substance/627494?name=214&mode=orpha&region=&status=all",
    "substance_id": "627494",
    "regulatory_url": "/en/drug/regulatory/627498?name=214&mode=orpha&region=",
    "regulatory_id": "627498",
    "orpha_substance_code": "ORPHA:214",
    "details": [
      "L-ergothioneine(Medicinal product                        - 21/06/2021)Disease(s) concernedORPHA:214 Cystinuria",
      "L-ergothioneine(Medicinal product                        - 21/06/2021)",
      "(Medicinal product                        - 21/06/2021)",
      "Disease(s) concernedORPHA:214 Cystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627494?name=214&mode=orpha&region=&status=all",
        "text": "L-ergothioneine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/214",
        "text": "ORPHA:214 Cystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627498?name=214&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "489774": {
    "name": "Tripotassium citrate monohydrate and potassium hydrogen carbonate",
    "substance_url": "/en/drug/substance/489774?name=214&mode=orpha&region=&status=all",
    "substance_id": "489774",
    "regulatory_url": "/en/drug/regulatory/588821?name=214&mode=orpha&region=",
    "regulatory_id": "588821",
    "orpha_substance_code": "ORPHA:214",
    "details": [
      "Tripotassium citrate monohydrate and potassium hydrogen carbonate(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:214 Cystinuria",
      "Tripotassium citrate monohydrate and potassium hydrogen carbonate(Medicinal product                        - 09/01/2020)",
      "(Medicinal product                        - 09/01/2020)",
      "Disease(s) concernedORPHA:214 Cystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489774?name=214&mode=orpha&region=&status=all",
        "text": "Tripotassium citrate monohydrate and potassium hydrogen carbonate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/214",
        "text": "ORPHA:214 Cystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588821?name=214&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "520905": {
    "name": "L-cystine bis(N-methylpiperazide)",
    "substance_url": "/en/drug/substance/520905?name=214&mode=orpha&region=&status=all",
    "substance_id": "520905",
    "regulatory_url": "/en/drug/regulatory/520913?name=214&mode=orpha&region=",
    "regulatory_id": "520913",
    "orpha_substance_code": "ORPHA:214",
    "details": [
      "L-cystine bis(N-methylpiperazide)(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:214 Cystinuria",
      "L-cystine bis(N-methylpiperazide)(Medicinal product                        - 27/06/2018)",
      "(Medicinal product                        - 27/06/2018)",
      "Disease(s) concernedORPHA:214 Cystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/520905?name=214&mode=orpha&region=&status=all",
        "text": "L-cystine bis(N-methylpiperazide)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/214",
        "text": "ORPHA:214 Cystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/520913?name=214&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_155": {
    "name": "THIOLA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131080?name=214&mode=orpha&region=",
    "regulatory_id": "131080",
    "orpha_substance_code": "ORPHA:214",
    "details": [
      "THIOLA(Tradename)Disease(s) concernedORPHA:214 Cystinuria",
      "THIOLA(Tradename)",
      "(Tradename)",
      "Disease(s) concernedORPHA:214 Cystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25072?name=214&mode=orpha&region=&status=all",
        "text": "THIOLA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/214",
        "text": "ORPHA:214 Cystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131080?name=214&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": null,
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "638983": {
    "name": "Fixed-dose combination of potassium citrate and potassium bicarbonate",
    "substance_url": "/en/drug/substance/638983?name=214&mode=orpha&region=&status=all",
    "substance_id": "638983",
    "regulatory_url": "/en/drug/regulatory/665276?name=214&mode=orpha&region=",
    "regulatory_id": "665276",
    "orpha_substance_code": "ORPHA:214",
    "details": [
      "Fixed-dose combination of potassium citrate and potassium bicarbonate(Medicinal product                        - 21/03/2024)Disease(s) concernedORPHA:214 Cystinuria",
      "Fixed-dose combination of potassium citrate and potassium bicarbonate(Medicinal product                        - 21/03/2024)",
      "(Medicinal product                        - 21/03/2024)",
      "Disease(s) concernedORPHA:214 Cystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/638983?name=214&mode=orpha&region=&status=all",
        "text": "Fixed-dose combination of potassium citrate and potassium bicarbonate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/214",
        "text": "ORPHA:214 Cystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665276?name=214&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "82350": {
    "name": "4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid",
    "substance_url": "/en/drug/substance/82350?name=225123&mode=orpha&region=&status=all",
    "substance_id": "82350",
    "regulatory_url": "/en/drug/regulatory/133860?name=225123&mode=orpha&region=",
    "regulatory_id": "133860",
    "orpha_substance_code": "ORPHA:220489",
    "details": [
      "4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid(Medicinal product                        - 12/12/2003)Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:53693 GRACILE syndromeORPHA:220489 Rare hereditary hemochromatosis",
      "4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid(Medicinal product                        - 12/12/2003)",
      "(Medicinal product                        - 12/12/2003)",
      "Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:53693 GRACILE syndromeORPHA:220489 Rare hereditary hemochromatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82350?name=225123&mode=orpha&region=&status=all",
        "text": "4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/846",
        "text": "ORPHA:846 Alpha-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/848",
        "text": "ORPHA:848 Beta-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/232",
        "text": "ORPHA:232 Sickle cell anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/53693",
        "text": "ORPHA:53693 GRACILE syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/220489",
        "text": "ORPHA:220489 Rare hereditary hemochromatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133860?name=225123&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:220489 Rare hereditary hemochromatosis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "69829": {
    "name": "Deferasirox",
    "substance_url": "/en/drug/substance/69829?name=225123&mode=orpha&region=&status=all",
    "substance_id": "69829",
    "regulatory_url": "/en/drug/regulatory/133773?name=225123&mode=orpha&region=",
    "regulatory_id": "133773",
    "orpha_substance_code": "ORPHA:220489",
    "details": [
      "Deferasirox(Medicinal product                        - 13/03/2002)Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:220489 Rare hereditary hemochromatosis",
      "Deferasirox(Medicinal product                        - 13/03/2002)",
      "(Medicinal product                        - 13/03/2002)",
      "Disease(s) concernedORPHA:846 Alpha-thalassemiaORPHA:848 Beta-thalassemiaORPHA:232 Sickle cell anemiaORPHA:220489 Rare hereditary hemochromatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/69829?name=225123&mode=orpha&region=&status=all",
        "text": "Deferasirox",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/846",
        "text": "ORPHA:846 Alpha-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/848",
        "text": "ORPHA:848 Beta-thalassemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/232",
        "text": "ORPHA:232 Sickle cell anemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/220489",
        "text": "ORPHA:220489 Rare hereditary hemochromatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133773?name=225123&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_159": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228329&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228329&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228329&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_160": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228329&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228329&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228329&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_161": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228329&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228329&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228329&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_162": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228337&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228337&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228337&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_163": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228337&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228337&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228337&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_164": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228337&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228337&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228337&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_165": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228343&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228343&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228343&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_166": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228343&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228343&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228343&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_167": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228343&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228343&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228343&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_168": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228346&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228346&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228346&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_169": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228346&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228346&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228346&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_170": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228346&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228346&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228346&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_171": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/686783?name=228349&mode=orpha&region=",
    "regulatory_id": "686783",
    "orpha_substance_code": "ORPHA:228349",
    "details": [
      "BRINEURA(Tradename                        - 24/07/2024)Disease(s) concernedORPHA:228349 CLN2 disease",
      "BRINEURA(Tradename                        - 24/07/2024)",
      "(Tradename                        - 24/07/2024)",
      "Disease(s) concernedORPHA:228349 CLN2 disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228349&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/228349",
        "text": "ORPHA:228349 CLN2 disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686783?name=228349&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_172": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228349&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228349&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228349&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_173": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228349&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228349&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228349&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_174": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228349&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228349&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228349&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_175": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228354&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228354&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_176": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228354&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228354&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_177": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228354&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228354&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_178": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228360&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228360&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228360&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_179": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228360&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228360&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228360&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_180": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228360&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228360&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228360&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_181": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228363&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228363&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228363&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_182": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228363&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228363&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228363&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_183": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228363&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228363&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228363&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "689479": {
    "name": "Adeno-associated viral vector serotype 9 encoding a codon-optimized human ceroid neuronal lipofuscinosis type 7 (CLN7) transgene",
    "substance_url": "/en/drug/substance/689479?name=228366&mode=orpha&region=&status=all",
    "substance_id": "689479",
    "regulatory_url": "/en/drug/regulatory/689714?name=228366&mode=orpha&region=",
    "regulatory_id": "689714",
    "orpha_substance_code": "ORPHA:228366",
    "details": [
      "Adeno-associated viral vector serotype 9 encoding a codon-optimized human ceroid neuronal lipofuscinosis type 7 (CLN7) transgene(Medicinal product                        - 29/10/2024)Disease(s) concernedORPHA:228366 CLN7 disease",
      "Adeno-associated viral vector serotype 9 encoding a codon-optimized human ceroid neuronal lipofuscinosis type 7 (CLN7) transgene(Medicinal product                        - 29/10/2024)",
      "(Medicinal product                        - 29/10/2024)",
      "Disease(s) concernedORPHA:228366 CLN7 disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689479?name=228366&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 encoding a codon-optimized human ceroid neuronal lipofuscinosis type 7 (CLN7) transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/228366",
        "text": "ORPHA:228366 CLN7 disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689714?name=228366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_185": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=228366&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228366&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=228366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_186": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=228366&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=228366&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=228366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_187": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=228366&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=228366&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=228366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_188": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=23&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=23&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=23&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "500711": {
    "name": "Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles",
    "substance_url": "/en/drug/substance/500711?name=23&mode=orpha&region=&status=all",
    "substance_id": "500711",
    "regulatory_url": "/en/drug/regulatory/500713?name=23&mode=orpha&region=",
    "regulatory_id": "500713",
    "orpha_substance_code": "ORPHA:23",
    "details": [
      "Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:23 Argininosuccinic aciduria",
      "Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles(Medicinal product                        - 12/12/2017)",
      "(Medicinal product                        - 12/12/2017)",
      "Disease(s) concernedORPHA:23 Argininosuccinic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/500711?name=23&mode=orpha&region=&status=all",
        "text": "Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/500713?name=23&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_190": {
    "name": "PHEBURANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/628626?name=23&mode=orpha&region=",
    "regulatory_id": "628626",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "PHEBURANE(Tradename                        - 17/06/2022)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "PHEBURANE(Tradename                        - 17/06/2022)",
      "(Tradename                        - 17/06/2022)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/628534?name=23&mode=orpha&region=&status=all",
        "text": "PHEBURANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628626?name=23&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_191": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=23&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=23&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=23&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_192": {
    "name": "BUPHENYL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131075?name=23&mode=orpha&region=",
    "regulatory_id": "131075",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "BUPHENYL(Tradename                        - 30/04/1996)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "BUPHENYL(Tradename                        - 30/04/1996)",
      "(Tradename                        - 30/04/1996)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25061?name=23&mode=orpha&region=&status=all",
        "text": "BUPHENYL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131075?name=23&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_193": {
    "name": "NORTHERA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/393920?name=230&mode=orpha&region=",
    "regulatory_id": "393920",
    "orpha_substance_code": "ORPHA:182058",
    "details": [
      "NORTHERA(Tradename                        - 18/02/2014)Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:102 Multiple system atrophyORPHA:182058 Primary orthostatic hypotension",
      "NORTHERA(Tradename                        - 18/02/2014)",
      "(Tradename                        - 18/02/2014)",
      "Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:102 Multiple system atrophyORPHA:182058 Primary orthostatic hypotension",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/393913?name=230&mode=orpha&region=&status=all",
        "text": "NORTHERA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/441",
        "text": "ORPHA:441 Pure autonomic failure",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/230",
        "text": "ORPHA:230 Dopamine beta-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/102",
        "text": "ORPHA:102 Multiple system atrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182058",
        "text": "ORPHA:182058 Primary orthostatic hypotension",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/393920?name=230&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "393911": {
    "name": "Droxidopa",
    "substance_url": "/en/drug/substance/393911?name=230&mode=orpha&region=&status=all",
    "substance_id": "393911",
    "regulatory_url": "/en/drug/regulatory/393921?name=230&mode=orpha&region=",
    "regulatory_id": "393921",
    "orpha_substance_code": "ORPHA:182058",
    "details": [
      "Droxidopa(Medicinal product                        - 17/01/2007)Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:182058 Primary orthostatic hypotension",
      "Droxidopa(Medicinal product                        - 17/01/2007)",
      "(Medicinal product                        - 17/01/2007)",
      "Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:182058 Primary orthostatic hypotension",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/393911?name=230&mode=orpha&region=&status=all",
        "text": "Droxidopa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/441",
        "text": "ORPHA:441 Pure autonomic failure",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/230",
        "text": "ORPHA:230 Dopamine beta-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182058",
        "text": "ORPHA:182058 Primary orthostatic hypotension",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/393921?name=230&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_195": {
    "name": "NORTHERA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/393920?name=230&mode=orpha&region=",
    "regulatory_id": "393920",
    "orpha_substance_code": "ORPHA:182058",
    "details": [
      "NORTHERA(Tradename                        - 18/02/2014)Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:102 Multiple system atrophyORPHA:182058 Primary orthostatic hypotension",
      "NORTHERA(Tradename                        - 18/02/2014)",
      "(Tradename                        - 18/02/2014)",
      "Disease(s) concernedORPHA:441 Pure autonomic failureORPHA:230 Dopamine beta-hydroxylase deficiencyORPHA:102 Multiple system atrophyORPHA:182058 Primary orthostatic hypotension",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/393913?name=230&mode=orpha&region=&status=all",
        "text": "NORTHERA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/441",
        "text": "ORPHA:441 Pure autonomic failure",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/230",
        "text": "ORPHA:230 Dopamine beta-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/102",
        "text": "ORPHA:102 Multiple system atrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182058",
        "text": "ORPHA:182058 Primary orthostatic hypotension",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/393920?name=230&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_196": {
    "name": "AMATINE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131101?name=230&mode=orpha&region=",
    "regulatory_id": "131101",
    "orpha_substance_code": "ORPHA:182058",
    "details": [
      "AMATINE(Tradename                        - 06/09/1996)Disease(s) concernedORPHA:182058 Primary orthostatic hypotension",
      "AMATINE(Tradename                        - 06/09/1996)",
      "(Tradename                        - 06/09/1996)",
      "Disease(s) concernedORPHA:182058 Primary orthostatic hypotension",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33485?name=230&mode=orpha&region=&status=all",
        "text": "AMATINE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182058",
        "text": "ORPHA:182058 Primary orthostatic hypotension",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131101?name=230&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "33486": {
    "name": "Midodrine hydrochloride",
    "substance_url": "/en/drug/substance/33486?name=230&mode=orpha&region=&status=all",
    "substance_id": "33486",
    "regulatory_url": "/en/drug/regulatory/136877?name=230&mode=orpha&region=",
    "regulatory_id": "136877",
    "orpha_substance_code": "ORPHA:182058",
    "details": [
      "Midodrine hydrochloride(Medicinal product                        - 21/06/1985)Disease(s) concernedORPHA:182058 Primary orthostatic hypotension",
      "Midodrine hydrochloride(Medicinal product                        - 21/06/1985)",
      "(Medicinal product                        - 21/06/1985)",
      "Disease(s) concernedORPHA:182058 Primary orthostatic hypotension",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/33486?name=230&mode=orpha&region=&status=all",
        "text": "Midodrine hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182058",
        "text": "ORPHA:182058 Primary orthostatic hypotension",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/136877?name=230&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_198": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=238475&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=238475&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=238475&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_199": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=238475&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=238475&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=238475&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_200": {
    "name": "SAPROPTERIN DIPHARMA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642262?name=238583&mode=orpha&region=",
    "regulatory_id": "642262",
    "orpha_substance_code": "ORPHA:238583",
    "details": [
      "SAPROPTERIN DIPHARMA(Tradename                        - 16/02/2022)Disease(s) concernedORPHA:716 PhenylketonuriaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "SAPROPTERIN DIPHARMA(Tradename                        - 16/02/2022)",
      "(Tradename                        - 16/02/2022)",
      "Disease(s) concernedORPHA:716 PhenylketonuriaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642261?name=238583&mode=orpha&region=&status=all",
        "text": "SAPROPTERIN DIPHARMA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642262?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "695211": {
    "name": "Adeno-associated virus vector serotype SNY001 containing the human PAH gene",
    "substance_url": "/en/drug/substance/695211?name=238583&mode=orpha&region=&status=all",
    "substance_id": "695211",
    "regulatory_url": "/en/drug/regulatory/695273?name=238583&mode=orpha&region=",
    "regulatory_id": "695273",
    "orpha_substance_code": "ORPHA:508523",
    "details": [
      "Adeno-associated virus vector serotype SNY001 containing the human PAH gene(Medicinal product                        - 26/02/2025)Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "Adeno-associated virus vector serotype SNY001 containing the human PAH gene(Medicinal product                        - 26/02/2025)",
      "(Medicinal product                        - 26/02/2025)",
      "Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695211?name=238583&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector serotype SNY001 containing the human PAH gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79651",
        "text": "ORPHA:79651 Mild hyperphenylalaninemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/508523",
        "text": "ORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695273?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "676581": {
    "name": "2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one",
    "substance_url": "/en/drug/substance/676581?name=238583&mode=orpha&region=&status=all",
    "substance_id": "676581",
    "regulatory_url": "/en/drug/regulatory/676596?name=238583&mode=orpha&region=",
    "regulatory_id": "676596",
    "orpha_substance_code": "ORPHA:508523",
    "details": [
      "2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one(Medicinal product                        - 24/05/2024)Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one(Medicinal product                        - 24/05/2024)",
      "(Medicinal product                        - 24/05/2024)",
      "Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/676581?name=238583&mode=orpha&region=&status=all",
        "text": "2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79651",
        "text": "ORPHA:79651 Mild hyperphenylalaninemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/508523",
        "text": "ORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/676596?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "646345": {
    "name": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase (S92G, H133M, I167K, L432I, V470A) and L-amino acid deaminase",
    "substance_url": "/en/drug/substance/646345?name=238583&mode=orpha&region=&status=all",
    "substance_id": "646345",
    "regulatory_url": "/en/drug/regulatory/646346?name=238583&mode=orpha&region=",
    "regulatory_id": "646346",
    "orpha_substance_code": "ORPHA:508523",
    "details": [
      "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase (S92G, H133M, I167K, L432I, V470A) and L-amino acid deaminase(Medicinal product                        - 21/04/2023)Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase (S92G, H133M, I167K, L432I, V470A) and L-amino acid deaminase(Medicinal product                        - 21/04/2023)",
      "(Medicinal product                        - 21/04/2023)",
      "Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/646345?name=238583&mode=orpha&region=&status=all",
        "text": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase (S92G, H133M, I167K, L432I, V470A) and L-amino acid deaminase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79651",
        "text": "ORPHA:79651 Mild hyperphenylalaninemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/508523",
        "text": "ORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/646346?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627485": {
    "name": "Sepiapterin",
    "substance_url": "/en/drug/substance/627485?name=238583&mode=orpha&region=&status=all",
    "substance_id": "627485",
    "regulatory_url": "/en/drug/regulatory/627490?name=238583&mode=orpha&region=",
    "regulatory_id": "627490",
    "orpha_substance_code": "ORPHA:508523",
    "details": [
      "Sepiapterin(Medicinal product                        - 20/05/2021)Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "Sepiapterin(Medicinal product                        - 20/05/2021)",
      "(Medicinal product                        - 20/05/2021)",
      "Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627485?name=238583&mode=orpha&region=&status=all",
        "text": "Sepiapterin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79651",
        "text": "ORPHA:79651 Mild hyperphenylalaninemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/508523",
        "text": "ORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627490?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "485095": {
    "name": "Phelimin",
    "substance_url": "/en/drug/substance/485095?name=238583&mode=orpha&region=&status=all",
    "substance_id": "485095",
    "regulatory_url": "/en/drug/regulatory/485099?name=238583&mode=orpha&region=",
    "regulatory_id": "485099",
    "orpha_substance_code": "ORPHA:238583",
    "details": [
      "Phelimin(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "Phelimin(Medicinal product                        - 18/11/2016)",
      "(Medicinal product                        - 18/11/2016)",
      "Disease(s) concernedORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/485095?name=238583&mode=orpha&region=&status=all",
        "text": "Phelimin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485099?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628462": {
    "name": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",
    "substance_url": "/en/drug/substance/628462?name=238583&mode=orpha&region=&status=all",
    "substance_id": "628462",
    "regulatory_url": "/en/drug/regulatory/628464?name=238583&mode=orpha&region=",
    "regulatory_id": "628464",
    "orpha_substance_code": "ORPHA:508523",
    "details": [
      "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase(Medicinal product                        - 21/06/2022)Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase(Medicinal product                        - 21/06/2022)",
      "(Medicinal product                        - 21/06/2022)",
      "Disease(s) concernedORPHA:79651 Mild hyperphenylalaninemiaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628462?name=238583&mode=orpha&region=&status=all",
        "text": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79651",
        "text": "ORPHA:79651 Mild hyperphenylalaninemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/508523",
        "text": "ORPHA:508523 Hyperphenylalaninemia due to DNAJC12 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628464?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_207": {
    "name": "KUVAN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/170109?name=238583&mode=orpha&region=",
    "regulatory_id": "170109",
    "orpha_substance_code": "ORPHA:293284",
    "details": [
      "KUVAN(Tradename                        - 02/12/2008)Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
      "KUVAN(Tradename                        - 02/12/2008)",
      "(Tradename                        - 02/12/2008)",
      "Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/84936?name=238583&mode=orpha&region=&status=all",
        "text": "KUVAN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/226",
        "text": "ORPHA:226 Dihydropteridine reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/170109?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_208": {
    "name": "KUVAN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131176?name=238583&mode=orpha&region=",
    "regulatory_id": "131176",
    "orpha_substance_code": "ORPHA:1578",
    "details": [
      "KUVAN(Tradename                        - 13/12/2007)Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:716 PhenylketonuriaORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiencyORPHA:2102 GTP cyclohydrolase I deficiencyORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
      "KUVAN(Tradename                        - 13/12/2007)",
      "(Tradename                        - 13/12/2007)",
      "Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:716 PhenylketonuriaORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiencyORPHA:2102 GTP cyclohydrolase I deficiencyORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/84936?name=238583&mode=orpha&region=&status=all",
        "text": "KUVAN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/226",
        "text": "ORPHA:226 Dihydropteridine reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/13",
        "text": "ORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2102",
        "text": "ORPHA:2102 GTP cyclohydrolase I deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1578",
        "text": "ORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131176?name=238583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "697639": {
    "name": "Pentadecanoic acid",
    "substance_url": "/en/drug/substance/697639?name=247262&mode=orpha&region=&status=all",
    "substance_id": "697639",
    "regulatory_url": "/en/drug/regulatory/697886?name=247262&mode=orpha&region=",
    "regulatory_id": "697886",
    "orpha_substance_code": "ORPHA:247262",
    "details": [
      "Pentadecanoic acid(Medicinal product                        - 05/03/2025)Disease(s) concernedORPHA:247262 Hyperphosphatasia-intellectual disability syndrome",
      "Pentadecanoic acid(Medicinal product                        - 05/03/2025)",
      "(Medicinal product                        - 05/03/2025)",
      "Disease(s) concernedORPHA:247262 Hyperphosphatasia-intellectual disability syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/697639?name=247262&mode=orpha&region=&status=all",
        "text": "Pentadecanoic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247262",
        "text": "ORPHA:247262 Hyperphosphatasia-intellectual disability syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/697886?name=247262&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_210": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=247525&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=247525&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=247525&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_211": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=247525&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=247525&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=247525&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_212": {
    "name": "AMMONAPS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131255?name=247525&mode=orpha&region=",
    "regulatory_id": "131255",
    "orpha_substance_code": "ORPHA:187",
    "details": [
      "AMMONAPS(Tradename                        - 08/12/1999)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "AMMONAPS(Tradename                        - 08/12/1999)",
      "(Tradename                        - 08/12/1999)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34205?name=247525&mode=orpha&region=&status=all",
        "text": "AMMONAPS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/187",
        "text": "ORPHA:187 Citrullinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131255?name=247525&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_213": {
    "name": "AMMONAPS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131255?name=247585&mode=orpha&region=",
    "regulatory_id": "131255",
    "orpha_substance_code": "ORPHA:187",
    "details": [
      "AMMONAPS(Tradename                        - 08/12/1999)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "AMMONAPS(Tradename                        - 08/12/1999)",
      "(Tradename                        - 08/12/1999)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34205?name=247585&mode=orpha&region=&status=all",
        "text": "AMMONAPS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/187",
        "text": "ORPHA:187 Citrullinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131255?name=247585&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_214": {
    "name": "AMMONAPS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131255?name=247598&mode=orpha&region=",
    "regulatory_id": "131255",
    "orpha_substance_code": "ORPHA:187",
    "details": [
      "AMMONAPS(Tradename                        - 08/12/1999)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "AMMONAPS(Tradename                        - 08/12/1999)",
      "(Tradename                        - 08/12/1999)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34205?name=247598&mode=orpha&region=&status=all",
        "text": "AMMONAPS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/187",
        "text": "ORPHA:187 Citrullinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131255?name=247598&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "686826": {
    "name": "Adeno-associated virus vector serotype 9 containing the human GCDH gene",
    "substance_url": "/en/drug/substance/686826?name=25&mode=orpha&region=&status=all",
    "substance_id": "686826",
    "regulatory_url": "/en/drug/regulatory/686862?name=25&mode=orpha&region=",
    "regulatory_id": "686862",
    "orpha_substance_code": "ORPHA:25",
    "details": [
      "Adeno-associated virus vector serotype 9 containing the human GCDH gene(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
      "Adeno-associated virus vector serotype 9 containing the human GCDH gene(Medicinal product                        - 21/08/2024)",
      "(Medicinal product                        - 21/08/2024)",
      "Disease(s) concernedORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/686826?name=25&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector serotype 9 containing the human GCDH gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/25",
        "text": "ORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686862?name=25&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "640975": {
    "name": "Adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene",
    "substance_url": "/en/drug/substance/640975?name=25&mode=orpha&region=&status=all",
    "substance_id": "640975",
    "regulatory_url": "/en/drug/regulatory/640976?name=25&mode=orpha&region=",
    "regulatory_id": "640976",
    "orpha_substance_code": "ORPHA:25",
    "details": [
      "Adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene(Medicinal product                        - 26/05/2022)Disease(s) concernedORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
      "Adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene(Medicinal product                        - 26/05/2022)",
      "(Medicinal product                        - 26/05/2022)",
      "Disease(s) concernedORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/640975?name=25&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/25",
        "text": "ORPHA:25 Glutaryl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/640976?name=25&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "489667": {
    "name": "Thymidine and deoxycytidine",
    "substance_url": "/en/drug/substance/489667?name=254875&mode=orpha&region=&status=all",
    "substance_id": "489667",
    "regulatory_url": "/en/drug/regulatory/489669?name=254875&mode=orpha&region=",
    "regulatory_id": "489669",
    "orpha_substance_code": "ORPHA:254875",
    "details": [
      "Thymidine and deoxycytidine(Medicinal product                        - 20/04/2017)Disease(s) concernedORPHA:254875 Mitochondrial DNA depletion syndrome, myopathic form",
      "Thymidine and deoxycytidine(Medicinal product                        - 20/04/2017)",
      "(Medicinal product                        - 20/04/2017)",
      "Disease(s) concernedORPHA:254875 Mitochondrial DNA depletion syndrome, myopathic form",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489667?name=254875&mode=orpha&region=&status=all",
        "text": "Thymidine and deoxycytidine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/254875",
        "text": "ORPHA:254875 Mitochondrial DNA depletion syndrome, myopathic form",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489669?name=254875&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_218": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=26&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=26&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_219": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131341?name=26&mode=orpha&region=",
    "regulatory_id": "131341",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "CYSTADANE(Tradename                        - 15/02/2007)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "CYSTADANE(Tradename                        - 15/02/2007)",
      "(Tradename                        - 15/02/2007)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=26&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131341?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "695213": {
    "name": "Hydroxocobalamin acetate",
    "substance_url": "/en/drug/substance/695213?name=26&mode=orpha&region=&status=all",
    "substance_id": "695213",
    "regulatory_url": "/en/drug/regulatory/695282?name=26&mode=orpha&region=",
    "regulatory_id": "695282",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "Hydroxocobalamin acetate(Medicinal product                        - 26/02/2025)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:28 Vitamin B12-responsive methylmalonic acidemiaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "Hydroxocobalamin acetate(Medicinal product                        - 26/02/2025)",
      "(Medicinal product                        - 26/02/2025)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:28 Vitamin B12-responsive methylmalonic acidemiaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695213?name=26&mode=orpha&region=&status=all",
        "text": "Hydroxocobalamin acetate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/28",
        "text": "ORPHA:28 Vitamin B12-responsive methylmalonic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695282?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628481": {
    "name": "Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671",
    "substance_url": "/en/drug/substance/628481?name=26&mode=orpha&region=&status=all",
    "substance_id": "628481",
    "regulatory_url": "/en/drug/regulatory/628485?name=26&mode=orpha&region=",
    "regulatory_id": "628485",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671(Medicinal product                        - 21/06/2022)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defectORPHA:289504 Combined malonic and methylmalonic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671(Medicinal product                        - 21/06/2022)",
      "(Medicinal product                        - 21/06/2022)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defectORPHA:289504 Combined malonic and methylmalonic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628481?name=26&mode=orpha&region=&status=all",
        "text": "Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/280183",
        "text": "ORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defect",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/289504",
        "text": "ORPHA:289504 Combined malonic and methylmalonic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628485?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627536": {
    "name": "Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase",
    "substance_url": "/en/drug/substance/627536?name=26&mode=orpha&region=&status=all",
    "substance_id": "627536",
    "regulatory_url": "/en/drug/regulatory/628290?name=26&mode=orpha&region=",
    "regulatory_id": "628290",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase(Medicinal product                        - 21/06/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defectORPHA:289504 Combined malonic and methylmalonic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase(Medicinal product                        - 21/06/2021)",
      "(Medicinal product                        - 21/06/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defectORPHA:289504 Combined malonic and methylmalonic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627536?name=26&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/280183",
        "text": "ORPHA:280183 Methylmalonic aciduria due to transcobalamin receptor defect",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/289504",
        "text": "ORPHA:289504 Combined malonic and methylmalonic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628290?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "35161": {
    "name": "Carglumic acid",
    "substance_url": "/en/drug/substance/35161?name=26&mode=orpha&region=&status=all",
    "substance_id": "35161",
    "regulatory_url": "/en/drug/regulatory/165067?name=26&mode=orpha&region=",
    "regulatory_id": "165067",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Carglumic acid(Medicinal product                        - 07/11/2008)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Carglumic acid(Medicinal product                        - 07/11/2008)",
      "(Medicinal product                        - 07/11/2008)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/35161?name=26&mode=orpha&region=&status=all",
        "text": "Carglumic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/165067?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_224": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622237?name=26&mode=orpha&region=",
    "regulatory_id": "622237",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 22/01/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 22/01/2021)",
      "(Tradename                        - 22/01/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=26&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622237?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_225": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131109?name=26&mode=orpha&region=",
    "regulatory_id": "131109",
    "orpha_substance_code": "ORPHA:2170",
    "details": [
      "CYSTADANE(Tradename                        - 25/10/1996)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "CYSTADANE(Tradename                        - 25/10/1996)",
      "(Tradename                        - 25/10/1996)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=26&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2169",
        "text": "ORPHA:2169 Methylcobalamin deficiency type cblE",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2170",
        "text": "ORPHA:2170 Methylcobalamin deficiency type cblG",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131109?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689523": {
    "name": "Hydroxocobalamin, methylcobalamin",
    "substance_url": "/en/drug/substance/689523?name=26&mode=orpha&region=&status=all",
    "substance_id": "689523",
    "regulatory_url": "/en/drug/regulatory/689684?name=26&mode=orpha&region=",
    "regulatory_id": "689684",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Hydroxocobalamin, methylcobalamin(Medicinal product                        - 25/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Hydroxocobalamin, methylcobalamin(Medicinal product                        - 25/10/2024)",
      "(Medicinal product                        - 25/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689523?name=26&mode=orpha&region=&status=all",
        "text": "Hydroxocobalamin, methylcobalamin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689684?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689483": {
    "name": "Adeno-associated virus 9 methylmalonyl Co-A mutase",
    "substance_url": "/en/drug/substance/689483?name=26&mode=orpha&region=&status=all",
    "substance_id": "689483",
    "regulatory_url": "/en/drug/regulatory/689641?name=26&mode=orpha&region=",
    "regulatory_id": "689641",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Adeno-associated virus 9 methylmalonyl Co-A mutase(Medicinal product                        - 25/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Adeno-associated virus 9 methylmalonyl Co-A mutase(Medicinal product                        - 25/10/2024)",
      "(Medicinal product                        - 25/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689483?name=26&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus 9 methylmalonyl Co-A mutase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689641?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689529": {
    "name": "Methylcobalamin",
    "substance_url": "/en/drug/substance/689529?name=26&mode=orpha&region=&status=all",
    "substance_id": "689529",
    "regulatory_url": "/en/drug/regulatory/689685?name=26&mode=orpha&region=",
    "regulatory_id": "689685",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Methylcobalamin(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Methylcobalamin(Medicinal product                        - 22/10/2024)",
      "(Medicinal product                        - 22/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689529?name=26&mode=orpha&region=&status=all",
        "text": "Methylcobalamin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689685?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689485": {
    "name": "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding MMAB",
    "substance_url": "/en/drug/substance/689485?name=26&mode=orpha&region=&status=all",
    "substance_id": "689485",
    "regulatory_url": "/en/drug/regulatory/689643?name=26&mode=orpha&region=",
    "regulatory_id": "689643",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding MMAB(Medicinal product                        - 16/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding MMAB(Medicinal product                        - 16/10/2024)",
      "(Medicinal product                        - 16/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689485?name=26&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding MMAB",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689643?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "87836": {
    "name": "Hydroxocobalamin",
    "substance_url": "/en/drug/substance/87836?name=26&mode=orpha&region=&status=all",
    "substance_id": "87836",
    "regulatory_url": "/en/drug/regulatory/689683?name=26&mode=orpha&region=",
    "regulatory_id": "689683",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Hydroxocobalamin(Medicinal product                        - 09/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Hydroxocobalamin(Medicinal product                        - 09/10/2024)",
      "(Medicinal product                        - 09/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/87836?name=26&mode=orpha&region=&status=all",
        "text": "Hydroxocobalamin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689683?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689487": {
    "name": "Adeno-Associated Virus 9 vector expressing human Metabolism of Cobalamin Associated C gene",
    "substance_url": "/en/drug/substance/689487?name=26&mode=orpha&region=&status=all",
    "substance_id": "689487",
    "regulatory_url": "/en/drug/regulatory/689645?name=26&mode=orpha&region=",
    "regulatory_id": "689645",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "Adeno-Associated Virus 9 vector expressing human Metabolism of Cobalamin Associated C gene(Medicinal product                        - 09/10/2024)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "Adeno-Associated Virus 9 vector expressing human Metabolism of Cobalamin Associated C gene(Medicinal product                        - 09/10/2024)",
      "(Medicinal product                        - 09/10/2024)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689487?name=26&mode=orpha&region=&status=all",
        "text": "Adeno-Associated Virus 9 vector expressing human Metabolism of Cobalamin Associated C gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689645?name=26&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_232": {
    "name": "ALKINDI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/505896?name=261476&mode=orpha&region=",
    "regulatory_id": "505896",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "ALKINDI(Tradename                        - 09/02/2018)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "ALKINDI(Tradename                        - 09/02/2018)",
      "(Tradename                        - 09/02/2018)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505888?name=261476&mode=orpha&region=&status=all",
        "text": "ALKINDI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/505896?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_233": {
    "name": "PLENADREN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/352529?name=261476&mode=orpha&region=",
    "regulatory_id": "352529",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "PLENADREN(Tradename                        - 03/11/2011)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "PLENADREN(Tradename                        - 03/11/2011)",
      "(Tradename                        - 03/11/2011)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/352513?name=261476&mode=orpha&region=&status=all",
        "text": "PLENADREN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/352529?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "505909": {
    "name": "Hydrocortisone",
    "substance_url": "/en/drug/substance/505909?name=261476&mode=orpha&region=&status=all",
    "substance_id": "505909",
    "regulatory_url": "/en/drug/regulatory/134118?name=261476&mode=orpha&region=",
    "regulatory_id": "134118",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Hydrocortisone(Medicinal product                        - 20/03/2007)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Hydrocortisone(Medicinal product                        - 20/03/2007)",
      "(Medicinal product                        - 20/03/2007)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/505909?name=261476&mode=orpha&region=&status=all",
        "text": "Hydrocortisone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134118?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "97925": {
    "name": "Prasterone",
    "substance_url": "/en/drug/substance/97925?name=261476&mode=orpha&region=&status=all",
    "substance_id": "97925",
    "regulatory_url": "/en/drug/regulatory/133836?name=261476&mode=orpha&region=",
    "regulatory_id": "133836",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Prasterone(Medicinal product                        - 28/07/2003)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Prasterone(Medicinal product                        - 28/07/2003)",
      "(Medicinal product                        - 28/07/2003)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/97925?name=261476&mode=orpha&region=&status=all",
        "text": "Prasterone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133836?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "65883": {
    "name": "Hydrocortisone (modified release tablet)",
    "substance_url": "/en/drug/substance/65883?name=261476&mode=orpha&region=&status=all",
    "substance_id": "65883",
    "regulatory_url": "/en/drug/regulatory/134049?name=261476&mode=orpha&region=",
    "regulatory_id": "134049",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Hydrocortisone (modified release tablet)(Medicinal product                        - 22/05/2006)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Hydrocortisone (modified release tablet)(Medicinal product                        - 22/05/2006)",
      "(Medicinal product                        - 22/05/2006)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/65883?name=261476&mode=orpha&region=&status=all",
        "text": "Hydrocortisone (modified release tablet)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134049?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_237": {
    "name": "KHINDIVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/704611?name=261476&mode=orpha&region=",
    "regulatory_id": "704611",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "KHINDIVI(Tradename                        - 28/05/2025)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "KHINDIVI(Tradename                        - 28/05/2025)",
      "(Tradename                        - 28/05/2025)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/704608?name=261476&mode=orpha&region=&status=all",
        "text": "KHINDIVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704611?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_238": {
    "name": "Alkindi Sprinkle",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623088?name=261476&mode=orpha&region=",
    "regulatory_id": "623088",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)",
      "(Tradename                        - 29/09/2020)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623087?name=261476&mode=orpha&region=&status=all",
        "text": "Alkindi Sprinkle",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623088?name=261476&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604968": {
    "name": "Human laminin-111, recombinant",
    "substance_url": "/en/drug/substance/604968?name=263494&mode=orpha&region=&status=all",
    "substance_id": "604968",
    "regulatory_url": "/en/drug/regulatory/604969?name=263494&mode=orpha&region=",
    "regulatory_id": "604969",
    "orpha_substance_code": "ORPHA:97242",
    "details": [
      "Human laminin-111, recombinant(Medicinal product                        - 06/01/2021)Disease(s) concernedORPHA:97242 Congenital muscular dystrophy",
      "Human laminin-111, recombinant(Medicinal product                        - 06/01/2021)",
      "(Medicinal product                        - 06/01/2021)",
      "Disease(s) concernedORPHA:97242 Congenital muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604968?name=263494&mode=orpha&region=&status=all",
        "text": "Human laminin-111, recombinant",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/97242",
        "text": "ORPHA:97242 Congenital muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604969?name=263494&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "632336": {
    "name": "Insulin-like Growth Factor-1",
    "substance_url": "/en/drug/substance/632336?name=263494&mode=orpha&region=&status=all",
    "substance_id": "632336",
    "regulatory_url": "/en/drug/regulatory/632337?name=263494&mode=orpha&region=",
    "regulatory_id": "632337",
    "orpha_substance_code": "ORPHA:97242",
    "details": [
      "Insulin-like Growth Factor-1(Medicinal product                        - 11/04/2022)Disease(s) concernedORPHA:97242 Congenital muscular dystrophy",
      "Insulin-like Growth Factor-1(Medicinal product                        - 11/04/2022)",
      "(Medicinal product                        - 11/04/2022)",
      "Disease(s) concernedORPHA:97242 Congenital muscular dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/632336?name=263494&mode=orpha&region=&status=all",
        "text": "Insulin-like Growth Factor-1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/97242",
        "text": "ORPHA:97242 Congenital muscular dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/632337?name=263494&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_241": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=263516&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=263516&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=263516&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_242": {
    "name": "DOJOLVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623538?name=26793&mode=orpha&region=",
    "regulatory_id": "623538",
    "orpha_substance_code": "ORPHA:26793",
    "details": [
      "DOJOLVI(Tradename                        - 30/06/2020)Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "DOJOLVI(Tradename                        - 30/06/2020)",
      "(Tradename                        - 30/06/2020)",
      "Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/615857?name=26793&mode=orpha&region=&status=all",
        "text": "DOJOLVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157",
        "text": "ORPHA:157 Carnitine palmitoyltransferase II deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/746",
        "text": "ORPHA:746 Mitochondrial trifunctional protein deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26793",
        "text": "ORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623538?name=26793&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "527449": {
    "name": "Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles",
    "substance_url": "/en/drug/substance/527449?name=27&mode=orpha&region=&status=all",
    "substance_id": "527449",
    "regulatory_url": "/en/drug/regulatory/527455?name=27&mode=orpha&region=",
    "regulatory_id": "527455",
    "orpha_substance_code": "ORPHA:27",
    "details": [
      "Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles(Medicinal product                        - 25/05/2018)Disease(s) concernedORPHA:27 Vitamin B12-unresponsive methylmalonic acidemia",
      "Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles(Medicinal product                        - 25/05/2018)",
      "(Medicinal product                        - 25/05/2018)",
      "Disease(s) concernedORPHA:27 Vitamin B12-unresponsive methylmalonic acidemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/527449?name=27&mode=orpha&region=&status=all",
        "text": "Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/27",
        "text": "ORPHA:27 Vitamin B12-unresponsive methylmalonic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527455?name=27&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_244": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=27&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=27&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=27&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_245": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622237?name=27&mode=orpha&region=",
    "regulatory_id": "622237",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 22/01/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 22/01/2021)",
      "(Tradename                        - 22/01/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=27&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622237?name=27&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_246": {
    "name": "KANUMA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/439150?name=275761&mode=orpha&region=",
    "regulatory_id": "439150",
    "orpha_substance_code": "ORPHA:275761",
    "details": [
      "KANUMA(Tradename                        - 01/09/2015)Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "KANUMA(Tradename                        - 01/09/2015)",
      "(Tradename                        - 01/09/2015)",
      "Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/439147?name=275761&mode=orpha&region=&status=all",
        "text": "KANUMA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/275761",
        "text": "ORPHA:275761 Lysosomal acid lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/439150?name=275761&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "240502": {
    "name": "Sebelipase alfa",
    "substance_url": "/en/drug/substance/240502?name=275761&mode=orpha&region=&status=all",
    "substance_id": "240502",
    "regulatory_url": "/en/drug/regulatory/260354?name=275761&mode=orpha&region=",
    "regulatory_id": "260354",
    "orpha_substance_code": "ORPHA:275761",
    "details": [
      "Sebelipase alfa(Medicinal product                        - 17/12/2010)Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "Sebelipase alfa(Medicinal product                        - 17/12/2010)",
      "(Medicinal product                        - 17/12/2010)",
      "Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/240502?name=275761&mode=orpha&region=&status=all",
        "text": "Sebelipase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/275761",
        "text": "ORPHA:275761 Lysosomal acid lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/260354?name=275761&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_248": {
    "name": "KANUMA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465099?name=275761&mode=orpha&region=",
    "regulatory_id": "465099",
    "orpha_substance_code": "ORPHA:275761",
    "details": [
      "KANUMA(Tradename                        - 08/12/2015)Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "KANUMA(Tradename                        - 08/12/2015)",
      "(Tradename                        - 08/12/2015)",
      "Disease(s) concernedORPHA:275761 Lysosomal acid lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/439147?name=275761&mode=orpha&region=&status=all",
        "text": "KANUMA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/275761",
        "text": "ORPHA:275761 Lysosomal acid lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465099?name=275761&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_249": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=275761&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=275761&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=275761&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_250": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=275761&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=275761&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=275761&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_251": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=276066&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=276066&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=276066&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_252": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=276066&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=276066&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=276066&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_253": {
    "name": "STRIMVELIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/459556?name=277&mode=orpha&region=",
    "regulatory_id": "459556",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "STRIMVELIS(Tradename                        - 26/05/2016)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "STRIMVELIS(Tradename                        - 26/05/2016)",
      "(Tradename                        - 26/05/2016)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/459552?name=277&mode=orpha&region=&status=all",
        "text": "STRIMVELIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/459556?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "330859": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene",
    "substance_url": "/en/drug/substance/330859?name=277&mode=orpha&region=&status=all",
    "substance_id": "330859",
    "regulatory_url": "/en/drug/regulatory/356813?name=277&mode=orpha&region=",
    "regulatory_id": "356813",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene(Medicinal product                        - 07/06/2013)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene(Medicinal product                        - 07/06/2013)",
      "(Medicinal product                        - 07/06/2013)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/330859?name=277&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/356813?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "65878": {
    "name": "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene",
    "substance_url": "/en/drug/substance/65878?name=277&mode=orpha&region=&status=all",
    "substance_id": "65878",
    "regulatory_url": "/en/drug/regulatory/133992?name=277&mode=orpha&region=",
    "regulatory_id": "133992",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene(Medicinal product                        - 26/08/2005)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene(Medicinal product                        - 26/08/2005)",
      "(Medicinal product                        - 26/08/2005)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/65878?name=277&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133992?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_256": {
    "name": "REVCOVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/528458?name=277&mode=orpha&region=",
    "regulatory_id": "528458",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "REVCOVI(Tradename                        - 10/05/2018)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "REVCOVI(Tradename                        - 10/05/2018)",
      "(Tradename                        - 10/05/2018)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/528454?name=277&mode=orpha&region=&status=all",
        "text": "REVCOVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/528458?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_257": {
    "name": "ADAGEN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131201?name=277&mode=orpha&region=",
    "regulatory_id": "131201",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "ADAGEN(Tradename                        - 21/03/1990)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "ADAGEN(Tradename                        - 21/03/1990)",
      "(Tradename                        - 21/03/1990)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/100846?name=277&mode=orpha&region=&status=all",
        "text": "ADAGEN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131201?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "412879": {
    "name": "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",
    "substance_url": "/en/drug/substance/412879?name=277&mode=orpha&region=&status=all",
    "substance_id": "412879",
    "regulatory_url": "/en/drug/regulatory/412881?name=277&mode=orpha&region=",
    "regulatory_id": "412881",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA(Medicinal product                        - 21/10/2014)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA(Medicinal product                        - 21/10/2014)",
      "(Medicinal product                        - 21/10/2014)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/412879?name=277&mode=orpha&region=&status=all",
        "text": "Autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412881?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "100845": {
    "name": "Pegademase bovine",
    "substance_url": "/en/drug/substance/100845?name=277&mode=orpha&region=&status=all",
    "substance_id": "100845",
    "regulatory_url": "/en/drug/regulatory/132187?name=277&mode=orpha&region=",
    "regulatory_id": "132187",
    "orpha_substance_code": "ORPHA:277",
    "details": [
      "Pegademase bovine(Medicinal product                        - 29/05/1984)Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "Pegademase bovine(Medicinal product                        - 29/05/1984)",
      "(Medicinal product                        - 29/05/1984)",
      "Disease(s) concernedORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/100845?name=277&mode=orpha&region=&status=all",
        "text": "Pegademase bovine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/277",
        "text": "ORPHA:277 Severe combined immunodeficiency due to adenosine deaminase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/132187?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_260": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=277&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=277&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_261": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=277&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=277&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_262": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=277&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=277&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_263": {
    "name": "HIZENTRA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/353616?name=277&mode=orpha&region=",
    "regulatory_id": "353616",
    "orpha_substance_code": "ORPHA:183660",
    "details": [
      "HIZENTRA(Tradename                        - 14/04/2011)Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
      "HIZENTRA(Tradename                        - 14/04/2011)",
      "(Tradename                        - 14/04/2011)",
      "Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/353563?name=277&mode=orpha&region=&status=all",
        "text": "HIZENTRA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/183660",
        "text": "ORPHA:183660 Severe combined immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/353616?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "392978": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
    "substance_url": "/en/drug/substance/392978?name=277&mode=orpha&region=&status=all",
    "substance_id": "392978",
    "regulatory_url": "/en/drug/regulatory/688391?name=277&mode=orpha&region=",
    "regulatory_id": "688391",
    "orpha_substance_code": "ORPHA:183660",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene(Medicinal product                        - 17/09/2024)Disease(s) concernedORPHA:183660 Severe combined immunodeficiency",
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene(Medicinal product                        - 17/09/2024)",
      "(Medicinal product                        - 17/09/2024)",
      "Disease(s) concernedORPHA:183660 Severe combined immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/392978?name=277&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/183660",
        "text": "ORPHA:183660 Severe combined immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688391?name=277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_265": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=28&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=28&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=28&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_266": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622237?name=28&mode=orpha&region=",
    "regulatory_id": "622237",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 22/01/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 22/01/2021)",
      "(Tradename                        - 22/01/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=28&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622237?name=28&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_267": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=280379&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=280379&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=280379&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "76236": {
    "name": "Enzastaurin",
    "substance_url": "/en/drug/substance/76236?name=2953&mode=orpha&region=&status=all",
    "substance_id": "76236",
    "regulatory_url": "/en/drug/regulatory/627654?name=2953&mode=orpha&region=",
    "regulatory_id": "627654",
    "orpha_substance_code": "ORPHA:98249",
    "details": [
      "Enzastaurin(Medicinal product                        - 24/02/2022)Disease(s) concernedORPHA:98249 Ehlers-Danlos syndrome",
      "Enzastaurin(Medicinal product                        - 24/02/2022)",
      "(Medicinal product                        - 24/02/2022)",
      "Disease(s) concernedORPHA:98249 Ehlers-Danlos syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/76236?name=2953&mode=orpha&region=&status=all",
        "text": "Enzastaurin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98249",
        "text": "ORPHA:98249 Ehlers-Danlos syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627654?name=2953&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "480330": {
    "name": "Dimethyl fumarate",
    "substance_url": "/en/drug/substance/480330?name=2971&mode=orpha&region=&status=all",
    "substance_id": "480330",
    "regulatory_url": "/en/drug/regulatory/626988?name=2971&mode=orpha&region=",
    "regulatory_id": "626988",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "Dimethyl fumarate(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:44 Neonatal adrenoleukodystrophyORPHA:2971 Peroxisomal acyl-CoA oxidase deficiencyORPHA:43 X-linked adrenoleukodystrophy",
      "Dimethyl fumarate(Medicinal product                        - 09/01/2020)",
      "(Medicinal product                        - 09/01/2020)",
      "Disease(s) concernedORPHA:44 Neonatal adrenoleukodystrophyORPHA:2971 Peroxisomal acyl-CoA oxidase deficiencyORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480330?name=2971&mode=orpha&region=&status=all",
        "text": "Dimethyl fumarate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/44",
        "text": "ORPHA:44 Neonatal adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2971",
        "text": "ORPHA:2971 Peroxisomal acyl-CoA oxidase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/626988?name=2971&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_270": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=2971&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=2971&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=2971&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_271": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=2971&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=2971&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=2971&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "686836": {
    "name": "Adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted)",
    "substance_url": "/en/drug/substance/686836?name=298&mode=orpha&region=&status=all",
    "substance_id": "686836",
    "regulatory_url": "/en/drug/regulatory/686924?name=298&mode=orpha&region=",
    "regulatory_id": "686924",
    "orpha_substance_code": "ORPHA:298",
    "details": [
      "Adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted)(Medicinal product                        - 25/07/2024)Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "Adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted)(Medicinal product                        - 25/07/2024)",
      "(Medicinal product                        - 25/07/2024)",
      "Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/686836?name=298&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/298",
        "text": "ORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686924?name=298&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "406542": {
    "name": "Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter",
    "substance_url": "/en/drug/substance/406542?name=298&mode=orpha&region=&status=all",
    "substance_id": "406542",
    "regulatory_url": "/en/drug/regulatory/412236?name=298&mode=orpha&region=",
    "regulatory_id": "412236",
    "orpha_substance_code": "ORPHA:298",
    "details": [
      "Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter(Medicinal product                        - 22/08/2014)Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter(Medicinal product                        - 22/08/2014)",
      "(Medicinal product                        - 22/08/2014)",
      "Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406542?name=298&mode=orpha&region=&status=all",
        "text": "Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/298",
        "text": "ORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412236?name=298&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "252239": {
    "name": "Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes",
    "substance_url": "/en/drug/substance/252239?name=298&mode=orpha&region=&status=all",
    "substance_id": "252239",
    "regulatory_url": "/en/drug/regulatory/275142?name=298&mode=orpha&region=",
    "regulatory_id": "275142",
    "orpha_substance_code": "ORPHA:298",
    "details": [
      "Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes(Medicinal product                        - 15/04/2011)Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes(Medicinal product                        - 15/04/2011)",
      "(Medicinal product                        - 15/04/2011)",
      "Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/252239?name=298&mode=orpha&region=&status=all",
        "text": "Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/298",
        "text": "ORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/275142?name=298&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "412975": {
    "name": "Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter",
    "substance_url": "/en/drug/substance/412975?name=298&mode=orpha&region=&status=all",
    "substance_id": "412975",
    "regulatory_url": "/en/drug/regulatory/412976?name=298&mode=orpha&region=",
    "regulatory_id": "412976",
    "orpha_substance_code": "ORPHA:298",
    "details": [
      "Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter(Medicinal product                        - 04/09/2014)Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter(Medicinal product                        - 04/09/2014)",
      "(Medicinal product                        - 04/09/2014)",
      "Disease(s) concernedORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/412975?name=298&mode=orpha&region=&status=all",
        "text": "Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/298",
        "text": "ORPHA:298 Mitochondrial neurogastrointestinal encephalomyopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412976?name=298&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "464941": {
    "name": "Uridine triacetate",
    "substance_url": "/en/drug/substance/464941?name=30&mode=orpha&region=&status=all",
    "substance_id": "464941",
    "regulatory_url": "/en/drug/regulatory/684468?name=30&mode=orpha&region=",
    "regulatory_id": "684468",
    "orpha_substance_code": "ORPHA:30",
    "details": [
      "Uridine triacetate(Medicinal product                        - 28/06/2024)Disease(s) concernedORPHA:30 Hereditary orotic aciduria",
      "Uridine triacetate(Medicinal product                        - 28/06/2024)",
      "(Medicinal product                        - 28/06/2024)",
      "Disease(s) concernedORPHA:30 Hereditary orotic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/464941?name=30&mode=orpha&region=&status=all",
        "text": "Uridine triacetate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/30",
        "text": "ORPHA:30 Hereditary orotic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684468?name=30&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_277": {
    "name": "XURIDEN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465173?name=30&mode=orpha&region=",
    "regulatory_id": "465173",
    "orpha_substance_code": "ORPHA:30",
    "details": [
      "XURIDEN(Tradename                        - 04/09/2015)Disease(s) concernedORPHA:30 Hereditary orotic aciduria",
      "XURIDEN(Tradename                        - 04/09/2015)",
      "(Tradename                        - 04/09/2015)",
      "Disease(s) concernedORPHA:30 Hereditary orotic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/465023?name=30&mode=orpha&region=&status=all",
        "text": "XURIDEN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/30",
        "text": "ORPHA:30 Hereditary orotic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465173?name=30&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_278": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=300&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=300&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=300&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_279": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=300&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=300&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=300&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_280": {
    "name": "BUCCOLAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/325650?name=3006&mode=orpha&region=",
    "regulatory_id": "325650",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "BUCCOLAM(Tradename                        - 05/09/2011)Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "BUCCOLAM(Tradename                        - 05/09/2011)",
      "(Tradename                        - 05/09/2011)",
      "Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/325618?name=3006&mode=orpha&region=&status=all",
        "text": "BUCCOLAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98259",
        "text": "ORPHA:98259 Childhood-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98260",
        "text": "ORPHA:98260 Adolescent-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/325650?name=3006&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:98260 Adolescent-onset epilepsy syndrome\n                                \n\n\n\n\n                                    ORPHA:693802 Neonatal-infantile onset epilepsy syndrome\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_281": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=3006&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=3006&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=3006&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_282": {
    "name": "SEZABY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/635898?name=3006&mode=orpha&region=",
    "regulatory_id": "635898",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "SEZABY(Tradename                        - 17/11/2022)Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "SEZABY(Tradename                        - 17/11/2022)",
      "(Tradename                        - 17/11/2022)",
      "Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/635897?name=3006&mode=orpha&region=&status=all",
        "text": "SEZABY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635898?name=3006&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_283": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=308425&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=308425&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=308425&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_284": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622237?name=308425&mode=orpha&region=",
    "regulatory_id": "622237",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 22/01/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 22/01/2021)",
      "(Tradename                        - 22/01/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=308425&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622237?name=308425&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_285": {
    "name": "ILARIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
    "regulatory_id": "216672",
    "orpha_substance_code": "ORPHA:309025",
    "details": [
      "ILARIS(Tradename                        - 23/10/2009)Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "ILARIS(Tradename                        - 23/10/2009)",
      "(Tradename                        - 23/10/2009)",
      "Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/170133?name=309025&mode=orpha&region=&status=all",
        "text": "ILARIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/342",
        "text": "ORPHA:342 Familial Mediterranean fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/343",
        "text": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/829",
        "text": "ORPHA:829 Adult-onset Still disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/32960",
        "text": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/85414",
        "text": "ORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101995",
        "text": "ORPHA:101995 Periodic fever syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/208650",
        "text": "ORPHA:208650 NLRP3-associated autoinflammatory disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309025",
        "text": "ORPHA:309025 Mevalonate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome\n                                \n\n\n\n\n                                    ORPHA:85414 Systemic-onset juvenile idiopathic arthritis\n                                \n\n\n\n\n                                    ORPHA:101995 Periodic fever syndrome\n                                \n\n\n\n\n                                    ORPHA:208650 NLRP3-associated autoinflammatory disease\n                                \n\n\n\n\n                                    ORPHA:309025 Mevalonate kinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_286": {
    "name": "ILARIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
    "regulatory_id": "216672",
    "orpha_substance_code": "ORPHA:309025",
    "details": [
      "ILARIS(Tradename                        - 23/10/2009)Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "ILARIS(Tradename                        - 23/10/2009)",
      "(Tradename                        - 23/10/2009)",
      "Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/170133?name=309025&mode=orpha&region=&status=all",
        "text": "ILARIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/342",
        "text": "ORPHA:342 Familial Mediterranean fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/343",
        "text": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/829",
        "text": "ORPHA:829 Adult-onset Still disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/32960",
        "text": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/85414",
        "text": "ORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101995",
        "text": "ORPHA:101995 Periodic fever syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/208650",
        "text": "ORPHA:208650 NLRP3-associated autoinflammatory disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309025",
        "text": "ORPHA:309025 Mevalonate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome\n                                \n\n\n\n\n                                    ORPHA:85414 Systemic-onset juvenile idiopathic arthritis\n                                \n\n\n\n\n                                    ORPHA:101995 Periodic fever syndrome\n                                \n\n\n\n\n                                    ORPHA:208650 NLRP3-associated autoinflammatory disease\n                                \n\n\n\n\n                                    ORPHA:309025 Mevalonate kinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_287": {
    "name": "ILARIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/405652?name=309025&mode=orpha&region=",
    "regulatory_id": "405652",
    "orpha_substance_code": "ORPHA:85414",
    "details": [
      "ILARIS(Tradename                        - 09/05/2013)Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:575 Muckle-Wells syndromeORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:47045 Familial cold urticariaORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
      "ILARIS(Tradename                        - 09/05/2013)",
      "(Tradename                        - 09/05/2013)",
      "Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:575 Muckle-Wells syndromeORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:47045 Familial cold urticariaORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/170133?name=309025&mode=orpha&region=&status=all",
        "text": "ILARIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/342",
        "text": "ORPHA:342 Familial Mediterranean fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/575",
        "text": "ORPHA:575 Muckle-Wells syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/343",
        "text": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/32960",
        "text": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/47045",
        "text": "ORPHA:47045 Familial cold urticaria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/85414",
        "text": "ORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/405652?name=309025&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever\n                                \n\n\n\n\n                                    ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome\n                                \n\n\n\n\n                                    ORPHA:47045 Familial cold urticaria\n                                \n\n\n\n\n                                    ORPHA:85414 Systemic-onset juvenile idiopathic arthritis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "89060": {
    "name": "Canakinumab",
    "substance_url": "/en/drug/substance/89060?name=309025&mode=orpha&region=&status=all",
    "substance_id": "89060",
    "regulatory_url": "/en/drug/regulatory/479868?name=309025&mode=orpha&region=",
    "regulatory_id": "479868",
    "orpha_substance_code": "ORPHA:343",
    "details": [
      "Canakinumab(Medicinal product                        - 05/12/2013)Disease(s) concernedORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
      "Canakinumab(Medicinal product                        - 05/12/2013)",
      "(Medicinal product                        - 05/12/2013)",
      "Disease(s) concernedORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/89060?name=309025&mode=orpha&region=&status=all",
        "text": "Canakinumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/343",
        "text": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/479868?name=309025&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_289": {
    "name": "ILARIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
    "regulatory_id": "216672",
    "orpha_substance_code": "ORPHA:309025",
    "details": [
      "ILARIS(Tradename                        - 23/10/2009)Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "ILARIS(Tradename                        - 23/10/2009)",
      "(Tradename                        - 23/10/2009)",
      "Disease(s) concernedORPHA:342 Familial Mediterranean feverORPHA:343 Hyperimmunoglobulinemia D with periodic feverORPHA:829 Adult-onset Still diseaseORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndromeORPHA:85414 Systemic-onset juvenile idiopathic arthritisORPHA:101995 Periodic fever syndromeORPHA:208650 NLRP3-associated autoinflammatory diseaseORPHA:309025 Mevalonate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/170133?name=309025&mode=orpha&region=&status=all",
        "text": "ILARIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/342",
        "text": "ORPHA:342 Familial Mediterranean fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/343",
        "text": "ORPHA:343 Hyperimmunoglobulinemia D with periodic fever",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/829",
        "text": "ORPHA:829 Adult-onset Still disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/32960",
        "text": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/85414",
        "text": "ORPHA:85414 Systemic-onset juvenile idiopathic arthritis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101995",
        "text": "ORPHA:101995 Periodic fever syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/208650",
        "text": "ORPHA:208650 NLRP3-associated autoinflammatory disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309025",
        "text": "ORPHA:309025 Mevalonate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/216672?name=309025&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:32960 Tumor necrosis factor receptor 1 associated periodic syndrome\n                                \n\n\n\n\n                                    ORPHA:85414 Systemic-onset juvenile idiopathic arthritis\n                                \n\n\n\n\n                                    ORPHA:101995 Periodic fever syndrome\n                                \n\n\n\n\n                                    ORPHA:208650 NLRP3-associated autoinflammatory disease\n                                \n\n\n\n\n                                    ORPHA:309025 Mevalonate kinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "83692": {
    "name": "Bacterial lipase",
    "substance_url": "/en/drug/substance/83692?name=309031&mode=orpha&region=&status=all",
    "substance_id": "83692",
    "regulatory_url": "/en/drug/regulatory/134002?name=309031&mode=orpha&region=",
    "regulatory_id": "134002",
    "orpha_substance_code": "ORPHA:309031",
    "details": [
      "Bacterial lipase(Medicinal product                        - 07/11/2005)Disease(s) concernedORPHA:586 Cystic fibrosisORPHA:676 Autosomal dominant hereditary chronic pancreatitisORPHA:811 Shwachman-Diamond syndromeORPHA:309031 Pancreatic triacylglycerol lipase deficiency",
      "Bacterial lipase(Medicinal product                        - 07/11/2005)",
      "(Medicinal product                        - 07/11/2005)",
      "Disease(s) concernedORPHA:586 Cystic fibrosisORPHA:676 Autosomal dominant hereditary chronic pancreatitisORPHA:811 Shwachman-Diamond syndromeORPHA:309031 Pancreatic triacylglycerol lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/83692?name=309031&mode=orpha&region=&status=all",
        "text": "Bacterial lipase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/586",
        "text": "ORPHA:586 Cystic fibrosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/676",
        "text": "ORPHA:676 Autosomal dominant hereditary chronic pancreatitis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/811",
        "text": "ORPHA:811 Shwachman-Diamond syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309031",
        "text": "ORPHA:309031 Pancreatic triacylglycerol lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134002?name=309031&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:309031 Pancreatic triacylglycerol lipase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_291": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=309246&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=309246&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_292": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=309246&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=309246&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "642434": {
    "name": "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol",
    "substance_url": "/en/drug/substance/642434?name=309246&mode=orpha&region=&status=all",
    "substance_id": "642434",
    "regulatory_url": "/en/drug/regulatory/642438?name=309246&mode=orpha&region=",
    "regulatory_id": "642438",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol(Medicinal product                        - 15/02/2023)",
      "(Medicinal product                        - 15/02/2023)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/642434?name=309246&mode=orpha&region=&status=all",
        "text": "(2S,3R,4R,5S)-1-[5-(2-fluoro-biphenyl-4-ylmethoxy)-pentyl]-2-hydroxymethyl-piperidine-3,4,5-triol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642438?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627916": {
    "name": "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes",
    "substance_url": "/en/drug/substance/627916?name=309246&mode=orpha&region=&status=all",
    "substance_id": "627916",
    "regulatory_url": "/en/drug/regulatory/627917?name=309246&mode=orpha&region=",
    "regulatory_id": "627917",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes(Medicinal product                        - 20/08/2021)",
      "(Medicinal product                        - 20/08/2021)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627916?name=309246&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627917?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "406512": {
    "name": "Venglustat",
    "substance_url": "/en/drug/substance/406512?name=309246&mode=orpha&region=&status=all",
    "substance_id": "406512",
    "regulatory_url": "/en/drug/regulatory/604849?name=309246&mode=orpha&region=",
    "regulatory_id": "604849",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "Venglustat(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "Venglustat(Medicinal product                        - 21/08/2020)",
      "(Medicinal product                        - 21/08/2020)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406512?name=309246&mode=orpha&region=&status=all",
        "text": "Venglustat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604849?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "572537": {
    "name": "Sinbaglustat",
    "substance_url": "/en/drug/substance/572537?name=309246&mode=orpha&region=&status=all",
    "substance_id": "572537",
    "regulatory_url": "/en/drug/regulatory/572539?name=309246&mode=orpha&region=",
    "regulatory_id": "572539",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "Sinbaglustat(Medicinal product                        - 13/11/2019)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "Sinbaglustat(Medicinal product                        - 13/11/2019)",
      "(Medicinal product                        - 13/11/2019)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/572537?name=309246&mode=orpha&region=&status=all",
        "text": "Sinbaglustat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/572539?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "510739": {
    "name": "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits",
    "substance_url": "/en/drug/substance/510739?name=309246&mode=orpha&region=&status=all",
    "substance_id": "510739",
    "regulatory_url": "/en/drug/regulatory/635786?name=309246&mode=orpha&region=",
    "regulatory_id": "635786",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits(Medicinal product                        - 17/01/2018)",
      "(Medicinal product                        - 17/01/2018)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/510739?name=309246&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635786?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "591528": {
    "name": "N-Acetyl-L-Leucine",
    "substance_url": "/en/drug/substance/591528?name=309246&mode=orpha&region=&status=all",
    "substance_id": "591528",
    "regulatory_url": "/en/drug/regulatory/634594?name=309246&mode=orpha&region=",
    "regulatory_id": "634594",
    "orpha_substance_code": "ORPHA:309152",
    "details": [
      "N-Acetyl-L-Leucine(Medicinal product                        - 11/01/2022)Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "N-Acetyl-L-Leucine(Medicinal product                        - 11/01/2022)",
      "(Medicinal product                        - 11/01/2022)",
      "Disease(s) concernedORPHA:309152 GM2 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/591528?name=309246&mode=orpha&region=&status=all",
        "text": "N-Acetyl-L-Leucine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309152",
        "text": "ORPHA:309152 GM2 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/634594?name=309246&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "406518": {
    "name": "Recombinant human apolipoprotein A-I in a complex with phospholipids",
    "substance_url": "/en/drug/substance/406518?name=31150&mode=orpha&region=&status=all",
    "substance_id": "406518",
    "regulatory_url": "/en/drug/regulatory/412150?name=31150&mode=orpha&region=",
    "regulatory_id": "412150",
    "orpha_substance_code": "ORPHA:31150",
    "details": [
      "Recombinant human apolipoprotein A-I in a complex with phospholipids(Medicinal product                        - 22/08/2014)Disease(s) concernedORPHA:31150 Tangier disease",
      "Recombinant human apolipoprotein A-I in a complex with phospholipids(Medicinal product                        - 22/08/2014)",
      "(Medicinal product                        - 22/08/2014)",
      "Disease(s) concernedORPHA:31150 Tangier disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406518?name=31150&mode=orpha&region=&status=all",
        "text": "Recombinant human apolipoprotein A-I in a complex with phospholipids",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/31150",
        "text": "ORPHA:31150 Tangier disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412150?name=31150&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_300": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=314629&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=314629&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=314629&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_301": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=314629&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=314629&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=314629&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_302": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=314629&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=314629&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=314629&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_303": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=314632&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=314632&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=314632&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_304": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=314632&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=314632&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=314632&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "412263": {
    "name": "Palovarotene",
    "substance_url": "/en/drug/substance/412263?name=321&mode=orpha&region=&status=all",
    "substance_id": "412263",
    "regulatory_url": "/en/drug/regulatory/520945?name=321&mode=orpha&region=",
    "regulatory_id": "520945",
    "orpha_substance_code": "ORPHA:321",
    "details": [
      "Palovarotene(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:321 Multiple osteochondromas",
      "Palovarotene(Medicinal product                        - 27/06/2018)",
      "(Medicinal product                        - 27/06/2018)",
      "Disease(s) concernedORPHA:321 Multiple osteochondromas",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/412263?name=321&mode=orpha&region=&status=all",
        "text": "Palovarotene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/321",
        "text": "ORPHA:321 Multiple osteochondromas",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/520945?name=321&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_306": {
    "name": "GALAFOLD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/624875?name=324&mode=orpha&region=",
    "regulatory_id": "624875",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "GALAFOLD(Tradename                        - 23/07/2021)Disease(s) concernedORPHA:324 Fabry disease",
      "GALAFOLD(Tradename                        - 23/07/2021)",
      "(Tradename                        - 23/07/2021)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
        "text": "GALAFOLD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/624875?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_307": {
    "name": "GALAFOLD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/459565?name=324&mode=orpha&region=",
    "regulatory_id": "459565",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "GALAFOLD(Tradename                        - 26/05/2016)Disease(s) concernedORPHA:324 Fabry disease",
      "GALAFOLD(Tradename                        - 26/05/2016)",
      "(Tradename                        - 26/05/2016)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
        "text": "GALAFOLD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/459565?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_308": {
    "name": "ELFABRIO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/650350?name=324&mode=orpha&region=",
    "regulatory_id": "650350",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "ELFABRIO(Tradename                        - 04/05/2023)Disease(s) concernedORPHA:324 Fabry disease",
      "ELFABRIO(Tradename                        - 04/05/2023)",
      "(Tradename                        - 04/05/2023)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/650349?name=324&mode=orpha&region=&status=all",
        "text": "ELFABRIO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650350?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_309": {
    "name": "REPLAGAL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131342?name=324&mode=orpha&region=",
    "regulatory_id": "131342",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "REPLAGAL(Tradename                        - 03/08/2001)Disease(s) concernedORPHA:324 Fabry disease",
      "REPLAGAL(Tradename                        - 03/08/2001)",
      "(Tradename                        - 03/08/2001)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34251?name=324&mode=orpha&region=&status=all",
        "text": "REPLAGAL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131342?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_310": {
    "name": "FABRAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131340?name=324&mode=orpha&region=",
    "regulatory_id": "131340",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "FABRAZYME(Tradename                        - 03/08/2001)Disease(s) concernedORPHA:324 Fabry disease",
      "FABRAZYME(Tradename                        - 03/08/2001)",
      "(Tradename                        - 03/08/2001)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33469?name=324&mode=orpha&region=&status=all",
        "text": "FABRAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131340?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604987": {
    "name": "Alpha galactosidase A",
    "substance_url": "/en/drug/substance/604987?name=324&mode=orpha&region=&status=all",
    "substance_id": "604987",
    "regulatory_url": "/en/drug/regulatory/604988?name=324&mode=orpha&region=",
    "regulatory_id": "604988",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Alpha galactosidase A(Medicinal product                        - 06/01/2021)Disease(s) concernedORPHA:324 Fabry disease",
      "Alpha galactosidase A(Medicinal product                        - 06/01/2021)",
      "(Medicinal product                        - 06/01/2021)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604987?name=324&mode=orpha&region=&status=all",
        "text": "Alpha galactosidase A",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604988?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "588539": {
    "name": "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA",
    "substance_url": "/en/drug/substance/588539?name=324&mode=orpha&region=&status=all",
    "substance_id": "588539",
    "regulatory_url": "/en/drug/regulatory/588540?name=324&mode=orpha&region=",
    "regulatory_id": "588540",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 28/02/2020)Disease(s) concernedORPHA:324 Fabry disease",
      "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 28/02/2020)",
      "(Medicinal product                        - 28/02/2020)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588539?name=324&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588540?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "588863": {
    "name": "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA",
    "substance_url": "/en/drug/substance/588863?name=324&mode=orpha&region=&status=all",
    "substance_id": "588863",
    "regulatory_url": "/en/drug/regulatory/588865?name=324&mode=orpha&region=",
    "regulatory_id": "588865",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:324 Fabry disease",
      "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA(Medicinal product                        - 09/01/2020)",
      "(Medicinal product                        - 09/01/2020)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588863?name=324&mode=orpha&region=&status=all",
        "text": "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588865?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "487922": {
    "name": "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene",
    "substance_url": "/en/drug/substance/487922?name=324&mode=orpha&region=&status=all",
    "substance_id": "487922",
    "regulatory_url": "/en/drug/regulatory/487926?name=324&mode=orpha&region=",
    "regulatory_id": "487926",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene(Medicinal product                        - 20/03/2017)Disease(s) concernedORPHA:324 Fabry disease",
      "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene(Medicinal product                        - 20/03/2017)",
      "(Medicinal product                        - 20/03/2017)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/487922?name=324&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/487926?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "317192": {
    "name": "Lucerastat",
    "substance_url": "/en/drug/substance/317192?name=324&mode=orpha&region=&status=all",
    "substance_id": "317192",
    "regulatory_url": "/en/drug/regulatory/327068?name=324&mode=orpha&region=",
    "regulatory_id": "327068",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Lucerastat(Medicinal product                        - 09/08/2012)Disease(s) concernedORPHA:324 Fabry disease",
      "Lucerastat(Medicinal product                        - 09/08/2012)",
      "(Medicinal product                        - 09/08/2012)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/317192?name=324&mode=orpha&region=&status=all",
        "text": "Lucerastat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/327068?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "89184": {
    "name": "Migalastat hydrochloride",
    "substance_url": "/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
    "substance_id": "89184",
    "regulatory_url": "/en/drug/regulatory/134045?name=324&mode=orpha&region=",
    "regulatory_id": "134045",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Migalastat hydrochloride(Medicinal product                        - 22/05/2006)Disease(s) concernedORPHA:324 Fabry disease",
      "Migalastat hydrochloride(Medicinal product                        - 22/05/2006)",
      "(Medicinal product                        - 22/05/2006)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/89184?name=324&mode=orpha&region=&status=all",
        "text": "Migalastat hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134045?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "628415": {
    "name": "Adeno-associated virus serotype C102 containing the human GLA gene",
    "substance_url": "/en/drug/substance/628415?name=324&mode=orpha&region=&status=all",
    "substance_id": "628415",
    "regulatory_url": "/en/drug/regulatory/628416?name=324&mode=orpha&region=",
    "regulatory_id": "628416",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Adeno-associated virus serotype C102 containing the human GLA gene(Medicinal product                        - 13/04/2022)Disease(s) concernedORPHA:324 Fabry disease",
      "Adeno-associated virus serotype C102 containing the human GLA gene(Medicinal product                        - 13/04/2022)",
      "(Medicinal product                        - 13/04/2022)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628415?name=324&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype C102 containing the human GLA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628416?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604880": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha",
    "substance_url": "/en/drug/substance/604880?name=324&mode=orpha&region=&status=all",
    "substance_id": "604880",
    "regulatory_url": "/en/drug/regulatory/604881?name=324&mode=orpha&region=",
    "regulatory_id": "604881",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:324 Fabry disease",
      "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604880?name=324&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604881?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "500669": {
    "name": "Pegunigalsidase alfa",
    "substance_url": "/en/drug/substance/500669?name=324&mode=orpha&region=&status=all",
    "substance_id": "500669",
    "regulatory_url": "/en/drug/regulatory/500671?name=324&mode=orpha&region=",
    "regulatory_id": "500671",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Pegunigalsidase alfa(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:324 Fabry disease",
      "Pegunigalsidase alfa(Medicinal product                        - 12/12/2017)",
      "(Medicinal product                        - 12/12/2017)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/500669?name=324&mode=orpha&region=&status=all",
        "text": "Pegunigalsidase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/500671?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "33470": {
    "name": "Agalsidase beta",
    "substance_url": "/en/drug/substance/33470?name=324&mode=orpha&region=&status=all",
    "substance_id": "33470",
    "regulatory_url": "/en/drug/regulatory/133689?name=324&mode=orpha&region=",
    "regulatory_id": "133689",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Agalsidase beta(Medicinal product                        - 08/08/2000)Disease(s) concernedORPHA:324 Fabry disease",
      "Agalsidase beta(Medicinal product                        - 08/08/2000)",
      "(Medicinal product                        - 08/08/2000)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/33470?name=324&mode=orpha&region=&status=all",
        "text": "Agalsidase beta",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133689?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "34115": {
    "name": "Agalsidase alfa",
    "substance_url": "/en/drug/substance/34115?name=324&mode=orpha&region=&status=all",
    "substance_id": "34115",
    "regulatory_url": "/en/drug/regulatory/133688?name=324&mode=orpha&region=",
    "regulatory_id": "133688",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Agalsidase alfa(Medicinal product                        - 08/08/2000)Disease(s) concernedORPHA:324 Fabry disease",
      "Agalsidase alfa(Medicinal product                        - 08/08/2000)",
      "(Medicinal product                        - 08/08/2000)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/34115?name=324&mode=orpha&region=&status=all",
        "text": "Agalsidase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133688?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_322": {
    "name": "FABRAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622163?name=324&mode=orpha&region=",
    "regulatory_id": "622163",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "FABRAZYME(Tradename                        - 11/03/2021)Disease(s) concernedORPHA:324 Fabry disease",
      "FABRAZYME(Tradename                        - 11/03/2021)",
      "(Tradename                        - 11/03/2021)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33469?name=324&mode=orpha&region=&status=all",
        "text": "FABRAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622163?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_323": {
    "name": "GALAFOLD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/527546?name=324&mode=orpha&region=",
    "regulatory_id": "527546",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "GALAFOLD(Tradename                        - 10/08/2018)Disease(s) concernedORPHA:324 Fabry disease",
      "GALAFOLD(Tradename                        - 10/08/2018)",
      "(Tradename                        - 10/08/2018)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/459564?name=324&mode=orpha&region=&status=all",
        "text": "GALAFOLD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527546?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "691429": {
    "name": "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)",
    "substance_url": "/en/drug/substance/691429?name=324&mode=orpha&region=&status=all",
    "substance_id": "691429",
    "regulatory_url": "/en/drug/regulatory/691596?name=324&mode=orpha&region=",
    "regulatory_id": "691596",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)(Medicinal product                        - 04/11/2024)Disease(s) concernedORPHA:324 Fabry disease",
      "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)(Medicinal product                        - 04/11/2024)",
      "(Medicinal product                        - 04/11/2024)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/691429?name=324&mode=orpha&region=&status=all",
        "text": "Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing human alpha-galactosidase A (hGLA)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/691596?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "688294": {
    "name": "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A",
    "substance_url": "/en/drug/substance/688294?name=324&mode=orpha&region=&status=all",
    "substance_id": "688294",
    "regulatory_url": "/en/drug/regulatory/688382?name=324&mode=orpha&region=",
    "regulatory_id": "688382",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A(Medicinal product                        - 19/09/2024)Disease(s) concernedORPHA:324 Fabry disease",
      "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A(Medicinal product                        - 19/09/2024)",
      "(Medicinal product                        - 19/09/2024)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688294?name=324&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 5 encoding human alpha-galactosidase A",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688382?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "676680": {
    "name": "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein",
    "substance_url": "/en/drug/substance/676680?name=324&mode=orpha&region=&status=all",
    "substance_id": "676680",
    "regulatory_url": "/en/drug/regulatory/676731?name=324&mode=orpha&region=",
    "regulatory_id": "676731",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein(Medicinal product                        - 24/05/2024)Disease(s) concernedORPHA:324 Fabry disease",
      "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein(Medicinal product                        - 24/05/2024)",
      "(Medicinal product                        - 24/05/2024)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/676680?name=324&mode=orpha&region=&status=all",
        "text": "Recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/676731?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "662638": {
    "name": "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene",
    "substance_url": "/en/drug/substance/662638?name=324&mode=orpha&region=&status=all",
    "substance_id": "662638",
    "regulatory_url": "/en/drug/regulatory/662837?name=324&mode=orpha&region=",
    "regulatory_id": "662837",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene(Medicinal product                        - 15/02/2024)Disease(s) concernedORPHA:324 Fabry disease",
      "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene(Medicinal product                        - 15/02/2024)",
      "(Medicinal product                        - 15/02/2024)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/662638?name=324&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/662837?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "663118": {
    "name": "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme",
    "substance_url": "/en/drug/substance/663118?name=324&mode=orpha&region=&status=all",
    "substance_id": "663118",
    "regulatory_url": "/en/drug/regulatory/663434?name=324&mode=orpha&region=",
    "regulatory_id": "663434",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme(Medicinal product                        - 19/09/2023)Disease(s) concernedORPHA:324 Fabry disease",
      "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme(Medicinal product                        - 19/09/2023)",
      "(Medicinal product                        - 19/09/2023)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/663118?name=324&mode=orpha&region=&status=all",
        "text": "Autologous B cells engineered to secrete intact alpha-galactosidase A enzyme",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/663434?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "666382": {
    "name": "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A",
    "substance_url": "/en/drug/substance/666382?name=324&mode=orpha&region=&status=all",
    "substance_id": "666382",
    "regulatory_url": "/en/drug/regulatory/666434?name=324&mode=orpha&region=",
    "regulatory_id": "666434",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A(Medicinal product                        - 11/08/2023)Disease(s) concernedORPHA:324 Fabry disease",
      "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A(Medicinal product                        - 11/08/2023)",
      "(Medicinal product                        - 11/08/2023)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666382?name=324&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666434?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "645663": {
    "name": "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene",
    "substance_url": "/en/drug/substance/645663?name=324&mode=orpha&region=&status=all",
    "substance_id": "645663",
    "regulatory_url": "/en/drug/regulatory/645664?name=324&mode=orpha&region=",
    "regulatory_id": "645664",
    "orpha_substance_code": "ORPHA:324",
    "details": [
      "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene(Medicinal product                        - 09/03/2020)Disease(s) concernedORPHA:324 Fabry disease",
      "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene(Medicinal product                        - 09/03/2020)",
      "(Medicinal product                        - 09/03/2020)",
      "Disease(s) concernedORPHA:324 Fabry disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/645663?name=324&mode=orpha&region=&status=all",
        "text": "Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/324",
        "text": "ORPHA:324 Fabry disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/645664?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_331": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=324&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=324&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_332": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=324&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=324&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=324&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_333": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=33&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=33&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=33&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "376876": {
    "name": "Recombinant human acid ceramidase",
    "substance_url": "/en/drug/substance/376876?name=333&mode=orpha&region=&status=all",
    "substance_id": "376876",
    "regulatory_url": "/en/drug/regulatory/398161?name=333&mode=orpha&region=",
    "regulatory_id": "398161",
    "orpha_substance_code": "ORPHA:333",
    "details": [
      "Recombinant human acid ceramidase(Medicinal product                        - 19/02/2014)Disease(s) concernedORPHA:333 Farber disease",
      "Recombinant human acid ceramidase(Medicinal product                        - 19/02/2014)",
      "(Medicinal product                        - 19/02/2014)",
      "Disease(s) concernedORPHA:333 Farber disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/376876?name=333&mode=orpha&region=&status=all",
        "text": "Recombinant human acid ceramidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/333",
        "text": "ORPHA:333 Farber disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/398161?name=333&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_335": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=333&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=333&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=333&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_336": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=333&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=333&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=333&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689489": {
    "name": "Adeno-associated virus serotype 9 (AAV9) vector containing a linear, self-complementary DNA genome encoding a codon-optimized, CpG motif-depleted, human fukutin-related protein (FKRP) gene under the control of a Syn100 promoter (scAAV9.Syn100.coHuFKRP)",
    "substance_url": "/en/drug/substance/689489?name=34515&mode=orpha&region=&status=all",
    "substance_id": "689489",
    "regulatory_url": "/en/drug/regulatory/689716?name=34515&mode=orpha&region=",
    "regulatory_id": "689716",
    "orpha_substance_code": "ORPHA:34515",
    "details": [
      "Adeno-associated virus serotype 9 (AAV9) vector containing a linear, self-complementary DNA genome encoding a codon-optimized, CpG motif-depleted, human fukutin-related protein (FKRP) gene under the control of a Syn100 promoter (scAAV9.Syn100.coHuFKRP)(Medicinal product                        - 17/10/2024)Disease(s) concernedORPHA:34515 FKRP-related limb-girdle muscular dystrophy R9",
      "Adeno-associated virus serotype 9 (AAV9) vector containing a linear, self-complementary DNA genome encoding a codon-optimized, CpG motif-depleted, human fukutin-related protein (FKRP) gene under the control of a Syn100 promoter (scAAV9.Syn100.coHuFKRP)(Medicinal product                        - 17/10/2024)",
      "(Medicinal product                        - 17/10/2024)",
      "Disease(s) concernedORPHA:34515 FKRP-related limb-girdle muscular dystrophy R9",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689489?name=34515&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 9 (AAV9) vector containing a linear, self-complementary DNA genome encoding a codon-optimized, CpG motif-depleted, human fukutin-related protein (FKRP) gene under the control of a Syn100 promoter (scAAV9.Syn100.coHuFKRP)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/34515",
        "text": "ORPHA:34515 FKRP-related limb-girdle muscular dystrophy R9",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689716?name=34515&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "704552": {
    "name": "Adeno-associated viral vector serotype 2i8 containing the human LAMP2 isoform B transgene",
    "substance_url": "/en/drug/substance/704552?name=34587&mode=orpha&region=&status=all",
    "substance_id": "704552",
    "regulatory_url": "/en/drug/regulatory/704566?name=34587&mode=orpha&region=",
    "regulatory_id": "704566",
    "orpha_substance_code": "ORPHA:34587",
    "details": [
      "Adeno-associated viral vector serotype 2i8 containing the human LAMP2 isoform B transgene(Medicinal product                        - 22/05/2025)Disease(s) concernedORPHA:34587 Danon disease",
      "Adeno-associated viral vector serotype 2i8 containing the human LAMP2 isoform B transgene(Medicinal product                        - 22/05/2025)",
      "(Medicinal product                        - 22/05/2025)",
      "Disease(s) concernedORPHA:34587 Danon disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/704552?name=34587&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 2i8 containing the human LAMP2 isoform B transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/34587",
        "text": "ORPHA:34587 Danon disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704566?name=34587&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "661218": {
    "name": "Adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene",
    "substance_url": "/en/drug/substance/661218?name=34587&mode=orpha&region=&status=all",
    "substance_id": "661218",
    "regulatory_url": "/en/drug/regulatory/661306?name=34587&mode=orpha&region=",
    "regulatory_id": "661306",
    "orpha_substance_code": "ORPHA:34587",
    "details": [
      "Adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene(Medicinal product                        - 16/08/2023)Disease(s) concernedORPHA:34587 Danon disease",
      "Adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene(Medicinal product                        - 16/08/2023)",
      "(Medicinal product                        - 16/08/2023)",
      "Disease(s) concernedORPHA:34587 Danon disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661218?name=34587&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/34587",
        "text": "ORPHA:34587 Danon disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661306?name=34587&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "673933": {
    "name": "Autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)",
    "substance_url": "/en/drug/substance/673933?name=34587&mode=orpha&region=&status=all",
    "substance_id": "673933",
    "regulatory_url": "/en/drug/regulatory/674144?name=34587&mode=orpha&region=",
    "regulatory_id": "674144",
    "orpha_substance_code": "ORPHA:34587",
    "details": [
      "Autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)(Medicinal product                        - 23/04/2024)Disease(s) concernedORPHA:34587 Danon disease",
      "Autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)(Medicinal product                        - 23/04/2024)",
      "(Medicinal product                        - 23/04/2024)",
      "Disease(s) concernedORPHA:34587 Danon disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/673933?name=34587&mode=orpha&region=&status=all",
        "text": "Autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/34587",
        "text": "ORPHA:34587 Danon disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/674144?name=34587&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "(DD)\n\n                    (Medicinal product                        - 23/04/2024)\n                \n\n\n\n\n                        Disease(s) concerned\n                    \n\n\n\n\n                                    ORPHA:34587 Danon disease\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_341": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131343?name=35&mode=orpha&region=",
    "regulatory_id": "131343",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 27/05/2011)Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 27/05/2011)",
      "(Tradename                        - 27/05/2011)",
      "Disease(s) concernedORPHA:33 Isovaleric acidemiaORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=35&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/33",
        "text": "ORPHA:33 Isovaleric acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131343?name=35&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "559538": {
    "name": "Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle",
    "substance_url": "/en/drug/substance/559538?name=35&mode=orpha&region=&status=all",
    "substance_id": "559538",
    "regulatory_url": "/en/drug/regulatory/559540?name=35&mode=orpha&region=",
    "regulatory_id": "559540",
    "orpha_substance_code": "ORPHA:35",
    "details": [
      "Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle(Medicinal product                        - 24/04/2019)Disease(s) concernedORPHA:35 Propionic acidemia",
      "Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle(Medicinal product                        - 24/04/2019)",
      "(Medicinal product                        - 24/04/2019)",
      "Disease(s) concernedORPHA:35 Propionic acidemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/559538?name=35&mode=orpha&region=&status=all",
        "text": "Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/559540?name=35&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_343": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622237?name=35&mode=orpha&region=",
    "regulatory_id": "622237",
    "orpha_substance_code": "ORPHA:293355",
    "details": [
      "CARBAGLU(Tradename                        - 22/01/2021)Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "CARBAGLU(Tradename                        - 22/01/2021)",
      "(Tradename                        - 22/01/2021)",
      "Disease(s) concernedORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:35 Propionic acidemiaORPHA:293355 Methylmalonic acidemia without homocystinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=35&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293355",
        "text": "ORPHA:293355 Methylmalonic acidemia without homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622237?name=35&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "688300": {
    "name": "Adeno-Associated Virus 9 vector expressing a wild-type cDNA encoding human Propionyl-CoA Carboxylase, subunit beta (AAV9-hPCCB)",
    "substance_url": "/en/drug/substance/688300?name=35&mode=orpha&region=&status=all",
    "substance_id": "688300",
    "regulatory_url": "/en/drug/regulatory/688385?name=35&mode=orpha&region=",
    "regulatory_id": "688385",
    "orpha_substance_code": "ORPHA:35",
    "details": [
      "Adeno-Associated Virus 9 vector expressing a wild-type cDNA encoding human Propionyl-CoA Carboxylase, subunit beta (AAV9-hPCCB)(Medicinal product                        - 10/09/2024)Disease(s) concernedORPHA:35 Propionic acidemia",
      "Adeno-Associated Virus 9 vector expressing a wild-type cDNA encoding human Propionyl-CoA Carboxylase, subunit beta (AAV9-hPCCB)(Medicinal product                        - 10/09/2024)",
      "(Medicinal product                        - 10/09/2024)",
      "Disease(s) concernedORPHA:35 Propionic acidemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688300?name=35&mode=orpha&region=&status=all",
        "text": "Adeno-Associated Virus 9 vector expressing a wild-type cDNA encoding human Propionyl-CoA Carboxylase, subunit beta (AAV9-hPCCB)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35",
        "text": "ORPHA:35 Propionic acidemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688385?name=35&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "559146": {
    "name": "9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester",
    "substance_url": "/en/drug/substance/559146?name=35069&mode=orpha&region=&status=all",
    "substance_id": "559146",
    "regulatory_url": "/en/drug/regulatory/559147?name=35069&mode=orpha&region=",
    "regulatory_id": "559147",
    "orpha_substance_code": "ORPHA:35069",
    "details": [
      "9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester(Medicinal product                        - 26/02/2019)Disease(s) concernedORPHA:35069 Infantile neuroaxonal dystrophy",
      "9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester(Medicinal product                        - 26/02/2019)",
      "(Medicinal product                        - 26/02/2019)",
      "Disease(s) concernedORPHA:35069 Infantile neuroaxonal dystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/559146?name=35069&mode=orpha&region=&status=all",
        "text": "9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35069",
        "text": "ORPHA:35069 Infantile neuroaxonal dystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/559147?name=35069&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "89109": {
    "name": "Sacrosidase",
    "substance_url": "/en/drug/substance/89109?name=35122&mode=orpha&region=&status=all",
    "substance_id": "89109",
    "regulatory_url": "/en/drug/regulatory/364483?name=35122&mode=orpha&region=",
    "regulatory_id": "364483",
    "orpha_substance_code": "ORPHA:35122",
    "details": [
      "Sacrosidase(Medicinal product                        - 05/08/2013)Disease(s) concernedORPHA:35122 Congenital sucrase-isomaltase deficiency",
      "Sacrosidase(Medicinal product                        - 05/08/2013)",
      "(Medicinal product                        - 05/08/2013)",
      "Disease(s) concernedORPHA:35122 Congenital sucrase-isomaltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/89109?name=35122&mode=orpha&region=&status=all",
        "text": "Sacrosidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35122",
        "text": "ORPHA:35122 Congenital sucrase-isomaltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/364483?name=35122&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_347": {
    "name": "SUCRAID",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131193?name=35122&mode=orpha&region=",
    "regulatory_id": "131193",
    "orpha_substance_code": "ORPHA:35122",
    "details": [
      "SUCRAID(Tradename                        - 09/04/1998)Disease(s) concernedORPHA:35122 Congenital sucrase-isomaltase deficiency",
      "SUCRAID(Tradename                        - 09/04/1998)",
      "(Tradename                        - 09/04/1998)",
      "Disease(s) concernedORPHA:35122 Congenital sucrase-isomaltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/89110?name=35122&mode=orpha&region=&status=all",
        "text": "SUCRAID",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35122",
        "text": "ORPHA:35122 Congenital sucrase-isomaltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131193?name=35122&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_348": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=352641&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=352641&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=352641&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_349": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=352641&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=352641&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=352641&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_350": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489549?name=352709&mode=orpha&region=",
    "regulatory_id": "489549",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 30/05/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 30/05/2017)",
      "(Tradename                        - 30/05/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=352709&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489549?name=352709&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_351": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=352709&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=352709&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=352709&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_352": {
    "name": "BRINEURA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/529817?name=352709&mode=orpha&region=",
    "regulatory_id": "529817",
    "orpha_substance_code": "ORPHA:216",
    "details": [
      "BRINEURA(Tradename                        - 27/04/2017)Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "BRINEURA(Tradename                        - 27/04/2017)",
      "(Tradename                        - 27/04/2017)",
      "Disease(s) concernedORPHA:216 Neuronal ceroid lipofuscinosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489546?name=352709&mode=orpha&region=&status=all",
        "text": "BRINEURA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/216",
        "text": "ORPHA:216 Neuronal ceroid lipofuscinosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/529817?name=352709&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "684449": {
    "name": "Nizubaglustat",
    "substance_url": "/en/drug/substance/684449?name=354&mode=orpha&region=&status=all",
    "substance_id": "684449",
    "regulatory_url": "/en/drug/regulatory/684465?name=354&mode=orpha&region=",
    "regulatory_id": "684465",
    "orpha_substance_code": "ORPHA:354",
    "details": [
      "Nizubaglustat(Medicinal product                        - 28/06/2024)Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "Nizubaglustat(Medicinal product                        - 28/06/2024)",
      "(Medicinal product                        - 28/06/2024)",
      "Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/684449?name=354&mode=orpha&region=&status=all",
        "text": "Nizubaglustat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/354",
        "text": "ORPHA:354 GM1 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684465?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604890": {
    "name": "Adeno-associated virus serotype hu68 containing the human GLB1 gene",
    "substance_url": "/en/drug/substance/604890?name=354&mode=orpha&region=&status=all",
    "substance_id": "604890",
    "regulatory_url": "/en/drug/regulatory/604891?name=354&mode=orpha&region=",
    "regulatory_id": "604891",
    "orpha_substance_code": "ORPHA:354",
    "details": [
      "Adeno-associated virus serotype hu68 containing the human GLB1 gene(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "Adeno-associated virus serotype hu68 containing the human GLB1 gene(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604890?name=354&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype hu68 containing the human GLB1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/354",
        "text": "ORPHA:354 GM1 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604891?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "488012": {
    "name": "Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase",
    "substance_url": "/en/drug/substance/488012?name=354&mode=orpha&region=&status=all",
    "substance_id": "488012",
    "regulatory_url": "/en/drug/regulatory/488013?name=354&mode=orpha&region=",
    "regulatory_id": "488013",
    "orpha_substance_code": "ORPHA:354",
    "details": [
      "Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase(Medicinal product                        - 20/03/2017)Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase(Medicinal product                        - 20/03/2017)",
      "(Medicinal product                        - 20/03/2017)",
      "Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/488012?name=354&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/354",
        "text": "ORPHA:354 GM1 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/488013?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "644160": {
    "name": "Aloxistatin",
    "substance_url": "/en/drug/substance/644160?name=354&mode=orpha&region=&status=all",
    "substance_id": "644160",
    "regulatory_url": "/en/drug/regulatory/644161?name=354&mode=orpha&region=",
    "regulatory_id": "644161",
    "orpha_substance_code": "ORPHA:354",
    "details": [
      "Aloxistatin(Medicinal product                        - 10/05/2022)Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "Aloxistatin(Medicinal product                        - 10/05/2022)",
      "(Medicinal product                        - 10/05/2022)",
      "Disease(s) concernedORPHA:354 GM1 gangliosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/644160?name=354&mode=orpha&region=&status=all",
        "text": "Aloxistatin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/354",
        "text": "ORPHA:354 GM1 gangliosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644161?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_357": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=354&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=354&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_358": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=354&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=354&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=354&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "527467": {
    "name": "Ambroxol hydrochloride",
    "substance_url": "/en/drug/substance/527467?name=355&mode=orpha&region=&status=all",
    "substance_id": "527467",
    "regulatory_url": "/en/drug/regulatory/661042?name=355&mode=orpha&region=",
    "regulatory_id": "661042",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Ambroxol hydrochloride(Medicinal product                        - 08/11/2023)Disease(s) concernedORPHA:355 Gaucher disease",
      "Ambroxol hydrochloride(Medicinal product                        - 08/11/2023)",
      "(Medicinal product                        - 08/11/2023)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/527467?name=355&mode=orpha&region=&status=all",
        "text": "Ambroxol hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661042?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627910": {
    "name": "Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant",
    "substance_url": "/en/drug/substance/627910?name=355&mode=orpha&region=&status=all",
    "substance_id": "627910",
    "regulatory_url": "/en/drug/regulatory/627911?name=355&mode=orpha&region=",
    "regulatory_id": "627911",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:355 Gaucher disease",
      "Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant(Medicinal product                        - 20/08/2021)",
      "(Medicinal product                        - 20/08/2021)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627910?name=355&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627911?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627202": {
    "name": "Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene",
    "substance_url": "/en/drug/substance/627202?name=355&mode=orpha&region=&status=all",
    "substance_id": "627202",
    "regulatory_url": "/en/drug/regulatory/627203?name=355&mode=orpha&region=",
    "regulatory_id": "627203",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene(Medicinal product                        - 19/02/2021)Disease(s) concernedORPHA:355 Gaucher disease",
      "Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene(Medicinal product                        - 19/02/2021)",
      "(Medicinal product                        - 19/02/2021)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627202?name=355&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627203?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "218401": {
    "name": "Taliglucerase alfa",
    "substance_url": "/en/drug/substance/218401?name=355&mode=orpha&region=&status=all",
    "substance_id": "218401",
    "regulatory_url": "/en/drug/regulatory/227037?name=355&mode=orpha&region=",
    "regulatory_id": "227037",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Taliglucerase alfa(Medicinal product                        - 23/03/2010)Disease(s) concernedORPHA:355 Gaucher disease",
      "Taliglucerase alfa(Medicinal product                        - 23/03/2010)",
      "(Medicinal product                        - 23/03/2010)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/218401?name=355&mode=orpha&region=&status=all",
        "text": "Taliglucerase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/227037?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "102668": {
    "name": "(1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt",
    "substance_url": "/en/drug/substance/102668?name=355&mode=orpha&region=&status=all",
    "substance_id": "102668",
    "regulatory_url": "/en/drug/regulatory/134188?name=355&mode=orpha&region=",
    "regulatory_id": "134188",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "(1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt(Medicinal product                        - 04/12/2007)Disease(s) concernedORPHA:355 Gaucher disease",
      "(1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt(Medicinal product                        - 04/12/2007)",
      "(Medicinal product                        - 04/12/2007)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/102668?name=355&mode=orpha&region=&status=all",
        "text": "(1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134188?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604851": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta",
    "substance_url": "/en/drug/substance/604851?name=355&mode=orpha&region=&status=all",
    "substance_id": "604851",
    "regulatory_url": "/en/drug/regulatory/604852?name=355&mode=orpha&region=",
    "regulatory_id": "604852",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:355 Gaucher disease",
      "Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta(Medicinal product                        - 21/08/2020)",
      "(Medicinal product                        - 21/08/2020)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604851?name=355&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604852?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "222655": {
    "name": "Velaglucerase alfa",
    "substance_url": "/en/drug/substance/222655?name=355&mode=orpha&region=&status=all",
    "substance_id": "222655",
    "regulatory_url": "/en/drug/regulatory/240350?name=355&mode=orpha&region=",
    "regulatory_id": "240350",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Velaglucerase alfa(Medicinal product                        - 06/06/2010)Disease(s) concernedORPHA:355 Gaucher disease",
      "Velaglucerase alfa(Medicinal product                        - 06/06/2010)",
      "(Medicinal product                        - 06/06/2010)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/222655?name=355&mode=orpha&region=&status=all",
        "text": "Velaglucerase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/240350?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "101417": {
    "name": "Isofagomine tartrate",
    "substance_url": "/en/drug/substance/101417?name=355&mode=orpha&region=&status=all",
    "substance_id": "101417",
    "regulatory_url": "/en/drug/regulatory/134167?name=355&mode=orpha&region=",
    "regulatory_id": "134167",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Isofagomine tartrate(Medicinal product                        - 22/10/2007)Disease(s) concernedORPHA:355 Gaucher disease",
      "Isofagomine tartrate(Medicinal product                        - 22/10/2007)",
      "(Medicinal product                        - 22/10/2007)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/101417?name=355&mode=orpha&region=&status=all",
        "text": "Isofagomine tartrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134167?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "700218": {
    "name": "Ambroxol",
    "substance_url": "/en/drug/substance/700218?name=355&mode=orpha&region=&status=all",
    "substance_id": "700218",
    "regulatory_url": "/en/drug/regulatory/700223?name=355&mode=orpha&region=",
    "regulatory_id": "700223",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Ambroxol(Medicinal product                        - 16/04/2025)Disease(s) concernedORPHA:355 Gaucher disease",
      "Ambroxol(Medicinal product                        - 16/04/2025)",
      "(Medicinal product                        - 16/04/2025)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/700218?name=355&mode=orpha&region=&status=all",
        "text": "Ambroxol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700223?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "688298": {
    "name": "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding glucosylceramidase beta 1",
    "substance_url": "/en/drug/substance/688298?name=355&mode=orpha&region=&status=all",
    "substance_id": "688298",
    "regulatory_url": "/en/drug/regulatory/688383?name=355&mode=orpha&region=",
    "regulatory_id": "688383",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding glucosylceramidase beta 1(Medicinal product                        - 09/09/2024)Disease(s) concernedORPHA:355 Gaucher disease",
      "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding glucosylceramidase beta 1(Medicinal product                        - 09/09/2024)",
      "(Medicinal product                        - 09/09/2024)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688298?name=355&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding glucosylceramidase beta 1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688383?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "666380": {
    "name": "Recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene",
    "substance_url": "/en/drug/substance/666380?name=355&mode=orpha&region=&status=all",
    "substance_id": "666380",
    "regulatory_url": "/en/drug/regulatory/666433?name=355&mode=orpha&region=",
    "regulatory_id": "666433",
    "orpha_substance_code": "ORPHA:355",
    "details": [
      "Recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene(Medicinal product                        - 05/10/2023)Disease(s) concernedORPHA:355 Gaucher disease",
      "Recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene(Medicinal product                        - 05/10/2023)",
      "(Medicinal product                        - 05/10/2023)",
      "Disease(s) concernedORPHA:355 Gaucher disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666380?name=355&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666433?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "24871": {
    "name": "Imiglucerase",
    "substance_url": "/en/drug/substance/24871?name=355&mode=orpha&region=&status=all",
    "substance_id": "24871",
    "regulatory_url": "/en/drug/regulatory/131914?name=355&mode=orpha&region=",
    "regulatory_id": "131914",
    "orpha_substance_code": "ORPHA:77261",
    "details": [
      "Imiglucerase(Medicinal product                        - 05/11/1991)Disease(s) concernedORPHA:355 Gaucher diseaseORPHA:77259 Gaucher disease type 1ORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "Imiglucerase(Medicinal product                        - 05/11/1991)",
      "(Medicinal product                        - 05/11/1991)",
      "Disease(s) concernedORPHA:355 Gaucher diseaseORPHA:77259 Gaucher disease type 1ORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24871?name=355&mode=orpha&region=&status=all",
        "text": "Imiglucerase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/355",
        "text": "ORPHA:355 Gaucher disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77260",
        "text": "ORPHA:77260 Gaucher disease type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77261",
        "text": "ORPHA:77261 Gaucher disease type 3",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131914?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "ORPHA:77259 Gaucher disease type 1\n                                \n\n\n\n\n                                    ORPHA:77260 Gaucher disease type 2\n                                \n\n\n\n\n                                    ORPHA:77261 Gaucher disease type 3\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_371": {
    "name": "CERDELGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/420555?name=355&mode=orpha&region=",
    "regulatory_id": "420555",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "CERDELGA(Tradename                        - 19/01/2015)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "CERDELGA(Tradename                        - 19/01/2015)",
      "(Tradename                        - 19/01/2015)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/410891?name=355&mode=orpha&region=&status=all",
        "text": "CERDELGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/420555?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_372": {
    "name": "MIGLUSTAT DIPHARMA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/557010?name=355&mode=orpha&region=",
    "regulatory_id": "557010",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "MIGLUSTAT DIPHARMA(Tradename                        - 18/02/2019)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "MIGLUSTAT DIPHARMA(Tradename                        - 18/02/2019)",
      "(Tradename                        - 18/02/2019)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/557002?name=355&mode=orpha&region=&status=all",
        "text": "MIGLUSTAT DIPHARMA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/557010?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_373": {
    "name": "MIGLUSTAT GEN. ORPH",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/501220?name=355&mode=orpha&region=",
    "regulatory_id": "501220",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "MIGLUSTAT GEN. ORPH(Tradename                        - 10/11/2017)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "MIGLUSTAT GEN. ORPH(Tradename                        - 10/11/2017)",
      "(Tradename                        - 10/11/2017)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/501216?name=355&mode=orpha&region=&status=all",
        "text": "MIGLUSTAT GEN. ORPH",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/501220?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_374": {
    "name": "YARGESA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/484359?name=355&mode=orpha&region=",
    "regulatory_id": "484359",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "YARGESA(Tradename                        - 22/03/2017)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "YARGESA(Tradename                        - 22/03/2017)",
      "(Tradename                        - 22/03/2017)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/484358?name=355&mode=orpha&region=&status=all",
        "text": "YARGESA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484359?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_375": {
    "name": "VPRIV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/242289?name=355&mode=orpha&region=",
    "regulatory_id": "242289",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "VPRIV(Tradename                        - 26/08/2010)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "VPRIV(Tradename                        - 26/08/2010)",
      "(Tradename                        - 26/08/2010)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/242288?name=355&mode=orpha&region=&status=all",
        "text": "VPRIV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/242289?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_376": {
    "name": "ZAVESCA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131346?name=355&mode=orpha&region=",
    "regulatory_id": "131346",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "ZAVESCA(Tradename                        - 21/11/2002)Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77259 Gaucher disease type 1",
      "ZAVESCA(Tradename                        - 21/11/2002)",
      "(Tradename                        - 21/11/2002)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/39961?name=355&mode=orpha&region=&status=all",
        "text": "ZAVESCA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131346?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n                                    ORPHA:77259 Gaucher disease type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_377": {
    "name": "CEREZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131238?name=355&mode=orpha&region=",
    "regulatory_id": "131238",
    "orpha_substance_code": "ORPHA:77261",
    "details": [
      "CEREZYME(Tradename                        - 17/11/1997)Disease(s) concernedORPHA:77259 Gaucher disease type 1ORPHA:77261 Gaucher disease type 3",
      "CEREZYME(Tradename                        - 17/11/1997)",
      "(Tradename                        - 17/11/1997)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1ORPHA:77261 Gaucher disease type 3",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24993?name=355&mode=orpha&region=&status=all",
        "text": "CEREZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77261",
        "text": "ORPHA:77261 Gaucher disease type 3",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131238?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n                                    ORPHA:77261 Gaucher disease type 3\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "443973": {
    "name": "adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene",
    "substance_url": "/en/drug/substance/443973?name=355&mode=orpha&region=&status=all",
    "substance_id": "443973",
    "regulatory_url": "/en/drug/regulatory/443977?name=355&mode=orpha&region=",
    "regulatory_id": "443977",
    "orpha_substance_code": "ORPHA:77261",
    "details": [
      "adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene(Medicinal product                        - 19/03/2015)Disease(s) concernedORPHA:2072 Gaucher disease-ophthalmoplegia-cardiovascular calcification syndromeORPHA:77259 Gaucher disease type 1ORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene(Medicinal product                        - 19/03/2015)",
      "(Medicinal product                        - 19/03/2015)",
      "Disease(s) concernedORPHA:2072 Gaucher disease-ophthalmoplegia-cardiovascular calcification syndromeORPHA:77259 Gaucher disease type 1ORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/443973?name=355&mode=orpha&region=&status=all",
        "text": "adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2072",
        "text": "ORPHA:2072 Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77260",
        "text": "ORPHA:77260 Gaucher disease type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77261",
        "text": "ORPHA:77261 Gaucher disease type 3",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/443977?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n                                    ORPHA:77260 Gaucher disease type 2\n                                \n\n\n\n\n                                    ORPHA:77261 Gaucher disease type 3\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_379": {
    "name": "CERDELGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/410893?name=355&mode=orpha&region=",
    "regulatory_id": "410893",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "CERDELGA(Tradename                        - 19/08/2014)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "CERDELGA(Tradename                        - 19/08/2014)",
      "(Tradename                        - 19/08/2014)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/410891?name=355&mode=orpha&region=&status=all",
        "text": "CERDELGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/410893?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_380": {
    "name": "ELELYSO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/394204?name=355&mode=orpha&region=",
    "regulatory_id": "394204",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "ELELYSO(Tradename                        - 01/05/2012)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "ELELYSO(Tradename                        - 01/05/2012)",
      "(Tradename                        - 01/05/2012)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/394203?name=355&mode=orpha&region=&status=all",
        "text": "ELELYSO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/394204?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_381": {
    "name": "VPRIV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465076?name=355&mode=orpha&region=",
    "regulatory_id": "465076",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "VPRIV(Tradename                        - 26/02/2010)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "VPRIV(Tradename                        - 26/02/2010)",
      "(Tradename                        - 26/02/2010)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/242288?name=355&mode=orpha&region=&status=all",
        "text": "VPRIV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465076?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_382": {
    "name": "CEREZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131062?name=355&mode=orpha&region=",
    "regulatory_id": "131062",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "CEREZYME(Tradename                        - 23/05/1994)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "CEREZYME(Tradename                        - 23/05/1994)",
      "(Tradename                        - 23/05/1994)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24993?name=355&mode=orpha&region=&status=all",
        "text": "CEREZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131062?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_383": {
    "name": "CEREDASE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131047?name=355&mode=orpha&region=",
    "regulatory_id": "131047",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "CEREDASE(Tradename                        - 05/04/1991)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "CEREDASE(Tradename                        - 05/04/1991)",
      "(Tradename                        - 05/04/1991)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24931?name=355&mode=orpha&region=&status=all",
        "text": "CEREDASE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131047?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "410889": {
    "name": "Eliglustat",
    "substance_url": "/en/drug/substance/410889?name=355&mode=orpha&region=&status=all",
    "substance_id": "410889",
    "regulatory_url": "/en/drug/regulatory/410892?name=355&mode=orpha&region=",
    "regulatory_id": "410892",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "Eliglustat(Medicinal product                        - 17/09/2008)Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "Eliglustat(Medicinal product                        - 17/09/2008)",
      "(Medicinal product                        - 17/09/2008)",
      "Disease(s) concernedORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/410889?name=355&mode=orpha&region=&status=all",
        "text": "Eliglustat",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/410892?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "24932": {
    "name": "Alglucerase",
    "substance_url": "/en/drug/substance/24932?name=355&mode=orpha&region=&status=all",
    "substance_id": "24932",
    "regulatory_url": "/en/drug/regulatory/131918?name=355&mode=orpha&region=",
    "regulatory_id": "131918",
    "orpha_substance_code": "ORPHA:77261",
    "details": [
      "Alglucerase(Medicinal product                        - 21/07/1995)Disease(s) concernedORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "Alglucerase(Medicinal product                        - 21/07/1995)",
      "(Medicinal product                        - 21/07/1995)",
      "Disease(s) concernedORPHA:77260 Gaucher disease type 2ORPHA:77261 Gaucher disease type 3",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24932?name=355&mode=orpha&region=&status=all",
        "text": "Alglucerase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77260",
        "text": "ORPHA:77260 Gaucher disease type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77261",
        "text": "ORPHA:77261 Gaucher disease type 3",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131918?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type 2\n                                \n\n\n\n\n                                    ORPHA:77261 Gaucher disease type 3\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_386": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=355&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=355&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_387": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=355&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=355&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=355&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627137": {
    "name": "Dodecyl creatine ester, dodecyl creatine ester hydrochloride",
    "substance_url": "/en/drug/substance/627137?name=35704&mode=orpha&region=&status=all",
    "substance_id": "627137",
    "regulatory_url": "/en/drug/regulatory/627139?name=35704&mode=orpha&region=",
    "regulatory_id": "627139",
    "orpha_substance_code": "ORPHA:79172",
    "details": [
      "Dodecyl creatine ester, dodecyl creatine ester hydrochloride(Medicinal product                        - 19/02/2021)Disease(s) concernedORPHA:79172 Creatine deficiency syndrome",
      "Dodecyl creatine ester, dodecyl creatine ester hydrochloride(Medicinal product                        - 19/02/2021)",
      "(Medicinal product                        - 19/02/2021)",
      "Disease(s) concernedORPHA:79172 Creatine deficiency syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627137?name=35704&mode=orpha&region=&status=all",
        "text": "Dodecyl creatine ester, dodecyl creatine ester hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79172",
        "text": "ORPHA:79172 Creatine deficiency syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627139?name=35704&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "480188": {
    "name": "Cyclocreatine",
    "substance_url": "/en/drug/substance/480188?name=35704&mode=orpha&region=&status=all",
    "substance_id": "480188",
    "regulatory_url": "/en/drug/regulatory/480190?name=35704&mode=orpha&region=",
    "regulatory_id": "480190",
    "orpha_substance_code": "ORPHA:79172",
    "details": [
      "Cyclocreatine(Medicinal product                        - 27/06/2016)Disease(s) concernedORPHA:79172 Creatine deficiency syndrome",
      "Cyclocreatine(Medicinal product                        - 27/06/2016)",
      "(Medicinal product                        - 27/06/2016)",
      "Disease(s) concernedORPHA:79172 Creatine deficiency syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480188?name=35704&mode=orpha&region=&status=all",
        "text": "Cyclocreatine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79172",
        "text": "ORPHA:79172 Creatine deficiency syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480190?name=35704&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_390": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=35706&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=35706&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=35706&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_391": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=35706&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=35706&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=35706&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_392": {
    "name": "UPSTAZA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629875?name=35708&mode=orpha&region=",
    "regulatory_id": "629875",
    "orpha_substance_code": "ORPHA:35708",
    "details": [
      "UPSTAZA(Tradename                        - 18/07/2022)Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "UPSTAZA(Tradename                        - 18/07/2022)",
      "(Tradename                        - 18/07/2022)",
      "Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629873?name=35708&mode=orpha&region=&status=all",
        "text": "UPSTAZA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35708",
        "text": "ORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629875?name=35708&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "485101": {
    "name": "Eladocagene exuparvovec",
    "substance_url": "/en/drug/substance/485101?name=35708&mode=orpha&region=&status=all",
    "substance_id": "485101",
    "regulatory_url": "/en/drug/regulatory/485102?name=35708&mode=orpha&region=",
    "regulatory_id": "485102",
    "orpha_substance_code": "ORPHA:35708",
    "details": [
      "Eladocagene exuparvovec(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "Eladocagene exuparvovec(Medicinal product                        - 18/11/2016)",
      "(Medicinal product                        - 18/11/2016)",
      "Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/485101?name=35708&mode=orpha&region=&status=all",
        "text": "Eladocagene exuparvovec",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35708",
        "text": "ORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485102?name=35708&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_394": {
    "name": "KEBILIDI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/691363?name=35708&mode=orpha&region=",
    "regulatory_id": "691363",
    "orpha_substance_code": "ORPHA:35708",
    "details": [
      "KEBILIDI(Tradename                        - 13/11/2024)Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "KEBILIDI(Tradename                        - 13/11/2024)",
      "(Tradename                        - 13/11/2024)",
      "Disease(s) concernedORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/691355?name=35708&mode=orpha&region=&status=all",
        "text": "KEBILIDI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/35708",
        "text": "ORPHA:35708 Aromatic L-amino acid decarboxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/691363?name=35708&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "403944": {
    "name": "Diazoxide choline",
    "substance_url": "/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
    "substance_id": "403944",
    "regulatory_url": "/en/drug/regulatory/692363?name=364&mode=orpha&region=",
    "regulatory_id": "692363",
    "orpha_substance_code": "ORPHA:364",
    "details": [
      "Diazoxide choline(Medicinal product                        - 13/12/2024)Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
      "Diazoxide choline(Medicinal product                        - 13/12/2024)",
      "(Medicinal product                        - 13/12/2024)",
      "Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
        "text": "Diazoxide choline",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/364",
        "text": "ORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692363?name=364&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glucose-6-phosphatase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "628240": {
    "name": "mRNA encoding human glucose-6-phosphatase variant S298C",
    "substance_url": "/en/drug/substance/628240?name=364&mode=orpha&region=&status=all",
    "substance_id": "628240",
    "regulatory_url": "/en/drug/regulatory/628244?name=364&mode=orpha&region=",
    "regulatory_id": "628244",
    "orpha_substance_code": "ORPHA:79258",
    "details": [
      "mRNA encoding human glucose-6-phosphatase variant S298C(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
      "mRNA encoding human glucose-6-phosphatase variant S298C(Medicinal product                        - 14/01/2022)",
      "(Medicinal product                        - 14/01/2022)",
      "Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628240?name=364&mode=orpha&region=&status=all",
        "text": "mRNA encoding human glucose-6-phosphatase variant S298C",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79258",
        "text": "ORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628244?name=364&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glucose-6-phosphatase deficiency type Ia\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "485069": {
    "name": "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene",
    "substance_url": "/en/drug/substance/485069?name=364&mode=orpha&region=&status=all",
    "substance_id": "485069",
    "regulatory_url": "/en/drug/regulatory/485070?name=364&mode=orpha&region=",
    "regulatory_id": "485070",
    "orpha_substance_code": "ORPHA:79258",
    "details": [
      "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
      "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene(Medicinal product                        - 18/11/2016)",
      "(Medicinal product                        - 18/11/2016)",
      "Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/485069?name=364&mode=orpha&region=&status=all",
        "text": "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79258",
        "text": "ORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485070?name=364&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glucose-6-phosphatase deficiency type Ia\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689527": {
    "name": "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene",
    "substance_url": "/en/drug/substance/689527?name=364&mode=orpha&region=&status=all",
    "substance_id": "689527",
    "regulatory_url": "/en/drug/regulatory/689729?name=364&mode=orpha&region=",
    "regulatory_id": "689729",
    "orpha_substance_code": "ORPHA:79259",
    "details": [
      "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene(Medicinal product                        - 04/10/2024)Disease(s) concernedORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
      "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene(Medicinal product                        - 04/10/2024)",
      "(Medicinal product                        - 04/10/2024)",
      "Disease(s) concernedORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689527?name=364&mode=orpha&region=&status=all",
        "text": "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79259",
        "text": "ORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689729?name=364&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glucose-6-phosphatase deficiency type Ib\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_399": {
    "name": "NEXVIADYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642385?name=365&mode=orpha&region=",
    "regulatory_id": "642385",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "NEXVIADYME(Tradename                        - 24/06/2022)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "NEXVIADYME(Tradename                        - 24/06/2022)",
      "(Tradename                        - 24/06/2022)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642384?name=365&mode=orpha&region=&status=all",
        "text": "NEXVIADYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642385?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_400": {
    "name": "MYOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131364?name=365&mode=orpha&region=",
    "regulatory_id": "131364",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "MYOZYME(Tradename                        - 29/03/2006)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "MYOZYME(Tradename                        - 29/03/2006)",
      "(Tradename                        - 29/03/2006)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/71308?name=365&mode=orpha&region=&status=all",
        "text": "MYOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131364?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "642483": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene",
    "substance_url": "/en/drug/substance/642483?name=365&mode=orpha&region=&status=all",
    "substance_id": "642483",
    "regulatory_url": "/en/drug/regulatory/642481?name=365&mode=orpha&region=",
    "regulatory_id": "642481",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene(Medicinal product                        - 15/02/2023)",
      "(Medicinal product                        - 15/02/2023)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/642483?name=365&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642481?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "563469": {
    "name": "Recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase",
    "substance_url": "/en/drug/substance/563469?name=365&mode=orpha&region=&status=all",
    "substance_id": "563469",
    "regulatory_url": "/en/drug/regulatory/563470?name=365&mode=orpha&region=",
    "regulatory_id": "563470",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase(Medicinal product                        - 28/06/2019)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase(Medicinal product                        - 28/06/2019)",
      "(Medicinal product                        - 28/06/2019)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/563469?name=365&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/563470?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "480884": {
    "name": "Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues",
    "substance_url": "/en/drug/substance/480884?name=365&mode=orpha&region=&status=all",
    "substance_id": "480884",
    "regulatory_url": "/en/drug/regulatory/480894?name=365&mode=orpha&region=",
    "regulatory_id": "480894",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues(Medicinal product                        - 29/08/2016)",
      "(Medicinal product                        - 29/08/2016)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480884?name=365&mode=orpha&region=&status=all",
        "text": "Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480894?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "95343": {
    "name": "Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene",
    "substance_url": "/en/drug/substance/95343?name=365&mode=orpha&region=&status=all",
    "substance_id": "95343",
    "regulatory_url": "/en/drug/regulatory/327150?name=365&mode=orpha&region=",
    "regulatory_id": "327150",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene(Medicinal product                        - 04/07/2012)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene(Medicinal product                        - 04/07/2012)",
      "(Medicinal product                        - 04/07/2012)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/95343?name=365&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/327150?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "275665": {
    "name": "Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase",
    "substance_url": "/en/drug/substance/275665?name=365&mode=orpha&region=&status=all",
    "substance_id": "275665",
    "regulatory_url": "/en/drug/regulatory/286433?name=365&mode=orpha&region=",
    "regulatory_id": "286433",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase(Medicinal product                        - 27/10/2011)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase(Medicinal product                        - 27/10/2011)",
      "(Medicinal product                        - 27/10/2011)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/275665?name=365&mode=orpha&region=&status=all",
        "text": "Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/286433?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "511722": {
    "name": "Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene",
    "substance_url": "/en/drug/substance/511722?name=365&mode=orpha&region=&status=all",
    "substance_id": "511722",
    "regulatory_url": "/en/drug/regulatory/511723?name=365&mode=orpha&region=",
    "regulatory_id": "511723",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene(Medicinal product                        - 16/04/2018)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene(Medicinal product                        - 16/04/2018)",
      "(Medicinal product                        - 16/04/2018)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/511722?name=365&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/511723?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "511219": {
    "name": "Cipaglucosidase alfa",
    "substance_url": "/en/drug/substance/511219?name=365&mode=orpha&region=&status=all",
    "substance_id": "511219",
    "regulatory_url": "/en/drug/regulatory/511220?name=365&mode=orpha&region=",
    "regulatory_id": "511220",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Cipaglucosidase alfa(Medicinal product                        - 21/03/2018)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Cipaglucosidase alfa(Medicinal product                        - 21/03/2018)",
      "(Medicinal product                        - 21/03/2018)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/511219?name=365&mode=orpha&region=&status=all",
        "text": "Cipaglucosidase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/511220?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "392969": {
    "name": "Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan",
    "substance_url": "/en/drug/substance/392969?name=365&mode=orpha&region=&status=all",
    "substance_id": "392969",
    "regulatory_url": "/en/drug/regulatory/401794?name=365&mode=orpha&region=",
    "regulatory_id": "401794",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan(Medicinal product                        - 26/03/2014)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan(Medicinal product                        - 26/03/2014)",
      "(Medicinal product                        - 26/03/2014)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/392969?name=365&mode=orpha&region=&status=all",
        "text": "Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/401794?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "58406": {
    "name": "Alglucosidase alfa",
    "substance_url": "/en/drug/substance/58406?name=365&mode=orpha&region=&status=all",
    "substance_id": "58406",
    "regulatory_url": "/en/drug/regulatory/133703?name=365&mode=orpha&region=",
    "regulatory_id": "133703",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Alglucosidase alfa(Medicinal product                        - 14/02/2001)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Alglucosidase alfa(Medicinal product                        - 14/02/2001)",
      "(Medicinal product                        - 14/02/2001)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/58406?name=365&mode=orpha&region=&status=all",
        "text": "Alglucosidase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133703?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_410": {
    "name": "Nexviazyme",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622306?name=365&mode=orpha&region=",
    "regulatory_id": "622306",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Nexviazyme(Tradename                        - 06/08/2021)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Nexviazyme(Tradename                        - 06/08/2021)",
      "(Tradename                        - 06/08/2021)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/622305?name=365&mode=orpha&region=&status=all",
        "text": "Nexviazyme",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622306?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_411": {
    "name": "LUMIZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/365791?name=365&mode=orpha&region=",
    "regulatory_id": "365791",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "LUMIZYME(Tradename                        - 24/05/2010)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "LUMIZYME(Tradename                        - 24/05/2010)",
      "(Tradename                        - 24/05/2010)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/365790?name=365&mode=orpha&region=&status=all",
        "text": "LUMIZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/365791?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "695340": {
    "name": "Recombinant adeno-associated virus serotype 9 vector expressing codon optimized human GAA gene",
    "substance_url": "/en/drug/substance/695340?name=365&mode=orpha&region=&status=all",
    "substance_id": "695340",
    "regulatory_url": "/en/drug/regulatory/695572?name=365&mode=orpha&region=",
    "regulatory_id": "695572",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Recombinant adeno-associated virus serotype 9 vector expressing codon optimized human GAA gene(Medicinal product                        - 28/02/2025)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Recombinant adeno-associated virus serotype 9 vector expressing codon optimized human GAA gene(Medicinal product                        - 28/02/2025)",
      "(Medicinal product                        - 28/02/2025)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695340?name=365&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus serotype 9 vector expressing codon optimized human GAA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695572?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "630481": {
    "name": "Selective inhibitor of GYS1",
    "substance_url": "/en/drug/substance/630481?name=365&mode=orpha&region=&status=all",
    "substance_id": "630481",
    "regulatory_url": "/en/drug/regulatory/630485?name=365&mode=orpha&region=",
    "regulatory_id": "630485",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Selective inhibitor of GYS1(Medicinal product                        - 12/08/2022)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Selective inhibitor of GYS1(Medicinal product                        - 12/08/2022)",
      "(Medicinal product                        - 12/08/2022)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/630481?name=365&mode=orpha&region=&status=all",
        "text": "Selective inhibitor of GYS1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/630485?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "644142": {
    "name": "CD71 Binding Centyrin-GYS1 siRNA",
    "substance_url": "/en/drug/substance/644142?name=365&mode=orpha&region=&status=all",
    "substance_id": "644142",
    "regulatory_url": "/en/drug/regulatory/644143?name=365&mode=orpha&region=",
    "regulatory_id": "644143",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "CD71 Binding Centyrin-GYS1 siRNA(Medicinal product                        - 01/08/2022)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "CD71 Binding Centyrin-GYS1 siRNA(Medicinal product                        - 01/08/2022)",
      "(Medicinal product                        - 01/08/2022)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/644142?name=365&mode=orpha&region=&status=all",
        "text": "CD71 Binding Centyrin-GYS1 siRNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644143?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "371630": {
    "name": "Clenbuterol",
    "substance_url": "/en/drug/substance/371630?name=365&mode=orpha&region=&status=all",
    "substance_id": "371630",
    "regulatory_url": "/en/drug/regulatory/412905?name=365&mode=orpha&region=",
    "regulatory_id": "412905",
    "orpha_substance_code": "ORPHA:365",
    "details": [
      "Clenbuterol(Medicinal product                        - 27/10/2014)Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "Clenbuterol(Medicinal product                        - 27/10/2014)",
      "(Medicinal product                        - 27/10/2014)",
      "Disease(s) concernedORPHA:365 Glycogen storage disease due to acid maltase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/371630?name=365&mode=orpha&region=&status=all",
        "text": "Clenbuterol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/365",
        "text": "ORPHA:365 Glycogen storage disease due to acid maltase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412905?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_416": {
    "name": "OPFOLDA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/653357?name=365&mode=orpha&region=",
    "regulatory_id": "653357",
    "orpha_substance_code": "ORPHA:420429",
    "details": [
      "OPFOLDA(Tradename                        - 26/06/2023)Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "OPFOLDA(Tradename                        - 26/06/2023)",
      "(Tradename                        - 26/06/2023)",
      "Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/653356?name=365&mode=orpha&region=&status=all",
        "text": "OPFOLDA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/420429",
        "text": "ORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/653357?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency, late-onset\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_417": {
    "name": "POMBILITI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/650359?name=365&mode=orpha&region=",
    "regulatory_id": "650359",
    "orpha_substance_code": "ORPHA:420429",
    "details": [
      "POMBILITI(Tradename                        - 20/03/2023)Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "POMBILITI(Tradename                        - 20/03/2023)",
      "(Tradename                        - 20/03/2023)",
      "Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/650357?name=365&mode=orpha&region=&status=all",
        "text": "POMBILITI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/420429",
        "text": "ORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650359?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency, late-onset\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_418": {
    "name": "POMBILITI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/660349?name=365&mode=orpha&region=",
    "regulatory_id": "660349",
    "orpha_substance_code": "ORPHA:420429",
    "details": [
      "POMBILITI(Tradename                        - 28/09/2023)Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "POMBILITI(Tradename                        - 28/09/2023)",
      "(Tradename                        - 28/09/2023)",
      "Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/650357?name=365&mode=orpha&region=&status=all",
        "text": "POMBILITI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/420429",
        "text": "ORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/660349?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency, late-onset\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_419": {
    "name": "OPFOLDA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/660357?name=365&mode=orpha&region=",
    "regulatory_id": "660357",
    "orpha_substance_code": "ORPHA:420429",
    "details": [
      "OPFOLDA(Tradename                        - 28/09/2023)Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "OPFOLDA(Tradename                        - 28/09/2023)",
      "(Tradename                        - 28/09/2023)",
      "Disease(s) concernedORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/653356?name=365&mode=orpha&region=&status=all",
        "text": "OPFOLDA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/420429",
        "text": "ORPHA:420429 Glycogen storage disease due to acid maltase deficiency, late-onset",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/660357?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency, late-onset\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_420": {
    "name": "MYOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131152?name=365&mode=orpha&region=",
    "regulatory_id": "131152",
    "orpha_substance_code": "ORPHA:308552",
    "details": [
      "MYOZYME(Tradename                        - 28/04/2006)Disease(s) concernedORPHA:308552 Glycogen storage disease due to acid maltase deficiency, infantile onset",
      "MYOZYME(Tradename                        - 28/04/2006)",
      "(Tradename                        - 28/04/2006)",
      "Disease(s) concernedORPHA:308552 Glycogen storage disease due to acid maltase deficiency, infantile onset",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/71308?name=365&mode=orpha&region=&status=all",
        "text": "MYOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/308552",
        "text": "ORPHA:308552 Glycogen storage disease due to acid maltase deficiency, infantile onset",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131152?name=365&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "due to acid maltase deficiency, infantile onset\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627810": {
    "name": "mRNA encoding the human glycogen debranching enzyme",
    "substance_url": "/en/drug/substance/627810?name=366&mode=orpha&region=&status=all",
    "substance_id": "627810",
    "regulatory_url": "/en/drug/regulatory/627811?name=366&mode=orpha&region=",
    "regulatory_id": "627811",
    "orpha_substance_code": "ORPHA:366",
    "details": [
      "mRNA encoding the human glycogen debranching enzyme(Medicinal product                        - 19/07/2021)Disease(s) concernedORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
      "mRNA encoding the human glycogen debranching enzyme(Medicinal product                        - 19/07/2021)",
      "(Medicinal product                        - 19/07/2021)",
      "Disease(s) concernedORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627810?name=366&mode=orpha&region=&status=all",
        "text": "mRNA encoding the human glycogen debranching enzyme",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/366",
        "text": "ORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627811?name=366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glycogen debranching enzyme deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604787": {
    "name": "Adeno-associated viral vector expressing acid alpha-glucosidase gene",
    "substance_url": "/en/drug/substance/604787?name=366&mode=orpha&region=&status=all",
    "substance_id": "604787",
    "regulatory_url": "/en/drug/regulatory/604788?name=366&mode=orpha&region=",
    "regulatory_id": "604788",
    "orpha_substance_code": "ORPHA:366",
    "details": [
      "Adeno-associated viral vector expressing acid alpha-glucosidase gene(Medicinal product                        - 27/07/2020)Disease(s) concernedORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
      "Adeno-associated viral vector expressing acid alpha-glucosidase gene(Medicinal product                        - 27/07/2020)",
      "(Medicinal product                        - 27/07/2020)",
      "Disease(s) concernedORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604787?name=366&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector expressing acid alpha-glucosidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/366",
        "text": "ORPHA:366 Glycogen storage disease due to glycogen debranching enzyme deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604788?name=366&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glycogen debranching enzyme deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "664801": {
    "name": "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",
    "substance_url": "/en/drug/substance/664801?name=367&mode=orpha&region=&status=all",
    "substance_id": "664801",
    "regulatory_url": "/en/drug/regulatory/694039?name=367&mode=orpha&region=",
    "regulatory_id": "694039",
    "orpha_substance_code": "ORPHA:367",
    "details": [
      "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide(Medicinal product                        - 16/01/2025)Disease(s) concernedORPHA:367 Glycogen storage disease due to glycogen branching enzyme deficiency",
      "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide(Medicinal product                        - 16/01/2025)",
      "(Medicinal product                        - 16/01/2025)",
      "Disease(s) concernedORPHA:367 Glycogen storage disease due to glycogen branching enzyme deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/664801?name=367&mode=orpha&region=&status=all",
        "text": "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/367",
        "text": "ORPHA:367 Glycogen storage disease due to glycogen branching enzyme deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/694039?name=367&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to glycogen branching enzyme deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "97923": {
    "name": "Valproic acid, sodium",
    "substance_url": "/en/drug/substance/97923?name=368&mode=orpha&region=&status=all",
    "substance_id": "97923",
    "regulatory_url": "/en/drug/regulatory/480689?name=368&mode=orpha&region=",
    "regulatory_id": "480689",
    "orpha_substance_code": "ORPHA:368",
    "details": [
      "Valproic acid, sodium(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:368 Glycogen storage disease due to muscle glycogen phosphorylase deficiency",
      "Valproic acid, sodium(Medicinal product                        - 29/08/2016)",
      "(Medicinal product                        - 29/08/2016)",
      "Disease(s) concernedORPHA:368 Glycogen storage disease due to muscle glycogen phosphorylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/97923?name=368&mode=orpha&region=&status=all",
        "text": "Valproic acid, sodium",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/368",
        "text": "ORPHA:368 Glycogen storage disease due to muscle glycogen phosphorylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480689?name=368&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to muscle glycogen phosphorylase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "695313": {
    "name": "Adeno-associated vector expressing human codon-optimized guanidinoacetate N-methyltransferase under a ubiquitous-expressing promoter",
    "substance_url": "/en/drug/substance/695313?name=382&mode=orpha&region=&status=all",
    "substance_id": "695313",
    "regulatory_url": "/en/drug/regulatory/695442?name=382&mode=orpha&region=",
    "regulatory_id": "695442",
    "orpha_substance_code": "ORPHA:382",
    "details": [
      "Adeno-associated vector expressing human codon-optimized guanidinoacetate N-methyltransferase under a ubiquitous-expressing promoter(Medicinal product                        - 18/02/2025)Disease(s) concernedORPHA:382 Guanidinoacetate methyltransferase deficiency",
      "Adeno-associated vector expressing human codon-optimized guanidinoacetate N-methyltransferase under a ubiquitous-expressing promoter(Medicinal product                        - 18/02/2025)",
      "(Medicinal product                        - 18/02/2025)",
      "Disease(s) concernedORPHA:382 Guanidinoacetate methyltransferase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695313?name=382&mode=orpha&region=&status=all",
        "text": "Adeno-associated vector expressing human codon-optimized guanidinoacetate N-methyltransferase under a ubiquitous-expressing promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/382",
        "text": "ORPHA:382 Guanidinoacetate methyltransferase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695442?name=382&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_426": {
    "name": "Evkeeza",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/650254?name=391665&mode=orpha&region=",
    "regulatory_id": "650254",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Evkeeza(Tradename                        - 17/06/2021)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Evkeeza(Tradename                        - 17/06/2021)",
      "(Tradename                        - 17/06/2021)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616444?name=391665&mode=orpha&region=&status=all",
        "text": "Evkeeza",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650254?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_427": {
    "name": "REPATHA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/440968?name=391665&mode=orpha&region=",
    "regulatory_id": "440968",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "REPATHA(Tradename                        - 17/07/2015)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "REPATHA(Tradename                        - 17/07/2015)",
      "(Tradename                        - 17/07/2015)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/440880?name=391665&mode=orpha&region=&status=all",
        "text": "REPATHA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/440968?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_428": {
    "name": "LOJUXTA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/392189?name=391665&mode=orpha&region=",
    "regulatory_id": "392189",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "LOJUXTA(Tradename                        - 31/07/2013)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "LOJUXTA(Tradename                        - 31/07/2013)",
      "(Tradename                        - 31/07/2013)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/360696?name=391665&mode=orpha&region=&status=all",
        "text": "LOJUXTA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/392189?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_429": {
    "name": "Evkeeza",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/644262?name=391665&mode=orpha&region=",
    "regulatory_id": "644262",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Evkeeza(Tradename                        - 21/03/2023)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Evkeeza(Tradename                        - 21/03/2023)",
      "(Tradename                        - 21/03/2023)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616444?name=391665&mode=orpha&region=&status=all",
        "text": "Evkeeza",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644262?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_430": {
    "name": "REPATHA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622253?name=391665&mode=orpha&region=",
    "regulatory_id": "622253",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "REPATHA(Tradename                        - 24/09/2021)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "REPATHA(Tradename                        - 24/09/2021)",
      "(Tradename                        - 24/09/2021)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/440880?name=391665&mode=orpha&region=&status=all",
        "text": "REPATHA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622253?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_431": {
    "name": "Praluent",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/622166?name=391665&mode=orpha&region=",
    "regulatory_id": "622166",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Praluent(Tradename                        - 01/04/2021)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Praluent(Tradename                        - 01/04/2021)",
      "(Tradename                        - 01/04/2021)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/622165?name=391665&mode=orpha&region=&status=all",
        "text": "Praluent",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622166?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_432": {
    "name": "Evkeeza",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623059?name=391665&mode=orpha&region=",
    "regulatory_id": "623059",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Evkeeza(Tradename                        - 11/02/2021)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Evkeeza(Tradename                        - 11/02/2021)",
      "(Tradename                        - 11/02/2021)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616444?name=391665&mode=orpha&region=&status=all",
        "text": "Evkeeza",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623059?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_433": {
    "name": "CRESTOR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/479947?name=391665&mode=orpha&region=",
    "regulatory_id": "479947",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "CRESTOR(Tradename                        - 27/05/2016)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "CRESTOR(Tradename                        - 27/05/2016)",
      "(Tradename                        - 27/05/2016)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/479943?name=391665&mode=orpha&region=&status=all",
        "text": "CRESTOR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/479947?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_434": {
    "name": "REPATHA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/440960?name=391665&mode=orpha&region=",
    "regulatory_id": "440960",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "REPATHA(Tradename                        - 27/08/2015)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "REPATHA(Tradename                        - 27/08/2015)",
      "(Tradename                        - 27/08/2015)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/440880?name=391665&mode=orpha&region=&status=all",
        "text": "REPATHA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/440960?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_435": {
    "name": "KYNAMRO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465151?name=391665&mode=orpha&region=",
    "regulatory_id": "465151",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "KYNAMRO(Tradename                        - 29/01/2013)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "KYNAMRO(Tradename                        - 29/01/2013)",
      "(Tradename                        - 29/01/2013)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464985?name=391665&mode=orpha&region=&status=all",
        "text": "KYNAMRO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465151?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_436": {
    "name": "JUXTAPID",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/392193?name=391665&mode=orpha&region=",
    "regulatory_id": "392193",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "JUXTAPID(Tradename                        - 21/12/2012)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "JUXTAPID(Tradename                        - 21/12/2012)",
      "(Tradename                        - 21/12/2012)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/460515?name=391665&mode=orpha&region=&status=all",
        "text": "JUXTAPID",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/392193?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "704647": {
    "name": "mRNA encoding the cholesterol degrading platform (CDP) fusion protein",
    "substance_url": "/en/drug/substance/704647?name=391665&mode=orpha&region=&status=all",
    "substance_id": "704647",
    "regulatory_url": "/en/drug/regulatory/704748?name=391665&mode=orpha&region=",
    "regulatory_id": "704748",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "mRNA encoding the cholesterol degrading platform (CDP) fusion protein(Medicinal product                        - 15/05/2025)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "mRNA encoding the cholesterol degrading platform (CDP) fusion protein(Medicinal product                        - 15/05/2025)",
      "(Medicinal product                        - 15/05/2025)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/704647?name=391665&mode=orpha&region=&status=all",
        "text": "mRNA encoding the cholesterol degrading platform (CDP) fusion protein",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704748?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "564109": {
    "name": "Alirocumab",
    "substance_url": "/en/drug/substance/564109?name=391665&mode=orpha&region=&status=all",
    "substance_id": "564109",
    "regulatory_url": "/en/drug/regulatory/564111?name=391665&mode=orpha&region=",
    "regulatory_id": "564111",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Alirocumab(Medicinal product                        - 15/06/2017)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Alirocumab(Medicinal product                        - 15/06/2017)",
      "(Medicinal product                        - 15/06/2017)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/564109?name=391665&mode=orpha&region=&status=all",
        "text": "Alirocumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/564111?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "441035": {
    "name": "Seladelpar",
    "substance_url": "/en/drug/substance/441035?name=391665&mode=orpha&region=&status=all",
    "substance_id": "441035",
    "regulatory_url": "/en/drug/regulatory/441043?name=391665&mode=orpha&region=",
    "regulatory_id": "441043",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Seladelpar(Medicinal product                        - 18/03/2015)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Seladelpar(Medicinal product                        - 18/03/2015)",
      "(Medicinal product                        - 18/03/2015)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/441035?name=391665&mode=orpha&region=&status=all",
        "text": "Seladelpar",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/441043?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "479941": {
    "name": "Rosuvastatin",
    "substance_url": "/en/drug/substance/479941?name=391665&mode=orpha&region=&status=all",
    "substance_id": "479941",
    "regulatory_url": "/en/drug/regulatory/479954?name=391665&mode=orpha&region=",
    "regulatory_id": "479954",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Rosuvastatin(Medicinal product                        - 14/02/2014)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Rosuvastatin(Medicinal product                        - 14/02/2014)",
      "(Medicinal product                        - 14/02/2014)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/479941?name=391665&mode=orpha&region=&status=all",
        "text": "Rosuvastatin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/479954?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "398923": {
    "name": "Gemcabene",
    "substance_url": "/en/drug/substance/398923?name=391665&mode=orpha&region=&status=all",
    "substance_id": "398923",
    "regulatory_url": "/en/drug/regulatory/398931?name=391665&mode=orpha&region=",
    "regulatory_id": "398931",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "Gemcabene(Medicinal product                        - 06/02/2014)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "Gemcabene(Medicinal product                        - 06/02/2014)",
      "(Medicinal product                        - 06/02/2014)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/398923?name=391665&mode=orpha&region=&status=all",
        "text": "Gemcabene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/398931?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "396217": {
    "name": "evolocumab",
    "substance_url": "/en/drug/substance/396217?name=391665&mode=orpha&region=&status=all",
    "substance_id": "396217",
    "regulatory_url": "/en/drug/regulatory/440957?name=391665&mode=orpha&region=",
    "regulatory_id": "440957",
    "orpha_substance_code": "ORPHA:391665",
    "details": [
      "evolocumab(Medicinal product                        - 12/09/2013)Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "evolocumab(Medicinal product                        - 12/09/2013)",
      "(Medicinal product                        - 12/09/2013)",
      "Disease(s) concernedORPHA:391665 Homozygous familial hypercholesterolemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/396217?name=391665&mode=orpha&region=&status=all",
        "text": "evolocumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391665",
        "text": "ORPHA:391665 Homozygous familial hypercholesterolemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/440957?name=391665&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_443": {
    "name": "AMVERSIO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642395?name=394&mode=orpha&region=",
    "regulatory_id": "642395",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "AMVERSIO(Tradename                        - 05/05/2022)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "AMVERSIO(Tradename                        - 05/05/2022)",
      "(Tradename                        - 05/05/2022)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642393?name=394&mode=orpha&region=&status=all",
        "text": "AMVERSIO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642395?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_444": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131341?name=394&mode=orpha&region=",
    "regulatory_id": "131341",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "CYSTADANE(Tradename                        - 15/02/2007)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "CYSTADANE(Tradename                        - 15/02/2007)",
      "(Tradename                        - 15/02/2007)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=394&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131341?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604899": {
    "name": "Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine gamma-lyase (Pyridoxal 5'-phosphate cofactor) (synthetic engineered human), tetramer",
    "substance_url": "/en/drug/substance/604899?name=394&mode=orpha&region=&status=all",
    "substance_id": "604899",
    "regulatory_url": "/en/drug/regulatory/604900?name=394&mode=orpha&region=",
    "regulatory_id": "604900",
    "orpha_substance_code": "ORPHA:394",
    "details": [
      "Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine gamma-lyase (Pyridoxal 5'-phosphate cofactor) (synthetic engineered human), tetramer(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine gamma-lyase (Pyridoxal 5'-phosphate cofactor) (synthetic engineered human), tetramer(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604899?name=394&mode=orpha&region=&status=all",
        "text": "Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine gamma-lyase (Pyridoxal 5'-phosphate cofactor) (synthetic engineered human), tetramer",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604900?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "480021": {
    "name": "polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase",
    "substance_url": "/en/drug/substance/480021?name=394&mode=orpha&region=&status=all",
    "substance_id": "480021",
    "regulatory_url": "/en/drug/regulatory/480022?name=394&mode=orpha&region=",
    "regulatory_id": "480022",
    "orpha_substance_code": "ORPHA:394",
    "details": [
      "polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase(Medicinal product                        - 30/05/2016)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase(Medicinal product                        - 30/05/2016)",
      "(Medicinal product                        - 30/05/2016)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480021?name=394&mode=orpha&region=&status=all",
        "text": "polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480022?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "33515": {
    "name": "Betaine anhydrous",
    "substance_url": "/en/drug/substance/33515?name=394&mode=orpha&region=&status=all",
    "substance_id": "33515",
    "regulatory_url": "/en/drug/regulatory/133728?name=394&mode=orpha&region=",
    "regulatory_id": "133728",
    "orpha_substance_code": "ORPHA:394",
    "details": [
      "Betaine anhydrous(Medicinal product                        - 09/07/2001)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "Betaine anhydrous(Medicinal product                        - 09/07/2001)",
      "(Medicinal product                        - 09/07/2001)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/33515?name=394&mode=orpha&region=&status=all",
        "text": "Betaine anhydrous",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133728?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_448": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131109?name=394&mode=orpha&region=",
    "regulatory_id": "131109",
    "orpha_substance_code": "ORPHA:2170",
    "details": [
      "CYSTADANE(Tradename                        - 25/10/1996)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "CYSTADANE(Tradename                        - 25/10/1996)",
      "(Tradename                        - 25/10/1996)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=394&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2169",
        "text": "ORPHA:2169 Methylcobalamin deficiency type cblE",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2170",
        "text": "ORPHA:2170 Methylcobalamin deficiency type cblG",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131109?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "687206": {
    "name": "Modified human cystathionine beta synthase messenger ribonucleic acid encapsulated in a lipid nanoparticle",
    "substance_url": "/en/drug/substance/687206?name=394&mode=orpha&region=&status=all",
    "substance_id": "687206",
    "regulatory_url": "/en/drug/regulatory/687539?name=394&mode=orpha&region=",
    "regulatory_id": "687539",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "Modified human cystathionine beta synthase messenger ribonucleic acid encapsulated in a lipid nanoparticle(Medicinal product                        - 18/07/2024)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "Modified human cystathionine beta synthase messenger ribonucleic acid encapsulated in a lipid nanoparticle(Medicinal product                        - 18/07/2024)",
      "(Medicinal product                        - 18/07/2024)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687206?name=394&mode=orpha&region=&status=all",
        "text": "Modified human cystathionine beta synthase messenger ribonucleic acid encapsulated in a lipid nanoparticle",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687539?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "636572": {
    "name": "Live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917",
    "substance_url": "/en/drug/substance/636572?name=394&mode=orpha&region=&status=all",
    "substance_id": "636572",
    "regulatory_url": "/en/drug/regulatory/636576?name=394&mode=orpha&region=",
    "regulatory_id": "636576",
    "orpha_substance_code": "ORPHA:394",
    "details": [
      "Live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917(Medicinal product                        - 22/11/2022)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "Live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917(Medicinal product                        - 22/11/2022)",
      "(Medicinal product                        - 22/11/2022)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/636572?name=394&mode=orpha&region=&status=all",
        "text": "Live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/636576?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "643857": {
    "name": "A modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila",
    "substance_url": "/en/drug/substance/643857?name=394&mode=orpha&region=&status=all",
    "substance_id": "643857",
    "regulatory_url": "/en/drug/regulatory/643858?name=394&mode=orpha&region=",
    "regulatory_id": "643858",
    "orpha_substance_code": "ORPHA:394",
    "details": [
      "A modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila(Medicinal product                        - 18/01/2022)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "A modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila(Medicinal product                        - 18/01/2022)",
      "(Medicinal product                        - 18/01/2022)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/643857?name=394&mode=orpha&region=&status=all",
        "text": "A modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/643858?name=394&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_452": {
    "name": "AMVERSIO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642395?name=395&mode=orpha&region=",
    "regulatory_id": "642395",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "AMVERSIO(Tradename                        - 05/05/2022)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "AMVERSIO(Tradename                        - 05/05/2022)",
      "(Tradename                        - 05/05/2022)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642393?name=395&mode=orpha&region=&status=all",
        "text": "AMVERSIO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642395?name=395&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_453": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131341?name=395&mode=orpha&region=",
    "regulatory_id": "131341",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "CYSTADANE(Tradename                        - 15/02/2007)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "CYSTADANE(Tradename                        - 15/02/2007)",
      "(Tradename                        - 15/02/2007)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=395&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131341?name=395&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_454": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131109?name=395&mode=orpha&region=",
    "regulatory_id": "131109",
    "orpha_substance_code": "ORPHA:2170",
    "details": [
      "CYSTADANE(Tradename                        - 25/10/1996)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "CYSTADANE(Tradename                        - 25/10/1996)",
      "(Tradename                        - 25/10/1996)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=395&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2169",
        "text": "ORPHA:2169 Methylcobalamin deficiency type cblE",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2170",
        "text": "ORPHA:2170 Methylcobalamin deficiency type cblG",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131109?name=395&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "541988": {
    "name": "Acetazolamide",
    "substance_url": "/en/drug/substance/541988?name=397750&mode=orpha&region=&status=all",
    "substance_id": "541988",
    "regulatory_url": "/en/drug/regulatory/570539?name=397750&mode=orpha&region=",
    "regulatory_id": "570539",
    "orpha_substance_code": "ORPHA:206976",
    "details": [
      "Acetazolamide(Medicinal product                        - 21/08/2019)Disease(s) concernedORPHA:206976 Periodic paralysis",
      "Acetazolamide(Medicinal product                        - 21/08/2019)",
      "(Medicinal product                        - 21/08/2019)",
      "Disease(s) concernedORPHA:206976 Periodic paralysis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/541988?name=397750&mode=orpha&region=&status=all",
        "text": "Acetazolamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/206976",
        "text": "ORPHA:206976 Periodic paralysis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/570539?name=397750&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "456170": {
    "name": "Diclofenamide",
    "substance_url": "/en/drug/substance/456170?name=397750&mode=orpha&region=&status=all",
    "substance_id": "456170",
    "regulatory_url": "/en/drug/regulatory/480192?name=397750&mode=orpha&region=",
    "regulatory_id": "480192",
    "orpha_substance_code": "ORPHA:206976",
    "details": [
      "Diclofenamide(Medicinal product                        - 27/06/2016)Disease(s) concernedORPHA:206976 Periodic paralysis",
      "Diclofenamide(Medicinal product                        - 27/06/2016)",
      "(Medicinal product                        - 27/06/2016)",
      "Disease(s) concernedORPHA:206976 Periodic paralysis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/456170?name=397750&mode=orpha&region=&status=all",
        "text": "Diclofenamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/206976",
        "text": "ORPHA:206976 Periodic paralysis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480192?name=397750&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_457": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=415&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=415&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=415&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_458": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=415&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=415&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=415&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "41778": {
    "name": "Stiripentol",
    "substance_url": "/en/drug/substance/41778?name=416&mode=orpha&region=&status=all",
    "substance_id": "41778",
    "regulatory_url": "/en/drug/regulatory/589315?name=416&mode=orpha&region=",
    "regulatory_id": "589315",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Stiripentol(Medicinal product                        - 26/06/2020)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Stiripentol(Medicinal product                        - 26/06/2020)",
      "(Medicinal product                        - 26/06/2020)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/41778?name=416&mode=orpha&region=&status=all",
        "text": "Stiripentol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589315?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "524602": {
    "name": "Nedosiran",
    "substance_url": "/en/drug/substance/524602?name=416&mode=orpha&region=&status=all",
    "substance_id": "524602",
    "regulatory_url": "/en/drug/regulatory/528536?name=416&mode=orpha&region=",
    "regulatory_id": "528536",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Nedosiran(Medicinal product                        - 31/07/2018)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Nedosiran(Medicinal product                        - 31/07/2018)",
      "(Medicinal product                        - 31/07/2018)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/524602?name=416&mode=orpha&region=&status=all",
        "text": "Nedosiran",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/528536?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "493796": {
    "name": "Bacillus subtilis oxalate decarboxylase",
    "substance_url": "/en/drug/substance/493796?name=416&mode=orpha&region=&status=all",
    "substance_id": "493796",
    "regulatory_url": "/en/drug/regulatory/494616?name=416&mode=orpha&region=",
    "regulatory_id": "494616",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Bacillus subtilis oxalate decarboxylase(Medicinal product                        - 17/07/2017)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Bacillus subtilis oxalate decarboxylase(Medicinal product                        - 17/07/2017)",
      "(Medicinal product                        - 17/07/2017)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/493796?name=416&mode=orpha&region=&status=all",
        "text": "Bacillus subtilis oxalate decarboxylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/494616?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "458734": {
    "name": "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
    "substance_url": "/en/drug/substance/458734?name=416&mode=orpha&region=&status=all",
    "substance_id": "458734",
    "regulatory_url": "/en/drug/regulatory/458735?name=416&mode=orpha&region=",
    "regulatory_id": "458735",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 21/03/2016)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 21/03/2016)",
      "(Medicinal product                        - 21/03/2016)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/458734?name=416&mode=orpha&region=&status=all",
        "text": "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/458735?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628274": {
    "name": "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",
    "substance_url": "/en/drug/substance/628274?name=416&mode=orpha&region=&status=all",
    "substance_id": "628274",
    "regulatory_url": "/en/drug/regulatory/628275?name=416&mode=orpha&region=",
    "regulatory_id": "628275",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 14/01/2022)",
      "(Medicinal product                        - 14/01/2022)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628274?name=416&mode=orpha&region=&status=all",
        "text": "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628275?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "695311": {
    "name": "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA",
    "substance_url": "/en/drug/substance/695311?name=416&mode=orpha&region=&status=all",
    "substance_id": "695311",
    "regulatory_url": "/en/drug/regulatory/695440?name=416&mode=orpha&region=",
    "regulatory_id": "695440",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA(Medicinal product                        - 02/02/2025)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA(Medicinal product                        - 02/02/2025)",
      "(Medicinal product                        - 02/02/2025)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/695311?name=416&mode=orpha&region=&status=all",
        "text": "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695440?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "688334": {
    "name": "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene",
    "substance_url": "/en/drug/substance/688334?name=416&mode=orpha&region=&status=all",
    "substance_id": "688334",
    "regulatory_url": "/en/drug/regulatory/688472?name=416&mode=orpha&region=",
    "regulatory_id": "688472",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene(Medicinal product                        - 20/09/2024)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene(Medicinal product                        - 20/09/2024)",
      "(Medicinal product                        - 20/09/2024)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688334?name=416&mode=orpha&region=&status=all",
        "text": "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688472?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "687138": {
    "name": "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid",
    "substance_url": "/en/drug/substance/687138?name=416&mode=orpha&region=&status=all",
    "substance_id": "687138",
    "regulatory_url": "/en/drug/regulatory/687314?name=416&mode=orpha&region=",
    "regulatory_id": "687314",
    "orpha_substance_code": "ORPHA:416",
    "details": [
      "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid(Medicinal product                        - 21/08/2024)",
      "(Medicinal product                        - 21/08/2024)",
      "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687138?name=416&mode=orpha&region=&status=all",
        "text": "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/416",
        "text": "ORPHA:416 Primary hyperoxaluria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687314?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_467": {
    "name": "Oxlumo",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/596200?name=416&mode=orpha&region=",
    "regulatory_id": "596200",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Oxlumo(Tradename                        - 19/11/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Oxlumo(Tradename                        - 19/11/2020)",
      "(Tradename                        - 19/11/2020)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
        "text": "Oxlumo",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/596200?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "75716": {
    "name": "Oxalobacter formigenes strain HC-1",
    "substance_url": "/en/drug/substance/75716?name=416&mode=orpha&region=&status=all",
    "substance_id": "75716",
    "regulatory_url": "/en/drug/regulatory/134032?name=416&mode=orpha&region=",
    "regulatory_id": "134032",
    "orpha_substance_code": "ORPHA:93599",
    "details": [
      "Oxalobacter formigenes strain HC-1(Medicinal product                        - 17/02/2006)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1ORPHA:93599 Primary hyperoxaluria type 2",
      "Oxalobacter formigenes strain HC-1(Medicinal product                        - 17/02/2006)",
      "(Medicinal product                        - 17/02/2006)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1ORPHA:93599 Primary hyperoxaluria type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/75716?name=416&mode=orpha&region=&status=all",
        "text": "Oxalobacter formigenes strain HC-1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93599",
        "text": "ORPHA:93599 Primary hyperoxaluria type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134032?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "444886": {
    "name": "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene",
    "substance_url": "/en/drug/substance/444886?name=416&mode=orpha&region=&status=all",
    "substance_id": "444886",
    "regulatory_url": "/en/drug/regulatory/444890?name=416&mode=orpha&region=",
    "regulatory_id": "444890",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene(Medicinal product                        - 28/07/2015)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene(Medicinal product                        - 28/07/2015)",
      "(Medicinal product                        - 28/07/2015)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/444886?name=416&mode=orpha&region=&status=all",
        "text": "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/444890?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "299531": {
    "name": "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene",
    "substance_url": "/en/drug/substance/299531?name=416&mode=orpha&region=&status=all",
    "substance_id": "299531",
    "regulatory_url": "/en/drug/regulatory/301092?name=416&mode=orpha&region=",
    "regulatory_id": "301092",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene(Medicinal product                        - 21/03/2012)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene(Medicinal product                        - 21/03/2012)",
      "(Medicinal product                        - 21/03/2012)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/299531?name=416&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/301092?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_471": {
    "name": "RIVFLOZA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/697177?name=416&mode=orpha&region=",
    "regulatory_id": "697177",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "RIVFLOZA(Tradename                        - 27/03/2025)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "RIVFLOZA(Tradename                        - 27/03/2025)",
      "(Tradename                        - 27/03/2025)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/660417?name=416&mode=orpha&region=&status=all",
        "text": "RIVFLOZA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/697177?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_472": {
    "name": "RIVFLOZA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/660486?name=416&mode=orpha&region=",
    "regulatory_id": "660486",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "RIVFLOZA(Tradename                        - 29/09/2023)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "RIVFLOZA(Tradename                        - 29/09/2023)",
      "(Tradename                        - 29/09/2023)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/660417?name=416&mode=orpha&region=&status=all",
        "text": "RIVFLOZA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/660486?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_473": {
    "name": "Oxlumo",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/633622?name=416&mode=orpha&region=",
    "regulatory_id": "633622",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Oxlumo(Tradename                        - 06/10/2022)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Oxlumo(Tradename                        - 06/10/2022)",
      "(Tradename                        - 06/10/2022)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
        "text": "Oxlumo",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/633622?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_474": {
    "name": "Oxlumo",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623117?name=416&mode=orpha&region=",
    "regulatory_id": "623117",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Oxlumo(Tradename                        - 23/11/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Oxlumo(Tradename                        - 23/11/2020)",
      "(Tradename                        - 23/11/2020)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
        "text": "Oxlumo",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623117?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "643876": {
    "name": "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",
    "substance_url": "/en/drug/substance/643876?name=416&mode=orpha&region=&status=all",
    "substance_id": "643876",
    "regulatory_url": "/en/drug/regulatory/643877?name=416&mode=orpha&region=",
    "regulatory_id": "643877",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 08/06/2022)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 08/06/2022)",
      "(Medicinal product                        - 08/06/2022)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/643876?name=416&mode=orpha&region=&status=all",
        "text": "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/643877?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "651177": {
    "name": "Glycolate oxidase inhibitor",
    "substance_url": "/en/drug/substance/651177?name=416&mode=orpha&region=&status=all",
    "substance_id": "651177",
    "regulatory_url": "/en/drug/regulatory/651178?name=416&mode=orpha&region=",
    "regulatory_id": "651178",
    "orpha_substance_code": "ORPHA:93598",
    "details": [
      "Glycolate oxidase inhibitor(Medicinal product                        - 10/09/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "Glycolate oxidase inhibitor(Medicinal product                        - 10/09/2020)",
      "(Medicinal product                        - 10/09/2020)",
      "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/651177?name=416&mode=orpha&region=&status=all",
        "text": "Glycolate oxidase inhibitor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93598",
        "text": "ORPHA:93598 Primary hyperoxaluria type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/651178?name=416&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "661189": {
    "name": "Riboflavin",
    "substance_url": "/en/drug/substance/661189?name=42&mode=orpha&region=&status=all",
    "substance_id": "661189",
    "regulatory_url": "/en/drug/regulatory/661280?name=42&mode=orpha&region=",
    "regulatory_id": "661280",
    "orpha_substance_code": "ORPHA:42",
    "details": [
      "Riboflavin(Medicinal product                        - 08/11/2023)Disease(s) concernedORPHA:42 Medium chain acyl-CoA dehydrogenase deficiency",
      "Riboflavin(Medicinal product                        - 08/11/2023)",
      "(Medicinal product                        - 08/11/2023)",
      "Disease(s) concernedORPHA:42 Medium chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661189?name=42&mode=orpha&region=&status=all",
        "text": "Riboflavin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/42",
        "text": "ORPHA:42 Medium chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661280?name=42&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_478": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=424027&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=424027&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=424027&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "631641": {
    "name": "potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",
    "substance_url": "/en/drug/substance/631641?name=43&mode=orpha&region=&status=all",
    "substance_id": "631641",
    "regulatory_url": "/en/drug/regulatory/638755?name=43&mode=orpha&region=",
    "regulatory_id": "638755",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate(Medicinal product                        - 09/12/2022)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate(Medicinal product                        - 09/12/2022)",
      "(Medicinal product                        - 09/12/2022)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/631641?name=43&mode=orpha&region=&status=all",
        "text": "potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/638755?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "635843": {
    "name": "(R)-deuteropioglitazone hydrochlorid",
    "substance_url": "/en/drug/substance/635843?name=43&mode=orpha&region=&status=all",
    "substance_id": "635843",
    "regulatory_url": "/en/drug/regulatory/635844?name=43&mode=orpha&region=",
    "regulatory_id": "635844",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "(R)-deuteropioglitazone hydrochlorid(Medicinal product                        - 10/11/2022)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "(R)-deuteropioglitazone hydrochlorid(Medicinal product                        - 10/11/2022)",
      "(Medicinal product                        - 10/11/2022)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/635843?name=43&mode=orpha&region=&status=all",
        "text": "(R)-deuteropioglitazone hydrochlorid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635844?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "635846": {
    "name": "Adeno-associated viral vector serotype 9 containing the human ABCD1 gene",
    "substance_url": "/en/drug/substance/635846?name=43&mode=orpha&region=&status=all",
    "substance_id": "635846",
    "regulatory_url": "/en/drug/regulatory/635847?name=43&mode=orpha&region=",
    "regulatory_id": "635847",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human ABCD1 gene(Medicinal product                        - 10/11/2022)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "Adeno-associated viral vector serotype 9 containing the human ABCD1 gene(Medicinal product                        - 10/11/2022)",
      "(Medicinal product                        - 10/11/2022)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/635846?name=43&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human ABCD1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635847?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "485024": {
    "name": "Hydroxypioglitazone",
    "substance_url": "/en/drug/substance/485024?name=43&mode=orpha&region=&status=all",
    "substance_id": "485024",
    "regulatory_url": "/en/drug/regulatory/485025?name=43&mode=orpha&region=",
    "regulatory_id": "485025",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "Hydroxypioglitazone(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "Hydroxypioglitazone(Medicinal product                        - 18/11/2016)",
      "(Medicinal product                        - 18/11/2016)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/485024?name=43&mode=orpha&region=&status=all",
        "text": "Hydroxypioglitazone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/485025?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "376874": {
    "name": "Pioglitazone",
    "substance_url": "/en/drug/substance/376874?name=43&mode=orpha&region=&status=all",
    "substance_id": "376874",
    "regulatory_url": "/en/drug/regulatory/398146?name=43&mode=orpha&region=",
    "regulatory_id": "398146",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "Pioglitazone(Medicinal product                        - 19/02/2014)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "Pioglitazone(Medicinal product                        - 19/02/2014)",
      "(Medicinal product                        - 19/02/2014)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/376874?name=43&mode=orpha&region=&status=all",
        "text": "Pioglitazone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/398146?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "300632": {
    "name": "Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel)",
    "substance_url": "/en/drug/substance/300632?name=43&mode=orpha&region=&status=all",
    "substance_id": "300632",
    "regulatory_url": "/en/drug/regulatory/302527?name=43&mode=orpha&region=",
    "regulatory_id": "302527",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel)(Medicinal product                        - 06/06/2012)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel)(Medicinal product                        - 06/06/2012)",
      "(Medicinal product                        - 06/06/2012)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/300632?name=43&mode=orpha&region=&status=all",
        "text": "Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/302527?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "632214": {
    "name": "(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride",
    "substance_url": "/en/drug/substance/632214?name=43&mode=orpha&region=&status=all",
    "substance_id": "632214",
    "regulatory_url": "/en/drug/regulatory/632215?name=43&mode=orpha&region=",
    "regulatory_id": "632215",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride(Medicinal product                        - 11/04/2022)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride(Medicinal product                        - 11/04/2022)",
      "(Medicinal product                        - 11/04/2022)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/632214?name=43&mode=orpha&region=&status=all",
        "text": "(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/632215?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "641602": {
    "name": "A non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene",
    "substance_url": "/en/drug/substance/641602?name=43&mode=orpha&region=&status=all",
    "substance_id": "641602",
    "regulatory_url": "/en/drug/regulatory/641603?name=43&mode=orpha&region=",
    "regulatory_id": "641603",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "A non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene(Medicinal product                        - 14/03/2022)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "A non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene(Medicinal product                        - 14/03/2022)",
      "(Medicinal product                        - 14/03/2022)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/641602?name=43&mode=orpha&region=&status=all",
        "text": "A non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/641603?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "649500": {
    "name": "2' 3,5'dichloro'4'  4'hydroxy'3' propan'2'yl phenyl methyl phenoxy 'N'methylacetamide",
    "substance_url": "/en/drug/substance/649500?name=43&mode=orpha&region=&status=all",
    "substance_id": "649500",
    "regulatory_url": "/en/drug/regulatory/649501?name=43&mode=orpha&region=",
    "regulatory_id": "649501",
    "orpha_substance_code": "ORPHA:43",
    "details": [
      "2' 3,5'dichloro'4'  4'hydroxy'3' propan'2'yl phenyl methyl phenoxy 'N'methylacetamide(Medicinal product                        - 22/07/2021)Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "2' 3,5'dichloro'4'  4'hydroxy'3' propan'2'yl phenyl methyl phenoxy 'N'methylacetamide(Medicinal product                        - 22/07/2021)",
      "(Medicinal product                        - 22/07/2021)",
      "Disease(s) concernedORPHA:43 X-linked adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/649500?name=43&mode=orpha&region=&status=all",
        "text": "2' 3,5'dichloro'4'  4'hydroxy'3' propan'2'yl phenyl methyl phenoxy 'N'methylacetamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/43",
        "text": "ORPHA:43 X-linked adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/649501?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "216915": {
    "name": "Fingolimod",
    "substance_url": "/en/drug/substance/216915?name=43&mode=orpha&region=&status=all",
    "substance_id": "216915",
    "regulatory_url": "/en/drug/regulatory/627633?name=43&mode=orpha&region=",
    "regulatory_id": "627633",
    "orpha_substance_code": "ORPHA:139396",
    "details": [
      "Fingolimod(Medicinal product                        - 12/11/2021)Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "Fingolimod(Medicinal product                        - 12/11/2021)",
      "(Medicinal product                        - 12/11/2021)",
      "Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/216915?name=43&mode=orpha&region=&status=all",
        "text": "Fingolimod",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/139396",
        "text": "ORPHA:139396 X-linked cerebral adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627633?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "82051": {
    "name": "Temsirolimus",
    "substance_url": "/en/drug/substance/82051?name=43&mode=orpha&region=&status=all",
    "substance_id": "82051",
    "regulatory_url": "/en/drug/regulatory/480062?name=43&mode=orpha&region=",
    "regulatory_id": "480062",
    "orpha_substance_code": "ORPHA:139396",
    "details": [
      "Temsirolimus(Medicinal product                        - 30/05/2016)Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "Temsirolimus(Medicinal product                        - 30/05/2016)",
      "(Medicinal product                        - 30/05/2016)",
      "Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82051?name=43&mode=orpha&region=&status=all",
        "text": "Temsirolimus",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/139396",
        "text": "ORPHA:139396 X-linked cerebral adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480062?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_490": {
    "name": "Skysona",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610558?name=43&mode=orpha&region=",
    "regulatory_id": "610558",
    "orpha_substance_code": "ORPHA:139396",
    "details": [
      "Skysona(Tradename                        - 16/07/2021)Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "Skysona(Tradename                        - 16/07/2021)",
      "(Tradename                        - 16/07/2021)",
      "Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/605019?name=43&mode=orpha&region=&status=all",
        "text": "Skysona",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/139396",
        "text": "ORPHA:139396 X-linked cerebral adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610558?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_491": {
    "name": "Skysona",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/631397?name=43&mode=orpha&region=",
    "regulatory_id": "631397",
    "orpha_substance_code": "ORPHA:139396",
    "details": [
      "Skysona(Tradename                        - 16/09/2022)Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "Skysona(Tradename                        - 16/09/2022)",
      "(Tradename                        - 16/09/2022)",
      "Disease(s) concernedORPHA:139396 X-linked cerebral adrenoleukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/605019?name=43&mode=orpha&region=&status=all",
        "text": "Skysona",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/139396",
        "text": "ORPHA:139396 X-linked cerebral adrenoleukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/631397?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_492": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=43&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=43&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_493": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=43&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=43&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_494": {
    "name": "ALKINDI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/505896?name=43&mode=orpha&region=",
    "regulatory_id": "505896",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "ALKINDI(Tradename                        - 09/02/2018)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "ALKINDI(Tradename                        - 09/02/2018)",
      "(Tradename                        - 09/02/2018)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505888?name=43&mode=orpha&region=&status=all",
        "text": "ALKINDI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/505896?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_495": {
    "name": "PLENADREN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/352529?name=43&mode=orpha&region=",
    "regulatory_id": "352529",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "PLENADREN(Tradename                        - 03/11/2011)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "PLENADREN(Tradename                        - 03/11/2011)",
      "(Tradename                        - 03/11/2011)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/352513?name=43&mode=orpha&region=&status=all",
        "text": "PLENADREN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/352529?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_496": {
    "name": "KHINDIVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/704611?name=43&mode=orpha&region=",
    "regulatory_id": "704611",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "KHINDIVI(Tradename                        - 28/05/2025)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "KHINDIVI(Tradename                        - 28/05/2025)",
      "(Tradename                        - 28/05/2025)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/704608?name=43&mode=orpha&region=&status=all",
        "text": "KHINDIVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704611?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_497": {
    "name": "Alkindi Sprinkle",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623088?name=43&mode=orpha&region=",
    "regulatory_id": "623088",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)",
      "(Tradename                        - 29/09/2020)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623087?name=43&mode=orpha&region=&status=all",
        "text": "Alkindi Sprinkle",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623088?name=43&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_498": {
    "name": "ALKINDI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/505896?name=44&mode=orpha&region=",
    "regulatory_id": "505896",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "ALKINDI(Tradename                        - 09/02/2018)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "ALKINDI(Tradename                        - 09/02/2018)",
      "(Tradename                        - 09/02/2018)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505888?name=44&mode=orpha&region=&status=all",
        "text": "ALKINDI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/505896?name=44&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_499": {
    "name": "PLENADREN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/352529?name=44&mode=orpha&region=",
    "regulatory_id": "352529",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "PLENADREN(Tradename                        - 03/11/2011)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "PLENADREN(Tradename                        - 03/11/2011)",
      "(Tradename                        - 03/11/2011)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/352513?name=44&mode=orpha&region=&status=all",
        "text": "PLENADREN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/352529?name=44&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_500": {
    "name": "KHINDIVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/704611?name=44&mode=orpha&region=",
    "regulatory_id": "704611",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "KHINDIVI(Tradename                        - 28/05/2025)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "KHINDIVI(Tradename                        - 28/05/2025)",
      "(Tradename                        - 28/05/2025)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/704608?name=44&mode=orpha&region=&status=all",
        "text": "KHINDIVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704611?name=44&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_501": {
    "name": "Alkindi Sprinkle",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623088?name=44&mode=orpha&region=",
    "regulatory_id": "623088",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)",
      "(Tradename                        - 29/09/2020)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623087?name=44&mode=orpha&region=&status=all",
        "text": "Alkindi Sprinkle",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623088?name=44&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_502": {
    "name": "SCENESSE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/138001?name=443197&mode=orpha&region=",
    "regulatory_id": "138001",
    "orpha_substance_code": "ORPHA:443197",
    "details": [
      "SCENESSE(Tradename                        - 22/12/2014)Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "SCENESSE(Tradename                        - 22/12/2014)",
      "(Tradename                        - 22/12/2014)",
      "Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/437244?name=443197&mode=orpha&region=&status=all",
        "text": "SCENESSE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79278",
        "text": "ORPHA:79278 Autosomal erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/443197",
        "text": "ORPHA:443197 X-linked erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/138001?name=443197&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "499844": {
    "name": "Bitopertin",
    "substance_url": "/en/drug/substance/499844?name=443197&mode=orpha&region=&status=all",
    "substance_id": "499844",
    "regulatory_url": "/en/drug/regulatory/642471?name=443197&mode=orpha&region=",
    "regulatory_id": "642471",
    "orpha_substance_code": "ORPHA:443197",
    "details": [
      "Bitopertin(Medicinal product                        - 15/02/2023)Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "Bitopertin(Medicinal product                        - 15/02/2023)",
      "(Medicinal product                        - 15/02/2023)",
      "Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/499844?name=443197&mode=orpha&region=&status=all",
        "text": "Bitopertin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79278",
        "text": "ORPHA:79278 Autosomal erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/443197",
        "text": "ORPHA:443197 X-linked erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642471?name=443197&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "622076": {
    "name": "Dersimelagon",
    "substance_url": "/en/drug/substance/622076?name=443197&mode=orpha&region=&status=all",
    "substance_id": "622076",
    "regulatory_url": "/en/drug/regulatory/622077?name=443197&mode=orpha&region=",
    "regulatory_id": "622077",
    "orpha_substance_code": "ORPHA:443197",
    "details": [
      "Dersimelagon(Medicinal product                        - 16/03/2022)Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "Dersimelagon(Medicinal product                        - 16/03/2022)",
      "(Medicinal product                        - 16/03/2022)",
      "Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/622076?name=443197&mode=orpha&region=&status=all",
        "text": "Dersimelagon",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79278",
        "text": "ORPHA:79278 Autosomal erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/443197",
        "text": "ORPHA:443197 X-linked erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622077?name=443197&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_505": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=443197&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=443197&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=443197&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_506": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=443811&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=443811&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=443811&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_507": {
    "name": "WAYLIVRA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/556976?name=444490&mode=orpha&region=",
    "regulatory_id": "556976",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "WAYLIVRA(Tradename                        - 03/05/2019)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "WAYLIVRA(Tradename                        - 03/05/2019)",
      "(Tradename                        - 03/05/2019)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/556969?name=444490&mode=orpha&region=&status=all",
        "text": "WAYLIVRA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/556976?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "622060": {
    "name": "Olezarsen",
    "substance_url": "/en/drug/substance/622060?name=444490&mode=orpha&region=&status=all",
    "substance_id": "622060",
    "regulatory_url": "/en/drug/regulatory/686872?name=444490&mode=orpha&region=",
    "regulatory_id": "686872",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "Olezarsen(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "Olezarsen(Medicinal product                        - 21/08/2024)",
      "(Medicinal product                        - 21/08/2024)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/622060?name=444490&mode=orpha&region=&status=all",
        "text": "Olezarsen",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686872?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627673": {
    "name": "Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
    "substance_url": "/en/drug/substance/627673?name=444490&mode=orpha&region=&status=all",
    "substance_id": "627673",
    "regulatory_url": "/en/drug/regulatory/627674?name=444490&mode=orpha&region=",
    "regulatory_id": "627674",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 19/07/2021)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 19/07/2021)",
      "(Medicinal product                        - 19/07/2021)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627673?name=444490&mode=orpha&region=&status=all",
        "text": "Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627674?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "376872": {
    "name": "Apolipotrotein C-III antisense oligonucleotide",
    "substance_url": "/en/drug/substance/376872?name=444490&mode=orpha&region=&status=all",
    "substance_id": "376872",
    "regulatory_url": "/en/drug/regulatory/397921?name=444490&mode=orpha&region=",
    "regulatory_id": "397921",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "Apolipotrotein C-III antisense oligonucleotide(Medicinal product                        - 19/02/2014)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "Apolipotrotein C-III antisense oligonucleotide(Medicinal product                        - 19/02/2014)",
      "(Medicinal product                        - 19/02/2014)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/376872?name=444490&mode=orpha&region=&status=all",
        "text": "Apolipotrotein C-III antisense oligonucleotide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/397921?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "240492": {
    "name": "Lomitapide",
    "substance_url": "/en/drug/substance/240492?name=444490&mode=orpha&region=&status=all",
    "substance_id": "240492",
    "regulatory_url": "/en/drug/regulatory/260317?name=444490&mode=orpha&region=",
    "regulatory_id": "260317",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "Lomitapide(Medicinal product                        - 17/12/2010)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "Lomitapide(Medicinal product                        - 17/12/2010)",
      "(Medicinal product                        - 17/12/2010)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/240492?name=444490&mode=orpha&region=&status=all",
        "text": "Lomitapide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/260317?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "317205": {
    "name": "Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt",
    "substance_url": "/en/drug/substance/317205?name=444490&mode=orpha&region=&status=all",
    "substance_id": "317205",
    "regulatory_url": "/en/drug/regulatory/360541?name=444490&mode=orpha&region=",
    "regulatory_id": "360541",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt(Medicinal product                        - 14/09/2013)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt(Medicinal product                        - 14/09/2013)",
      "(Medicinal product                        - 14/09/2013)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/317205?name=444490&mode=orpha&region=&status=all",
        "text": "Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/360541?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_513": {
    "name": "TRYNGOLZA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/692505?name=444490&mode=orpha&region=",
    "regulatory_id": "692505",
    "orpha_substance_code": "ORPHA:444490",
    "details": [
      "TRYNGOLZA(Tradename                        - 19/12/2024)Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "TRYNGOLZA(Tradename                        - 19/12/2024)",
      "(Tradename                        - 19/12/2024)",
      "Disease(s) concernedORPHA:444490 Familial chylomicronemia syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/692409?name=444490&mode=orpha&region=&status=all",
        "text": "TRYNGOLZA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/444490",
        "text": "ORPHA:444490 Familial chylomicronemia syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692505?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_514": {
    "name": "GLYBERA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/352359?name=444490&mode=orpha&region=",
    "regulatory_id": "352359",
    "orpha_substance_code": "ORPHA:309015",
    "details": [
      "GLYBERA(Tradename                        - 25/10/2012)Disease(s) concernedORPHA:309015 Familial lipoprotein lipase deficiency",
      "GLYBERA(Tradename                        - 25/10/2012)",
      "(Tradename                        - 25/10/2012)",
      "Disease(s) concernedORPHA:309015 Familial lipoprotein lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/352356?name=444490&mode=orpha&region=&status=all",
        "text": "GLYBERA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309015",
        "text": "ORPHA:309015 Familial lipoprotein lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/352359?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "82361": {
    "name": "Alipogene tiparvovec",
    "substance_url": "/en/drug/substance/82361?name=444490&mode=orpha&region=&status=all",
    "substance_id": "82361",
    "regulatory_url": "/en/drug/regulatory/133874?name=444490&mode=orpha&region=",
    "regulatory_id": "133874",
    "orpha_substance_code": "ORPHA:309015",
    "details": [
      "Alipogene tiparvovec(Medicinal product                        - 08/03/2004)Disease(s) concernedORPHA:309015 Familial lipoprotein lipase deficiency",
      "Alipogene tiparvovec(Medicinal product                        - 08/03/2004)",
      "(Medicinal product                        - 08/03/2004)",
      "Disease(s) concernedORPHA:309015 Familial lipoprotein lipase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82361?name=444490&mode=orpha&region=&status=all",
        "text": "Alipogene tiparvovec",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309015",
        "text": "ORPHA:309015 Familial lipoprotein lipase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133874?name=444490&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_516": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=445038&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=445038&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=445038&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_517": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=445038&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=445038&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=445038&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_518": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=445038&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=445038&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=445038&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_519": {
    "name": "FABHALTA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/676579?name=447&mode=orpha&region=",
    "regulatory_id": "676579",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "FABHALTA(Tradename                        - 17/05/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "FABHALTA(Tradename                        - 17/05/2024)",
      "(Tradename                        - 17/05/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/660409?name=447&mode=orpha&region=&status=all",
        "text": "FABHALTA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/676579?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_520": {
    "name": "VOYDEYA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673826?name=447&mode=orpha&region=",
    "regulatory_id": "673826",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "VOYDEYA(Tradename                        - 19/04/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "VOYDEYA(Tradename                        - 19/04/2024)",
      "(Tradename                        - 19/04/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/665114?name=447&mode=orpha&region=&status=all",
        "text": "VOYDEYA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673826?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_521": {
    "name": "ASPAVELI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/624357?name=447&mode=orpha&region=",
    "regulatory_id": "624357",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "ASPAVELI(Tradename                        - 13/12/2021)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "ASPAVELI(Tradename                        - 13/12/2021)",
      "(Tradename                        - 13/12/2021)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/624355?name=447&mode=orpha&region=&status=all",
        "text": "ASPAVELI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/624357?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_522": {
    "name": "PIASKY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/687035?name=447&mode=orpha&region=",
    "regulatory_id": "687035",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "PIASKY(Tradename                        - 22/08/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "PIASKY(Tradename                        - 22/08/2024)",
      "(Tradename                        - 22/08/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/684344?name=447&mode=orpha&region=&status=all",
        "text": "PIASKY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687035?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_523": {
    "name": "EPYSQLI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/650347?name=447&mode=orpha&region=",
    "regulatory_id": "650347",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "EPYSQLI(Tradename                        - 26/05/2023)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "EPYSQLI(Tradename                        - 26/05/2023)",
      "(Tradename                        - 26/05/2023)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/650346?name=447&mode=orpha&region=&status=all",
        "text": "EPYSQLI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650347?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_524": {
    "name": "ULTOMIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/557038?name=447&mode=orpha&region=",
    "regulatory_id": "557038",
    "orpha_substance_code": "ORPHA:71211",
    "details": [
      "ULTOMIRIS(Tradename                        - 05/05/2023)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuriaORPHA:71211 Neuromyelitis optica spectrum disorder",
      "ULTOMIRIS(Tradename                        - 05/05/2023)",
      "(Tradename                        - 05/05/2023)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuriaORPHA:71211 Neuromyelitis optica spectrum disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/557036?name=447&mode=orpha&region=&status=all",
        "text": "ULTOMIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71211",
        "text": "ORPHA:71211 Neuromyelitis optica spectrum disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/557038?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_525": {
    "name": "BEKEMV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/650353?name=447&mode=orpha&region=",
    "regulatory_id": "650353",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "BEKEMV(Tradename                        - 19/04/2023)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "BEKEMV(Tradename                        - 19/04/2023)",
      "(Tradename                        - 19/04/2023)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/650352?name=447&mode=orpha&region=&status=all",
        "text": "BEKEMV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/650353?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_526": {
    "name": "SOLIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/563093?name=447&mode=orpha&region=",
    "regulatory_id": "563093",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "SOLIRIS(Tradename                        - 20/06/2007)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "SOLIRIS(Tradename                        - 20/06/2007)",
      "(Tradename                        - 20/06/2007)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/82335?name=447&mode=orpha&region=&status=all",
        "text": "SOLIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/563093?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "536870": {
    "name": "Iptacopan",
    "substance_url": "/en/drug/substance/536870?name=447&mode=orpha&region=&status=all",
    "substance_id": "536870",
    "regulatory_url": "/en/drug/regulatory/589275?name=447&mode=orpha&region=",
    "regulatory_id": "589275",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Iptacopan(Medicinal product                        - 04/06/2020)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Iptacopan(Medicinal product                        - 04/06/2020)",
      "(Medicinal product                        - 04/06/2020)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/536870?name=447&mode=orpha&region=&status=all",
        "text": "Iptacopan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589275?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "500656": {
    "name": "Danicopan",
    "substance_url": "/en/drug/substance/500656?name=447&mode=orpha&region=&status=all",
    "substance_id": "500656",
    "regulatory_url": "/en/drug/regulatory/500657?name=447&mode=orpha&region=",
    "regulatory_id": "500657",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Danicopan(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Danicopan(Medicinal product                        - 12/12/2017)",
      "(Medicinal product                        - 12/12/2017)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/500656?name=447&mode=orpha&region=&status=all",
        "text": "Danicopan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/500657?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "489701": {
    "name": "PEGylated peptide inhibitor of complement C3",
    "substance_url": "/en/drug/substance/489701?name=447&mode=orpha&region=&status=all",
    "substance_id": "489701",
    "regulatory_url": "/en/drug/regulatory/489702?name=447&mode=orpha&region=",
    "regulatory_id": "489702",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "PEGylated peptide inhibitor of complement C3(Medicinal product                        - 22/05/2017)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "PEGylated peptide inhibitor of complement C3(Medicinal product                        - 22/05/2017)",
      "(Medicinal product                        - 22/05/2017)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489701?name=447&mode=orpha&region=&status=all",
        "text": "PEGylated peptide inhibitor of complement C3",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489702?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "480224": {
    "name": "Coversin",
    "substance_url": "/en/drug/substance/480224?name=447&mode=orpha&region=&status=all",
    "substance_id": "480224",
    "regulatory_url": "/en/drug/regulatory/480229?name=447&mode=orpha&region=",
    "regulatory_id": "480229",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Coversin(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Coversin(Medicinal product                        - 29/08/2016)",
      "(Medicinal product                        - 29/08/2016)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480224?name=447&mode=orpha&region=&status=all",
        "text": "Coversin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480229?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "406538": {
    "name": "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",
    "substance_url": "/en/drug/substance/406538?name=447&mode=orpha&region=&status=all",
    "substance_id": "406538",
    "regulatory_url": "/en/drug/regulatory/412201?name=447&mode=orpha&region=",
    "regulatory_id": "412201",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)(Medicinal product                        - 22/08/2014)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)(Medicinal product                        - 22/08/2014)",
      "(Medicinal product                        - 22/08/2014)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406538?name=447&mode=orpha&region=&status=all",
        "text": "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412201?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "627324": {
    "name": "(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide",
    "substance_url": "/en/drug/substance/627324?name=447&mode=orpha&region=&status=all",
    "substance_id": "627324",
    "regulatory_url": "/en/drug/regulatory/627326?name=447&mode=orpha&region=",
    "regulatory_id": "627326",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide(Medicinal product                        - 19/02/2021)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide(Medicinal product                        - 19/02/2021)",
      "(Medicinal product                        - 19/02/2021)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627324?name=447&mode=orpha&region=&status=all",
        "text": "(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627326?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "484834": {
    "name": "15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker",
    "substance_url": "/en/drug/substance/484834?name=447&mode=orpha&region=&status=all",
    "substance_id": "484834",
    "regulatory_url": "/en/drug/regulatory/484838?name=447&mode=orpha&region=",
    "regulatory_id": "484838",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker(Medicinal product                        - 14/10/2016)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker(Medicinal product                        - 14/10/2016)",
      "(Medicinal product                        - 14/10/2016)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/484834?name=447&mode=orpha&region=&status=all",
        "text": "15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484838?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "479982": {
    "name": "Ravulizumab",
    "substance_url": "/en/drug/substance/479982?name=447&mode=orpha&region=&status=all",
    "substance_id": "479982",
    "regulatory_url": "/en/drug/regulatory/479983?name=447&mode=orpha&region=",
    "regulatory_id": "479983",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Ravulizumab(Medicinal product                        - 30/05/2016)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Ravulizumab(Medicinal product                        - 30/05/2016)",
      "(Medicinal product                        - 30/05/2016)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/479982?name=447&mode=orpha&region=&status=all",
        "text": "Ravulizumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/479983?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "82334": {
    "name": "Eculizumab",
    "substance_url": "/en/drug/substance/82334?name=447&mode=orpha&region=&status=all",
    "substance_id": "82334",
    "regulatory_url": "/en/drug/regulatory/133846?name=447&mode=orpha&region=",
    "regulatory_id": "133846",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Eculizumab(Medicinal product                        - 17/10/2003)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Eculizumab(Medicinal product                        - 17/10/2003)",
      "(Medicinal product                        - 17/10/2003)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82334?name=447&mode=orpha&region=&status=all",
        "text": "Eculizumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133846?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "82336": {
    "name": "Myristoylated-peptidyl-recombinant Human CD59",
    "substance_url": "/en/drug/substance/82336?name=447&mode=orpha&region=&status=all",
    "substance_id": "82336",
    "regulatory_url": "/en/drug/regulatory/133795?name=447&mode=orpha&region=",
    "regulatory_id": "133795",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Myristoylated-peptidyl-recombinant Human CD59(Medicinal product                        - 11/09/2002)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Myristoylated-peptidyl-recombinant Human CD59(Medicinal product                        - 11/09/2002)",
      "(Medicinal product                        - 11/09/2002)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82336?name=447&mode=orpha&region=&status=all",
        "text": "Myristoylated-peptidyl-recombinant Human CD59",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133795?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_537": {
    "name": "PIASKY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/684345?name=447&mode=orpha&region=",
    "regulatory_id": "684345",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "PIASKY(Tradename                        - 20/06/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "PIASKY(Tradename                        - 20/06/2024)",
      "(Tradename                        - 20/06/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/684344?name=447&mode=orpha&region=&status=all",
        "text": "PIASKY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684345?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_538": {
    "name": "VOYDEYA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/665126?name=447&mode=orpha&region=",
    "regulatory_id": "665126",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "VOYDEYA(Tradename                        - 29/03/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "VOYDEYA(Tradename                        - 29/03/2024)",
      "(Tradename                        - 29/03/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/665114?name=447&mode=orpha&region=&status=all",
        "text": "VOYDEYA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665126?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_539": {
    "name": "FABHALTA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/660482?name=447&mode=orpha&region=",
    "regulatory_id": "660482",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "FABHALTA(Tradename                        - 05/12/2023)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "FABHALTA(Tradename                        - 05/12/2023)",
      "(Tradename                        - 05/12/2023)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/660409?name=447&mode=orpha&region=&status=all",
        "text": "FABHALTA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/660482?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_540": {
    "name": "ULTOMIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623286?name=447&mode=orpha&region=",
    "regulatory_id": "623286",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "ULTOMIRIS(Tradename                        - 07/06/2021)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "ULTOMIRIS(Tradename                        - 07/06/2021)",
      "(Tradename                        - 07/06/2021)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/557036?name=447&mode=orpha&region=&status=all",
        "text": "ULTOMIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623286?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_541": {
    "name": "Empaveli",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623243?name=447&mode=orpha&region=",
    "regulatory_id": "623243",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Empaveli(Tradename                        - 14/05/2021)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Empaveli(Tradename                        - 14/05/2021)",
      "(Tradename                        - 14/05/2021)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616471?name=447&mode=orpha&region=&status=all",
        "text": "Empaveli",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623243?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_542": {
    "name": "ULTOMIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623284?name=447&mode=orpha&region=",
    "regulatory_id": "623284",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "ULTOMIRIS(Tradename                        - 09/10/2020)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "ULTOMIRIS(Tradename                        - 09/10/2020)",
      "(Tradename                        - 09/10/2020)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/557036?name=447&mode=orpha&region=&status=all",
        "text": "ULTOMIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623284?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_543": {
    "name": "ULTOMIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/543097?name=447&mode=orpha&region=",
    "regulatory_id": "543097",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "ULTOMIRIS(Tradename                        - 21/12/2018)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "ULTOMIRIS(Tradename                        - 21/12/2018)",
      "(Tradename                        - 21/12/2018)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/557036?name=447&mode=orpha&region=&status=all",
        "text": "ULTOMIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/543097?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_544": {
    "name": "SOLIRIS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131171?name=447&mode=orpha&region=",
    "regulatory_id": "131171",
    "orpha_substance_code": "ORPHA:391490",
    "details": [
      "SOLIRIS(Tradename                        - 16/03/2007)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuriaORPHA:2134 Atypical hemolytic uremic syndromeORPHA:71211 Neuromyelitis optica spectrum disorderORPHA:391490 Adult-onset myasthenia gravis",
      "SOLIRIS(Tradename                        - 16/03/2007)",
      "(Tradename                        - 16/03/2007)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuriaORPHA:2134 Atypical hemolytic uremic syndromeORPHA:71211 Neuromyelitis optica spectrum disorderORPHA:391490 Adult-onset myasthenia gravis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/82335?name=447&mode=orpha&region=&status=all",
        "text": "SOLIRIS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2134",
        "text": "ORPHA:2134 Atypical hemolytic uremic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71211",
        "text": "ORPHA:71211 Neuromyelitis optica spectrum disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/391490",
        "text": "ORPHA:391490 Adult-onset myasthenia gravis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131171?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:71211 Neuromyelitis optica spectrum disorder\n                                \n\n\n\n\n                                    ORPHA:391490 Adult-onset myasthenia gravis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "692559": {
    "name": "Small molecule inhibitor of complement factor B",
    "substance_url": "/en/drug/substance/692559?name=447&mode=orpha&region=&status=all",
    "substance_id": "692559",
    "regulatory_url": "/en/drug/regulatory/692632?name=447&mode=orpha&region=",
    "regulatory_id": "692632",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Small molecule inhibitor of complement factor B(Medicinal product                        - 11/12/2024)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Small molecule inhibitor of complement factor B(Medicinal product                        - 11/12/2024)",
      "(Medicinal product                        - 11/12/2024)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/692559?name=447&mode=orpha&region=&status=all",
        "text": "Small molecule inhibitor of complement factor B",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692632?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "666398": {
    "name": "Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody",
    "substance_url": "/en/drug/substance/666398?name=447&mode=orpha&region=&status=all",
    "substance_id": "666398",
    "regulatory_url": "/en/drug/regulatory/666464?name=447&mode=orpha&region=",
    "regulatory_id": "666464",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody(Medicinal product                        - 20/12/2023)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody(Medicinal product                        - 20/12/2023)",
      "(Medicinal product                        - 20/12/2023)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666398?name=447&mode=orpha&region=&status=all",
        "text": "Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666464?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "634413": {
    "name": "Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody",
    "substance_url": "/en/drug/substance/634413?name=447&mode=orpha&region=&status=all",
    "substance_id": "634413",
    "regulatory_url": "/en/drug/regulatory/634414?name=447&mode=orpha&region=",
    "regulatory_id": "634414",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody(Medicinal product                        - 05/10/2022)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody(Medicinal product                        - 05/10/2022)",
      "(Medicinal product                        - 05/10/2022)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/634413?name=447&mode=orpha&region=&status=all",
        "text": "Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/634414?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "637255": {
    "name": "OMS906",
    "substance_url": "/en/drug/substance/637255?name=447&mode=orpha&region=&status=all",
    "substance_id": "637255",
    "regulatory_url": "/en/drug/regulatory/637256?name=447&mode=orpha&region=",
    "regulatory_id": "637256",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "OMS906(Medicinal product                        - 28/07/2022)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "OMS906(Medicinal product                        - 28/07/2022)",
      "(Medicinal product                        - 28/07/2022)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/637255?name=447&mode=orpha&region=&status=all",
        "text": "OMS906",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/637256?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "637340": {
    "name": "Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus",
    "substance_url": "/en/drug/substance/637340?name=447&mode=orpha&region=&status=all",
    "substance_id": "637340",
    "regulatory_url": "/en/drug/regulatory/637341?name=447&mode=orpha&region=",
    "regulatory_id": "637341",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus(Medicinal product                        - 20/07/2022)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus(Medicinal product                        - 20/07/2022)",
      "(Medicinal product                        - 20/07/2022)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/637340?name=447&mode=orpha&region=&status=all",
        "text": "Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/637341?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "504663": {
    "name": "Cemdisiran",
    "substance_url": "/en/drug/substance/504663?name=447&mode=orpha&region=&status=all",
    "substance_id": "504663",
    "regulatory_url": "/en/drug/regulatory/634568?name=447&mode=orpha&region=",
    "regulatory_id": "634568",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Cemdisiran(Medicinal product                        - 10/02/2022)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Cemdisiran(Medicinal product                        - 10/02/2022)",
      "(Medicinal product                        - 10/02/2022)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/504663?name=447&mode=orpha&region=&status=all",
        "text": "Cemdisiran",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/634568?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "622067": {
    "name": "BCX9930",
    "substance_url": "/en/drug/substance/622067?name=447&mode=orpha&region=&status=all",
    "substance_id": "622067",
    "regulatory_url": "/en/drug/regulatory/622068?name=447&mode=orpha&region=",
    "regulatory_id": "622068",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "BCX9930(Medicinal product                        - 28/08/2020)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "BCX9930(Medicinal product                        - 28/08/2020)",
      "(Medicinal product                        - 28/08/2020)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/622067?name=447&mode=orpha&region=&status=all",
        "text": "BCX9930",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/622068?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "590018": {
    "name": "Nomacopan",
    "substance_url": "/en/drug/substance/590018?name=447&mode=orpha&region=&status=all",
    "substance_id": "590018",
    "regulatory_url": "/en/drug/regulatory/480232?name=447&mode=orpha&region=",
    "regulatory_id": "480232",
    "orpha_substance_code": "ORPHA:447",
    "details": [
      "Nomacopan(Medicinal product                        - 08/09/2016)Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "Nomacopan(Medicinal product                        - 08/09/2016)",
      "(Medicinal product                        - 08/09/2016)",
      "Disease(s) concernedORPHA:447 Paroxysmal nocturnal hemoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/590018?name=447&mode=orpha&region=&status=all",
        "text": "Nomacopan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/447",
        "text": "ORPHA:447 Paroxysmal nocturnal hemoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480232?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_553": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=447&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=447&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_554": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=447&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=447&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=447&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_555": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=470&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=470&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_556": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=470&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=470&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_557": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=470&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=470&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "448814": {
    "name": "tadekinig alfa",
    "substance_url": "/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
    "substance_id": "448814",
    "regulatory_url": "/en/drug/regulatory/484711?name=470&mode=orpha&region=",
    "regulatory_id": "484711",
    "orpha_substance_code": "ORPHA:158032",
    "details": [
      "tadekinig alfa(Medicinal product                        - 14/10/2016)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "tadekinig alfa(Medicinal product                        - 14/10/2016)",
      "(Medicinal product                        - 14/10/2016)",
      "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/448814?name=470&mode=orpha&region=&status=all",
        "text": "tadekinig alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158032",
        "text": "ORPHA:158032 Hemophagocytic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484711?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "222653": {
    "name": "emapalumab",
    "substance_url": "/en/drug/substance/222653?name=470&mode=orpha&region=&status=all",
    "substance_id": "222653",
    "regulatory_url": "/en/drug/regulatory/240327?name=470&mode=orpha&region=",
    "regulatory_id": "240327",
    "orpha_substance_code": "ORPHA:158032",
    "details": [
      "emapalumab(Medicinal product                        - 09/06/2010)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "emapalumab(Medicinal product                        - 09/06/2010)",
      "(Medicinal product                        - 09/06/2010)",
      "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/222653?name=470&mode=orpha&region=&status=all",
        "text": "emapalumab",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158032",
        "text": "ORPHA:158032 Hemophagocytic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/240327?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_560": {
    "name": "GAMIFANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/539493?name=470&mode=orpha&region=",
    "regulatory_id": "539493",
    "orpha_substance_code": "ORPHA:158038",
    "details": [
      "GAMIFANT(Tradename                        - 20/11/2018)Disease(s) concernedORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
      "GAMIFANT(Tradename                        - 20/11/2018)",
      "(Tradename                        - 20/11/2018)",
      "Disease(s) concernedORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/539491?name=470&mode=orpha&region=&status=all",
        "text": "GAMIFANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158038",
        "text": "ORPHA:158038 Primary hemophagocytic lymphohistiocytosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/539493?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689517": {
    "name": "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma",
    "substance_url": "/en/drug/substance/689517?name=470&mode=orpha&region=&status=all",
    "substance_id": "689517",
    "regulatory_url": "/en/drug/regulatory/689727?name=470&mode=orpha&region=",
    "regulatory_id": "689727",
    "orpha_substance_code": "ORPHA:158032",
    "details": [
      "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma(Medicinal product                        - 02/10/2024)Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma(Medicinal product                        - 02/10/2024)",
      "(Medicinal product                        - 02/10/2024)",
      "Disease(s) concernedORPHA:158032 Hemophagocytic syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689517?name=470&mode=orpha&region=&status=all",
        "text": "Fully human IgG1 monoclonal antibody directed against human signal regulatory protein (SIRP)alpha, SIRPbeta1, and SIRPgamma",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/158032",
        "text": "ORPHA:158032 Hemophagocytic syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689727?name=470&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627727": {
    "name": "Encaleret sulfate",
    "substance_url": "/en/drug/substance/627727?name=480&mode=orpha&region=&status=all",
    "substance_id": "627727",
    "regulatory_url": "/en/drug/regulatory/627728?name=480&mode=orpha&region=",
    "regulatory_id": "627728",
    "orpha_substance_code": "ORPHA:208593",
    "details": [
      "Encaleret sulfate(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:181405 Rare hypoparathyroidismORPHA:208593 Genetic hypoparathyroidism",
      "Encaleret sulfate(Medicinal product                        - 15/10/2021)",
      "(Medicinal product                        - 15/10/2021)",
      "Disease(s) concernedORPHA:181405 Rare hypoparathyroidismORPHA:208593 Genetic hypoparathyroidism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627727?name=480&mode=orpha&region=&status=all",
        "text": "Encaleret sulfate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/181405",
        "text": "ORPHA:181405 Rare hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/208593",
        "text": "ORPHA:208593 Genetic hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627728?name=480&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604906": {
    "name": "Palopegteriparatide",
    "substance_url": "/en/drug/substance/604906?name=480&mode=orpha&region=&status=all",
    "substance_id": "604906",
    "regulatory_url": "/en/drug/regulatory/604907?name=480&mode=orpha&region=",
    "regulatory_id": "604907",
    "orpha_substance_code": "ORPHA:208593",
    "details": [
      "Palopegteriparatide(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:2238 Familial isolated hypoparathyroidismORPHA:181405 Rare hypoparathyroidismORPHA:208593 Genetic hypoparathyroidism",
      "Palopegteriparatide(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:2238 Familial isolated hypoparathyroidismORPHA:181405 Rare hypoparathyroidismORPHA:208593 Genetic hypoparathyroidism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604906?name=480&mode=orpha&region=&status=all",
        "text": "Palopegteriparatide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2238",
        "text": "ORPHA:2238 Familial isolated hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/181405",
        "text": "ORPHA:181405 Rare hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/208593",
        "text": "ORPHA:208593 Genetic hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604907?name=480&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "367963": {
    "name": "Recombinant human parathyroid hormone",
    "substance_url": "/en/drug/substance/367963?name=480&mode=orpha&region=&status=all",
    "substance_id": "367963",
    "regulatory_url": "/en/drug/regulatory/377573?name=480&mode=orpha&region=",
    "regulatory_id": "377573",
    "orpha_substance_code": "ORPHA:181402",
    "details": [
      "Recombinant human parathyroid hormone(Medicinal product                        - 16/01/2014)Disease(s) concernedORPHA:2238 Familial isolated hypoparathyroidismORPHA:3453 Autoimmune polyendocrinopathy type 1ORPHA:181402 Syndrome with hypoparathyroidism",
      "Recombinant human parathyroid hormone(Medicinal product                        - 16/01/2014)",
      "(Medicinal product                        - 16/01/2014)",
      "Disease(s) concernedORPHA:2238 Familial isolated hypoparathyroidismORPHA:3453 Autoimmune polyendocrinopathy type 1ORPHA:181402 Syndrome with hypoparathyroidism",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/367963?name=480&mode=orpha&region=&status=all",
        "text": "Recombinant human parathyroid hormone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2238",
        "text": "ORPHA:2238 Familial isolated hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3453",
        "text": "ORPHA:3453 Autoimmune polyendocrinopathy type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/181402",
        "text": "ORPHA:181402 Syndrome with hypoparathyroidism",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/377573?name=480&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "with hypoparathyroidism\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "627996": {
    "name": "Adeno-associated virus serotype rh10 containing the human GALC gene",
    "substance_url": "/en/drug/substance/627996?name=487&mode=orpha&region=&status=all",
    "substance_id": "627996",
    "regulatory_url": "/en/drug/regulatory/627997?name=487&mode=orpha&region=",
    "regulatory_id": "627997",
    "orpha_substance_code": "ORPHA:487",
    "details": [
      "Adeno-associated virus serotype rh10 containing the human GALC gene(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:487 Krabbe disease",
      "Adeno-associated virus serotype rh10 containing the human GALC gene(Medicinal product                        - 15/10/2021)",
      "(Medicinal product                        - 15/10/2021)",
      "Disease(s) concernedORPHA:487 Krabbe disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627996?name=487&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype rh10 containing the human GALC gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/487",
        "text": "ORPHA:487 Krabbe disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627997?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604150": {
    "name": "Adeno-associated virus serotype hu68 containing the human GALC gene",
    "substance_url": "/en/drug/substance/604150?name=487&mode=orpha&region=&status=all",
    "substance_id": "604150",
    "regulatory_url": "/en/drug/regulatory/627355?name=487&mode=orpha&region=",
    "regulatory_id": "627355",
    "orpha_substance_code": "ORPHA:487",
    "details": [
      "Adeno-associated virus serotype hu68 containing the human GALC gene(Medicinal product                        - 26/03/2021)Disease(s) concernedORPHA:487 Krabbe disease",
      "Adeno-associated virus serotype hu68 containing the human GALC gene(Medicinal product                        - 26/03/2021)",
      "(Medicinal product                        - 26/03/2021)",
      "Disease(s) concernedORPHA:487 Krabbe disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604150?name=487&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype hu68 containing the human GALC gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/487",
        "text": "ORPHA:487 Krabbe disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627355?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "275267": {
    "name": "Recombinant human galactocerebrosidase",
    "substance_url": "/en/drug/substance/275267?name=487&mode=orpha&region=&status=all",
    "substance_id": "275267",
    "regulatory_url": "/en/drug/regulatory/285901?name=487&mode=orpha&region=",
    "regulatory_id": "285901",
    "orpha_substance_code": "ORPHA:487",
    "details": [
      "Recombinant human galactocerebrosidase(Medicinal product                        - 27/09/2011)Disease(s) concernedORPHA:487 Krabbe disease",
      "Recombinant human galactocerebrosidase(Medicinal product                        - 27/09/2011)",
      "(Medicinal product                        - 27/09/2011)",
      "Disease(s) concernedORPHA:487 Krabbe disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/275267?name=487&mode=orpha&region=&status=all",
        "text": "Recombinant human galactocerebrosidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/487",
        "text": "ORPHA:487 Krabbe disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/285901?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689594": {
    "name": "Recombinant serotype 9 adeno-associated virus (AAV) encoding a human galactosylceramidase (GALC) transgene (hGALC)",
    "substance_url": "/en/drug/substance/689594?name=487&mode=orpha&region=&status=all",
    "substance_id": "689594",
    "regulatory_url": "/en/drug/regulatory/690331?name=487&mode=orpha&region=",
    "regulatory_id": "690331",
    "orpha_substance_code": "ORPHA:487",
    "details": [
      "Recombinant serotype 9 adeno-associated virus (AAV) encoding a human galactosylceramidase (GALC) transgene (hGALC)(Medicinal product                        - 29/10/2024)Disease(s) concernedORPHA:487 Krabbe disease",
      "Recombinant serotype 9 adeno-associated virus (AAV) encoding a human galactosylceramidase (GALC) transgene (hGALC)(Medicinal product                        - 29/10/2024)",
      "(Medicinal product                        - 29/10/2024)",
      "Disease(s) concernedORPHA:487 Krabbe disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689594?name=487&mode=orpha&region=&status=all",
        "text": "Recombinant serotype 9 adeno-associated virus (AAV) encoding a human galactosylceramidase (GALC) transgene (hGALC)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/487",
        "text": "ORPHA:487 Krabbe disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/690331?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "644118": {
    "name": "Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2)",
    "substance_url": "/en/drug/substance/644118?name=487&mode=orpha&region=&status=all",
    "substance_id": "644118",
    "regulatory_url": "/en/drug/regulatory/644120?name=487&mode=orpha&region=",
    "regulatory_id": "644120",
    "orpha_substance_code": "ORPHA:487",
    "details": [
      "Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2)(Medicinal product                        - 10/02/2022)Disease(s) concernedORPHA:487 Krabbe disease",
      "Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2)(Medicinal product                        - 10/02/2022)",
      "(Medicinal product                        - 10/02/2022)",
      "Disease(s) concernedORPHA:487 Krabbe disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/644118?name=487&mode=orpha&region=&status=all",
        "text": "Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/487",
        "text": "ORPHA:487 Krabbe disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644120?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_570": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=487&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=487&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_571": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=487&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=487&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=487&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604812": {
    "name": "Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate",
    "substance_url": "/en/drug/substance/604812?name=5&mode=orpha&region=&status=all",
    "substance_id": "604812",
    "regulatory_url": "/en/drug/regulatory/604835?name=5&mode=orpha&region=",
    "regulatory_id": "604835",
    "orpha_substance_code": "ORPHA:5",
    "details": [
      "Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
      "Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate(Medicinal product                        - 21/08/2020)",
      "(Medicinal product                        - 21/08/2020)",
      "Disease(s) concernedORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604812?name=5&mode=orpha&region=&status=all",
        "text": "Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604835?name=5&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_573": {
    "name": "DOJOLVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623538?name=5&mode=orpha&region=",
    "regulatory_id": "623538",
    "orpha_substance_code": "ORPHA:26793",
    "details": [
      "DOJOLVI(Tradename                        - 30/06/2020)Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "DOJOLVI(Tradename                        - 30/06/2020)",
      "(Tradename                        - 30/06/2020)",
      "Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/615857?name=5&mode=orpha&region=&status=all",
        "text": "DOJOLVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157",
        "text": "ORPHA:157 Carnitine palmitoyltransferase II deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/746",
        "text": "ORPHA:746 Mitochondrial trifunctional protein deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26793",
        "text": "ORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623538?name=5&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "661174": {
    "name": "Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate",
    "substance_url": "/en/drug/substance/661174?name=506&mode=orpha&region=&status=all",
    "substance_id": "661174",
    "regulatory_url": "/en/drug/regulatory/661270?name=506&mode=orpha&region=",
    "regulatory_id": "661270",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate(Medicinal product                        - 13/12/2023)Disease(s) concernedORPHA:506 Leigh syndrome",
      "Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate(Medicinal product                        - 13/12/2023)",
      "(Medicinal product                        - 13/12/2023)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661174?name=506&mode=orpha&region=&status=all",
        "text": "Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661270?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "65861": {
    "name": "Sildenafil citrate",
    "substance_url": "/en/drug/substance/65861?name=506&mode=orpha&region=&status=all",
    "substance_id": "65861",
    "regulatory_url": "/en/drug/regulatory/661066?name=506&mode=orpha&region=",
    "regulatory_id": "661066",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "Sildenafil citrate(Medicinal product                        - 13/10/2023)Disease(s) concernedORPHA:506 Leigh syndrome",
      "Sildenafil citrate(Medicinal product                        - 13/10/2023)",
      "(Medicinal product                        - 13/10/2023)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/65861?name=506&mode=orpha&region=&status=all",
        "text": "Sildenafil citrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661066?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "398846": {
    "name": "Cannabidiol",
    "substance_url": "/en/drug/substance/398846?name=506&mode=orpha&region=&status=all",
    "substance_id": "398846",
    "regulatory_url": "/en/drug/regulatory/654062?name=506&mode=orpha&region=",
    "regulatory_id": "654062",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "Cannabidiol(Medicinal product                        - 25/07/2023)Disease(s) concernedORPHA:506 Leigh syndrome",
      "Cannabidiol(Medicinal product                        - 25/07/2023)",
      "(Medicinal product                        - 25/07/2023)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/398846?name=506&mode=orpha&region=&status=all",
        "text": "Cannabidiol",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/654062?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "628149": {
    "name": "Adeno-associated viral vector serotype 9 containing the human SURF1 gene",
    "substance_url": "/en/drug/substance/628149?name=506&mode=orpha&region=&status=all",
    "substance_id": "628149",
    "regulatory_url": "/en/drug/regulatory/628151?name=506&mode=orpha&region=",
    "regulatory_id": "628151",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human SURF1 gene(Medicinal product                        - 12/11/2021)Disease(s) concernedORPHA:506 Leigh syndrome",
      "Adeno-associated viral vector serotype 9 containing the human SURF1 gene(Medicinal product                        - 12/11/2021)",
      "(Medicinal product                        - 12/11/2021)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628149?name=506&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human SURF1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628151?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "410354": {
    "name": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",
    "substance_url": "/en/drug/substance/410354?name=506&mode=orpha&region=&status=all",
    "substance_id": "410354",
    "regulatory_url": "/en/drug/regulatory/414139?name=506&mode=orpha&region=",
    "regulatory_id": "414139",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride(Medicinal product                        - 15/10/2014)Disease(s) concernedORPHA:506 Leigh syndrome",
      "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride(Medicinal product                        - 15/10/2014)",
      "(Medicinal product                        - 15/10/2014)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/410354?name=506&mode=orpha&region=&status=all",
        "text": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/414139?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689481": {
    "name": "Adeno-associated virus 9 human NADH:ubiquinone oxidoreductase subunit S4",
    "substance_url": "/en/drug/substance/689481?name=506&mode=orpha&region=&status=all",
    "substance_id": "689481",
    "regulatory_url": "/en/drug/regulatory/689639?name=506&mode=orpha&region=",
    "regulatory_id": "689639",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "Adeno-associated virus 9 human NADH:ubiquinone oxidoreductase subunit S4(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:506 Leigh syndrome",
      "Adeno-associated virus 9 human NADH:ubiquinone oxidoreductase subunit S4(Medicinal product                        - 22/10/2024)",
      "(Medicinal product                        - 22/10/2024)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689481?name=506&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus 9 human NADH:ubiquinone oxidoreductase subunit S4",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689639?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "688278": {
    "name": "2-((hydroxy((R)-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)oxy)-3-(((E)-octadec-2-en-1-yl)oxy)propoxy)phosphoryl)oxy)ethan-1-ammonium",
    "substance_url": "/en/drug/substance/688278?name=506&mode=orpha&region=&status=all",
    "substance_id": "688278",
    "regulatory_url": "/en/drug/regulatory/688364?name=506&mode=orpha&region=",
    "regulatory_id": "688364",
    "orpha_substance_code": "ORPHA:506",
    "details": [
      "2-((hydroxy((R)-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)oxy)-3-(((E)-octadec-2-en-1-yl)oxy)propoxy)phosphoryl)oxy)ethan-1-ammonium(Medicinal product                        - 26/09/2024)Disease(s) concernedORPHA:506 Leigh syndrome",
      "2-((hydroxy((R)-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)oxy)-3-(((E)-octadec-2-en-1-yl)oxy)propoxy)phosphoryl)oxy)ethan-1-ammonium(Medicinal product                        - 26/09/2024)",
      "(Medicinal product                        - 26/09/2024)",
      "Disease(s) concernedORPHA:506 Leigh syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688278?name=506&mode=orpha&region=&status=all",
        "text": "2-((hydroxy((R)-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)oxy)-3-(((E)-octadec-2-en-1-yl)oxy)propoxy)phosphoryl)oxy)ethan-1-ammonium",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506",
        "text": "ORPHA:506 Leigh syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688364?name=506&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_581": {
    "name": "ALKINDI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/505896?name=506334&mode=orpha&region=",
    "regulatory_id": "505896",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "ALKINDI(Tradename                        - 09/02/2018)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "ALKINDI(Tradename                        - 09/02/2018)",
      "(Tradename                        - 09/02/2018)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505888?name=506334&mode=orpha&region=&status=all",
        "text": "ALKINDI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/505896?name=506334&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_582": {
    "name": "PLENADREN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/352529?name=506334&mode=orpha&region=",
    "regulatory_id": "352529",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "PLENADREN(Tradename                        - 03/11/2011)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "PLENADREN(Tradename                        - 03/11/2011)",
      "(Tradename                        - 03/11/2011)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/352513?name=506334&mode=orpha&region=&status=all",
        "text": "PLENADREN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/352529?name=506334&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_583": {
    "name": "KHINDIVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/704611?name=506334&mode=orpha&region=",
    "regulatory_id": "704611",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "KHINDIVI(Tradename                        - 28/05/2025)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "KHINDIVI(Tradename                        - 28/05/2025)",
      "(Tradename                        - 28/05/2025)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/704608?name=506334&mode=orpha&region=&status=all",
        "text": "KHINDIVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704611?name=506334&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_584": {
    "name": "Alkindi Sprinkle",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623088?name=506334&mode=orpha&region=",
    "regulatory_id": "623088",
    "orpha_substance_code": "ORPHA:101958",
    "details": [
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "Alkindi Sprinkle(Tradename                        - 29/09/2020)",
      "(Tradename                        - 29/09/2020)",
      "Disease(s) concernedORPHA:101958 Primary adrenal insufficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623087?name=506334&mode=orpha&region=&status=all",
        "text": "Alkindi Sprinkle",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101958",
        "text": "ORPHA:101958 Primary adrenal insufficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623088?name=506334&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "216913": {
    "name": "Ecopipam",
    "substance_url": "/en/drug/substance/216913?name=510&mode=orpha&region=&status=all",
    "substance_id": "216913",
    "regulatory_url": "/en/drug/regulatory/225977?name=510&mode=orpha&region=",
    "regulatory_id": "225977",
    "orpha_substance_code": "ORPHA:510",
    "details": [
      "Ecopipam(Medicinal product                        - 03/02/2010)Disease(s) concernedORPHA:510 Lesch-Nyhan syndrome",
      "Ecopipam(Medicinal product                        - 03/02/2010)",
      "(Medicinal product                        - 03/02/2010)",
      "Disease(s) concernedORPHA:510 Lesch-Nyhan syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/216913?name=510&mode=orpha&region=&status=all",
        "text": "Ecopipam",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/510",
        "text": "ORPHA:510 Lesch-Nyhan syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/225977?name=510&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "531812": {
    "name": "Glycine, L-alanine, L-arginine, L-aspartic acid, L -cysteine, L-cystine, L- glutamic acid, L-histidine, L-lysine monohydrate, L -methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine",
    "substance_url": "/en/drug/substance/531812?name=511&mode=orpha&region=&status=all",
    "substance_id": "531812",
    "regulatory_url": "/en/drug/regulatory/531813?name=511&mode=orpha&region=",
    "regulatory_id": "531813",
    "orpha_substance_code": "ORPHA:511",
    "details": [
      "Glycine, L-alanine, L-arginine, L-aspartic acid, L -cysteine, L-cystine, L- glutamic acid, L-histidine, L-lysine monohydrate, L -methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine(Medicinal product                        - 26/10/2018)Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "Glycine, L-alanine, L-arginine, L-aspartic acid, L -cysteine, L-cystine, L- glutamic acid, L-histidine, L-lysine monohydrate, L -methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine(Medicinal product                        - 26/10/2018)",
      "(Medicinal product                        - 26/10/2018)",
      "Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/531812?name=511&mode=orpha&region=&status=all",
        "text": "Glycine, L-alanine, L-arginine, L-aspartic acid, L -cysteine, L-cystine, L- glutamic acid, L-histidine, L-lysine monohydrate, L -methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/511",
        "text": "ORPHA:511 Maple syrup urine disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/531813?name=511&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "704655": {
    "name": "Recombinant AAV9 vector expressing functional, codon-optimized, human BCKDHA and BCKDHB genes which encode for catalytic E1alpha and E1beta subunits, respectively, of the BCKDH holoenzyme",
    "substance_url": "/en/drug/substance/704655?name=511&mode=orpha&region=&status=all",
    "substance_id": "704655",
    "regulatory_url": "/en/drug/regulatory/704791?name=511&mode=orpha&region=",
    "regulatory_id": "704791",
    "orpha_substance_code": "ORPHA:511",
    "details": [
      "Recombinant AAV9 vector expressing functional, codon-optimized, human BCKDHA and BCKDHB genes which encode for catalytic E1alpha and E1beta subunits, respectively, of the BCKDH holoenzyme(Medicinal product                        - 15/05/2025)Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "Recombinant AAV9 vector expressing functional, codon-optimized, human BCKDHA and BCKDHB genes which encode for catalytic E1alpha and E1beta subunits, respectively, of the BCKDH holoenzyme(Medicinal product                        - 15/05/2025)",
      "(Medicinal product                        - 15/05/2025)",
      "Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/704655?name=511&mode=orpha&region=&status=all",
        "text": "Recombinant AAV9 vector expressing functional, codon-optimized, human BCKDHA and BCKDHB genes which encode for catalytic E1alpha and E1beta subunits, respectively, of the BCKDH holoenzyme",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/511",
        "text": "ORPHA:511 Maple syrup urine disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/704791?name=511&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "638953": {
    "name": "Modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium",
    "substance_url": "/en/drug/substance/638953?name=511&mode=orpha&region=&status=all",
    "substance_id": "638953",
    "regulatory_url": "/en/drug/regulatory/638957?name=511&mode=orpha&region=",
    "regulatory_id": "638957",
    "orpha_substance_code": "ORPHA:511",
    "details": [
      "Modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium(Medicinal product                        - 20/12/2022)Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "Modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium(Medicinal product                        - 20/12/2022)",
      "(Medicinal product                        - 20/12/2022)",
      "Disease(s) concernedORPHA:511 Maple syrup urine disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/638953?name=511&mode=orpha&region=&status=all",
        "text": "Modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/511",
        "text": "ORPHA:511 Maple syrup urine disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/638957?name=511&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_589": {
    "name": "Libmeldy",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/596218?name=512&mode=orpha&region=",
    "regulatory_id": "596218",
    "orpha_substance_code": "ORPHA:512",
    "details": [
      "Libmeldy(Tradename                        - 17/12/2020)Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "Libmeldy(Tradename                        - 17/12/2020)",
      "(Tradename                        - 17/12/2020)",
      "Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/596216?name=512&mode=orpha&region=&status=all",
        "text": "Libmeldy",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/512",
        "text": "ORPHA:512 Metachromatic leukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/596218?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "79944": {
    "name": "Cerebroside sulfatase",
    "substance_url": "/en/drug/substance/79944?name=512&mode=orpha&region=&status=all",
    "substance_id": "79944",
    "regulatory_url": "/en/drug/regulatory/252199?name=512&mode=orpha&region=",
    "regulatory_id": "252199",
    "orpha_substance_code": "ORPHA:512",
    "details": [
      "Cerebroside sulfatase(Medicinal product                        - 26/11/2010)Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "Cerebroside sulfatase(Medicinal product                        - 26/11/2010)",
      "(Medicinal product                        - 26/11/2010)",
      "Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/79944?name=512&mode=orpha&region=&status=all",
        "text": "Cerebroside sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/512",
        "text": "ORPHA:512 Metachromatic leukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/252199?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "520969": {
    "name": "Atidarsagene autotemcel",
    "substance_url": "/en/drug/substance/520969?name=512&mode=orpha&region=&status=all",
    "substance_id": "520969",
    "regulatory_url": "/en/drug/regulatory/134123?name=512&mode=orpha&region=",
    "regulatory_id": "134123",
    "orpha_substance_code": "ORPHA:512",
    "details": [
      "Atidarsagene autotemcel(Medicinal product                        - 13/04/2007)Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "Atidarsagene autotemcel(Medicinal product                        - 13/04/2007)",
      "(Medicinal product                        - 13/04/2007)",
      "Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/520969?name=512&mode=orpha&region=&status=all",
        "text": "Atidarsagene autotemcel",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/512",
        "text": "ORPHA:512 Metachromatic leukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/134123?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "589722": {
    "name": "Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene",
    "substance_url": "/en/drug/substance/589722?name=512&mode=orpha&region=&status=all",
    "substance_id": "589722",
    "regulatory_url": "/en/drug/regulatory/589723?name=512&mode=orpha&region=",
    "regulatory_id": "589723",
    "orpha_substance_code": "ORPHA:512",
    "details": [
      "Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene(Medicinal product                        - 26/06/2020)Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene(Medicinal product                        - 26/06/2020)",
      "(Medicinal product                        - 26/06/2020)",
      "Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/589722?name=512&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/512",
        "text": "ORPHA:512 Metachromatic leukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/589723?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "666386": {
    "name": "Recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin",
    "substance_url": "/en/drug/substance/666386?name=512&mode=orpha&region=&status=all",
    "substance_id": "666386",
    "regulatory_url": "/en/drug/regulatory/666443?name=512&mode=orpha&region=",
    "regulatory_id": "666443",
    "orpha_substance_code": "ORPHA:512",
    "details": [
      "Recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin(Medicinal product                        - 15/12/2023)Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "Recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin(Medicinal product                        - 15/12/2023)",
      "(Medicinal product                        - 15/12/2023)",
      "Disease(s) concernedORPHA:512 Metachromatic leukodystrophy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666386?name=512&mode=orpha&region=&status=all",
        "text": "Recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/512",
        "text": "ORPHA:512 Metachromatic leukodystrophy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666443?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_594": {
    "name": "LENMELDY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/665125?name=512&mode=orpha&region=",
    "regulatory_id": "665125",
    "orpha_substance_code": "ORPHA:309263",
    "details": [
      "LENMELDY(Tradename                        - 18/03/2024)Disease(s) concernedORPHA:309256 Metachromatic leukodystrophy, late infantile formORPHA:309263 Metachromatic leukodystrophy, juvenile form",
      "LENMELDY(Tradename                        - 18/03/2024)",
      "(Tradename                        - 18/03/2024)",
      "Disease(s) concernedORPHA:309256 Metachromatic leukodystrophy, late infantile formORPHA:309263 Metachromatic leukodystrophy, juvenile form",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/665112?name=512&mode=orpha&region=&status=all",
        "text": "LENMELDY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309256",
        "text": "ORPHA:309256 Metachromatic leukodystrophy, late infantile form",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309263",
        "text": "ORPHA:309263 Metachromatic leukodystrophy, juvenile form",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665125?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_595": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=512&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=512&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_596": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=512&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=512&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=512&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "24974": {
    "name": "Eflornithine hydrochloride",
    "substance_url": "/en/drug/substance/24974?name=544488&mode=orpha&region=&status=all",
    "substance_id": "24974",
    "regulatory_url": "/en/drug/regulatory/665251?name=544488&mode=orpha&region=",
    "regulatory_id": "665251",
    "orpha_substance_code": "ORPHA:544488",
    "details": [
      "Eflornithine hydrochloride(Medicinal product                        - 11/03/2024)Disease(s) concernedORPHA:544488 Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome",
      "Eflornithine hydrochloride(Medicinal product                        - 11/03/2024)",
      "(Medicinal product                        - 11/03/2024)",
      "Disease(s) concernedORPHA:544488 Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24974?name=544488&mode=orpha&region=&status=all",
        "text": "Eflornithine hydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/544488",
        "text": "ORPHA:544488 Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665251?name=544488&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "500664": {
    "name": "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",
    "substance_url": "/en/drug/substance/500664?name=550&mode=orpha&region=&status=all",
    "substance_id": "500664",
    "regulatory_url": "/en/drug/regulatory/500665?name=550&mode=orpha&region=",
    "regulatory_id": "500665",
    "orpha_substance_code": "ORPHA:550",
    "details": [
      "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione(Medicinal product                        - 12/12/2017)Disease(s) concernedORPHA:550 MELAS",
      "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione(Medicinal product                        - 12/12/2017)",
      "(Medicinal product                        - 12/12/2017)",
      "Disease(s) concernedORPHA:550 MELAS",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/500664?name=550&mode=orpha&region=&status=all",
        "text": "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/550",
        "text": "ORPHA:550 MELAS",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/500665?name=550&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_599": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=551&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=551&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=551&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_600": {
    "name": "NITYR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/644947?name=56&mode=orpha&region=",
    "regulatory_id": "644947",
    "orpha_substance_code": "ORPHA:56",
    "details": [
      "NITYR(Tradename                        - 28/11/2022)Disease(s) concernedORPHA:56 Alkaptonuria",
      "NITYR(Tradename                        - 28/11/2022)",
      "(Tradename                        - 28/11/2022)",
      "Disease(s) concernedORPHA:56 Alkaptonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/527350?name=56&mode=orpha&region=&status=all",
        "text": "NITYR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/56",
        "text": "ORPHA:56 Alkaptonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644947?name=56&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_601": {
    "name": "ORFADIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/647330?name=56&mode=orpha&region=",
    "regulatory_id": "647330",
    "orpha_substance_code": "ORPHA:56",
    "details": [
      "ORFADIN(Tradename                        - 22/10/2020)Disease(s) concernedORPHA:56 Alkaptonuria",
      "ORFADIN(Tradename                        - 22/10/2020)",
      "(Tradename                        - 22/10/2020)",
      "Disease(s) concernedORPHA:56 Alkaptonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/56898?name=56&mode=orpha&region=&status=all",
        "text": "ORFADIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/56",
        "text": "ORPHA:56 Alkaptonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/647330?name=56&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "25029": {
    "name": "Methotrexate",
    "substance_url": "/en/drug/substance/25029?name=56&mode=orpha&region=&status=all",
    "substance_id": "25029",
    "regulatory_url": "/en/drug/regulatory/480856?name=56&mode=orpha&region=",
    "regulatory_id": "480856",
    "orpha_substance_code": "ORPHA:56",
    "details": [
      "Methotrexate(Medicinal product                        - 29/08/2016)Disease(s) concernedORPHA:56 Alkaptonuria",
      "Methotrexate(Medicinal product                        - 29/08/2016)",
      "(Medicinal product                        - 29/08/2016)",
      "Disease(s) concernedORPHA:56 Alkaptonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/25029?name=56&mode=orpha&region=&status=all",
        "text": "Methotrexate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/56",
        "text": "ORPHA:56 Alkaptonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480856?name=56&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "56899": {
    "name": "Nitisinone",
    "substance_url": "/en/drug/substance/56899?name=56&mode=orpha&region=&status=all",
    "substance_id": "56899",
    "regulatory_url": "/en/drug/regulatory/133777?name=56&mode=orpha&region=",
    "regulatory_id": "133777",
    "orpha_substance_code": "ORPHA:56",
    "details": [
      "Nitisinone(Medicinal product                        - 13/03/2002)Disease(s) concernedORPHA:56 Alkaptonuria",
      "Nitisinone(Medicinal product                        - 13/03/2002)",
      "(Medicinal product                        - 13/03/2002)",
      "Disease(s) concernedORPHA:56 Alkaptonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/56899?name=56&mode=orpha&region=&status=all",
        "text": "Nitisinone",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/56",
        "text": "ORPHA:56 Alkaptonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133777?name=56&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "661180": {
    "name": "Elesclomol-copper",
    "substance_url": "/en/drug/substance/661180?name=565&mode=orpha&region=&status=all",
    "substance_id": "661180",
    "regulatory_url": "/en/drug/regulatory/661273?name=565&mode=orpha&region=",
    "regulatory_id": "661273",
    "orpha_substance_code": "ORPHA:565",
    "details": [
      "Elesclomol-copper(Medicinal product                        - 08/11/2023)Disease(s) concernedORPHA:565 Menkes disease",
      "Elesclomol-copper(Medicinal product                        - 08/11/2023)",
      "(Medicinal product                        - 08/11/2023)",
      "Disease(s) concernedORPHA:565 Menkes disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661180?name=565&mode=orpha&region=&status=all",
        "text": "Elesclomol-copper",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565",
        "text": "ORPHA:565 Menkes disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661273?name=565&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "635863": {
    "name": "Copper nanocluster conjugated to acetate, histidinate and ascorbate",
    "substance_url": "/en/drug/substance/635863?name=565&mode=orpha&region=&status=all",
    "substance_id": "635863",
    "regulatory_url": "/en/drug/regulatory/635867?name=565&mode=orpha&region=",
    "regulatory_id": "635867",
    "orpha_substance_code": "ORPHA:565",
    "details": [
      "Copper nanocluster conjugated to acetate, histidinate and ascorbate(Medicinal product                        - 11/11/2022)Disease(s) concernedORPHA:565 Menkes disease",
      "Copper nanocluster conjugated to acetate, histidinate and ascorbate(Medicinal product                        - 11/11/2022)",
      "(Medicinal product                        - 11/11/2022)",
      "Disease(s) concernedORPHA:565 Menkes disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/635863?name=565&mode=orpha&region=&status=all",
        "text": "Copper nanocluster conjugated to acetate, histidinate and ascorbate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565",
        "text": "ORPHA:565 Menkes disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635867?name=565&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604837": {
    "name": "Copper histidinate",
    "substance_url": "/en/drug/substance/604837?name=565&mode=orpha&region=&status=all",
    "substance_id": "604837",
    "regulatory_url": "/en/drug/regulatory/604838?name=565&mode=orpha&region=",
    "regulatory_id": "604838",
    "orpha_substance_code": "ORPHA:565",
    "details": [
      "Copper histidinate(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:565 Menkes disease",
      "Copper histidinate(Medicinal product                        - 21/08/2020)",
      "(Medicinal product                        - 21/08/2020)",
      "Disease(s) concernedORPHA:565 Menkes disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604837?name=565&mode=orpha&region=&status=all",
        "text": "Copper histidinate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565",
        "text": "ORPHA:565 Menkes disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604838?name=565&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687224": {
    "name": "Recombinant adeno-associated virus vector serotype-9 carrying the human ATP7A transgene",
    "substance_url": "/en/drug/substance/687224?name=565&mode=orpha&region=&status=all",
    "substance_id": "687224",
    "regulatory_url": "/en/drug/regulatory/687566?name=565&mode=orpha&region=",
    "regulatory_id": "687566",
    "orpha_substance_code": "ORPHA:565",
    "details": [
      "Recombinant adeno-associated virus vector serotype-9 carrying the human ATP7A transgene(Medicinal product                        - 30/07/2024)Disease(s) concernedORPHA:565 Menkes disease",
      "Recombinant adeno-associated virus vector serotype-9 carrying the human ATP7A transgene(Medicinal product                        - 30/07/2024)",
      "(Medicinal product                        - 30/07/2024)",
      "Disease(s) concernedORPHA:565 Menkes disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687224?name=565&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus vector serotype-9 carrying the human ATP7A transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565",
        "text": "ORPHA:565 Menkes disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687566?name=565&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "399726": {
    "name": "rsATP7A cDNA",
    "substance_url": "/en/drug/substance/399726?name=565&mode=orpha&region=&status=all",
    "substance_id": "399726",
    "regulatory_url": "/en/drug/regulatory/399743?name=565&mode=orpha&region=",
    "regulatory_id": "399743",
    "orpha_substance_code": "ORPHA:565",
    "details": [
      "rsATP7A cDNA(Medicinal product                        - 10/01/2014)Disease(s) concernedORPHA:565 Menkes disease",
      "rsATP7A cDNA(Medicinal product                        - 10/01/2014)",
      "(Medicinal product                        - 10/01/2014)",
      "Disease(s) concernedORPHA:565 Menkes disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/399726?name=565&mode=orpha&region=&status=all",
        "text": "rsATP7A cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/565",
        "text": "ORPHA:565 Menkes disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/399743?name=565&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_609": {
    "name": "ALDURAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131351?name=579&mode=orpha&region=",
    "regulatory_id": "131351",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "ALDURAZYME(Tradename                        - 10/06/2003)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "ALDURAZYME(Tradename                        - 10/06/2003)",
      "(Tradename                        - 10/06/2003)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/42576?name=579&mode=orpha&region=&status=all",
        "text": "ALDURAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131351?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627351": {
    "name": "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor",
    "substance_url": "/en/drug/substance/627351?name=579&mode=orpha&region=&status=all",
    "substance_id": "627351",
    "regulatory_url": "/en/drug/regulatory/627353?name=579&mode=orpha&region=",
    "regulatory_id": "627353",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 26/03/2021)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 26/03/2021)",
      "(Medicinal product                        - 26/03/2021)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627351?name=579&mode=orpha&region=&status=all",
        "text": "Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627353?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "531808": {
    "name": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",
    "substance_url": "/en/drug/substance/531808?name=579&mode=orpha&region=&status=all",
    "substance_id": "531808",
    "regulatory_url": "/en/drug/regulatory/531809?name=579&mode=orpha&region=",
    "regulatory_id": "531809",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA(Medicinal product                        - 26/10/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA(Medicinal product                        - 26/10/2018)",
      "(Medicinal product                        - 26/10/2018)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/531808?name=579&mode=orpha&region=&status=all",
        "text": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/531809?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "520947": {
    "name": "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene",
    "substance_url": "/en/drug/substance/520947?name=579&mode=orpha&region=&status=all",
    "substance_id": "520947",
    "regulatory_url": "/en/drug/regulatory/520948?name=579&mode=orpha&region=",
    "regulatory_id": "520948",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene(Medicinal product                        - 27/06/2018)",
      "(Medicinal product                        - 27/06/2018)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/520947?name=579&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/520948?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "480798": {
    "name": "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",
    "substance_url": "/en/drug/substance/480798?name=579&mode=orpha&region=&status=all",
    "substance_id": "480798",
    "regulatory_url": "/en/drug/regulatory/480800?name=579&mode=orpha&region=",
    "regulatory_id": "480800",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate(Medicinal product                        - 22/09/2016)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate(Medicinal product                        - 22/09/2016)",
      "(Medicinal product                        - 22/09/2016)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480798?name=579&mode=orpha&region=&status=all",
        "text": "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480800?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "412265": {
    "name": "Pentosan polysulfate sodium",
    "substance_url": "/en/drug/substance/412265?name=579&mode=orpha&region=&status=all",
    "substance_id": "412265",
    "regulatory_url": "/en/drug/regulatory/637758?name=579&mode=orpha&region=",
    "regulatory_id": "637758",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Pentosan polysulfate sodium(Medicinal product                        - 19/11/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Pentosan polysulfate sodium(Medicinal product                        - 19/11/2014)",
      "(Medicinal product                        - 19/11/2014)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/412265?name=579&mode=orpha&region=&status=all",
        "text": "Pentosan polysulfate sodium",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/637758?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627993": {
    "name": "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase",
    "substance_url": "/en/drug/substance/627993?name=579&mode=orpha&region=&status=all",
    "substance_id": "627993",
    "regulatory_url": "/en/drug/regulatory/627994?name=579&mode=orpha&region=",
    "regulatory_id": "627994",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase(Medicinal product                        - 15/10/2021)",
      "(Medicinal product                        - 15/10/2021)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627993?name=579&mode=orpha&region=&status=all",
        "text": "Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627994?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "510771": {
    "name": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene",
    "substance_url": "/en/drug/substance/510771?name=579&mode=orpha&region=&status=all",
    "substance_id": "510771",
    "regulatory_url": "/en/drug/regulatory/510772?name=579&mode=orpha&region=",
    "regulatory_id": "510772",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene(Medicinal product                        - 17/01/2018)",
      "(Medicinal product                        - 17/01/2018)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/510771?name=579&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/510772?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "82038": {
    "name": "Ataluren",
    "substance_url": "/en/drug/substance/82038?name=579&mode=orpha&region=&status=all",
    "substance_id": "82038",
    "regulatory_url": "/en/drug/regulatory/625924?name=579&mode=orpha&region=",
    "regulatory_id": "625924",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Ataluren(Medicinal product                        - 19/11/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Ataluren(Medicinal product                        - 19/11/2014)",
      "(Medicinal product                        - 19/11/2014)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/82038?name=579&mode=orpha&region=&status=all",
        "text": "Ataluren",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/625924?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "410400": {
    "name": "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase",
    "substance_url": "/en/drug/substance/410400?name=579&mode=orpha&region=&status=all",
    "substance_id": "410400",
    "regulatory_url": "/en/drug/regulatory/415075?name=579&mode=orpha&region=",
    "regulatory_id": "415075",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase(Medicinal product                        - 15/10/2014)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase(Medicinal product                        - 15/10/2014)",
      "(Medicinal product                        - 15/10/2014)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/410400?name=579&mode=orpha&region=&status=all",
        "text": "Recombinant human insulin receptor monoclonal antibody-fused-alpha-L-iduronidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/415075?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "42577": {
    "name": "Laronidase",
    "substance_url": "/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
    "substance_id": "42577",
    "regulatory_url": "/en/drug/regulatory/133654?name=579&mode=orpha&region=",
    "regulatory_id": "133654",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Laronidase(Medicinal product                        - 14/02/2001)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Laronidase(Medicinal product                        - 14/02/2001)",
      "(Medicinal product                        - 14/02/2001)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/42577?name=579&mode=orpha&region=&status=all",
        "text": "Laronidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133654?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_620": {
    "name": "ALDURAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131132?name=579&mode=orpha&region=",
    "regulatory_id": "131132",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "ALDURAZYME(Tradename                        - 30/04/2003)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "ALDURAZYME(Tradename                        - 30/04/2003)",
      "(Tradename                        - 30/04/2003)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/42576?name=579&mode=orpha&region=&status=all",
        "text": "ALDURAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131132?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "673959": {
    "name": "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene",
    "substance_url": "/en/drug/substance/673959?name=579&mode=orpha&region=&status=all",
    "substance_id": "673959",
    "regulatory_url": "/en/drug/regulatory/674191?name=579&mode=orpha&region=",
    "regulatory_id": "674191",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene(Medicinal product                        - 08/04/2024)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene(Medicinal product                        - 08/04/2024)",
      "(Medicinal product                        - 08/04/2024)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/673959?name=579&mode=orpha&region=&status=all",
        "text": "Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/674191?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "643872": {
    "name": "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion",
    "substance_url": "/en/drug/substance/643872?name=579&mode=orpha&region=&status=all",
    "substance_id": "643872",
    "regulatory_url": "/en/drug/regulatory/643873?name=579&mode=orpha&region=",
    "regulatory_id": "643873",
    "orpha_substance_code": "ORPHA:579",
    "details": [
      "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion(Medicinal product                        - 01/07/2022)Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion(Medicinal product                        - 01/07/2022)",
      "(Medicinal product                        - 01/07/2022)",
      "Disease(s) concernedORPHA:579 Mucopolysaccharidosis type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/643872?name=579&mode=orpha&region=&status=all",
        "text": "Alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/579",
        "text": "ORPHA:579 Mucopolysaccharidosis type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/643873?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_623": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=579&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=579&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_624": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=579&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=579&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=579&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_625": {
    "name": "ELAPRASE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131369?name=580&mode=orpha&region=",
    "regulatory_id": "131369",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "ELAPRASE(Tradename                        - 08/01/2007)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "ELAPRASE(Tradename                        - 08/01/2007)",
      "(Tradename                        - 08/01/2007)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/75869?name=580&mode=orpha&region=&status=all",
        "text": "ELAPRASE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131369?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627620": {
    "name": "Idursulfase beta",
    "substance_url": "/en/drug/substance/627620?name=580&mode=orpha&region=&status=all",
    "substance_id": "627620",
    "regulatory_url": "/en/drug/regulatory/627621?name=580&mode=orpha&region=",
    "regulatory_id": "627621",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Idursulfase beta(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Idursulfase beta(Medicinal product                        - 15/10/2021)",
      "(Medicinal product                        - 15/10/2021)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627620?name=580&mode=orpha&region=&status=all",
        "text": "Idursulfase beta",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627621?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "627878": {
    "name": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene",
    "substance_url": "/en/drug/substance/627878?name=580&mode=orpha&region=&status=all",
    "substance_id": "627878",
    "regulatory_url": "/en/drug/regulatory/627881?name=580&mode=orpha&region=",
    "regulatory_id": "627881",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene(Medicinal product                        - 20/08/2021)",
      "(Medicinal product                        - 20/08/2021)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/627878?name=580&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/627881?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "558944": {
    "name": "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase",
    "substance_url": "/en/drug/substance/558944?name=580&mode=orpha&region=&status=all",
    "substance_id": "558944",
    "regulatory_url": "/en/drug/regulatory/558948?name=580&mode=orpha&region=",
    "regulatory_id": "558948",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase(Medicinal product                        - 26/02/2019)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase(Medicinal product                        - 26/02/2019)",
      "(Medicinal product                        - 26/02/2019)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/558944?name=580&mode=orpha&region=&status=all",
        "text": "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/558948?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "446352": {
    "name": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
    "substance_url": "/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
    "substance_id": "446352",
    "regulatory_url": "/en/drug/regulatory/500508?name=580&mode=orpha&region=",
    "regulatory_id": "500508",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 08/11/2017)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 08/11/2017)",
      "(Medicinal product                        - 08/11/2017)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/500508?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628332": {
    "name": "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase",
    "substance_url": "/en/drug/substance/628332?name=580&mode=orpha&region=&status=all",
    "substance_id": "628332",
    "regulatory_url": "/en/drug/regulatory/628334?name=580&mode=orpha&region=",
    "regulatory_id": "628334",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase(Medicinal product                        - 16/03/2022)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase(Medicinal product                        - 16/03/2022)",
      "(Medicinal product                        - 16/03/2022)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628332?name=580&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628334?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "70916": {
    "name": "Idursulfase",
    "substance_url": "/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
    "substance_id": "70916",
    "regulatory_url": "/en/drug/regulatory/604974?name=580&mode=orpha&region=",
    "regulatory_id": "604974",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Idursulfase(Medicinal product                        - 06/01/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Idursulfase(Medicinal product                        - 06/01/2021)",
      "(Medicinal product                        - 06/01/2021)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
        "text": "Idursulfase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604974?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "510774": {
    "name": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene",
    "substance_url": "/en/drug/substance/510774?name=580&mode=orpha&region=&status=all",
    "substance_id": "510774",
    "regulatory_url": "/en/drug/regulatory/510775?name=580&mode=orpha&region=",
    "regulatory_id": "510775",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene(Medicinal product                        - 17/01/2018)",
      "(Medicinal product                        - 17/01/2018)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/510774?name=580&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/510775?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "365255": {
    "name": "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)",
    "substance_url": "/en/drug/substance/365255?name=580&mode=orpha&region=&status=all",
    "substance_id": "365255",
    "regulatory_url": "/en/drug/regulatory/377614?name=580&mode=orpha&region=",
    "regulatory_id": "377614",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)(Medicinal product                        - 13/11/2013)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)(Medicinal product                        - 13/11/2013)",
      "(Medicinal product                        - 13/11/2013)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/365255?name=580&mode=orpha&region=&status=all",
        "text": "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/377614?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_634": {
    "name": "ELAPRASE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131158?name=580&mode=orpha&region=",
    "regulatory_id": "131158",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "ELAPRASE(Tradename                        - 24/07/2006)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "ELAPRASE(Tradename                        - 24/07/2006)",
      "(Tradename                        - 24/07/2006)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/75869?name=580&mode=orpha&region=&status=all",
        "text": "ELAPRASE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131158?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "644779": {
    "name": "Adeno-associated virus vector expressing human iduronate-2-sulfatase",
    "substance_url": "/en/drug/substance/644779?name=580&mode=orpha&region=&status=all",
    "substance_id": "644779",
    "regulatory_url": "/en/drug/regulatory/644791?name=580&mode=orpha&region=",
    "regulatory_id": "644791",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Adeno-associated virus vector expressing human iduronate-2-sulfatase(Medicinal product                        - 28/03/2023)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Adeno-associated virus vector expressing human iduronate-2-sulfatase(Medicinal product                        - 28/03/2023)",
      "(Medicinal product                        - 28/03/2023)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/644779?name=580&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus vector expressing human iduronate-2-sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644791?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "637364": {
    "name": "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)",
    "substance_url": "/en/drug/substance/637364?name=580&mode=orpha&region=&status=all",
    "substance_id": "637364",
    "regulatory_url": "/en/drug/regulatory/637365?name=580&mode=orpha&region=",
    "regulatory_id": "637365",
    "orpha_substance_code": "ORPHA:580",
    "details": [
      "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)(Medicinal product                        - 14/07/2022)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)(Medicinal product                        - 14/07/2022)",
      "(Medicinal product                        - 14/07/2022)",
      "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/637364?name=580&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/580",
        "text": "ORPHA:580 Mucopolysaccharidosis type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/637365?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_637": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=580&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=580&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_638": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=580&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=580&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=580&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "299549": {
    "name": "Genistein sodium salt dihydrate",
    "substance_url": "/en/drug/substance/299549?name=581&mode=orpha&region=&status=all",
    "substance_id": "299549",
    "regulatory_url": "/en/drug/regulatory/301149?name=581&mode=orpha&region=",
    "regulatory_id": "301149",
    "orpha_substance_code": "ORPHA:581",
    "details": [
      "Genistein sodium salt dihydrate(Medicinal product                        - 02/04/2012)Disease(s) concernedORPHA:581 Mucopolysaccharidosis type 3",
      "Genistein sodium salt dihydrate(Medicinal product                        - 02/04/2012)",
      "(Medicinal product                        - 02/04/2012)",
      "Disease(s) concernedORPHA:581 Mucopolysaccharidosis type 3",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/299549?name=581&mode=orpha&region=&status=all",
        "text": "Genistein sodium salt dihydrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/581",
        "text": "ORPHA:581 Mucopolysaccharidosis type 3",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/301149?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "165346": {
    "name": "Recombinant human heparan-N-sulfatase",
    "substance_url": "/en/drug/substance/165346?name=581&mode=orpha&region=&status=all",
    "substance_id": "165346",
    "regulatory_url": "/en/drug/regulatory/661148?name=581&mode=orpha&region=",
    "regulatory_id": "661148",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Recombinant human heparan-N-sulfatase(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Recombinant human heparan-N-sulfatase(Medicinal product                        - 12/01/2024)",
      "(Medicinal product                        - 12/01/2024)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/165346?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant human heparan-N-sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661148?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "628237": {
    "name": "N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting the human transferrin receptor",
    "substance_url": "/en/drug/substance/628237?name=581&mode=orpha&region=&status=all",
    "substance_id": "628237",
    "regulatory_url": "/en/drug/regulatory/628238?name=581&mode=orpha&region=",
    "regulatory_id": "628238",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting the human transferrin receptor(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting the human transferrin receptor(Medicinal product                        - 14/01/2022)",
      "(Medicinal product                        - 14/01/2022)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628237?name=581&mode=orpha&region=&status=all",
        "text": "N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting the human transferrin receptor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628238?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "531913": {
    "name": "Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene",
    "substance_url": "/en/drug/substance/531913?name=581&mode=orpha&region=&status=all",
    "substance_id": "531913",
    "regulatory_url": "/en/drug/regulatory/531914?name=581&mode=orpha&region=",
    "regulatory_id": "531914",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene(Medicinal product                        - 12/01/2017)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene(Medicinal product                        - 12/01/2017)",
      "(Medicinal product                        - 12/01/2017)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/531913?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/531914?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "484789": {
    "name": "Chemically modified human recombinant sulfamidase",
    "substance_url": "/en/drug/substance/484789?name=581&mode=orpha&region=&status=all",
    "substance_id": "484789",
    "regulatory_url": "/en/drug/regulatory/484790?name=581&mode=orpha&region=",
    "regulatory_id": "484790",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Chemically modified human recombinant sulfamidase(Medicinal product                        - 14/10/2016)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Chemically modified human recombinant sulfamidase(Medicinal product                        - 14/10/2016)",
      "(Medicinal product                        - 14/10/2016)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/484789?name=581&mode=orpha&region=&status=all",
        "text": "Chemically modified human recombinant sulfamidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484790?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "484726": {
    "name": "Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene",
    "substance_url": "/en/drug/substance/484726?name=581&mode=orpha&region=&status=all",
    "substance_id": "484726",
    "regulatory_url": "/en/drug/regulatory/484745?name=581&mode=orpha&region=",
    "regulatory_id": "484745",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene(Medicinal product                        - 20/09/2016)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene(Medicinal product                        - 20/09/2016)",
      "(Medicinal product                        - 20/09/2016)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/484726?name=581&mode=orpha&region=&status=all",
        "text": "Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484745?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "444449": {
    "name": "adeno-associated viral vector serotype 9 containing the human HGSNAT gene",
    "substance_url": "/en/drug/substance/444449?name=581&mode=orpha&region=&status=all",
    "substance_id": "444449",
    "regulatory_url": "/en/drug/regulatory/444451?name=581&mode=orpha&region=",
    "regulatory_id": "444451",
    "orpha_substance_code": "ORPHA:79271",
    "details": [
      "adeno-associated viral vector serotype 9 containing the human HGSNAT gene(Medicinal product                        - 21/05/2015)Disease(s) concernedORPHA:79271 Sanfilippo syndrome type C",
      "adeno-associated viral vector serotype 9 containing the human HGSNAT gene(Medicinal product                        - 21/05/2015)",
      "(Medicinal product                        - 21/05/2015)",
      "Disease(s) concernedORPHA:79271 Sanfilippo syndrome type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/444449?name=581&mode=orpha&region=&status=all",
        "text": "adeno-associated viral vector serotype 9 containing the human HGSNAT gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79271",
        "text": "ORPHA:79271 Sanfilippo syndrome type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/444451?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "418092": {
    "name": "Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2",
    "substance_url": "/en/drug/substance/418092?name=581&mode=orpha&region=&status=all",
    "substance_id": "418092",
    "regulatory_url": "/en/drug/regulatory/437343?name=581&mode=orpha&region=",
    "regulatory_id": "437343",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2(Medicinal product                        - 15/01/2015)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2(Medicinal product                        - 15/01/2015)",
      "(Medicinal product                        - 15/01/2015)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/418092?name=581&mode=orpha&region=&status=all",
        "text": "Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/437343?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "414082": {
    "name": "Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA",
    "substance_url": "/en/drug/substance/414082?name=581&mode=orpha&region=&status=all",
    "substance_id": "414082",
    "regulatory_url": "/en/drug/regulatory/437406?name=581&mode=orpha&region=",
    "regulatory_id": "437406",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA(Medicinal product                        - 16/12/2014)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA(Medicinal product                        - 16/12/2014)",
      "(Medicinal product                        - 16/12/2014)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/414082?name=581&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/437406?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "399640": {
    "name": "Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene",
    "substance_url": "/en/drug/substance/399640?name=581&mode=orpha&region=&status=all",
    "substance_id": "399640",
    "regulatory_url": "/en/drug/regulatory/406120?name=581&mode=orpha&region=",
    "regulatory_id": "406120",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene(Medicinal product                        - 10/06/2014)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene(Medicinal product                        - 10/06/2014)",
      "(Medicinal product                        - 10/06/2014)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/399640?name=581&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/406120?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "275655": {
    "name": "Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene",
    "substance_url": "/en/drug/substance/275655?name=581&mode=orpha&region=&status=all",
    "substance_id": "275655",
    "regulatory_url": "/en/drug/regulatory/286416?name=581&mode=orpha&region=",
    "regulatory_id": "286416",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene(Medicinal product                        - 27/10/2011)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene(Medicinal product                        - 27/10/2011)",
      "(Medicinal product                        - 27/10/2011)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/275655?name=581&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/286416?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "260412": {
    "name": "Adeno-associated viral vector serotype 9 containing the human sulfamidase gene",
    "substance_url": "/en/drug/substance/260412?name=581&mode=orpha&region=&status=all",
    "substance_id": "260412",
    "regulatory_url": "/en/drug/regulatory/275275?name=581&mode=orpha&region=",
    "regulatory_id": "275275",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human sulfamidase gene(Medicinal product                        - 21/06/2011)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Adeno-associated viral vector serotype 9 containing the human sulfamidase gene(Medicinal product                        - 21/06/2011)",
      "(Medicinal product                        - 21/06/2011)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/260412?name=581&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human sulfamidase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/275275?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "230772": {
    "name": "Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs",
    "substance_url": "/en/drug/substance/230772?name=581&mode=orpha&region=&status=all",
    "substance_id": "230772",
    "regulatory_url": "/en/drug/regulatory/246930?name=581&mode=orpha&region=",
    "regulatory_id": "246930",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs(Medicinal product                        - 20/09/2010)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs(Medicinal product                        - 20/09/2010)",
      "(Medicinal product                        - 20/09/2010)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/230772?name=581&mode=orpha&region=&status=all",
        "text": "Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/246930?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "332867": {
    "name": "Recombinant human alpha-N-acetylglucosaminidase",
    "substance_url": "/en/drug/substance/332867?name=581&mode=orpha&region=&status=all",
    "substance_id": "332867",
    "regulatory_url": "/en/drug/regulatory/359498?name=581&mode=orpha&region=",
    "regulatory_id": "359498",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Recombinant human alpha-N-acetylglucosaminidase(Medicinal product                        - 19/06/2013)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Recombinant human alpha-N-acetylglucosaminidase(Medicinal product                        - 19/06/2013)",
      "(Medicinal product                        - 19/06/2013)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/332867?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant human alpha-N-acetylglucosaminidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/359498?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "321495": {
    "name": "Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene",
    "substance_url": "/en/drug/substance/321495?name=581&mode=orpha&region=&status=all",
    "substance_id": "321495",
    "regulatory_url": "/en/drug/regulatory/323618?name=581&mode=orpha&region=",
    "regulatory_id": "323618",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene(Medicinal product                        - 24/01/2013)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene(Medicinal product                        - 24/01/2013)",
      "(Medicinal product                        - 24/01/2013)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/321495?name=581&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/323618?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "699865": {
    "name": "Recombinant glycoprotein consisting of modified human alpha-N-acetylglucosaminidase (mhNAGLU) and a humanized antibody that specifically recognizes hTfR",
    "substance_url": "/en/drug/substance/699865?name=581&mode=orpha&region=&status=all",
    "substance_id": "699865",
    "regulatory_url": "/en/drug/regulatory/700142?name=581&mode=orpha&region=",
    "regulatory_id": "700142",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Recombinant glycoprotein consisting of modified human alpha-N-acetylglucosaminidase (mhNAGLU) and a humanized antibody that specifically recognizes hTfR(Medicinal product                        - 25/04/2025)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Recombinant glycoprotein consisting of modified human alpha-N-acetylglucosaminidase (mhNAGLU) and a humanized antibody that specifically recognizes hTfR(Medicinal product                        - 25/04/2025)",
      "(Medicinal product                        - 25/04/2025)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/699865?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant glycoprotein consisting of modified human alpha-N-acetylglucosaminidase (mhNAGLU) and a humanized antibody that specifically recognizes hTfR",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700142?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "662636": {
    "name": "N-sulfoglucosamine sulfohydrolase",
    "substance_url": "/en/drug/substance/662636?name=581&mode=orpha&region=&status=all",
    "substance_id": "662636",
    "regulatory_url": "/en/drug/regulatory/662828?name=581&mode=orpha&region=",
    "regulatory_id": "662828",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "N-sulfoglucosamine sulfohydrolase(Medicinal product                        - 20/02/2024)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "N-sulfoglucosamine sulfohydrolase(Medicinal product                        - 20/02/2024)",
      "(Medicinal product                        - 20/02/2024)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/662636?name=581&mode=orpha&region=&status=all",
        "text": "N-sulfoglucosamine sulfohydrolase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/662828?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "663169": {
    "name": "Recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS)",
    "substance_url": "/en/drug/substance/663169?name=581&mode=orpha&region=&status=all",
    "substance_id": "663169",
    "regulatory_url": "/en/drug/regulatory/663252?name=581&mode=orpha&region=",
    "regulatory_id": "663252",
    "orpha_substance_code": "ORPHA:79272",
    "details": [
      "Recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS)(Medicinal product                        - 16/01/2024)Disease(s) concernedORPHA:79272 Sanfilippo syndrome type D",
      "Recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS)(Medicinal product                        - 16/01/2024)",
      "(Medicinal product                        - 16/01/2024)",
      "Disease(s) concernedORPHA:79272 Sanfilippo syndrome type D",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/663169?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79272",
        "text": "ORPHA:79272 Sanfilippo syndrome type D",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/663252?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type D\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "664315": {
    "name": "Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor",
    "substance_url": "/en/drug/substance/664315?name=581&mode=orpha&region=&status=all",
    "substance_id": "664315",
    "regulatory_url": "/en/drug/regulatory/664317?name=581&mode=orpha&region=",
    "regulatory_id": "664317",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 12/12/2023)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor(Medicinal product                        - 12/12/2023)",
      "(Medicinal product                        - 12/12/2023)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/664315?name=581&mode=orpha&region=&status=all",
        "text": "Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/664317?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "666378": {
    "name": "Recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene",
    "substance_url": "/en/drug/substance/666378?name=581&mode=orpha&region=&status=all",
    "substance_id": "666378",
    "regulatory_url": "/en/drug/regulatory/666429?name=581&mode=orpha&region=",
    "regulatory_id": "666429",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene(Medicinal product                        - 01/08/2023)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene(Medicinal product                        - 01/08/2023)",
      "(Medicinal product                        - 01/08/2023)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666378?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666429?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "646592": {
    "name": "Recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene",
    "substance_url": "/en/drug/substance/646592?name=581&mode=orpha&region=&status=all",
    "substance_id": "646592",
    "regulatory_url": "/en/drug/regulatory/646689?name=581&mode=orpha&region=",
    "regulatory_id": "646689",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene(Medicinal product                        - 26/04/2023)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene(Medicinal product                        - 26/04/2023)",
      "(Medicinal product                        - 26/04/2023)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/646592?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/646689?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "404220": {
    "name": "Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase",
    "substance_url": "/en/drug/substance/404220?name=581&mode=orpha&region=&status=all",
    "substance_id": "404220",
    "regulatory_url": "/en/drug/regulatory/404221?name=581&mode=orpha&region=",
    "regulatory_id": "404221",
    "orpha_substance_code": "ORPHA:79270",
    "details": [
      "Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase(Medicinal product                        - 30/04/2014)Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase(Medicinal product                        - 30/04/2014)",
      "(Medicinal product                        - 30/04/2014)",
      "Disease(s) concernedORPHA:79270 Sanfilippo syndrome type B",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/404220?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79270",
        "text": "ORPHA:79270 Sanfilippo syndrome type B",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/404221?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type B\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "404267": {
    "name": "Recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase",
    "substance_url": "/en/drug/substance/404267?name=581&mode=orpha&region=&status=all",
    "substance_id": "404267",
    "regulatory_url": "/en/drug/regulatory/405616?name=581&mode=orpha&region=",
    "regulatory_id": "405616",
    "orpha_substance_code": "ORPHA:79269",
    "details": [
      "Recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase(Medicinal product                        - 29/04/2014)Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "Recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase(Medicinal product                        - 29/04/2014)",
      "(Medicinal product                        - 29/04/2014)",
      "Disease(s) concernedORPHA:79269 Sanfilippo syndrome type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/404267?name=581&mode=orpha&region=&status=all",
        "text": "Recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79269",
        "text": "ORPHA:79269 Sanfilippo syndrome type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/405616?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type A\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_662": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=581&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=581&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_663": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=581&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=581&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=581&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "170129": {
    "name": "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase",
    "substance_url": "/en/drug/substance/170129?name=582&mode=orpha&region=&status=all",
    "substance_id": "170129",
    "regulatory_url": "/en/drug/regulatory/180793?name=582&mode=orpha&region=",
    "regulatory_id": "180793",
    "orpha_substance_code": "ORPHA:582",
    "details": [
      "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 27/02/2009)Disease(s) concernedORPHA:582 Mucopolysaccharidosis type 4",
      "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 27/02/2009)",
      "(Medicinal product                        - 27/02/2009)",
      "Disease(s) concernedORPHA:582 Mucopolysaccharidosis type 4",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/170129?name=582&mode=orpha&region=&status=all",
        "text": "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/582",
        "text": "ORPHA:582 Mucopolysaccharidosis type 4",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/180793?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_665": {
    "name": "VIMIZIM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/404819?name=582&mode=orpha&region=",
    "regulatory_id": "404819",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "VIMIZIM(Tradename                        - 28/04/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "VIMIZIM(Tradename                        - 28/04/2014)",
      "(Tradename                        - 28/04/2014)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
        "text": "VIMIZIM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/404819?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "629835": {
    "name": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA",
    "substance_url": "/en/drug/substance/629835?name=582&mode=orpha&region=&status=all",
    "substance_id": "629835",
    "regulatory_url": "/en/drug/regulatory/629838?name=582&mode=orpha&region=",
    "regulatory_id": "629838",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA(Medicinal product                        - 10/08/2022)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA(Medicinal product                        - 10/08/2022)",
      "(Medicinal product                        - 10/08/2022)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/629835?name=582&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629838?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "588825": {
    "name": "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene",
    "substance_url": "/en/drug/substance/588825?name=582&mode=orpha&region=&status=all",
    "substance_id": "588825",
    "regulatory_url": "/en/drug/regulatory/588832?name=582&mode=orpha&region=",
    "regulatory_id": "588832",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene(Medicinal product                        - 09/01/2020)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene(Medicinal product                        - 09/01/2020)",
      "(Medicinal product                        - 09/01/2020)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/588825?name=582&mode=orpha&region=&status=all",
        "text": "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/588832?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "189159": {
    "name": "Elosulfase alfa",
    "substance_url": "/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
    "substance_id": "189159",
    "regulatory_url": "/en/drug/regulatory/211596?name=582&mode=orpha&region=",
    "regulatory_id": "211596",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "Elosulfase alfa(Medicinal product                        - 24/07/2009)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "Elosulfase alfa(Medicinal product                        - 24/07/2009)",
      "(Medicinal product                        - 24/07/2009)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/189159?name=582&mode=orpha&region=&status=all",
        "text": "Elosulfase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/211596?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_669": {
    "name": "VIMIZIM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/393922?name=582&mode=orpha&region=",
    "regulatory_id": "393922",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "VIMIZIM(Tradename                        - 24/02/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "VIMIZIM(Tradename                        - 24/02/2014)",
      "(Tradename                        - 24/02/2014)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
        "text": "VIMIZIM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/393922?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_670": {
    "name": "VIMIZIM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/405043?name=582&mode=orpha&region=",
    "regulatory_id": "405043",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "VIMIZIM(Tradename                        - 14/02/2014)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "VIMIZIM(Tradename                        - 14/02/2014)",
      "(Tradename                        - 14/02/2014)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/404818?name=582&mode=orpha&region=&status=all",
        "text": "VIMIZIM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/405043?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "688296": {
    "name": "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase",
    "substance_url": "/en/drug/substance/688296?name=582&mode=orpha&region=&status=all",
    "substance_id": "688296",
    "regulatory_url": "/en/drug/regulatory/688384?name=582&mode=orpha&region=",
    "regulatory_id": "688384",
    "orpha_substance_code": "ORPHA:309297",
    "details": [
      "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 20/09/2024)Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase(Medicinal product                        - 20/09/2024)",
      "(Medicinal product                        - 20/09/2024)",
      "Disease(s) concernedORPHA:309297 Mucopolysaccharidosis type 4A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688296?name=582&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309297",
        "text": "ORPHA:309297 Mucopolysaccharidosis type 4A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688384?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_672": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=582&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=582&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_673": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=582&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=582&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=582&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_674": {
    "name": "NAGLAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131360?name=583&mode=orpha&region=",
    "regulatory_id": "131360",
    "orpha_substance_code": "ORPHA:583",
    "details": [
      "NAGLAZYME(Tradename                        - 24/01/2006)Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "NAGLAZYME(Tradename                        - 24/01/2006)",
      "(Tradename                        - 24/01/2006)",
      "Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/65850?name=583&mode=orpha&region=&status=all",
        "text": "NAGLAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/583",
        "text": "ORPHA:583 Mucopolysaccharidosis type 6",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131360?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "496372": {
    "name": "Odiparcil",
    "substance_url": "/en/drug/substance/496372?name=583&mode=orpha&region=&status=all",
    "substance_id": "496372",
    "regulatory_url": "/en/drug/regulatory/496376?name=583&mode=orpha&region=",
    "regulatory_id": "496376",
    "orpha_substance_code": "ORPHA:583",
    "details": [
      "Odiparcil(Medicinal product                        - 23/08/2017)Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "Odiparcil(Medicinal product                        - 23/08/2017)",
      "(Medicinal product                        - 23/08/2017)",
      "Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/496372?name=583&mode=orpha&region=&status=all",
        "text": "Odiparcil",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/583",
        "text": "ORPHA:583 Mucopolysaccharidosis type 6",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/496376?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "260393": {
    "name": "Adeno-associated viral vector containing the human ARSB gene",
    "substance_url": "/en/drug/substance/260393?name=583&mode=orpha&region=&status=all",
    "substance_id": "260393",
    "regulatory_url": "/en/drug/regulatory/275214?name=583&mode=orpha&region=",
    "regulatory_id": "275214",
    "orpha_substance_code": "ORPHA:583",
    "details": [
      "Adeno-associated viral vector containing the human ARSB gene(Medicinal product                        - 13/05/2011)Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "Adeno-associated viral vector containing the human ARSB gene(Medicinal product                        - 13/05/2011)",
      "(Medicinal product                        - 13/05/2011)",
      "Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/260393?name=583&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector containing the human ARSB gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/583",
        "text": "ORPHA:583 Mucopolysaccharidosis type 6",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/275214?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "65852": {
    "name": "Galsulfase",
    "substance_url": "/en/drug/substance/65852?name=583&mode=orpha&region=&status=all",
    "substance_id": "65852",
    "regulatory_url": "/en/drug/regulatory/133710?name=583&mode=orpha&region=",
    "regulatory_id": "133710",
    "orpha_substance_code": "ORPHA:583",
    "details": [
      "Galsulfase(Medicinal product                        - 14/02/2001)Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "Galsulfase(Medicinal product                        - 14/02/2001)",
      "(Medicinal product                        - 14/02/2001)",
      "Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/65852?name=583&mode=orpha&region=&status=all",
        "text": "Galsulfase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/583",
        "text": "ORPHA:583 Mucopolysaccharidosis type 6",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133710?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_678": {
    "name": "NAGLAZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131149?name=583&mode=orpha&region=",
    "regulatory_id": "131149",
    "orpha_substance_code": "ORPHA:583",
    "details": [
      "NAGLAZYME(Tradename                        - 31/05/2005)Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "NAGLAZYME(Tradename                        - 31/05/2005)",
      "(Tradename                        - 31/05/2005)",
      "Disease(s) concernedORPHA:583 Mucopolysaccharidosis type 6",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/65850?name=583&mode=orpha&region=&status=all",
        "text": "NAGLAZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/583",
        "text": "ORPHA:583 Mucopolysaccharidosis type 6",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131149?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_679": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=583&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=583&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_680": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=583&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=583&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=583&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_681": {
    "name": "MEPSEVII",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/527322?name=584&mode=orpha&region=",
    "regulatory_id": "527322",
    "orpha_substance_code": "ORPHA:584",
    "details": [
      "MEPSEVII(Tradename                        - 23/08/2018)Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "MEPSEVII(Tradename                        - 23/08/2018)",
      "(Tradename                        - 23/08/2018)",
      "Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/501414?name=584&mode=orpha&region=&status=all",
        "text": "MEPSEVII",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/584",
        "text": "ORPHA:584 Mucopolysaccharidosis type 7",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527322?name=584&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "299541": {
    "name": "vestronidase alfa",
    "substance_url": "/en/drug/substance/299541?name=584&mode=orpha&region=&status=all",
    "substance_id": "299541",
    "regulatory_url": "/en/drug/regulatory/301158?name=584&mode=orpha&region=",
    "regulatory_id": "301158",
    "orpha_substance_code": "ORPHA:584",
    "details": [
      "vestronidase alfa(Medicinal product                        - 21/03/2012)Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "vestronidase alfa(Medicinal product                        - 21/03/2012)",
      "(Medicinal product                        - 21/03/2012)",
      "Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/299541?name=584&mode=orpha&region=&status=all",
        "text": "vestronidase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/584",
        "text": "ORPHA:584 Mucopolysaccharidosis type 7",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/301158?name=584&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_683": {
    "name": "MEPSEVII",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/501416?name=584&mode=orpha&region=",
    "regulatory_id": "501416",
    "orpha_substance_code": "ORPHA:584",
    "details": [
      "MEPSEVII(Tradename                        - 15/11/2017)Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "MEPSEVII(Tradename                        - 15/11/2017)",
      "(Tradename                        - 15/11/2017)",
      "Disease(s) concernedORPHA:584 Mucopolysaccharidosis type 7",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/501414?name=584&mode=orpha&region=&status=all",
        "text": "MEPSEVII",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/584",
        "text": "ORPHA:584 Mucopolysaccharidosis type 7",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/501416?name=584&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_684": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=584&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=584&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=584&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_685": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=584&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=584&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=584&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "688358": {
    "name": "Recombinant serotype 9 adeno-associated virus encoding codon optimized human sulfatase modifying factor 1",
    "substance_url": "/en/drug/substance/688358?name=585&mode=orpha&region=&status=all",
    "substance_id": "688358",
    "regulatory_url": "/en/drug/regulatory/688512?name=585&mode=orpha&region=",
    "regulatory_id": "688512",
    "orpha_substance_code": "ORPHA:585",
    "details": [
      "Recombinant serotype 9 adeno-associated virus encoding codon optimized human sulfatase modifying factor 1(Medicinal product                        - 20/09/2024)Disease(s) concernedORPHA:585 Multiple sulfatase deficiency",
      "Recombinant serotype 9 adeno-associated virus encoding codon optimized human sulfatase modifying factor 1(Medicinal product                        - 20/09/2024)",
      "(Medicinal product                        - 20/09/2024)",
      "Disease(s) concernedORPHA:585 Multiple sulfatase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/688358?name=585&mode=orpha&region=&status=all",
        "text": "Recombinant serotype 9 adeno-associated virus encoding codon optimized human sulfatase modifying factor 1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/585",
        "text": "ORPHA:585 Multiple sulfatase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688512?name=585&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_687": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=585&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=585&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=585&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_688": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=585&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=585&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=585&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "458757": {
    "name": "N-acetyl-D-mannosamine monohydrate",
    "substance_url": "/en/drug/substance/458757?name=602&mode=orpha&region=&status=all",
    "substance_id": "458757",
    "regulatory_url": "/en/drug/regulatory/458767?name=602&mode=orpha&region=",
    "regulatory_id": "458767",
    "orpha_substance_code": "ORPHA:602",
    "details": [
      "N-acetyl-D-mannosamine monohydrate(Medicinal product                        - 21/03/2016)Disease(s) concernedORPHA:602 GNE myopathy",
      "N-acetyl-D-mannosamine monohydrate(Medicinal product                        - 21/03/2016)",
      "(Medicinal product                        - 21/03/2016)",
      "Disease(s) concernedORPHA:602 GNE myopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/458757?name=602&mode=orpha&region=&status=all",
        "text": "N-acetyl-D-mannosamine monohydrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/602",
        "text": "ORPHA:602 GNE myopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/458767?name=602&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "299544": {
    "name": "Sialic acid",
    "substance_url": "/en/drug/substance/299544?name=602&mode=orpha&region=&status=all",
    "substance_id": "299544",
    "regulatory_url": "/en/drug/regulatory/301021?name=602&mode=orpha&region=",
    "regulatory_id": "301021",
    "orpha_substance_code": "ORPHA:602",
    "details": [
      "Sialic acid(Medicinal product                        - 05/03/2012)Disease(s) concernedORPHA:602 GNE myopathy",
      "Sialic acid(Medicinal product                        - 05/03/2012)",
      "(Medicinal product                        - 05/03/2012)",
      "Disease(s) concernedORPHA:602 GNE myopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/299544?name=602&mode=orpha&region=&status=all",
        "text": "Sialic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/602",
        "text": "ORPHA:602 GNE myopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/301021?name=602&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "697206": {
    "name": "6'-sialyllactose (SL) sodium salt",
    "substance_url": "/en/drug/substance/697206?name=602&mode=orpha&region=&status=all",
    "substance_id": "697206",
    "regulatory_url": "/en/drug/regulatory/697706?name=602&mode=orpha&region=",
    "regulatory_id": "697706",
    "orpha_substance_code": "ORPHA:602",
    "details": [
      "6'-sialyllactose (SL) sodium salt(Medicinal product                        - 27/03/2025)Disease(s) concernedORPHA:602 GNE myopathy",
      "6'-sialyllactose (SL) sodium salt(Medicinal product                        - 27/03/2025)",
      "(Medicinal product                        - 27/03/2025)",
      "Disease(s) concernedORPHA:602 GNE myopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/697206?name=602&mode=orpha&region=&status=all",
        "text": "6'-sialyllactose (SL) sodium salt",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/602",
        "text": "ORPHA:602 GNE myopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/697706?name=602&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_692": {
    "name": "LAMZEDE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/505832?name=61&mode=orpha&region=",
    "regulatory_id": "505832",
    "orpha_substance_code": "ORPHA:61",
    "details": [
      "LAMZEDE(Tradename                        - 23/03/2018)Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "LAMZEDE(Tradename                        - 23/03/2018)",
      "(Tradename                        - 23/03/2018)",
      "Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505801?name=61&mode=orpha&region=&status=all",
        "text": "LAMZEDE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/61",
        "text": "ORPHA:61 Alpha-mannosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/505832?name=61&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "79947": {
    "name": "Lamazym",
    "substance_url": "/en/drug/substance/79947?name=61&mode=orpha&region=&status=all",
    "substance_id": "79947",
    "regulatory_url": "/en/drug/regulatory/133939?name=61&mode=orpha&region=",
    "regulatory_id": "133939",
    "orpha_substance_code": "ORPHA:61",
    "details": [
      "Lamazym(Medicinal product                        - 26/01/2005)Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "Lamazym(Medicinal product                        - 26/01/2005)",
      "(Medicinal product                        - 26/01/2005)",
      "Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/79947?name=61&mode=orpha&region=&status=all",
        "text": "Lamazym",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/61",
        "text": "ORPHA:61 Alpha-mannosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133939?name=61&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_694": {
    "name": "LAMZEDE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642509?name=61&mode=orpha&region=",
    "regulatory_id": "642509",
    "orpha_substance_code": "ORPHA:61",
    "details": [
      "LAMZEDE(Tradename                        - 16/02/2023)Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "LAMZEDE(Tradename                        - 16/02/2023)",
      "(Tradename                        - 16/02/2023)",
      "Disease(s) concernedORPHA:61 Alpha-mannosidosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/505801?name=61&mode=orpha&region=&status=all",
        "text": "LAMZEDE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/61",
        "text": "ORPHA:61 Alpha-mannosidosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642509?name=61&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_695": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629878?name=618891&mode=orpha&region=",
    "regulatory_id": "629878",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 24/06/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 24/06/2022)",
      "(Tradename                        - 24/06/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=618891&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629878?name=618891&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_696": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=618891&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=618891&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=618891&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_697": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=618891&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=618891&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=618891&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_698": {
    "name": "OFEV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/692773?name=618891&mode=orpha&region=",
    "regulatory_id": "692773",
    "orpha_substance_code": "ORPHA:182095",
    "details": [
      "OFEV(Tradename                        - 13/07/2020)Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "OFEV(Tradename                        - 13/07/2020)",
      "(Tradename                        - 13/07/2020)",
      "Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/412134?name=618891&mode=orpha&region=&status=all",
        "text": "OFEV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182095",
        "text": "ORPHA:182095 Interstitial lung disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692773?name=618891&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_699": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629911?name=618891&mode=orpha&region=",
    "regulatory_id": "629911",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 31/08/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 31/08/2022)",
      "(Tradename                        - 31/08/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=618891&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629911?name=618891&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_700": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=619979&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=619979&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=619979&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_701": {
    "name": "AMVERSIO",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642395?name=622&mode=orpha&region=",
    "regulatory_id": "642395",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "AMVERSIO(Tradename                        - 05/05/2022)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "AMVERSIO(Tradename                        - 05/05/2022)",
      "(Tradename                        - 05/05/2022)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642393?name=622&mode=orpha&region=&status=all",
        "text": "AMVERSIO",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642395?name=622&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_702": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131341?name=622&mode=orpha&region=",
    "regulatory_id": "131341",
    "orpha_substance_code": "ORPHA:622",
    "details": [
      "CYSTADANE(Tradename                        - 15/02/2007)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "CYSTADANE(Tradename                        - 15/02/2007)",
      "(Tradename                        - 15/02/2007)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:622 Homocystinuria without methylmalonic aciduria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=622&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/622",
        "text": "ORPHA:622 Homocystinuria without methylmalonic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131341?name=622&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_703": {
    "name": "CYSTADANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131109?name=622&mode=orpha&region=",
    "regulatory_id": "131109",
    "orpha_substance_code": "ORPHA:2170",
    "details": [
      "CYSTADANE(Tradename                        - 25/10/1996)Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "CYSTADANE(Tradename                        - 25/10/1996)",
      "(Tradename                        - 25/10/1996)",
      "Disease(s) concernedORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiencyORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiencyORPHA:26 Methylmalonic acidemia with homocystinuriaORPHA:2169 Methylcobalamin deficiency type cblEORPHA:2170 Methylcobalamin deficiency type cblG",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/33514?name=622&mode=orpha&region=&status=all",
        "text": "CYSTADANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/394",
        "text": "ORPHA:394 Homocystinuria due to cystathionine beta-synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/395",
        "text": "ORPHA:395 Homocystinuria due to methylene tetrahydrofolate reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26",
        "text": "ORPHA:26 Methylmalonic acidemia with homocystinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2169",
        "text": "ORPHA:2169 Methylcobalamin deficiency type cblE",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2170",
        "text": "ORPHA:2170 Methylcobalamin deficiency type cblG",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131109?name=622&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_704": {
    "name": "MIGLUSTAT GEN. ORPH",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/645014?name=646&mode=orpha&region=",
    "regulatory_id": "645014",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "MIGLUSTAT GEN. ORPH(Tradename                        - 29/04/2019)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "MIGLUSTAT GEN. ORPH(Tradename                        - 29/04/2019)",
      "(Tradename                        - 29/04/2019)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/501216?name=646&mode=orpha&region=&status=all",
        "text": "MIGLUSTAT GEN. ORPH",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/645014?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_705": {
    "name": "YARGESA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642646?name=646&mode=orpha&region=",
    "regulatory_id": "642646",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "YARGESA(Tradename                        - 15/04/2019)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "YARGESA(Tradename                        - 15/04/2019)",
      "(Tradename                        - 15/04/2019)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/484358?name=646&mode=orpha&region=&status=all",
        "text": "YARGESA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642646?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_706": {
    "name": "ZAVESCA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131346?name=646&mode=orpha&region=",
    "regulatory_id": "131346",
    "orpha_substance_code": "ORPHA:77259",
    "details": [
      "ZAVESCA(Tradename                        - 21/11/2002)Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77259 Gaucher disease type 1",
      "ZAVESCA(Tradename                        - 21/11/2002)",
      "(Tradename                        - 21/11/2002)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77259 Gaucher disease type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/39961?name=646&mode=orpha&region=&status=all",
        "text": "ZAVESCA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77259",
        "text": "ORPHA:77259 Gaucher disease type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131346?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n                                    ORPHA:77259 Gaucher disease type 1\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "661195": {
    "name": "Adeno-associated viral vector serotype 9 containing the human NPC1 gene",
    "substance_url": "/en/drug/substance/661195?name=646&mode=orpha&region=&status=all",
    "substance_id": "661195",
    "regulatory_url": "/en/drug/regulatory/661291?name=646&mode=orpha&region=",
    "regulatory_id": "661291",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "Adeno-associated viral vector serotype 9 containing the human NPC1 gene(Medicinal product                        - 13/10/2023)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "Adeno-associated viral vector serotype 9 containing the human NPC1 gene(Medicinal product                        - 13/10/2023)",
      "(Medicinal product                        - 13/10/2023)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661195?name=646&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 containing the human NPC1 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661291?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "25078": {
    "name": "Ursodeoxycholic acid",
    "substance_url": "/en/drug/substance/25078?name=646&mode=orpha&region=&status=all",
    "substance_id": "25078",
    "regulatory_url": "/en/drug/regulatory/489675?name=646&mode=orpha&region=",
    "regulatory_id": "489675",
    "orpha_substance_code": "ORPHA:77293",
    "details": [
      "Ursodeoxycholic acid(Medicinal product                        - 22/05/2017)Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
      "Ursodeoxycholic acid(Medicinal product                        - 22/05/2017)",
      "(Medicinal product                        - 22/05/2017)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type CORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiencyORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/25078?name=646&mode=orpha&region=&status=all",
        "text": "Ursodeoxycholic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77292",
        "text": "ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77293",
        "text": "ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489675?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n                                    ORPHA:77292 Infantile neurovisceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n                                    ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "412253": {
    "name": "Arimoclomol citrate",
    "substance_url": "/en/drug/substance/412253?name=646&mode=orpha&region=&status=all",
    "substance_id": "412253",
    "regulatory_url": "/en/drug/regulatory/479979?name=646&mode=orpha&region=",
    "regulatory_id": "479979",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "Arimoclomol citrate(Medicinal product                        - 19/11/2014)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "Arimoclomol citrate(Medicinal product                        - 19/11/2014)",
      "(Medicinal product                        - 19/11/2014)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/412253?name=646&mode=orpha&region=&status=all",
        "text": "Arimoclomol citrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/479979?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "327849": {
    "name": "Hydroxy-Propyl-Beta-Cyclodextrin",
    "substance_url": "/en/drug/substance/327849?name=646&mode=orpha&region=&status=all",
    "substance_id": "327849",
    "regulatory_url": "/en/drug/regulatory/332931?name=646&mode=orpha&region=",
    "regulatory_id": "332931",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "Hydroxy-Propyl-Beta-Cyclodextrin(Medicinal product                        - 26/04/2013)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "Hydroxy-Propyl-Beta-Cyclodextrin(Medicinal product                        - 26/04/2013)",
      "(Medicinal product                        - 26/04/2013)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/327849?name=646&mode=orpha&region=&status=all",
        "text": "Hydroxy-Propyl-Beta-Cyclodextrin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/332931?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "323224": {
    "name": "Recombinant human heat shock protein 70",
    "substance_url": "/en/drug/substance/323224?name=646&mode=orpha&region=&status=all",
    "substance_id": "323224",
    "regulatory_url": "/en/drug/regulatory/331029?name=646&mode=orpha&region=",
    "regulatory_id": "331029",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "Recombinant human heat shock protein 70(Medicinal product                        - 12/03/2013)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "Recombinant human heat shock protein 70(Medicinal product                        - 12/03/2013)",
      "(Medicinal product                        - 12/03/2013)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/323224?name=646&mode=orpha&region=&status=all",
        "text": "Recombinant human heat shock protein 70",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/331029?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_712": {
    "name": "AQNEURSA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/688270?name=646&mode=orpha&region=",
    "regulatory_id": "688270",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "AQNEURSA(Tradename                        - 24/09/2024)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "AQNEURSA(Tradename                        - 24/09/2024)",
      "(Tradename                        - 24/09/2024)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/688269?name=646&mode=orpha&region=&status=all",
        "text": "AQNEURSA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688270?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_713": {
    "name": "MIPLYFFA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/688261?name=646&mode=orpha&region=",
    "regulatory_id": "688261",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "MIPLYFFA(Tradename                        - 20/09/2024)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "MIPLYFFA(Tradename                        - 20/09/2024)",
      "(Tradename                        - 20/09/2024)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/688260?name=646&mode=orpha&region=&status=all",
        "text": "MIPLYFFA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/688261?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "689507": {
    "name": "cholesteryl oleate",
    "substance_url": "/en/drug/substance/689507?name=646&mode=orpha&region=&status=all",
    "substance_id": "689507",
    "regulatory_url": "/en/drug/regulatory/689919?name=646&mode=orpha&region=",
    "regulatory_id": "689919",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "cholesteryl oleate(Medicinal product                        - 28/10/2024)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "cholesteryl oleate(Medicinal product                        - 28/10/2024)",
      "(Medicinal product                        - 28/10/2024)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689507?name=646&mode=orpha&region=&status=all",
        "text": "cholesteryl oleate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689919?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687146": {
    "name": "AAV9-hNPC1 is an Adeno-Associated Virus 9 (AAV9) vector expressing a human cDNA encoding Niemann-Pick C1 (NPC1), under control of the Elongation Factor 1 alpha Short (EF1S) promoter",
    "substance_url": "/en/drug/substance/687146?name=646&mode=orpha&region=&status=all",
    "substance_id": "687146",
    "regulatory_url": "/en/drug/regulatory/687327?name=646&mode=orpha&region=",
    "regulatory_id": "687327",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "AAV9-hNPC1 is an Adeno-Associated Virus 9 (AAV9) vector expressing a human cDNA encoding Niemann-Pick C1 (NPC1), under control of the Elongation Factor 1 alpha Short (EF1S) promoter(Medicinal product                        - 23/08/2024)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "AAV9-hNPC1 is an Adeno-Associated Virus 9 (AAV9) vector expressing a human cDNA encoding Niemann-Pick C1 (NPC1), under control of the Elongation Factor 1 alpha Short (EF1S) promoter(Medicinal product                        - 23/08/2024)",
      "(Medicinal product                        - 23/08/2024)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687146?name=646&mode=orpha&region=&status=all",
        "text": "AAV9-hNPC1 is an Adeno-Associated Virus 9 (AAV9) vector expressing a human cDNA encoding Niemann-Pick C1 (NPC1), under control of the Elongation Factor 1 alpha Short (EF1S) promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687327?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "641702": {
    "name": "Biphenyl-substituted L-ido configured deoxynojirimycin derivative",
    "substance_url": "/en/drug/substance/641702?name=646&mode=orpha&region=&status=all",
    "substance_id": "641702",
    "regulatory_url": "/en/drug/regulatory/644171?name=646&mode=orpha&region=",
    "regulatory_id": "644171",
    "orpha_substance_code": "ORPHA:646",
    "details": [
      "Biphenyl-substituted L-ido configured deoxynojirimycin derivative(Medicinal product                        - 07/03/2022)Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "Biphenyl-substituted L-ido configured deoxynojirimycin derivative(Medicinal product                        - 07/03/2022)",
      "(Medicinal product                        - 07/03/2022)",
      "Disease(s) concernedORPHA:646 Niemann-Pick disease type C",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/641702?name=646&mode=orpha&region=&status=all",
        "text": "Biphenyl-substituted L-ido configured deoxynojirimycin derivative",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/646",
        "text": "ORPHA:646 Niemann-Pick disease type C",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/644171?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "type C\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_717": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=646&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=646&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_718": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=646&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=646&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_719": {
    "name": "OFEV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/692773?name=646&mode=orpha&region=",
    "regulatory_id": "692773",
    "orpha_substance_code": "ORPHA:182095",
    "details": [
      "OFEV(Tradename                        - 13/07/2020)Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "OFEV(Tradename                        - 13/07/2020)",
      "(Tradename                        - 13/07/2020)",
      "Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/412134?name=646&mode=orpha&region=&status=all",
        "text": "OFEV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182095",
        "text": "ORPHA:182095 Interstitial lung disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692773?name=646&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "643920": {
    "name": "Recombinant human apolipoprotein A-I/phospholipid complexes",
    "substance_url": "/en/drug/substance/643920?name=650&mode=orpha&region=&status=all",
    "substance_id": "643920",
    "regulatory_url": "/en/drug/regulatory/643921?name=650&mode=orpha&region=",
    "regulatory_id": "643921",
    "orpha_substance_code": "ORPHA:650",
    "details": [
      "Recombinant human apolipoprotein A-I/phospholipid complexes(Medicinal product                        - 01/10/2022)Disease(s) concernedORPHA:650 LCAT deficiency",
      "Recombinant human apolipoprotein A-I/phospholipid complexes(Medicinal product                        - 01/10/2022)",
      "(Medicinal product                        - 01/10/2022)",
      "Disease(s) concernedORPHA:650 LCAT deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/643920?name=650&mode=orpha&region=&status=all",
        "text": "Recombinant human apolipoprotein A-I/phospholipid complexes",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/650",
        "text": "ORPHA:650 LCAT deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/643921?name=650&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "317259": {
    "name": "Recombinant human lecithin cholesterol acyltransferase",
    "substance_url": "/en/drug/substance/317259?name=650&mode=orpha&region=&status=all",
    "substance_id": "317259",
    "regulatory_url": "/en/drug/regulatory/360204?name=650&mode=orpha&region=",
    "regulatory_id": "360204",
    "orpha_substance_code": "ORPHA:79293",
    "details": [
      "Recombinant human lecithin cholesterol acyltransferase(Medicinal product                        - 10/10/2012)Disease(s) concernedORPHA:79293 Familial LCAT deficiency",
      "Recombinant human lecithin cholesterol acyltransferase(Medicinal product                        - 10/10/2012)",
      "(Medicinal product                        - 10/10/2012)",
      "Disease(s) concernedORPHA:79293 Familial LCAT deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/317259?name=650&mode=orpha&region=&status=all",
        "text": "Recombinant human lecithin cholesterol acyltransferase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79293",
        "text": "ORPHA:79293 Familial LCAT deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/360204?name=650&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_722": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=65682&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=65682&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=65682&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_723": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=659672&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=659672&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=659672&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_724": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=661412&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=661412&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=661412&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_725": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=662216&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=662216&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=662216&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_726": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=662216&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=662216&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=662216&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_727": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=664&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=664&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_728": {
    "name": "AMMONAPS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131255?name=664&mode=orpha&region=",
    "regulatory_id": "131255",
    "orpha_substance_code": "ORPHA:187",
    "details": [
      "AMMONAPS(Tradename                        - 08/12/1999)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "AMMONAPS(Tradename                        - 08/12/1999)",
      "(Tradename                        - 08/12/1999)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:187 Citrullinemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34205?name=664&mode=orpha&region=&status=all",
        "text": "AMMONAPS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/187",
        "text": "ORPHA:187 Citrullinemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131255?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "641137": {
    "name": "Adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene",
    "substance_url": "/en/drug/substance/641137?name=664&mode=orpha&region=&status=all",
    "substance_id": "641137",
    "regulatory_url": "/en/drug/regulatory/641138?name=664&mode=orpha&region=",
    "regulatory_id": "641138",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene(Medicinal product                        - 09/12/2022)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene(Medicinal product                        - 09/12/2022)",
      "(Medicinal product                        - 09/12/2022)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/641137?name=664&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/641138?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "629631": {
    "name": "mRNA encoding modified human ornithine transcarbamylase",
    "substance_url": "/en/drug/substance/629631?name=664&mode=orpha&region=&status=all",
    "substance_id": "629631",
    "regulatory_url": "/en/drug/regulatory/629632?name=664&mode=orpha&region=",
    "regulatory_id": "629632",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "mRNA encoding modified human ornithine transcarbamylase(Medicinal product                        - 18/07/2022)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "mRNA encoding modified human ornithine transcarbamylase(Medicinal product                        - 18/07/2022)",
      "(Medicinal product                        - 18/07/2022)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/629631?name=664&mode=orpha&region=&status=all",
        "text": "mRNA encoding modified human ornithine transcarbamylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629632?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "489661": {
    "name": "Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles",
    "substance_url": "/en/drug/substance/489661?name=664&mode=orpha&region=&status=all",
    "substance_id": "489661",
    "regulatory_url": "/en/drug/regulatory/489665?name=664&mode=orpha&region=",
    "regulatory_id": "489665",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles(Medicinal product                        - 20/04/2017)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles(Medicinal product                        - 20/04/2017)",
      "(Medicinal product                        - 20/04/2017)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/489661?name=664&mode=orpha&region=&status=all",
        "text": "Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489665?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "487928": {
    "name": "Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase",
    "substance_url": "/en/drug/substance/487928?name=664&mode=orpha&region=&status=all",
    "substance_id": "487928",
    "regulatory_url": "/en/drug/regulatory/488010?name=664&mode=orpha&region=",
    "regulatory_id": "488010",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase(Medicinal product                        - 20/03/2017)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase(Medicinal product                        - 20/03/2017)",
      "(Medicinal product                        - 20/03/2017)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/487928?name=664&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/488010?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "458744": {
    "name": "Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase",
    "substance_url": "/en/drug/substance/458744?name=664&mode=orpha&region=&status=all",
    "substance_id": "458744",
    "regulatory_url": "/en/drug/regulatory/458748?name=664&mode=orpha&region=",
    "regulatory_id": "458748",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase(Medicinal product                        - 21/03/2016)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase(Medicinal product                        - 21/03/2016)",
      "(Medicinal product                        - 21/03/2016)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/458744?name=664&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/458748?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "520928": {
    "name": "Codon -optimised human ornithine transcarbamylase mRNA  complexed with lipid -based  nanoparticle",
    "substance_url": "/en/drug/substance/520928?name=664&mode=orpha&region=&status=all",
    "substance_id": "520928",
    "regulatory_url": "/en/drug/regulatory/520929?name=664&mode=orpha&region=",
    "regulatory_id": "520929",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Codon -optimised human ornithine transcarbamylase mRNA  complexed with lipid -based  nanoparticle(Medicinal product                        - 27/06/2018)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Codon -optimised human ornithine transcarbamylase mRNA  complexed with lipid -based  nanoparticle(Medicinal product                        - 27/06/2018)",
      "(Medicinal product                        - 27/06/2018)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/520928?name=664&mode=orpha&region=&status=all",
        "text": "Codon -optimised human ornithine transcarbamylase mRNA  complexed with lipid -based  nanoparticle",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/520929?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_735": {
    "name": "PHEBURANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/628626?name=664&mode=orpha&region=",
    "regulatory_id": "628626",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "PHEBURANE(Tradename                        - 17/06/2022)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "PHEBURANE(Tradename                        - 17/06/2022)",
      "(Tradename                        - 17/06/2022)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/628534?name=664&mode=orpha&region=&status=all",
        "text": "PHEBURANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628626?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_736": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=664&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=664&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_737": {
    "name": "BUPHENYL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131075?name=664&mode=orpha&region=",
    "regulatory_id": "131075",
    "orpha_substance_code": "ORPHA:147",
    "details": [
      "BUPHENYL(Tradename                        - 30/04/1996)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "BUPHENYL(Tradename                        - 30/04/1996)",
      "(Tradename                        - 30/04/1996)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25061?name=664&mode=orpha&region=&status=all",
        "text": "BUPHENYL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131075?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "661817": {
    "name": "Replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase",
    "substance_url": "/en/drug/substance/661817?name=664&mode=orpha&region=&status=all",
    "substance_id": "661817",
    "regulatory_url": "/en/drug/regulatory/661818?name=664&mode=orpha&region=",
    "regulatory_id": "661818",
    "orpha_substance_code": "ORPHA:664",
    "details": [
      "Replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase(Medicinal product                        - 24/07/2023)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "Replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase(Medicinal product                        - 24/07/2023)",
      "(Medicinal product                        - 24/07/2023)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661817?name=664&mode=orpha&region=&status=all",
        "text": "Replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661818?name=664&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_739": {
    "name": "CORLANOR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/543215?name=66634&mode=orpha&region=",
    "regulatory_id": "543215",
    "orpha_substance_code": "ORPHA:217604",
    "details": [
      "CORLANOR(Tradename                        - 22/04/2019)Disease(s) concernedORPHA:217604 Dilated cardiomyopathy",
      "CORLANOR(Tradename                        - 22/04/2019)",
      "(Tradename                        - 22/04/2019)",
      "Disease(s) concernedORPHA:217604 Dilated cardiomyopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/543214?name=66634&mode=orpha&region=&status=all",
        "text": "CORLANOR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/217604",
        "text": "ORPHA:217604 Dilated cardiomyopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/543215?name=66634&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_740": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=67041&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=67041&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=67041&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_741": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=67041&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=67041&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=67041&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687202": {
    "name": "Mixture of decanoic acid (C10; tricaprin) and octanoic acid (C8; tricaprylin)",
    "substance_url": "/en/drug/substance/687202?name=71277&mode=orpha&region=&status=all",
    "substance_id": "687202",
    "regulatory_url": "/en/drug/regulatory/687530?name=71277&mode=orpha&region=",
    "regulatory_id": "687530",
    "orpha_substance_code": "ORPHA:71277",
    "details": [
      "Mixture of decanoic acid (C10; tricaprin) and octanoic acid (C8; tricaprylin)(Medicinal product                        - 16/07/2024)Disease(s) concernedORPHA:71277 Classic glucose transporter type 1 deficiency syndrome",
      "Mixture of decanoic acid (C10; tricaprin) and octanoic acid (C8; tricaprylin)(Medicinal product                        - 16/07/2024)",
      "(Medicinal product                        - 16/07/2024)",
      "Disease(s) concernedORPHA:71277 Classic glucose transporter type 1 deficiency syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687202?name=71277&mode=orpha&region=&status=all",
        "text": "Mixture of decanoic acid (C10; tricaprin) and octanoic acid (C8; tricaprylin)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/71277",
        "text": "ORPHA:71277 Classic glucose transporter type 1 deficiency syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687530?name=71277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_743": {
    "name": "BUCCOLAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/325650?name=71277&mode=orpha&region=",
    "regulatory_id": "325650",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "BUCCOLAM(Tradename                        - 05/09/2011)Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "BUCCOLAM(Tradename                        - 05/09/2011)",
      "(Tradename                        - 05/09/2011)",
      "Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/325618?name=71277&mode=orpha&region=&status=all",
        "text": "BUCCOLAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98259",
        "text": "ORPHA:98259 Childhood-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98260",
        "text": "ORPHA:98260 Adolescent-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/325650?name=71277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:98260 Adolescent-onset epilepsy syndrome\n                                \n\n\n\n\n                                    ORPHA:693802 Neonatal-infantile onset epilepsy syndrome\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_744": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=71277&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=71277&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=71277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_745": {
    "name": "SEZABY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/635898?name=71277&mode=orpha&region=",
    "regulatory_id": "635898",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "SEZABY(Tradename                        - 17/11/2022)Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "SEZABY(Tradename                        - 17/11/2022)",
      "(Tradename                        - 17/11/2022)",
      "Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/635897?name=71277&mode=orpha&region=&status=all",
        "text": "SEZABY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635898?name=71277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_746": {
    "name": "PALYNZIQ",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/556967?name=716&mode=orpha&region=",
    "regulatory_id": "556967",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "PALYNZIQ(Tradename                        - 03/05/2019)Disease(s) concernedORPHA:716 Phenylketonuria",
      "PALYNZIQ(Tradename                        - 03/05/2019)",
      "(Tradename                        - 03/05/2019)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/527598?name=716&mode=orpha&region=&status=all",
        "text": "PALYNZIQ",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/556967?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_747": {
    "name": "SAPROPTERIN DIPHARMA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642262?name=716&mode=orpha&region=",
    "regulatory_id": "642262",
    "orpha_substance_code": "ORPHA:238583",
    "details": [
      "SAPROPTERIN DIPHARMA(Tradename                        - 16/02/2022)Disease(s) concernedORPHA:716 PhenylketonuriaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "SAPROPTERIN DIPHARMA(Tradename                        - 16/02/2022)",
      "(Tradename                        - 16/02/2022)",
      "Disease(s) concernedORPHA:716 PhenylketonuriaORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642261?name=716&mode=orpha&region=&status=all",
        "text": "SAPROPTERIN DIPHARMA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/238583",
        "text": "ORPHA:238583 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642262?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "673921": {
    "name": "(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide",
    "substance_url": "/en/drug/substance/673921?name=716&mode=orpha&region=&status=all",
    "substance_id": "673921",
    "regulatory_url": "/en/drug/regulatory/684452?name=716&mode=orpha&region=",
    "regulatory_id": "684452",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide(Medicinal product                        - 28/06/2024)Disease(s) concernedORPHA:716 Phenylketonuria",
      "(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide(Medicinal product                        - 28/06/2024)",
      "(Medicinal product                        - 28/06/2024)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/673921?name=716&mode=orpha&region=&status=all",
        "text": "(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/684452?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "576895": {
    "name": "adeno-associated virus vector encoding human phenylalanine hydroxylase",
    "substance_url": "/en/drug/substance/576895?name=716&mode=orpha&region=&status=all",
    "substance_id": "576895",
    "regulatory_url": "/en/drug/regulatory/576896?name=716&mode=orpha&region=",
    "regulatory_id": "576896",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "adeno-associated virus vector encoding human phenylalanine hydroxylase(Medicinal product                        - 16/12/2019)Disease(s) concernedORPHA:716 Phenylketonuria",
      "adeno-associated virus vector encoding human phenylalanine hydroxylase(Medicinal product                        - 16/12/2019)",
      "(Medicinal product                        - 16/12/2019)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/576895?name=716&mode=orpha&region=&status=all",
        "text": "adeno-associated virus vector encoding human phenylalanine hydroxylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/576896?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "216724": {
    "name": "Pegylated recombinant phenylalanine ammonia lyase",
    "substance_url": "/en/drug/substance/216724?name=716&mode=orpha&region=&status=all",
    "substance_id": "216724",
    "regulatory_url": "/en/drug/regulatory/226002?name=716&mode=orpha&region=",
    "regulatory_id": "226002",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Pegylated recombinant phenylalanine ammonia lyase(Medicinal product                        - 28/01/2010)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Pegylated recombinant phenylalanine ammonia lyase(Medicinal product                        - 28/01/2010)",
      "(Medicinal product                        - 28/01/2010)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/216724?name=716&mode=orpha&region=&status=all",
        "text": "Pegylated recombinant phenylalanine ammonia lyase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/226002?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "35292": {
    "name": "Tetrahydrobiopterin",
    "substance_url": "/en/drug/substance/35292?name=716&mode=orpha&region=&status=all",
    "substance_id": "35292",
    "regulatory_url": "/en/drug/regulatory/133843?name=716&mode=orpha&region=",
    "regulatory_id": "133843",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Tetrahydrobiopterin(Medicinal product                        - 02/10/2003)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Tetrahydrobiopterin(Medicinal product                        - 02/10/2003)",
      "(Medicinal product                        - 02/10/2003)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/35292?name=716&mode=orpha&region=&status=all",
        "text": "Tetrahydrobiopterin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133843?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628328": {
    "name": "Adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase",
    "substance_url": "/en/drug/substance/628328?name=716&mode=orpha&region=&status=all",
    "substance_id": "628328",
    "regulatory_url": "/en/drug/regulatory/628330?name=716&mode=orpha&region=",
    "regulatory_id": "628330",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase(Medicinal product                        - 16/03/2022)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase(Medicinal product                        - 16/03/2022)",
      "(Medicinal product                        - 16/03/2022)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628328?name=716&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628330?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "536901": {
    "name": "Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase",
    "substance_url": "/en/drug/substance/536901?name=716&mode=orpha&region=&status=all",
    "substance_id": "536901",
    "regulatory_url": "/en/drug/regulatory/536917?name=716&mode=orpha&region=",
    "regulatory_id": "536917",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase(Medicinal product                        - 14/12/2018)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase(Medicinal product                        - 14/12/2018)",
      "(Medicinal product                        - 14/12/2018)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/536901?name=716&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/536917?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "69296": {
    "name": "Sapropterin",
    "substance_url": "/en/drug/substance/69296?name=716&mode=orpha&region=&status=all",
    "substance_id": "69296",
    "regulatory_url": "/en/drug/regulatory/133987?name=716&mode=orpha&region=",
    "regulatory_id": "133987",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Sapropterin(Medicinal product                        - 26/08/2005)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Sapropterin(Medicinal product                        - 26/08/2005)",
      "(Medicinal product                        - 26/08/2005)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/69296?name=716&mode=orpha&region=&status=all",
        "text": "Sapropterin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133987?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_755": {
    "name": "PALYNZIQ",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/527601?name=716&mode=orpha&region=",
    "regulatory_id": "527601",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "PALYNZIQ(Tradename                        - 24/05/2018)Disease(s) concernedORPHA:716 Phenylketonuria",
      "PALYNZIQ(Tradename                        - 24/05/2018)",
      "(Tradename                        - 24/05/2018)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/527598?name=716&mode=orpha&region=&status=all",
        "text": "PALYNZIQ",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527601?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_756": {
    "name": "KUVAN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131176?name=716&mode=orpha&region=",
    "regulatory_id": "131176",
    "orpha_substance_code": "ORPHA:1578",
    "details": [
      "KUVAN(Tradename                        - 13/12/2007)Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:716 PhenylketonuriaORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiencyORPHA:2102 GTP cyclohydrolase I deficiencyORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
      "KUVAN(Tradename                        - 13/12/2007)",
      "(Tradename                        - 13/12/2007)",
      "Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:716 PhenylketonuriaORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiencyORPHA:2102 GTP cyclohydrolase I deficiencyORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/84936?name=716&mode=orpha&region=&status=all",
        "text": "KUVAN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/226",
        "text": "ORPHA:226 Dihydropteridine reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/13",
        "text": "ORPHA:13 6-pyruvoyl-tetrahydropterin synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2102",
        "text": "ORPHA:2102 GTP cyclohydrolase I deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1578",
        "text": "ORPHA:1578 Pterin-4 alpha-carbinolamine dehydratase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131176?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "689497": {
    "name": "In vivo target-primed reverse transcription genome editing product consisting of a messenger RNA and a template guide RNA formulated to target the R408W mutation in the phenylalanine hydroxylase gene",
    "substance_url": "/en/drug/substance/689497?name=716&mode=orpha&region=&status=all",
    "substance_id": "689497",
    "regulatory_url": "/en/drug/regulatory/689911?name=716&mode=orpha&region=",
    "regulatory_id": "689911",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "In vivo target-primed reverse transcription genome editing product consisting of a messenger RNA and a template guide RNA formulated to target the R408W mutation in the phenylalanine hydroxylase gene(Medicinal product                        - 09/10/2024)Disease(s) concernedORPHA:716 Phenylketonuria",
      "In vivo target-primed reverse transcription genome editing product consisting of a messenger RNA and a template guide RNA formulated to target the R408W mutation in the phenylalanine hydroxylase gene(Medicinal product                        - 09/10/2024)",
      "(Medicinal product                        - 09/10/2024)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689497?name=716&mode=orpha&region=&status=all",
        "text": "In vivo target-primed reverse transcription genome editing product consisting of a messenger RNA and a template guide RNA formulated to target the R408W mutation in the phenylalanine hydroxylase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/689911?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "666480": {
    "name": "Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants",
    "substance_url": "/en/drug/substance/666480?name=716&mode=orpha&region=&status=all",
    "substance_id": "666480",
    "regulatory_url": "/en/drug/regulatory/666522?name=716&mode=orpha&region=",
    "regulatory_id": "666522",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants(Medicinal product                        - 27/12/2023)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants(Medicinal product                        - 27/12/2023)",
      "(Medicinal product                        - 27/12/2023)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/666480?name=716&mode=orpha&region=&status=all",
        "text": "Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/666522?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "661933": {
    "name": "Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA",
    "substance_url": "/en/drug/substance/661933?name=716&mode=orpha&region=&status=all",
    "substance_id": "661933",
    "regulatory_url": "/en/drug/regulatory/661934?name=716&mode=orpha&region=",
    "regulatory_id": "661934",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA(Medicinal product                        - 08/09/2023)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA(Medicinal product                        - 08/09/2023)",
      "(Medicinal product                        - 08/09/2023)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/661933?name=716&mode=orpha&region=&status=all",
        "text": "Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/661934?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "650971": {
    "name": "Phenylalanine consuming engineered bacteria",
    "substance_url": "/en/drug/substance/650971?name=716&mode=orpha&region=&status=all",
    "substance_id": "650971",
    "regulatory_url": "/en/drug/regulatory/651012?name=716&mode=orpha&region=",
    "regulatory_id": "651012",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Phenylalanine consuming engineered bacteria(Medicinal product                        - 08/05/2023)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Phenylalanine consuming engineered bacteria(Medicinal product                        - 08/05/2023)",
      "(Medicinal product                        - 08/05/2023)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/650971?name=716&mode=orpha&region=&status=all",
        "text": "Phenylalanine consuming engineered bacteria",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/651012?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "641304": {
    "name": "Recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH)",
    "substance_url": "/en/drug/substance/641304?name=716&mode=orpha&region=&status=all",
    "substance_id": "641304",
    "regulatory_url": "/en/drug/regulatory/641308?name=716&mode=orpha&region=",
    "regulatory_id": "641308",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH)(Medicinal product                        - 09/01/2023)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH)(Medicinal product                        - 09/01/2023)",
      "(Medicinal product                        - 09/01/2023)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/641304?name=716&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/641308?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "640972": {
    "name": "Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase",
    "substance_url": "/en/drug/substance/640972?name=716&mode=orpha&region=&status=all",
    "substance_id": "640972",
    "regulatory_url": "/en/drug/regulatory/640973?name=716&mode=orpha&region=",
    "regulatory_id": "640973",
    "orpha_substance_code": "ORPHA:716",
    "details": [
      "Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase(Medicinal product                        - 27/05/2022)Disease(s) concernedORPHA:716 Phenylketonuria",
      "Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase(Medicinal product                        - 27/05/2022)",
      "(Medicinal product                        - 27/05/2022)",
      "Disease(s) concernedORPHA:716 Phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/640972?name=716&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/716",
        "text": "ORPHA:716 Phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/640973?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_763": {
    "name": "KUVAN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/170109?name=716&mode=orpha&region=",
    "regulatory_id": "170109",
    "orpha_substance_code": "ORPHA:293284",
    "details": [
      "KUVAN(Tradename                        - 02/12/2008)Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
      "KUVAN(Tradename                        - 02/12/2008)",
      "(Tradename                        - 02/12/2008)",
      "Disease(s) concernedORPHA:226 Dihydropteridine reductase deficiencyORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/84936?name=716&mode=orpha&region=&status=all",
        "text": "KUVAN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/226",
        "text": "ORPHA:226 Dihydropteridine reductase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/293284",
        "text": "ORPHA:293284 Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/170109?name=716&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_764": {
    "name": "DOJOLVI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623538?name=746&mode=orpha&region=",
    "regulatory_id": "623538",
    "orpha_substance_code": "ORPHA:26793",
    "details": [
      "DOJOLVI(Tradename                        - 30/06/2020)Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "DOJOLVI(Tradename                        - 30/06/2020)",
      "(Tradename                        - 30/06/2020)",
      "Disease(s) concernedORPHA:157 Carnitine palmitoyltransferase II deficiencyORPHA:156 Carnitine palmitoyl transferase 1A deficiencyORPHA:746 Mitochondrial trifunctional protein deficiencyORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiencyORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/615857?name=746&mode=orpha&region=&status=all",
        "text": "DOJOLVI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/157",
        "text": "ORPHA:157 Carnitine palmitoyltransferase II deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/156",
        "text": "ORPHA:156 Carnitine palmitoyl transferase 1A deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/746",
        "text": "ORPHA:746 Mitochondrial trifunctional protein deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/5",
        "text": "ORPHA:5 Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/26793",
        "text": "ORPHA:26793 Very long chain acyl-CoA dehydrogenase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623538?name=746&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_765": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=760&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=760&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=760&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_766": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=760&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=760&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=760&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_767": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=760&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=760&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=760&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_768": {
    "name": "Pyrukynd",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/635841?name=766&mode=orpha&region=",
    "regulatory_id": "635841",
    "orpha_substance_code": "ORPHA:766",
    "details": [
      "Pyrukynd(Tradename                        - 09/11/2022)Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "Pyrukynd(Tradename                        - 09/11/2022)",
      "(Tradename                        - 09/11/2022)",
      "Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623132?name=766&mode=orpha&region=&status=all",
        "text": "Pyrukynd",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/766",
        "text": "ORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635841?name=766&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "628215": {
    "name": "Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene",
    "substance_url": "/en/drug/substance/628215?name=766&mode=orpha&region=&status=all",
    "substance_id": "628215",
    "regulatory_url": "/en/drug/regulatory/628216?name=766&mode=orpha&region=",
    "regulatory_id": "628216",
    "orpha_substance_code": "ORPHA:766",
    "details": [
      "Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene(Medicinal product                        - 24/02/2022)Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene(Medicinal product                        - 24/02/2022)",
      "(Medicinal product                        - 24/02/2022)",
      "Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/628215?name=766&mode=orpha&region=&status=all",
        "text": "Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/766",
        "text": "ORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/628216?name=766&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "504971": {
    "name": "Mitapivat sulfate",
    "substance_url": "/en/drug/substance/504971?name=766&mode=orpha&region=&status=all",
    "substance_id": "504971",
    "regulatory_url": "/en/drug/regulatory/590144?name=766&mode=orpha&region=",
    "regulatory_id": "590144",
    "orpha_substance_code": "ORPHA:766",
    "details": [
      "Mitapivat sulfate(Medicinal product                        - 22/04/2020)Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "Mitapivat sulfate(Medicinal product                        - 22/04/2020)",
      "(Medicinal product                        - 22/04/2020)",
      "Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/504971?name=766&mode=orpha&region=&status=all",
        "text": "Mitapivat sulfate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/766",
        "text": "ORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/590144?name=766&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "406532": {
    "name": "Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene",
    "substance_url": "/en/drug/substance/406532?name=766&mode=orpha&region=&status=all",
    "substance_id": "406532",
    "regulatory_url": "/en/drug/regulatory/412031?name=766&mode=orpha&region=",
    "regulatory_id": "412031",
    "orpha_substance_code": "ORPHA:766",
    "details": [
      "Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene(Medicinal product                        - 22/08/2014)Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene(Medicinal product                        - 22/08/2014)",
      "(Medicinal product                        - 22/08/2014)",
      "Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/406532?name=766&mode=orpha&region=&status=all",
        "text": "Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/766",
        "text": "ORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/412031?name=766&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_772": {
    "name": "Pyrukynd",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623133?name=766&mode=orpha&region=",
    "regulatory_id": "623133",
    "orpha_substance_code": "ORPHA:766",
    "details": [
      "Pyrukynd(Tradename                        - 17/02/2022)Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "Pyrukynd(Tradename                        - 17/02/2022)",
      "(Tradename                        - 17/02/2022)",
      "Disease(s) concernedORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623132?name=766&mode=orpha&region=&status=all",
        "text": "Pyrukynd",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/766",
        "text": "ORPHA:766 Hemolytic anemia due to red cell pyruvate kinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623133?name=766&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_773": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629878?name=77292&mode=orpha&region=",
    "regulatory_id": "629878",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 24/06/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 24/06/2022)",
      "(Tradename                        - 24/06/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77292&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629878?name=77292&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_774": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=77292&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=77292&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=77292&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_775": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=77292&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=77292&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=77292&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_776": {
    "name": "OFEV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/692773?name=77292&mode=orpha&region=",
    "regulatory_id": "692773",
    "orpha_substance_code": "ORPHA:182095",
    "details": [
      "OFEV(Tradename                        - 13/07/2020)Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "OFEV(Tradename                        - 13/07/2020)",
      "(Tradename                        - 13/07/2020)",
      "Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/412134?name=77292&mode=orpha&region=&status=all",
        "text": "OFEV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182095",
        "text": "ORPHA:182095 Interstitial lung disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692773?name=77292&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_777": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629911?name=77292&mode=orpha&region=",
    "regulatory_id": "629911",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 31/08/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 31/08/2022)",
      "(Tradename                        - 31/08/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77292&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629911?name=77292&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "225655": {
    "name": "Olipudase alfa",
    "substance_url": "/en/drug/substance/225655?name=77293&mode=orpha&region=&status=all",
    "substance_id": "225655",
    "regulatory_url": "/en/drug/regulatory/133739?name=77293&mode=orpha&region=",
    "regulatory_id": "133739",
    "orpha_substance_code": "ORPHA:77293",
    "details": [
      "Olipudase alfa(Medicinal product                        - 19/09/2001)Disease(s) concernedORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
      "Olipudase alfa(Medicinal product                        - 19/09/2001)",
      "(Medicinal product                        - 19/09/2001)",
      "Disease(s) concernedORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/225655?name=77293&mode=orpha&region=&status=all",
        "text": "Olipudase alfa",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/77293",
        "text": "ORPHA:77293 Chronic visceral acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133739?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_779": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629878?name=77293&mode=orpha&region=",
    "regulatory_id": "629878",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 24/06/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 24/06/2022)",
      "(Tradename                        - 24/06/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77293&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629878?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_780": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=77293&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=77293&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_781": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=77293&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=77293&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_782": {
    "name": "OFEV",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/692773?name=77293&mode=orpha&region=",
    "regulatory_id": "692773",
    "orpha_substance_code": "ORPHA:182095",
    "details": [
      "OFEV(Tradename                        - 13/07/2020)Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "OFEV(Tradename                        - 13/07/2020)",
      "(Tradename                        - 13/07/2020)",
      "Disease(s) concernedORPHA:182095 Interstitial lung disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/412134?name=77293&mode=orpha&region=&status=all",
        "text": "OFEV",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/182095",
        "text": "ORPHA:182095 Interstitial lung disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/692773?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_783": {
    "name": "XENPOZYME",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/629911?name=77293&mode=orpha&region=",
    "regulatory_id": "629911",
    "orpha_substance_code": "ORPHA:618899",
    "details": [
      "XENPOZYME(Tradename                        - 31/08/2022)Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "XENPOZYME(Tradename                        - 31/08/2022)",
      "(Tradename                        - 31/08/2022)",
      "Disease(s) concernedORPHA:618899 Acid sphingomyelinase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/629877?name=77293&mode=orpha&region=&status=all",
        "text": "XENPOZYME",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/618899",
        "text": "ORPHA:618899 Acid sphingomyelinase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629911?name=77293&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_784": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=773&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=773&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=773&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_785": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=773&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=773&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=773&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_786": {
    "name": "KOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/399979?name=79095&mode=orpha&region=",
    "regulatory_id": "399979",
    "orpha_substance_code": "ORPHA:209902",
    "details": [
      "KOLBAM(Tradename                        - 04/04/2014)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "KOLBAM(Tradename                        - 04/04/2014)",
      "(Tradename                        - 04/04/2014)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/399978?name=79095&mode=orpha&region=&status=all",
        "text": "KOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79095",
        "text": "ORPHA:79095 Congenital bile acid synthesis defect type 4",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/209902",
        "text": "ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/399979?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_787": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=79095&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=79095&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_788": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=79095&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=79095&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_789": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=79095&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=79095&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "686824": {
    "name": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
    "substance_url": "/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
    "substance_id": "686824",
    "regulatory_url": "/en/drug/regulatory/686861?name=79095&mode=orpha&region=",
    "regulatory_id": "686861",
    "orpha_substance_code": "ORPHA:485631",
    "details": [
      "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
      "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 21/08/2024)",
      "(Medicinal product                        - 21/08/2024)",
      "Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/485631",
        "text": "ORPHA:485631 Congenital bile acid synthesis defect",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/686861?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_791": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=79095&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=79095&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=79095&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "410392": {
    "name": "Pyridoxal 5'-phosphate",
    "substance_url": "/en/drug/substance/410392?name=79096&mode=orpha&region=&status=all",
    "substance_id": "410392",
    "regulatory_url": "/en/drug/regulatory/629598?name=79096&mode=orpha&region=",
    "regulatory_id": "629598",
    "orpha_substance_code": "ORPHA:79096",
    "details": [
      "Pyridoxal 5'-phosphate(Medicinal product                        - 18/07/2022)Disease(s) concernedORPHA:79096 Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy",
      "Pyridoxal 5'-phosphate(Medicinal product                        - 18/07/2022)",
      "(Medicinal product                        - 18/07/2022)",
      "Disease(s) concernedORPHA:79096 Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/410392?name=79096&mode=orpha&region=&status=all",
        "text": "Pyridoxal 5'-phosphate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79096",
        "text": "ORPHA:79096 Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/629598?name=79096&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_793": {
    "name": "BUCCOLAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/325650?name=79096&mode=orpha&region=",
    "regulatory_id": "325650",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "BUCCOLAM(Tradename                        - 05/09/2011)Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "BUCCOLAM(Tradename                        - 05/09/2011)",
      "(Tradename                        - 05/09/2011)",
      "Disease(s) concernedORPHA:98259 Childhood-onset epilepsy syndromeORPHA:98260 Adolescent-onset epilepsy syndromeORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/325618?name=79096&mode=orpha&region=&status=all",
        "text": "BUCCOLAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98259",
        "text": "ORPHA:98259 Childhood-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/98260",
        "text": "ORPHA:98260 Adolescent-onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/325650?name=79096&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:98260 Adolescent-onset epilepsy syndrome\n                                \n\n\n\n\n                                    ORPHA:693802 Neonatal-infantile onset epilepsy syndrome\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_794": {
    "name": "LIBERVANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/673903?name=79096&mode=orpha&region=",
    "regulatory_id": "673903",
    "orpha_substance_code": "ORPHA:166463",
    "details": [
      "LIBERVANT(Tradename                        - 26/04/2024)Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "LIBERVANT(Tradename                        - 26/04/2024)",
      "(Tradename                        - 26/04/2024)",
      "Disease(s) concernedORPHA:166463 Epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/673890?name=79096&mode=orpha&region=&status=all",
        "text": "LIBERVANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/166463",
        "text": "ORPHA:166463 Epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/673903?name=79096&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_795": {
    "name": "SEZABY",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/635898?name=79096&mode=orpha&region=",
    "regulatory_id": "635898",
    "orpha_substance_code": "ORPHA:693802",
    "details": [
      "SEZABY(Tradename                        - 17/11/2022)Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "SEZABY(Tradename                        - 17/11/2022)",
      "(Tradename                        - 17/11/2022)",
      "Disease(s) concernedORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/635897?name=79096&mode=orpha&region=&status=all",
        "text": "SEZABY",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/693802",
        "text": "ORPHA:693802 Neonatal-infantile onset epilepsy syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635898?name=79096&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_796": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/573501?name=79273&mode=orpha&region=",
    "regulatory_id": "573501",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 02/03/2020)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 02/03/2020)",
      "(Tradename                        - 02/03/2020)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79273&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/573501?name=79273&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_797": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/574106?name=79273&mode=orpha&region=",
    "regulatory_id": "574106",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 20/11/2019)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 20/11/2019)",
      "(Tradename                        - 20/11/2019)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79273&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/574106?name=79273&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_798": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=79273&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=79273&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=79273&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "178058": {
    "name": "Adeno-associated viral vector containing porphobilinogen deaminase gene",
    "substance_url": "/en/drug/substance/178058?name=79276&mode=orpha&region=&status=all",
    "substance_id": "178058",
    "regulatory_url": "/en/drug/regulatory/189191?name=79276&mode=orpha&region=",
    "regulatory_id": "189191",
    "orpha_substance_code": "ORPHA:79276",
    "details": [
      "Adeno-associated viral vector containing porphobilinogen deaminase gene(Medicinal product                        - 29/04/2009)Disease(s) concernedORPHA:79276 Acute intermittent porphyria",
      "Adeno-associated viral vector containing porphobilinogen deaminase gene(Medicinal product                        - 29/04/2009)",
      "(Medicinal product                        - 29/04/2009)",
      "Disease(s) concernedORPHA:79276 Acute intermittent porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/178058?name=79276&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector containing porphobilinogen deaminase gene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79276",
        "text": "ORPHA:79276 Acute intermittent porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/189191?name=79276&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "133637": {
    "name": "Recombinant human porphobilinogen deaminase",
    "substance_url": "/en/drug/substance/133637?name=79276&mode=orpha&region=&status=all",
    "substance_id": "133637",
    "regulatory_url": "/en/drug/regulatory/133784?name=79276&mode=orpha&region=",
    "regulatory_id": "133784",
    "orpha_substance_code": "ORPHA:79276",
    "details": [
      "Recombinant human porphobilinogen deaminase(Medicinal product                        - 12/06/2002)Disease(s) concernedORPHA:79276 Acute intermittent porphyria",
      "Recombinant human porphobilinogen deaminase(Medicinal product                        - 12/06/2002)",
      "(Medicinal product                        - 12/06/2002)",
      "Disease(s) concernedORPHA:79276 Acute intermittent porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/133637?name=79276&mode=orpha&region=&status=all",
        "text": "Recombinant human porphobilinogen deaminase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79276",
        "text": "ORPHA:79276 Acute intermittent porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133784?name=79276&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_801": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/573501?name=79276&mode=orpha&region=",
    "regulatory_id": "573501",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 02/03/2020)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 02/03/2020)",
      "(Tradename                        - 02/03/2020)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79276&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/573501?name=79276&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_802": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/574106?name=79276&mode=orpha&region=",
    "regulatory_id": "574106",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 20/11/2019)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 20/11/2019)",
      "(Tradename                        - 20/11/2019)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79276&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/574106?name=79276&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_803": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=79276&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=79276&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=79276&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "510758": {
    "name": "Ciclopirox",
    "substance_url": "/en/drug/substance/510758?name=79277&mode=orpha&region=&status=all",
    "substance_id": "510758",
    "regulatory_url": "/en/drug/regulatory/510762?name=79277&mode=orpha&region=",
    "regulatory_id": "510762",
    "orpha_substance_code": "ORPHA:79277",
    "details": [
      "Ciclopirox(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:79277 Congenital erythropoietic porphyria",
      "Ciclopirox(Medicinal product                        - 17/01/2018)",
      "(Medicinal product                        - 17/01/2018)",
      "Disease(s) concernedORPHA:79277 Congenital erythropoietic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/510758?name=79277&mode=orpha&region=&status=all",
        "text": "Ciclopirox",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79277",
        "text": "ORPHA:79277 Congenital erythropoietic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/510762?name=79277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "189146": {
    "name": "Afamelanotide",
    "substance_url": "/en/drug/substance/189146?name=79277&mode=orpha&region=&status=all",
    "substance_id": "189146",
    "regulatory_url": "/en/drug/regulatory/138002?name=79277&mode=orpha&region=",
    "regulatory_id": "138002",
    "orpha_substance_code": "ORPHA:79277",
    "details": [
      "Afamelanotide(Medicinal product                        - 08/05/2008)Disease(s) concernedORPHA:79277 Congenital erythropoietic porphyria",
      "Afamelanotide(Medicinal product                        - 08/05/2008)",
      "(Medicinal product                        - 08/05/2008)",
      "Disease(s) concernedORPHA:79277 Congenital erythropoietic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/189146?name=79277&mode=orpha&region=&status=all",
        "text": "Afamelanotide",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79277",
        "text": "ORPHA:79277 Congenital erythropoietic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/138002?name=79277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_806": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=79277&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=79277&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=79277&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_807": {
    "name": "SCENESSE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/138001?name=79278&mode=orpha&region=",
    "regulatory_id": "138001",
    "orpha_substance_code": "ORPHA:443197",
    "details": [
      "SCENESSE(Tradename                        - 22/12/2014)Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "SCENESSE(Tradename                        - 22/12/2014)",
      "(Tradename                        - 22/12/2014)",
      "Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyriaORPHA:443197 X-linked erythropoietic protoporphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/437244?name=79278&mode=orpha&region=&status=all",
        "text": "SCENESSE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79278",
        "text": "ORPHA:79278 Autosomal erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/443197",
        "text": "ORPHA:443197 X-linked erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/138001?name=79278&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_808": {
    "name": "SCENESSE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/565793?name=79278&mode=orpha&region=",
    "regulatory_id": "565793",
    "orpha_substance_code": "ORPHA:79278",
    "details": [
      "SCENESSE(Tradename                        - 08/10/2019)Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyria",
      "SCENESSE(Tradename                        - 08/10/2019)",
      "(Tradename                        - 08/10/2019)",
      "Disease(s) concernedORPHA:79278 Autosomal erythropoietic protoporphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/437244?name=79278&mode=orpha&region=&status=all",
        "text": "SCENESSE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79278",
        "text": "ORPHA:79278 Autosomal erythropoietic protoporphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/565793?name=79278&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_809": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=79278&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=79278&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=79278&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_810": {
    "name": "ORPHACOL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/363950?name=79301&mode=orpha&region=",
    "regulatory_id": "363950",
    "orpha_substance_code": "ORPHA:79303",
    "details": [
      "ORPHACOL(Tradename                        - 12/09/2013)Disease(s) concernedORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
      "ORPHACOL(Tradename                        - 12/09/2013)",
      "(Tradename                        - 12/09/2013)",
      "Disease(s) concernedORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/135763?name=79301&mode=orpha&region=&status=all",
        "text": "ORPHACOL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79301",
        "text": "ORPHA:79301 Congenital bile acid synthesis defect type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79303",
        "text": "ORPHA:79303 Congenital bile acid synthesis defect type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/363950?name=79301&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_811": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=79301&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=79301&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=79301&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_812": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=79301&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=79301&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=79301&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_813": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=79302&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=79302&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=79302&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_814": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=79302&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=79302&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=79302&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_815": {
    "name": "ORPHACOL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/363950?name=79303&mode=orpha&region=",
    "regulatory_id": "363950",
    "orpha_substance_code": "ORPHA:79303",
    "details": [
      "ORPHACOL(Tradename                        - 12/09/2013)Disease(s) concernedORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
      "ORPHACOL(Tradename                        - 12/09/2013)",
      "(Tradename                        - 12/09/2013)",
      "Disease(s) concernedORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/135763?name=79303&mode=orpha&region=&status=all",
        "text": "ORPHACOL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79301",
        "text": "ORPHA:79301 Congenital bile acid synthesis defect type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79303",
        "text": "ORPHA:79303 Congenital bile acid synthesis defect type 2",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/363950?name=79303&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_816": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=79303&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=79303&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=79303&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_817": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=79303&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=79303&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=79303&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "528554": {
    "name": "Liposomal mannose-1-phosphate",
    "substance_url": "/en/drug/substance/528554?name=79318&mode=orpha&region=&status=all",
    "substance_id": "528554",
    "regulatory_url": "/en/drug/regulatory/528560?name=79318&mode=orpha&region=",
    "regulatory_id": "528560",
    "orpha_substance_code": "ORPHA:79318",
    "details": [
      "Liposomal mannose-1-phosphate(Medicinal product                        - 31/07/2018)Disease(s) concernedORPHA:79318 PMM2-CDG",
      "Liposomal mannose-1-phosphate(Medicinal product                        - 31/07/2018)",
      "(Medicinal product                        - 31/07/2018)",
      "Disease(s) concernedORPHA:79318 PMM2-CDG",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/528554?name=79318&mode=orpha&region=&status=all",
        "text": "Liposomal mannose-1-phosphate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79318",
        "text": "ORPHA:79318 PMM2-CDG",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/528560?name=79318&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_819": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=79330&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=79330&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_820": {
    "name": "HYQVIA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/353482?name=79330&mode=orpha&region=",
    "regulatory_id": "353482",
    "orpha_substance_code": "ORPHA:101977",
    "details": [
      "HYQVIA(Tradename                        - 16/05/2013)Disease(s) concernedORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "HYQVIA(Tradename                        - 16/05/2013)",
      "(Tradename                        - 16/05/2013)",
      "Disease(s) concernedORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/353503?name=79330&mode=orpha&region=&status=all",
        "text": "HYQVIA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/353482?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_821": {
    "name": "HIZENTRA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/353616?name=79330&mode=orpha&region=",
    "regulatory_id": "353616",
    "orpha_substance_code": "ORPHA:183660",
    "details": [
      "HIZENTRA(Tradename                        - 14/04/2011)Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
      "HIZENTRA(Tradename                        - 14/04/2011)",
      "(Tradename                        - 14/04/2011)",
      "Disease(s) concernedORPHA:101977 Immunodeficiency predominantly affecting antibody productionORPHA:183660 Severe combined immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/353563?name=79330&mode=orpha&region=&status=all",
        "text": "HIZENTRA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/183660",
        "text": "ORPHA:183660 Severe combined immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/353616?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_822": {
    "name": "PRIVIGEN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/211740?name=79330&mode=orpha&region=",
    "regulatory_id": "211740",
    "orpha_substance_code": "ORPHA:101977",
    "details": [
      "PRIVIGEN(Tradename                        - 25/04/2008)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "PRIVIGEN(Tradename                        - 25/04/2008)",
      "(Tradename                        - 25/04/2008)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211737?name=79330&mode=orpha&region=&status=all",
        "text": "PRIVIGEN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1959",
        "text": "ORPHA:1959 Evans syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/211740?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:1959 Evans syndrome\n                                \n\n\n\n\n                                    ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101977 Immunodeficiency predominantly affecting antibody production\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_823": {
    "name": "FLEBOGAMMA DIF",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/353506?name=79330&mode=orpha&region=",
    "regulatory_id": "353506",
    "orpha_substance_code": "ORPHA:101977",
    "details": [
      "FLEBOGAMMA DIF(Tradename                        - 23/07/2007)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "FLEBOGAMMA DIF(Tradename                        - 23/07/2007)",
      "(Tradename                        - 23/07/2007)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/353505?name=79330&mode=orpha&region=&status=all",
        "text": "FLEBOGAMMA DIF",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1959",
        "text": "ORPHA:1959 Evans syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/353506?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:1959 Evans syndrome\n                                \n\n\n\n\n                                    ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101977 Immunodeficiency predominantly affecting antibody production\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_824": {
    "name": "KIOVIG",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/353696?name=79330&mode=orpha&region=",
    "regulatory_id": "353696",
    "orpha_substance_code": "ORPHA:101977",
    "details": [
      "KIOVIG(Tradename                        - 19/01/2006)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "KIOVIG(Tradename                        - 19/01/2006)",
      "(Tradename                        - 19/01/2006)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:1959 Evans syndromeORPHA:2103 Guillain-Barré syndromeORPHA:641 Multifocal motor neuropathyORPHA:101977 Immunodeficiency predominantly affecting antibody production",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/353561?name=79330&mode=orpha&region=&status=all",
        "text": "KIOVIG",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/1959",
        "text": "ORPHA:1959 Evans syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101977",
        "text": "ORPHA:101977 Immunodeficiency predominantly affecting antibody production",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/353696?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:1959 Evans syndrome\n                                \n\n\n\n\n                                    ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101977 Immunodeficiency predominantly affecting antibody production\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "689525": {
    "name": "IgA extracted from human milk",
    "substance_url": "/en/drug/substance/689525?name=79330&mode=orpha&region=&status=all",
    "substance_id": "689525",
    "regulatory_url": "/en/drug/regulatory/690029?name=79330&mode=orpha&region=",
    "regulatory_id": "690029",
    "orpha_substance_code": "ORPHA:696851",
    "details": [
      "IgA extracted from human milk(Medicinal product                        - 25/10/2024)Disease(s) concernedORPHA:696851 Common variable immunodeficiency and related disorders",
      "IgA extracted from human milk(Medicinal product                        - 25/10/2024)",
      "(Medicinal product                        - 25/10/2024)",
      "Disease(s) concernedORPHA:696851 Common variable immunodeficiency and related disorders",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/689525?name=79330&mode=orpha&region=&status=all",
        "text": "IgA extracted from human milk",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/696851",
        "text": "ORPHA:696851 Common variable immunodeficiency and related disorders",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/690029?name=79330&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_826": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/573501?name=79473&mode=orpha&region=",
    "regulatory_id": "573501",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 02/03/2020)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 02/03/2020)",
      "(Tradename                        - 02/03/2020)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79473&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/573501?name=79473&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_827": {
    "name": "GIVLAARI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/574106?name=79473&mode=orpha&region=",
    "regulatory_id": "574106",
    "orpha_substance_code": "ORPHA:95157",
    "details": [
      "GIVLAARI(Tradename                        - 20/11/2019)Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "GIVLAARI(Tradename                        - 20/11/2019)",
      "(Tradename                        - 20/11/2019)",
      "Disease(s) concernedORPHA:95157 Acute hepatic porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/573500?name=79473&mode=orpha&region=&status=all",
        "text": "GIVLAARI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/95157",
        "text": "ORPHA:95157 Acute hepatic porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/574106?name=79473&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_828": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=79473&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=79473&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=79473&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_829": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=796&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=796&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=796&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_830": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=796&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=796&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=796&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_831": {
    "name": "Nulibry",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/631432?name=833&mode=orpha&region=",
    "regulatory_id": "631432",
    "orpha_substance_code": "ORPHA:308386",
    "details": [
      "Nulibry(Tradename                        - 15/09/2022)Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "Nulibry(Tradename                        - 15/09/2022)",
      "(Tradename                        - 15/09/2022)",
      "Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616452?name=833&mode=orpha&region=&status=all",
        "text": "Nulibry",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/308386",
        "text": "ORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/631432?name=833&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "230780": {
    "name": "Fosdenopterin",
    "substance_url": "/en/drug/substance/230780?name=833&mode=orpha&region=&status=all",
    "substance_id": "230780",
    "regulatory_url": "/en/drug/regulatory/246952?name=833&mode=orpha&region=",
    "regulatory_id": "246952",
    "orpha_substance_code": "ORPHA:308386",
    "details": [
      "Fosdenopterin(Medicinal product                        - 20/09/2010)Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "Fosdenopterin(Medicinal product                        - 20/09/2010)",
      "(Medicinal product                        - 20/09/2010)",
      "Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/230780?name=833&mode=orpha&region=&status=all",
        "text": "Fosdenopterin",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/308386",
        "text": "ORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/246952?name=833&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_833": {
    "name": "Nulibry",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623071?name=833&mode=orpha&region=",
    "regulatory_id": "623071",
    "orpha_substance_code": "ORPHA:308386",
    "details": [
      "Nulibry(Tradename                        - 26/02/2021)Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "Nulibry(Tradename                        - 26/02/2021)",
      "(Tradename                        - 26/02/2021)",
      "Disease(s) concernedORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/616452?name=833&mode=orpha&region=&status=all",
        "text": "Nulibry",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/308386",
        "text": "ORPHA:308386 Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623071?name=833&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_834": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=84065&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=84065&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=84065&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_835": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=845&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=845&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=845&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_836": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=845&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=845&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=845&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_837": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=859&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=859&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=859&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_838": {
    "name": "NITYR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/527354?name=882&mode=orpha&region=",
    "regulatory_id": "527354",
    "orpha_substance_code": "ORPHA:882",
    "details": [
      "NITYR(Tradename                        - 26/07/2018)Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "NITYR(Tradename                        - 26/07/2018)",
      "(Tradename                        - 26/07/2018)",
      "Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/527350?name=882&mode=orpha&region=&status=all",
        "text": "NITYR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/882",
        "text": "ORPHA:882 Tyrosinemia type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/527354?name=882&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_839": {
    "name": "NITISINONE MDK",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/494384?name=882&mode=orpha&region=",
    "regulatory_id": "494384",
    "orpha_substance_code": "ORPHA:882",
    "details": [
      "NITISINONE MDK(Tradename                        - 24/08/2017)Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "NITISINONE MDK(Tradename                        - 24/08/2017)",
      "(Tradename                        - 24/08/2017)",
      "Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/494377?name=882&mode=orpha&region=&status=all",
        "text": "NITISINONE MDK",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/882",
        "text": "ORPHA:882 Tyrosinemia type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/494384?name=882&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_840": {
    "name": "ORFADIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131358?name=882&mode=orpha&region=",
    "regulatory_id": "131358",
    "orpha_substance_code": "ORPHA:882",
    "details": [
      "ORFADIN(Tradename                        - 24/02/2005)Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "ORFADIN(Tradename                        - 24/02/2005)",
      "(Tradename                        - 24/02/2005)",
      "Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/56898?name=882&mode=orpha&region=&status=all",
        "text": "ORFADIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/882",
        "text": "ORPHA:882 Tyrosinemia type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131358?name=882&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_841": {
    "name": "ORFADIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/676502?name=882&mode=orpha&region=",
    "regulatory_id": "676502",
    "orpha_substance_code": "ORPHA:882",
    "details": [
      "ORFADIN(Tradename                        - 22/04/2016)Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "ORFADIN(Tradename                        - 22/04/2016)",
      "(Tradename                        - 22/04/2016)",
      "Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/56898?name=882&mode=orpha&region=&status=all",
        "text": "ORFADIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/882",
        "text": "ORPHA:882 Tyrosinemia type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/676502?name=882&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_842": {
    "name": "ORFADIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131141?name=882&mode=orpha&region=",
    "regulatory_id": "131141",
    "orpha_substance_code": "ORPHA:882",
    "details": [
      "ORFADIN(Tradename                        - 18/01/2002)Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "ORFADIN(Tradename                        - 18/01/2002)",
      "(Tradename                        - 18/01/2002)",
      "Disease(s) concernedORPHA:882 Tyrosinemia type 1",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/56898?name=882&mode=orpha&region=&status=all",
        "text": "ORFADIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/882",
        "text": "ORPHA:882 Tyrosinemia type 1",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131141?name=882&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_843": {
    "name": "LOARGYS",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/660248?name=90&mode=orpha&region=",
    "regulatory_id": "660248",
    "orpha_substance_code": "ORPHA:90",
    "details": [
      "LOARGYS(Tradename                        - 15/12/2023)Disease(s) concernedORPHA:90 Argininemia",
      "LOARGYS(Tradename                        - 15/12/2023)",
      "(Tradename                        - 15/12/2023)",
      "Disease(s) concernedORPHA:90 Argininemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/660236?name=90&mode=orpha&region=&status=all",
        "text": "LOARGYS",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/660248?name=90&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_844": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/445606?name=90&mode=orpha&region=",
    "regulatory_id": "445606",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 27/11/2015)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 27/11/2015)",
      "(Tradename                        - 27/11/2015)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=90&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/445606?name=90&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "480350": {
    "name": "Pegzilarginase",
    "substance_url": "/en/drug/substance/480350?name=90&mode=orpha&region=&status=all",
    "substance_id": "480350",
    "regulatory_url": "/en/drug/regulatory/480356?name=90&mode=orpha&region=",
    "regulatory_id": "480356",
    "orpha_substance_code": "ORPHA:90",
    "details": [
      "Pegzilarginase(Medicinal product                        - 14/07/2016)Disease(s) concernedORPHA:90 Argininemia",
      "Pegzilarginase(Medicinal product                        - 14/07/2016)",
      "(Medicinal product                        - 14/07/2016)",
      "Disease(s) concernedORPHA:90 Argininemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/480350?name=90&mode=orpha&region=&status=all",
        "text": "Pegzilarginase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/480356?name=90&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_846": {
    "name": "RAVICTI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465104?name=90&mode=orpha&region=",
    "regulatory_id": "465104",
    "orpha_substance_code": "ORPHA:247525",
    "details": [
      "RAVICTI(Tradename                        - 01/02/2013)Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "RAVICTI(Tradename                        - 01/02/2013)",
      "(Tradename                        - 01/02/2013)",
      "Disease(s) concernedORPHA:664 Ornithine transcarbamylase deficiencyORPHA:90 ArgininemiaORPHA:23 Argininosuccinic aciduriaORPHA:147 Carbamoyl-phosphate synthetase 1 deficiencyORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndromeORPHA:247525 Citrullinemia type I",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/445605?name=90&mode=orpha&region=&status=all",
        "text": "RAVICTI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/664",
        "text": "ORPHA:664 Ornithine transcarbamylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/23",
        "text": "ORPHA:23 Argininosuccinic aciduria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/147",
        "text": "ORPHA:147 Carbamoyl-phosphate synthetase 1 deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/415",
        "text": "ORPHA:415 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/247525",
        "text": "ORPHA:247525 Citrullinemia type I",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465104?name=90&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:247525 Citrullinemia type I\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "691380": {
    "name": "Adeno-associated vector expressing human codon-optimized arginase 1 under a liver-specific promoter",
    "substance_url": "/en/drug/substance/691380?name=90&mode=orpha&region=&status=all",
    "substance_id": "691380",
    "regulatory_url": "/en/drug/regulatory/691494?name=90&mode=orpha&region=",
    "regulatory_id": "691494",
    "orpha_substance_code": "ORPHA:90",
    "details": [
      "Adeno-associated vector expressing human codon-optimized arginase 1 under a liver-specific promoter(Medicinal product                        - 12/11/2024)Disease(s) concernedORPHA:90 Argininemia",
      "Adeno-associated vector expressing human codon-optimized arginase 1 under a liver-specific promoter(Medicinal product                        - 12/11/2024)",
      "(Medicinal product                        - 12/11/2024)",
      "Disease(s) concernedORPHA:90 Argininemia",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/691380?name=90&mode=orpha&region=&status=all",
        "text": "Adeno-associated vector expressing human codon-optimized arginase 1 under a liver-specific promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/90",
        "text": "ORPHA:90 Argininemia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/691494?name=90&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_848": {
    "name": "DEQSIGA",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/700589?name=90045&mode=orpha&region=",
    "regulatory_id": "700589",
    "orpha_substance_code": "ORPHA:101997",
    "details": [
      "DEQSIGA(Tradename                        - 02/05/2025)Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "DEQSIGA(Tradename                        - 02/05/2025)",
      "(Tradename                        - 02/05/2025)",
      "Disease(s) concernedORPHA:3002 Immune thrombocytopeniaORPHA:2331 Kawasaki diseaseORPHA:2103 Guillain-Barré syndromeORPHA:2932 Chronic inflammatory demyelinating polyneuropathyORPHA:641 Multifocal motor neuropathyORPHA:101997 Primary immunodeficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/700586?name=90045&mode=orpha&region=&status=all",
        "text": "DEQSIGA",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/3002",
        "text": "ORPHA:3002 Immune thrombocytopenia",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2331",
        "text": "ORPHA:2331 Kawasaki disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2103",
        "text": "ORPHA:2103 Guillain-Barré syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/2932",
        "text": "ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/641",
        "text": "ORPHA:641 Multifocal motor neuropathy",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/101997",
        "text": "ORPHA:101997 Primary immunodeficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/700589?name=90045&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:2103 Guillain-Barré syndrome\n                                \n\n\n\n\n                                    ORPHA:2932 Chronic inflammatory demyelinating polyneuropathy\n                                \n\n\n\n\n                                    ORPHA:641 Multifocal motor neuropathy\n                                \n\n\n\n\n                                    ORPHA:101997 Primary immunodeficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US",
      "EU"
    ]
  },
  "drug_849": {
    "name": "CUFENCE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/562975?name=905&mode=orpha&region=",
    "regulatory_id": "562975",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "CUFENCE(Tradename                        - 25/07/2019)Disease(s) concernedORPHA:905 Wilson disease",
      "CUFENCE(Tradename                        - 25/07/2019)",
      "(Tradename                        - 25/07/2019)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/562971?name=905&mode=orpha&region=&status=all",
        "text": "CUFENCE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/562975?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_850": {
    "name": "CUPRIOR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/494341?name=905&mode=orpha&region=",
    "regulatory_id": "494341",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "CUPRIOR(Tradename                        - 05/09/2017)Disease(s) concernedORPHA:905 Wilson disease",
      "CUPRIOR(Tradename                        - 05/09/2017)",
      "(Tradename                        - 05/09/2017)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/494340?name=905&mode=orpha&region=&status=all",
        "text": "CUPRIOR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/494341?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_851": {
    "name": "WILZIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131357?name=905&mode=orpha&region=",
    "regulatory_id": "131357",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "WILZIN(Tradename                        - 18/10/2004)Disease(s) concernedORPHA:905 Wilson disease",
      "WILZIN(Tradename                        - 18/10/2004)",
      "(Tradename                        - 18/10/2004)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/56896?name=905&mode=orpha&region=&status=all",
        "text": "WILZIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131357?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "605131": {
    "name": "Adeno-associated viral vector serotype 9 encoding human ATP7B",
    "substance_url": "/en/drug/substance/605131?name=905&mode=orpha&region=&status=all",
    "substance_id": "605131",
    "regulatory_url": "/en/drug/regulatory/605132?name=905&mode=orpha&region=",
    "regulatory_id": "605132",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Adeno-associated viral vector serotype 9 encoding human ATP7B(Medicinal product                        - 09/12/2020)Disease(s) concernedORPHA:905 Wilson disease",
      "Adeno-associated viral vector serotype 9 encoding human ATP7B(Medicinal product                        - 09/12/2020)",
      "(Medicinal product                        - 09/12/2020)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/605131?name=905&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 encoding human ATP7B",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/605132?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "604840": {
    "name": "Adeno-associated viral vector serotype 3B encoding shortened human ATP7B",
    "substance_url": "/en/drug/substance/604840?name=905&mode=orpha&region=&status=all",
    "substance_id": "604840",
    "regulatory_url": "/en/drug/regulatory/604841?name=905&mode=orpha&region=",
    "regulatory_id": "604841",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Adeno-associated viral vector serotype 3B encoding shortened human ATP7B(Medicinal product                        - 21/08/2020)Disease(s) concernedORPHA:905 Wilson disease",
      "Adeno-associated viral vector serotype 3B encoding shortened human ATP7B(Medicinal product                        - 21/08/2020)",
      "(Medicinal product                        - 21/08/2020)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604840?name=905&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 3B encoding shortened human ATP7B",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604841?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "447658": {
    "name": "adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
    "substance_url": "/en/drug/substance/447658?name=905&mode=orpha&region=&status=all",
    "substance_id": "447658",
    "regulatory_url": "/en/drug/regulatory/447662?name=905&mode=orpha&region=",
    "regulatory_id": "447662",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter(Medicinal product                        - 11/11/2015)Disease(s) concernedORPHA:905 Wilson disease",
      "adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter(Medicinal product                        - 11/11/2015)",
      "(Medicinal product                        - 11/11/2015)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/447658?name=905&mode=orpha&region=&status=all",
        "text": "adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/447662?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "321503": {
    "name": "Choline tetrathiomolybdate",
    "substance_url": "/en/drug/substance/321503?name=905&mode=orpha&region=&status=all",
    "substance_id": "321503",
    "regulatory_url": "/en/drug/regulatory/323537?name=905&mode=orpha&region=",
    "regulatory_id": "323537",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Choline tetrathiomolybdate(Medicinal product                        - 24/01/2013)Disease(s) concernedORPHA:905 Wilson disease",
      "Choline tetrathiomolybdate(Medicinal product                        - 24/01/2013)",
      "(Medicinal product                        - 24/01/2013)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/321503?name=905&mode=orpha&region=&status=all",
        "text": "Choline tetrathiomolybdate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/323537?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "137334": {
    "name": "Ammonium tetrathiomolybdate",
    "substance_url": "/en/drug/substance/137334?name=905&mode=orpha&region=&status=all",
    "substance_id": "137334",
    "regulatory_url": "/en/drug/regulatory/137335?name=905&mode=orpha&region=",
    "regulatory_id": "137335",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Ammonium tetrathiomolybdate(Medicinal product                        - 01/04/2008)Disease(s) concernedORPHA:905 Wilson disease",
      "Ammonium tetrathiomolybdate(Medicinal product                        - 01/04/2008)",
      "(Medicinal product                        - 01/04/2008)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/137334?name=905&mode=orpha&region=&status=all",
        "text": "Ammonium tetrathiomolybdate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/137335?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "496340": {
    "name": "Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
    "substance_url": "/en/drug/substance/496340?name=905&mode=orpha&region=&status=all",
    "substance_id": "496340",
    "regulatory_url": "/en/drug/regulatory/496344?name=905&mode=orpha&region=",
    "regulatory_id": "496344",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter(Medicinal product                        - 23/08/2017)Disease(s) concernedORPHA:905 Wilson disease",
      "Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter(Medicinal product                        - 23/08/2017)",
      "(Medicinal product                        - 23/08/2017)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/496340?name=905&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/496344?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "444360": {
    "name": "trientine tetrahydrochloride",
    "substance_url": "/en/drug/substance/444360?name=905&mode=orpha&region=&status=all",
    "substance_id": "444360",
    "regulatory_url": "/en/drug/regulatory/444361?name=905&mode=orpha&region=",
    "regulatory_id": "444361",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "trientine tetrahydrochloride(Medicinal product                        - 19/03/2015)Disease(s) concernedORPHA:905 Wilson disease",
      "trientine tetrahydrochloride(Medicinal product                        - 19/03/2015)",
      "(Medicinal product                        - 19/03/2015)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/444360?name=905&mode=orpha&region=&status=all",
        "text": "trientine tetrahydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/444361?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "24924": {
    "name": "Trientine dihydrochloride",
    "substance_url": "/en/drug/substance/24924?name=905&mode=orpha&region=&status=all",
    "substance_id": "24924",
    "regulatory_url": "/en/drug/regulatory/133852?name=905&mode=orpha&region=",
    "regulatory_id": "133852",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Trientine dihydrochloride(Medicinal product                        - 24/10/2003)Disease(s) concernedORPHA:905 Wilson disease",
      "Trientine dihydrochloride(Medicinal product                        - 24/10/2003)",
      "(Medicinal product                        - 24/10/2003)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/24924?name=905&mode=orpha&region=&status=all",
        "text": "Trientine dihydrochloride",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133852?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "56897": {
    "name": "Zinc acetate",
    "substance_url": "/en/drug/substance/56897?name=905&mode=orpha&region=&status=all",
    "substance_id": "56897",
    "regulatory_url": "/en/drug/regulatory/133733?name=905&mode=orpha&region=",
    "regulatory_id": "133733",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Zinc acetate(Medicinal product                        - 31/07/2001)Disease(s) concernedORPHA:905 Wilson disease",
      "Zinc acetate(Medicinal product                        - 31/07/2001)",
      "(Medicinal product                        - 31/07/2001)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/56897?name=905&mode=orpha&region=&status=all",
        "text": "Zinc acetate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/133733?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_861": {
    "name": "CUVRIOR",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/623591?name=905&mode=orpha&region=",
    "regulatory_id": "623591",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "CUVRIOR(Tradename                        - 28/04/2022)Disease(s) concernedORPHA:905 Wilson disease",
      "CUVRIOR(Tradename                        - 28/04/2022)",
      "(Tradename                        - 28/04/2022)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/623586?name=905&mode=orpha&region=&status=all",
        "text": "CUVRIOR",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/623591?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_862": {
    "name": "GALZIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131083?name=905&mode=orpha&region=",
    "regulatory_id": "131083",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "GALZIN(Tradename                        - 28/01/1997)Disease(s) concernedORPHA:905 Wilson disease",
      "GALZIN(Tradename                        - 28/01/1997)",
      "(Tradename                        - 28/01/1997)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/25082?name=905&mode=orpha&region=&status=all",
        "text": "GALZIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131083?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_863": {
    "name": "SYPRINE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131121?name=905&mode=orpha&region=",
    "regulatory_id": "131121",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "SYPRINE(Tradename                        - 08/11/1985)Disease(s) concernedORPHA:905 Wilson disease",
      "SYPRINE(Tradename                        - 08/11/1985)",
      "(Tradename                        - 08/11/1985)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/34566?name=905&mode=orpha&region=&status=all",
        "text": "SYPRINE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131121?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "697602": {
    "name": "Modified human P-type copper transporting ATPase (hATP7B) messenger ribonucleic acid encapsulated in a lipid nanoparticle (hATP7B mRNA-LNP)",
    "substance_url": "/en/drug/substance/697602?name=905&mode=orpha&region=&status=all",
    "substance_id": "697602",
    "regulatory_url": "/en/drug/regulatory/697875?name=905&mode=orpha&region=",
    "regulatory_id": "697875",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Modified human P-type copper transporting ATPase (hATP7B) messenger ribonucleic acid encapsulated in a lipid nanoparticle (hATP7B mRNA-LNP)(Medicinal product                        - 13/03/2025)Disease(s) concernedORPHA:905 Wilson disease",
      "Modified human P-type copper transporting ATPase (hATP7B) messenger ribonucleic acid encapsulated in a lipid nanoparticle (hATP7B mRNA-LNP)(Medicinal product                        - 13/03/2025)",
      "(Medicinal product                        - 13/03/2025)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/697602?name=905&mode=orpha&region=&status=all",
        "text": "Modified human P-type copper transporting ATPase (hATP7B) messenger ribonucleic acid encapsulated in a lipid nanoparticle (hATP7B mRNA-LNP)",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/697875?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687222": {
    "name": "Recombinant adeno-associated viral vector of serotype 8 carrying the coding sequence of human ATP7B gene and a hepatic-specific promoter",
    "substance_url": "/en/drug/substance/687222?name=905&mode=orpha&region=&status=all",
    "substance_id": "687222",
    "regulatory_url": "/en/drug/regulatory/687562?name=905&mode=orpha&region=",
    "regulatory_id": "687562",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Recombinant adeno-associated viral vector of serotype 8 carrying the coding sequence of human ATP7B gene and a hepatic-specific promoter(Medicinal product                        - 06/08/2024)Disease(s) concernedORPHA:905 Wilson disease",
      "Recombinant adeno-associated viral vector of serotype 8 carrying the coding sequence of human ATP7B gene and a hepatic-specific promoter(Medicinal product                        - 06/08/2024)",
      "(Medicinal product                        - 06/08/2024)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687222?name=905&mode=orpha&region=&status=all",
        "text": "Recombinant adeno-associated viral vector of serotype 8 carrying the coding sequence of human ATP7B gene and a hepatic-specific promoter",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687562?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "687200": {
    "name": "Methanobactin SB2",
    "substance_url": "/en/drug/substance/687200?name=905&mode=orpha&region=&status=all",
    "substance_id": "687200",
    "regulatory_url": "/en/drug/regulatory/687529?name=905&mode=orpha&region=",
    "regulatory_id": "687529",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Methanobactin SB2(Medicinal product                        - 06/08/2024)Disease(s) concernedORPHA:905 Wilson disease",
      "Methanobactin SB2(Medicinal product                        - 06/08/2024)",
      "(Medicinal product                        - 06/08/2024)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/687200?name=905&mode=orpha&region=&status=all",
        "text": "Methanobactin SB2",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/687529?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "632181": {
    "name": "Methyl (R)-4-(3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-yl-methyl)amino)butyl)amino) hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl) pentan",
    "substance_url": "/en/drug/substance/632181?name=905&mode=orpha&region=&status=all",
    "substance_id": "632181",
    "regulatory_url": "/en/drug/regulatory/632185?name=905&mode=orpha&region=",
    "regulatory_id": "632185",
    "orpha_substance_code": "ORPHA:905",
    "details": [
      "Methyl (R)-4-(3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-yl-methyl)amino)butyl)amino) hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl) pentan(Medicinal product                        - 12/05/2022)Disease(s) concernedORPHA:905 Wilson disease",
      "Methyl (R)-4-(3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-yl-methyl)amino)butyl)amino) hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl) pentan(Medicinal product                        - 12/05/2022)",
      "(Medicinal product                        - 12/05/2022)",
      "Disease(s) concernedORPHA:905 Wilson disease",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/632181?name=905&mode=orpha&region=&status=all",
        "text": "Methyl (R)-4-(3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-yl-methyl)amino)butyl)amino) hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl) pentan",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/905",
        "text": "ORPHA:905 Wilson disease",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/632185?name=905&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_868": {
    "name": "CHENODEOXYCHOLIC ACID LEADIANT",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/484325?name=909&mode=orpha&region=",
    "regulatory_id": "484325",
    "orpha_substance_code": "ORPHA:909",
    "details": [
      "CHENODEOXYCHOLIC ACID LEADIANT(Tradename                        - 10/04/2017)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "CHENODEOXYCHOLIC ACID LEADIANT(Tradename                        - 10/04/2017)",
      "(Tradename                        - 10/04/2017)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/484324?name=909&mode=orpha&region=&status=all",
        "text": "CHENODEOXYCHOLIC ACID LEADIANT",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/484325?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_869": {
    "name": "KOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/399979?name=909&mode=orpha&region=",
    "regulatory_id": "399979",
    "orpha_substance_code": "ORPHA:209902",
    "details": [
      "KOLBAM(Tradename                        - 04/04/2014)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "KOLBAM(Tradename                        - 04/04/2014)",
      "(Tradename                        - 04/04/2014)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/399978?name=909&mode=orpha&region=&status=all",
        "text": "KOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79095",
        "text": "ORPHA:79095 Congenital bile acid synthesis defect type 4",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/209902",
        "text": "ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/399979?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "414121": {
    "name": "Chenodeoxycholic acid",
    "substance_url": "/en/drug/substance/414121?name=909&mode=orpha&region=&status=all",
    "substance_id": "414121",
    "regulatory_url": "/en/drug/regulatory/441322?name=909&mode=orpha&region=",
    "regulatory_id": "441322",
    "orpha_substance_code": "ORPHA:909",
    "details": [
      "Chenodeoxycholic acid(Medicinal product                        - 16/12/2014)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "Chenodeoxycholic acid(Medicinal product                        - 16/12/2014)",
      "(Medicinal product                        - 16/12/2014)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/414121?name=909&mode=orpha&region=&status=all",
        "text": "Chenodeoxycholic acid",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/441322?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_871": {
    "name": "CTEXLI",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/695300?name=909&mode=orpha&region=",
    "regulatory_id": "695300",
    "orpha_substance_code": "ORPHA:909",
    "details": [
      "CTEXLI(Tradename                        - 21/02/2025)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "CTEXLI(Tradename                        - 21/02/2025)",
      "(Tradename                        - 21/02/2025)",
      "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/695293?name=909&mode=orpha&region=&status=all",
        "text": "CTEXLI",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/909",
        "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/695300?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_872": {
    "name": "VEDROP",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/213892?name=909&mode=orpha&region=",
    "regulatory_id": "213892",
    "orpha_substance_code": "ORPHA:284385",
    "details": [
      "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "VEDROP(Tradename                        - 24/07/2009)",
      "(Tradename                        - 24/07/2009)",
      "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/211746?name=909&mode=orpha&region=&status=all",
        "text": "VEDROP",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/52",
        "text": "ORPHA:52 Alagille syndrome",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/284385",
        "text": "ORPHA:284385 Familial intrahepatic cholestasis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/213892?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_873": {
    "name": "CHOLBAM",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465123?name=909&mode=orpha&region=",
    "regulatory_id": "465123",
    "orpha_substance_code": "ORPHA:79168",
    "details": [
      "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "CHOLBAM(Tradename                        - 17/03/2015)",
      "(Tradename                        - 17/03/2015)",
      "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/464955?name=909&mode=orpha&region=&status=all",
        "text": "CHOLBAM",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/79168",
        "text": "ORPHA:79168 Disorder of bile acid synthesis",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465123?name=909&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_874": {
    "name": "PLERIXAFOR ACCORD",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/642317?name=926&mode=orpha&region=",
    "regulatory_id": "642317",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
      "(Tradename                        - 16/12/2022)",
      "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/642316?name=926&mode=orpha&region=&status=all",
        "text": "PLERIXAFOR ACCORD",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/29073",
        "text": "ORPHA:29073 Multiple myeloma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/223735",
        "text": "ORPHA:223735 Lymphoma",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/642317?name=926&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_875": {
    "name": "Thiotepa Riemser",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/610636?name=926&mode=orpha&region=",
    "regulatory_id": "610636",
    "orpha_substance_code": "ORPHA:506219",
    "details": [
      "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "Thiotepa Riemser(Tradename                        - 26/03/2021)",
      "(Tradename                        - 26/03/2021)",
      "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/610616?name=926&mode=orpha&region=&status=all",
        "text": "Thiotepa Riemser",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/506219",
        "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/610636?name=926&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_876": {
    "name": "UCEDANE",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/489568?name=927&mode=orpha&region=",
    "regulatory_id": "489568",
    "orpha_substance_code": "ORPHA:927",
    "details": [
      "UCEDANE(Tradename                        - 23/06/2017)Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "UCEDANE(Tradename                        - 23/06/2017)",
      "(Tradename                        - 23/06/2017)",
      "Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/489567?name=927&mode=orpha&region=&status=all",
        "text": "UCEDANE",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/927",
        "text": "ORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/489568?name=927&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_877": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/439222?name=927&mode=orpha&region=",
    "regulatory_id": "439222",
    "orpha_substance_code": "ORPHA:927",
    "details": [
      "CARBAGLU(Tradename                        - 28/01/2003)Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "CARBAGLU(Tradename                        - 28/01/2003)",
      "(Tradename                        - 28/01/2003)",
      "Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=927&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/927",
        "text": "ORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/439222?name=927&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_878": {
    "name": "CARBAGLU",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/465048?name=927&mode=orpha&region=",
    "regulatory_id": "465048",
    "orpha_substance_code": "ORPHA:927",
    "details": [
      "CARBAGLU(Tradename                        - 18/03/2010)Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "CARBAGLU(Tradename                        - 18/03/2010)",
      "(Tradename                        - 18/03/2010)",
      "Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/35160?name=927&mode=orpha&region=&status=all",
        "text": "CARBAGLU",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/927",
        "text": "ORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/465048?name=927&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "drug_879": {
    "name": "AMMONUL",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131189?name=927&mode=orpha&region=",
    "regulatory_id": "131189",
    "orpha_substance_code": "ORPHA:927",
    "details": [
      "AMMONUL(Tradename                        - 17/02/2005)Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "AMMONUL(Tradename                        - 17/02/2005)",
      "(Tradename                        - 17/02/2005)",
      "Disease(s) concernedORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/87863?name=927&mode=orpha&region=&status=all",
        "text": "AMMONUL",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/927",
        "text": "ORPHA:927 Hyperammonemia due to N-acetylglutamate synthase deficiency",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131189?name=927&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "604867": {
    "name": "Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene",
    "substance_url": "/en/drug/substance/604867?name=93&mode=orpha&region=&status=all",
    "substance_id": "604867",
    "regulatory_url": "/en/drug/regulatory/604868?name=93&mode=orpha&region=",
    "regulatory_id": "604868",
    "orpha_substance_code": "ORPHA:93",
    "details": [
      "Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene(Medicinal product                        - 19/10/2020)Disease(s) concernedORPHA:93 Aspartylglucosaminuria",
      "Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene(Medicinal product                        - 19/10/2020)",
      "(Medicinal product                        - 19/10/2020)",
      "Disease(s) concernedORPHA:93 Aspartylglucosaminuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/604867?name=93&mode=orpha&region=&status=all",
        "text": "Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93",
        "text": "ORPHA:93 Aspartylglucosaminuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/604868?name=93&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "418152": {
    "name": "Recombinant human aspartylglucosaminidase",
    "substance_url": "/en/drug/substance/418152?name=93&mode=orpha&region=&status=all",
    "substance_id": "418152",
    "regulatory_url": "/en/drug/regulatory/437286?name=93&mode=orpha&region=",
    "regulatory_id": "437286",
    "orpha_substance_code": "ORPHA:93",
    "details": [
      "Recombinant human aspartylglucosaminidase(Medicinal product                        - 15/01/2015)Disease(s) concernedORPHA:93 Aspartylglucosaminuria",
      "Recombinant human aspartylglucosaminidase(Medicinal product                        - 15/01/2015)",
      "(Medicinal product                        - 15/01/2015)",
      "Disease(s) concernedORPHA:93 Aspartylglucosaminuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/418152?name=93&mode=orpha&region=&status=all",
        "text": "Recombinant human aspartylglucosaminidase",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/93",
        "text": "ORPHA:93 Aspartylglucosaminuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/437286?name=93&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "611053": {
    "name": "Beta Hydroxybutyrate",
    "substance_url": "/en/drug/substance/611053?name=943&mode=orpha&region=&status=all",
    "substance_id": "611053",
    "regulatory_url": "/en/drug/regulatory/665249?name=943&mode=orpha&region=",
    "regulatory_id": "665249",
    "orpha_substance_code": "ORPHA:309133",
    "details": [
      "Beta Hydroxybutyrate(Medicinal product                        - 18/03/2024)Disease(s) concernedORPHA:309133 Metabolic disease due to other fatty acid oxidation disorder",
      "Beta Hydroxybutyrate(Medicinal product                        - 18/03/2024)",
      "(Medicinal product                        - 18/03/2024)",
      "Disease(s) concernedORPHA:309133 Metabolic disease due to other fatty acid oxidation disorder",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/611053?name=943&mode=orpha&region=&status=all",
        "text": "Beta Hydroxybutyrate",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/309133",
        "text": "ORPHA:309133 Metabolic disease due to other fatty acid oxidation disorder",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/665249?name=943&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": "due to other fatty acid oxidation disorder\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
    "regions": [
      "US"
    ]
  },
  "drug_883": {
    "name": "PANHEMATIN",
    "substance_url": null,
    "substance_id": null,
    "regulatory_url": "/en/drug/regulatory/131060?name=95159&mode=orpha&region=",
    "regulatory_id": "131060",
    "orpha_substance_code": "ORPHA:738",
    "details": [
      "PANHEMATIN(Tradename                        - 20/07/1990)Disease(s) concernedORPHA:738 Porphyria",
      "PANHEMATIN(Tradename                        - 20/07/1990)",
      "(Tradename                        - 20/07/1990)",
      "Disease(s) concernedORPHA:738 Porphyria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/trade_name/24989?name=95159&mode=orpha&region=&status=all",
        "text": "PANHEMATIN",
        "type": "trade_name_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/738",
        "text": "ORPHA:738 Porphyria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/131060?name=95159&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Tradename",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  },
  "45213": {
    "name": "Hydroxychloroquine",
    "substance_url": "/en/drug/substance/45213?name=99845&mode=orpha&region=&status=all",
    "substance_id": "45213",
    "regulatory_url": "/en/drug/regulatory/635827?name=99845&mode=orpha&region=",
    "regulatory_id": "635827",
    "orpha_substance_code": "ORPHA:99845",
    "details": [
      "Hydroxychloroquine(Medicinal product                        - 08/10/2009)Disease(s) concernedORPHA:99845 Genetic recurrent myoglobinuria",
      "Hydroxychloroquine(Medicinal product                        - 08/10/2009)",
      "(Medicinal product                        - 08/10/2009)",
      "Disease(s) concernedORPHA:99845 Genetic recurrent myoglobinuria",
      "More details on the regulatory status"
    ],
    "links": [
      {
        "url": "https://www.orpha.net/en/drug/substance/45213?name=99845&mode=orpha&region=&status=all",
        "text": "Hydroxychloroquine",
        "type": "substance_details"
      },
      {
        "url": "https://www.orpha.net/en/disease/detail/99845",
        "text": "ORPHA:99845 Genetic recurrent myoglobinuria",
        "type": "disease_details"
      },
      {
        "url": "https://www.orpha.net/en/drug/regulatory/635827?name=99845&mode=orpha&region=",
        "text": "More details on the regulatory status",
        "type": "regulatory_status"
      }
    ],
    "status": "Medicinal product",
    "manufacturer": null,
    "indication": null,
    "regions": [
      "US"
    ]
  }
}